{"PMC6926485": [["IntroductionPathogens and concurrent tissue damage elicit complex context-dependent inflammatory response programs (Hotamisligil, 2017).", [["tissue", "ANATOMY", 37, 43], ["tissue damage", "DISEASE", 37, 50], ["tissue", "TISSUE", 37, 43], ["IntroductionPathogens", "TREATMENT", 0, 21], ["concurrent tissue damage", "PROBLEM", 26, 50], ["dependent inflammatory response programs", "PROBLEM", 74, 114], ["concurrent tissue", "OBSERVATION_MODIFIER", 26, 43], ["damage", "OBSERVATION", 44, 50], ["dependent", "OBSERVATION_MODIFIER", 74, 83], ["inflammatory", "OBSERVATION_MODIFIER", 84, 96]]], ["Chronic infections represent a particular challenge for the host organism, which is exposed to prolonged inflammation that may predispose to various co-morbidities, such as susceptibility to secondary infections and cancer (Okin and Medzhitov, 2012, Rehermann and Nascimbeni, 2005, Virgin et al., 2009).", [["cancer", "ANATOMY", 216, 222], ["Chronic infections", "DISEASE", 0, 18], ["inflammation", "DISEASE", 105, 117], ["infections", "DISEASE", 201, 211], ["cancer", "DISEASE", 216, 222], ["cancer", "CANCER", 216, 222], ["Chronic infections", "PROBLEM", 0, 18], ["the host organism", "PROBLEM", 56, 73], ["prolonged inflammation", "PROBLEM", 95, 117], ["various co-morbidities", "PROBLEM", 141, 163], ["secondary infections", "PROBLEM", 191, 211], ["cancer", "PROBLEM", 216, 222], ["infections", "OBSERVATION", 8, 18], ["prolonged", "OBSERVATION_MODIFIER", 95, 104], ["inflammation", "OBSERVATION", 105, 117], ["secondary", "OBSERVATION_MODIFIER", 191, 200], ["infections", "OBSERVATION", 201, 211], ["cancer", "OBSERVATION", 216, 222]]], ["The same inflammatory pathways can also control cellular tissue homeostasis and metabolism (Kotas and Medzhitov, 2015, Medzhitov, 2008, O\u2019Neill and Pearce, 2016).", [["cellular tissue", "ANATOMY", 48, 63], ["cellular tissue", "TISSUE", 48, 63], ["inflammatory", "OBSERVATION", 9, 21], ["cellular tissue homeostasis", "OBSERVATION", 48, 75]]], ["Different cell types and organs communicate with each other through soluble cytokines, thereby determining the quality, magnitude, and duration of both local and systemic immune responses (Medzhitov, 2008).", [["cell", "ANATOMY", 10, 14], ["organs", "ANATOMY", 25, 31], ["cell", "CELL", 10, 14], ["organs", "ORGAN", 25, 31], ["cytokines", "PROTEIN", 76, 85], ["soluble cytokines", "TEST", 68, 85], ["cell types", "OBSERVATION", 10, 20]]], ["The liver is a central metabolic organ but also represents an immunoregulatory hub between blood-borne pathogens and the immune system (Jenne and Kubes, 2013, Protzer et al., 2012, Racanelli and Rehermann, 2006).", [["liver", "ANATOMY", 4, 9], ["organ", "ANATOMY", 33, 38], ["blood", "ANATOMY", 91, 96], ["immune system", "ANATOMY", 121, 134], ["liver", "ORGAN", 4, 9], ["organ", "ORGAN", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["a central metabolic organ", "PROBLEM", 13, 38], ["Kubes", "TEST", 146, 151], ["liver", "ANATOMY", 4, 9], ["central", "ANATOMY_MODIFIER", 15, 22], ["metabolic organ", "OBSERVATION", 23, 38]]], ["Hepatocytes are the functional unit of the liver parenchyma and the most abundant cell type of the liver.", [["Hepatocytes", "ANATOMY", 0, 11], ["liver parenchyma", "ANATOMY", 43, 59], ["cell", "ANATOMY", 82, 86], ["liver", "ANATOMY", 99, 104], ["Hepatocytes", "CELL", 0, 11], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 43, 59], ["cell type", "CELL", 82, 91], ["liver", "ORGAN", 99, 104], ["functional unit", "OBSERVATION", 20, 35], ["liver", "ANATOMY", 43, 48], ["parenchyma", "ANATOMY_MODIFIER", 49, 59], ["most", "OBSERVATION_MODIFIER", 68, 72], ["abundant cell type", "OBSERVATION", 73, 91], ["liver", "ANATOMY", 99, 104]]], ["Yet they are also important immune signaling platforms that produce and react to a range of cytokines upon inflammation (Crispe, 2016, Racanelli and Rehermann, 2006, Zhou et al., 2016).", [["inflammation", "DISEASE", 107, 119], ["cytokines", "PROTEIN", 92, 101], ["inflammation", "PROBLEM", 107, 119], ["inflammation", "OBSERVATION", 107, 119]]], ["Hepatocytes themselves are permissible to a variety of chronic viruses, including hepatitis B virus (HBV) and hepatitis C virus (HCV) in humans and lymphocytic choriomeningitis virus (LCMV) in mice (Guidotti et al., 1999, Rehermann and Nascimbeni, 2005).", [["Hepatocytes", "ANATOMY", 0, 11], ["hepatitis B virus (HBV) and hepatitis C", "DISEASE", 82, 121], ["lymphocytic choriomeningitis virus", "DISEASE", 148, 182], ["Hepatocytes", "CELL", 0, 11], ["hepatitis B virus", "ORGANISM", 82, 99], ["HBV", "ORGANISM", 101, 104], ["hepatitis C virus", "ORGANISM", 110, 127], ["HCV", "ORGANISM", 129, 132], ["humans", "ORGANISM", 137, 143], ["lymphocytic choriomeningitis virus", "ORGANISM", 148, 182], ["LCMV", "ORGANISM", 184, 188], ["mice", "ORGANISM", 193, 197], ["hepatitis B virus", "SPECIES", 82, 99], ["hepatitis C virus", "SPECIES", 110, 127], ["humans", "SPECIES", 137, 143], ["lymphocytic choriomeningitis virus", "SPECIES", 148, 182], ["mice", "SPECIES", 193, 197], ["hepatitis B virus", "SPECIES", 82, 99], ["HBV", "SPECIES", 101, 104], ["hepatitis C virus", "SPECIES", 110, 127], ["HCV", "SPECIES", 129, 132], ["humans", "SPECIES", 137, 143], ["lymphocytic choriomeningitis virus", "SPECIES", 148, 182], ["LCMV", "SPECIES", 184, 188], ["mice", "SPECIES", 193, 197], ["Hepatocytes themselves", "PROBLEM", 0, 22], ["chronic viruses", "PROBLEM", 55, 70], ["hepatitis B virus", "PROBLEM", 82, 99], ["HBV", "PROBLEM", 101, 104], ["hepatitis C virus (HCV) in humans", "PROBLEM", 110, 143], ["lymphocytic choriomeningitis virus", "PROBLEM", 148, 182], ["variety", "OBSERVATION_MODIFIER", 44, 51], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["viruses", "OBSERVATION", 63, 70], ["hepatitis", "OBSERVATION", 82, 91], ["lymphocytic choriomeningitis virus", "OBSERVATION", 148, 182]]], ["The chronic infection model of LCMV represents a well-established and pathophysiologically relevant experimental model for the study of host-pathogen interactions and immune responses that induce a vigorous CD8 T-cell-dependent hepatitis (Zehn and Wherry, 2015, Zinkernagel et al., 1986).", [["CD8 T-cell", "ANATOMY", 207, 217], ["chronic infection", "DISEASE", 4, 21], ["hepatitis", "DISEASE", 228, 237], ["LCMV", "ORGANISM", 31, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 207, 210], ["LCMV", "SPECIES", 31, 35], ["The chronic infection", "PROBLEM", 0, 21], ["LCMV", "PROBLEM", 31, 35], ["the study", "TEST", 123, 132], ["immune responses", "TEST", 167, 183], ["dependent hepatitis", "PROBLEM", 218, 237], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21], ["LCMV", "OBSERVATION", 31, 35], ["vigorous", "OBSERVATION_MODIFIER", 198, 206], ["dependent", "OBSERVATION_MODIFIER", 218, 227], ["hepatitis", "OBSERVATION", 228, 237]]], ["The involved immunopathologic mechanisms seen in the LCMV model are similar to those observed in patients chronically infected with HBV or HCV (Guidotti et al., 1999, Rehermann and Nascimbeni, 2005).IntroductionSoluble inflammatory signals act mainly through cytokine receptors (Hotamisligil, 2017, Protzer et al., 2012, Racanelli and Rehermann, 2006).", [["chronically infected with HBV or HCV", "DISEASE", 106, 142], ["LCMV", "ORGANISM", 53, 57], ["patients", "ORGANISM", 97, 105], ["HBV", "ORGANISM", 132, 135], ["HCV", "ORGANISM", 139, 142], ["cytokine receptors", "PROTEIN", 259, 277], ["patients", "SPECIES", 97, 105], ["HBV", "SPECIES", 132, 135], ["HCV", "SPECIES", 139, 142], ["The involved immunopathologic mechanisms", "PROBLEM", 0, 40], ["HBV", "PROBLEM", 132, 135], ["HCV", "PROBLEM", 139, 142], ["IntroductionSoluble inflammatory signals", "PROBLEM", 199, 239], ["immunopathologic", "OBSERVATION", 13, 29], ["LCMV model", "OBSERVATION", 53, 63], ["chronically", "OBSERVATION_MODIFIER", 106, 117], ["infected", "OBSERVATION", 118, 126], ["HBV", "OBSERVATION", 132, 135], ["inflammatory", "OBSERVATION", 219, 231]]], ["Type I interferons (IFN-Is) are central antiviral cytokines that signal through the ubiquitously expressed IFNAR receptor, which is composed of the two subunits IFNAR1 and IFNAR2.", [["Type I interferons", "GENE_OR_GENE_PRODUCT", 0, 18], ["IFN-Is", "GENE_OR_GENE_PRODUCT", 20, 26], ["IFNAR receptor", "GENE_OR_GENE_PRODUCT", 107, 121], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 161, 167], ["IFNAR2", "GENE_OR_GENE_PRODUCT", 172, 178], ["Type I interferons", "PROTEIN", 0, 18], ["IFN", "PROTEIN", 20, 23], ["antiviral cytokines", "PROTEIN", 40, 59], ["IFNAR receptor", "PROTEIN", 107, 121], ["IFNAR1", "PROTEIN", 161, 167], ["IFNAR2", "PROTEIN", 172, 178], ["Type I interferons (IFN", "TREATMENT", 0, 23], ["central antiviral cytokines", "PROBLEM", 32, 59], ["central", "ANATOMY_MODIFIER", 32, 39], ["antiviral cytokines", "OBSERVATION", 40, 59]]], ["This induces the expression of a broad array of genes described as interferon-stimulated genes (ISGs).", [["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 67, 94], ["interferon-stimulated genes", "DNA", 67, 94], ["ISGs", "DNA", 96, 100], ["a broad array of genes", "PROBLEM", 31, 53], ["interferon-stimulated genes", "TREATMENT", 67, 94]]], ["ISGs exert antiviral functions by direct interference with viral replication and immunoregulatory properties (McNab et al., 2015, Schoggins et al., 2011).", [["ISGs", "PROTEIN", 0, 4], ["immunoregulatory", "PROTEIN", 81, 97], ["viral replication", "TREATMENT", 59, 76], ["antiviral functions", "OBSERVATION", 11, 30]]], ["More recently, IFN-Is are also recognized as modulators of metabolism, such as cellular lipid metabolism and redox homeostasis (Bhattacharya et al., 2015, Pantel et al., 2014, Wu et al., 2016, York et al., 2015).", [["cellular", "ANATOMY", 79, 87], ["IFN-Is", "GENE_OR_GENE_PRODUCT", 15, 21], ["cellular", "CELL", 79, 87], ["IFN", "PROTEIN", 15, 18], ["lipid metabolism", "OBSERVATION", 88, 104], ["redox homeostasis", "OBSERVATION", 109, 126]]], ["Cytokine-induced regulation of liver metabolism is expected to result in altered metabolite turnover and release that impacts distal organs (van den Berghe, 1991, Norata et al., 2015).", [["liver", "ANATOMY", 31, 36], ["distal organs", "ANATOMY", 126, 139], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["liver", "ORGAN", 31, 36], ["organs", "ORGAN", 133, 139], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine", "TREATMENT", 0, 8], ["liver metabolism", "PROBLEM", 31, 47], ["altered metabolite turnover", "PROBLEM", 73, 100], ["liver", "ANATOMY", 31, 36], ["metabolite turnover", "OBSERVATION", 81, 100], ["distal", "ANATOMY_MODIFIER", 126, 132], ["organs", "ANATOMY", 133, 139]]], ["Immune cells and in particular T cells critically depend on certain metabolites to efficiently perform their functions and are thus susceptible to altered metabolite availability (Chang et al., 2015, Geiger et al., 2016, Johnson et al., 2018, Pearce et al., 2009).", [["Immune cells", "ANATOMY", 0, 12], ["T cells", "ANATOMY", 31, 38], ["Immune cells", "CELL", 0, 12], ["T cells", "CELL", 31, 38], ["Immune cells", "CELL_TYPE", 0, 12], ["T cells", "CELL_TYPE", 31, 38], ["Immune cells", "PROBLEM", 0, 12]]], ["In line with this, a frequent immune evasion mechanism of cancer is the depletion of essential amino acids or glucose in the tumor microenvironment (Buck et al., 2017, Chang et al., 2015, Ma et al., 2017, Murray, 2016).IntroductionIn this study, we investigated the chronic infection model of LCMV using an unbiased integrative approach to unveil inflammation-driven endogenous regulation of liver metabolism and its impact on systemic immune responses and tissue pathology.Identification of Inflammatory-Metabolic Changes in the Liver during Chronic Infection ::: ResultsWe infected C57BL/6J wild-type mice with 2 \u00d7 106 focus forming units (FFUs) of the chronic strain clone 13 of LCMV and quantified infectious virus particles and viral RNA in the liver (Figure 1A).", [["cancer", "ANATOMY", 58, 64], ["tumor", "ANATOMY", 125, 130], ["liver", "ANATOMY", 392, 397], ["tissue", "ANATOMY", 457, 463], ["Liver", "ANATOMY", 530, 535], ["liver", "ANATOMY", 750, 755], ["cancer", "DISEASE", 58, 64], ["amino acids", "CHEMICAL", 95, 106], ["glucose", "CHEMICAL", 110, 117], ["tumor", "DISEASE", 125, 130], ["chronic infection", "DISEASE", 266, 283], ["inflammation", "DISEASE", 347, 359], ["amino acids", "CHEMICAL", 95, 106], ["glucose", "CHEMICAL", 110, 117], ["cancer", "CANCER", 58, 64], ["amino acids", "AMINO_ACID", 95, 106], ["glucose", "SIMPLE_CHEMICAL", 110, 117], ["tumor", "CANCER", 125, 130], ["LCMV", "ORGANISM", 293, 297], ["liver", "ORGAN", 392, 397], ["tissue", "TISSUE", 457, 463], ["Liver", "ORGAN", 530, 535], ["C57BL/6J wild-type mice", "ORGANISM", 584, 607], ["LCMV", "ORGANISM", 682, 686], ["liver", "ORGAN", 750, 755], ["infectious virus particles", "RNA", 702, 728], ["viral RNA", "RNA", 733, 742], ["mice", "SPECIES", 603, 607], ["LCMV", "SPECIES", 293, 297], ["mice", "SPECIES", 603, 607], ["LCMV", "SPECIES", 682, 686], ["a frequent immune evasion mechanism", "TREATMENT", 19, 54], ["cancer", "PROBLEM", 58, 64], ["essential amino acids", "TREATMENT", 85, 106], ["this study", "TEST", 234, 244], ["the chronic infection model of LCMV", "PROBLEM", 262, 297], ["an unbiased integrative approach", "TREATMENT", 304, 336], ["unveil inflammation", "PROBLEM", 340, 359], ["liver metabolism", "PROBLEM", 392, 408], ["systemic immune responses", "TREATMENT", 427, 452], ["tissue pathology", "TEST", 457, 473], ["Inflammatory-Metabolic Changes in the Liver", "PROBLEM", 492, 535], ["Chronic Infection", "PROBLEM", 543, 560], ["the chronic strain clone", "PROBLEM", 651, 675], ["LCMV", "PROBLEM", 682, 686], ["quantified infectious virus particles", "PROBLEM", 691, 728], ["viral RNA in the liver", "PROBLEM", 733, 755], ["cancer", "OBSERVATION", 58, 64], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["infection", "OBSERVATION", 274, 283], ["LCMV", "OBSERVATION", 293, 297], ["inflammation", "OBSERVATION", 347, 359], ["liver", "ANATOMY", 392, 397], ["Inflammatory", "OBSERVATION", 492, 504], ["Metabolic Changes", "OBSERVATION", 505, 522], ["Liver", "ANATOMY", 530, 535], ["Chronic", "OBSERVATION_MODIFIER", 543, 550], ["Infection", "OBSERVATION", 551, 560], ["chronic", "OBSERVATION_MODIFIER", 655, 662], ["infectious virus", "OBSERVATION", 702, 718], ["viral RNA", "OBSERVATION", 733, 742], ["liver", "ANATOMY", 750, 755]]], ["This confirmed the peak of viral propagation around day 8 after infection with a subsequent decline of viral loads.", [["infection", "DISEASE", 64, 73], ["viral propagation", "PROBLEM", 27, 44], ["infection", "PROBLEM", 64, 73], ["viral loads", "PROBLEM", 103, 114], ["viral propagation", "OBSERVATION", 27, 44], ["infection", "OBSERVATION", 64, 73], ["viral loads", "OBSERVATION", 103, 114]]], ["Liver damage was assessed by the clinical hallmark parameters alanine aminotransferase (ALT) and aspartate aminotransferase (AST) that peaked on day 8\u201312 after infection (Figure 1B).", [["Liver", "ANATOMY", 0, 5], ["Liver damage", "DISEASE", 0, 12], ["alanine", "CHEMICAL", 62, 69], ["aspartate", "CHEMICAL", 97, 106], ["infection", "DISEASE", 160, 169], ["alanine", "CHEMICAL", 62, 69], ["aspartate", "CHEMICAL", 97, 106], ["Liver", "ORGAN", 0, 5], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 62, 86], ["ALT", "SIMPLE_CHEMICAL", 88, 91], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 97, 123], ["AST", "SIMPLE_CHEMICAL", 125, 128], ["alanine aminotransferase", "PROTEIN", 62, 86], ["ALT", "PROTEIN", 88, 91], ["aspartate aminotransferase", "PROTEIN", 97, 123], ["AST", "PROTEIN", 125, 128], ["Liver damage", "PROBLEM", 0, 12], ["alanine aminotransferase", "TEST", 62, 86], ["ALT", "TEST", 88, 91], ["aspartate aminotransferase", "TEST", 97, 123], ["AST", "TEST", 125, 128], ["infection", "PROBLEM", 160, 169], ["damage", "OBSERVATION", 6, 12]]], ["In an unbiased approach to virus-induced changes in the liver, we collected liver tissue from infected mice at different phases of infection (day 2 \u2248 innate phase; day 8 \u2248 peak of disease; day 30 \u2248 chronic phase; day 60 \u2248 resolving phase) and performed transcriptome analyses by RNA sequencing (RNA-seq).", [["liver", "ANATOMY", 56, 61], ["liver tissue", "ANATOMY", 76, 88], ["infection", "DISEASE", 131, 140], ["liver", "ORGAN", 56, 61], ["liver tissue", "TISSUE", 76, 88], ["mice", "ORGANISM", 103, 107], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 103, 107], ["virus", "PROBLEM", 27, 32], ["changes in the liver", "PROBLEM", 41, 61], ["collected liver tissue", "PROBLEM", 66, 88], ["infection", "PROBLEM", 131, 140], ["disease", "PROBLEM", 180, 187], ["transcriptome analyses", "TEST", 253, 275], ["RNA sequencing", "TEST", 279, 293], ["virus", "OBSERVATION", 27, 32], ["liver", "ANATOMY", 56, 61], ["liver", "ANATOMY", 76, 81], ["infected", "OBSERVATION", 94, 102], ["different phases", "OBSERVATION_MODIFIER", 111, 127], ["infection", "OBSERVATION", 131, 140]]], ["The transcriptomic data showed high intra-replica reproducibility and individual samples clustered according to the time course of infection (Figure 1C), highlighting phase-specific changes in gene expression and the gradual recovery of mice by 60 days after infection.", [["samples", "ANATOMY", 81, 88], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 259, 268], ["mice", "ORGANISM", 237, 241], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 237, 241], ["The transcriptomic data", "TEST", 0, 23], ["high intra-replica reproducibility", "PROBLEM", 31, 65], ["individual samples", "PROBLEM", 70, 88], ["infection", "PROBLEM", 131, 140], ["infection", "PROBLEM", 259, 268], ["infection", "OBSERVATION", 131, 140], ["infection", "OBSERVATION", 259, 268]]], ["In total, 3,626 transcripts were differentially regulated (Table S1A) and the most differentially expressed genes were found on days 2 and 8 after infection (Figure S1A).", [["infection", "DISEASE", 147, 156], ["Table S1A", "GENE_OR_GENE_PRODUCT", 59, 68], ["infection", "PROBLEM", 147, 156]]], ["Hierarchical clustering identified three broad categories of gene expression programs, including transcripts that were found already regulated on day 2 (clusters 1\u20134) or induced on day 8 (clusters 5\u201310) as well as transcripts that were repressed during infection (clusters 11\u201315; Figure 1D; Table S2A).", [["infection", "DISEASE", 253, 262], ["gene expression programs", "TREATMENT", 61, 85]]], ["To corroborate transcriptional alterations, we performed tissue proteomics and quantified 5,586 proteins in the liver (Table S1B).", [["tissue", "ANATOMY", 57, 63], ["liver", "ANATOMY", 112, 117], ["tissue", "TISSUE", 57, 63], ["liver", "ORGAN", 112, 117], ["5,586 proteins", "PROTEIN", 90, 104], ["transcriptional alterations", "PROBLEM", 15, 42], ["tissue proteomics", "TEST", 57, 74], ["transcriptional alterations", "OBSERVATION", 15, 42], ["liver", "ANATOMY", 112, 117]]], ["Protein changes correlated with differentially expressed transcripts (Figures 1E and S1B; Table S2C).", [["Table S2C", "GENE_OR_GENE_PRODUCT", 90, 99], ["S1B", "PROTEIN", 85, 88], ["Protein changes", "PROBLEM", 0, 15]]], ["Of the identified clusters, differentially expressed genes associated with antiviral IFN-I signaling were found to be enriched on day 2 (clusters 1\u20134; Figure 1F; Table S2B) although leukocyte-associated genes were mainly found on day 8 after infection (clusters 5\u201310; Figure 1F; Table S2B).", [["leukocyte", "ANATOMY", 182, 191], ["infection", "DISEASE", 242, 251], ["IFN-I", "GENE_OR_GENE_PRODUCT", 85, 90], ["Table S2B", "GENE_OR_GENE_PRODUCT", 162, 171], ["leukocyte", "CELL", 182, 191], ["IFN", "PROTEIN", 85, 88], ["leukocyte-associated genes", "DNA", 182, 208], ["antiviral IFN", "TREATMENT", 75, 88], ["clusters", "TEST", 137, 145], ["Figure", "TEST", 151, 157], ["Table S2B", "TEST", 162, 171], ["leukocyte", "TEST", 182, 191], ["infection", "PROBLEM", 242, 251], ["clusters", "OBSERVATION_MODIFIER", 18, 26]]], ["Some of these differential expression changes are likely to reflect hepatic immune cell infiltration (Figure S1C).Identification of Inflammatory-Metabolic Changes in the Liver during Chronic Infection ::: ResultsOur enrichment analyses indicated widespread metabolic reprogramming of liver tissue during LCMV infection (Figure S1D), with particularly pronounced effects seen for downregulated metabolic pathways relating to lipid and amino acid metabolism on days 2 and 8 after infection (clusters 11\u201315; Figure 1F; Table S2B).", [["hepatic immune cell", "ANATOMY", 68, 87], ["Liver", "ANATOMY", 170, 175], ["liver tissue", "ANATOMY", 284, 296], ["LCMV infection", "DISEASE", 304, 318], ["amino acid", "CHEMICAL", 434, 444], ["infection", "DISEASE", 478, 487], ["amino acid", "CHEMICAL", 434, 444], ["hepatic immune cell", "CELL", 68, 87], ["Liver", "ORGAN", 170, 175], ["liver tissue", "TISSUE", 284, 296], ["LCMV", "ORGANISM", 304, 308], ["lipid", "SIMPLE_CHEMICAL", 424, 429], ["amino acid", "AMINO_ACID", 434, 444], ["LCMV", "SPECIES", 304, 308], ["these differential expression changes", "PROBLEM", 8, 45], ["hepatic immune cell infiltration", "PROBLEM", 68, 100], ["Inflammatory-Metabolic Changes in the Liver", "PROBLEM", 132, 175], ["Chronic Infection", "PROBLEM", 183, 200], ["ResultsOur enrichment analyses", "TEST", 205, 235], ["liver tissue", "PROBLEM", 284, 296], ["LCMV infection", "PROBLEM", 304, 318], ["downregulated metabolic pathways", "PROBLEM", 379, 411], ["lipid and amino acid metabolism", "TREATMENT", 424, 455], ["infection", "PROBLEM", 478, 487], ["differential", "OBSERVATION_MODIFIER", 14, 26], ["expression", "OBSERVATION", 27, 37], ["likely to reflect", "UNCERTAINTY", 50, 67], ["hepatic", "ANATOMY", 68, 75], ["immune cell infiltration", "OBSERVATION", 76, 100], ["Inflammatory", "OBSERVATION", 132, 144], ["Metabolic Changes", "OBSERVATION", 145, 162], ["Liver", "ANATOMY", 170, 175], ["Chronic", "OBSERVATION_MODIFIER", 183, 190], ["Infection", "OBSERVATION", 191, 200], ["widespread", "OBSERVATION_MODIFIER", 246, 256], ["metabolic reprogramming", "OBSERVATION", 257, 280], ["liver", "ANATOMY", 284, 289], ["LCMV", "OBSERVATION_MODIFIER", 304, 308], ["infection", "OBSERVATION", 309, 318], ["infection", "OBSERVATION", 478, 487]]], ["This is in line with our recent study about the modulation of circulating lipids during acute LCMV infection (Kosack et al., 2017).", [["LCMV infection", "DISEASE", 94, 108], ["lipids", "SIMPLE_CHEMICAL", 74, 80], ["LCMV", "ORGANISM", 94, 98], ["LCMV", "SPECIES", 94, 98], ["our recent study", "TEST", 21, 37], ["circulating lipids", "TREATMENT", 62, 80], ["acute LCMV infection", "PROBLEM", 88, 108], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["LCMV infection", "OBSERVATION", 94, 108]]], ["For an in-depth integration of these metabolic changes, we performed enrichment analyses of the union of differentially regulated transcripts and proteins at each stage of viral infection on Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways.", [["viral infection", "DISEASE", 172, 187], ["these metabolic changes", "PROBLEM", 31, 54], ["enrichment analyses", "TEST", 69, 88], ["viral infection", "PROBLEM", 172, 187], ["Genes and Genomes (KEGG) metabolic pathways", "PROBLEM", 213, 256], ["metabolic changes", "OBSERVATION", 37, 54], ["viral infection", "OBSERVATION", 172, 187]]], ["We identified global reprogramming of processes related to all the major classes of metabolites.", [["global reprogramming of processes", "PROBLEM", 14, 47], ["global reprogramming", "OBSERVATION", 14, 34], ["metabolites", "OBSERVATION_MODIFIER", 84, 95]]], ["Modulation of hepatic pathways involving lipids and essential amino acids was initiated on day 2 and peaking on day 8 after infection (Figure 1G; Table S1C).", [["hepatic", "ANATOMY", 14, 21], ["amino acids", "CHEMICAL", 62, 73], ["infection", "DISEASE", 124, 133], ["amino acids", "CHEMICAL", 62, 73], ["hepatic", "MULTI-TISSUE_STRUCTURE", 14, 21], ["lipids", "SIMPLE_CHEMICAL", 41, 47], ["amino acids", "AMINO_ACID", 62, 73], ["Modulation of hepatic pathways", "PROBLEM", 0, 30], ["lipids", "TREATMENT", 41, 47], ["essential amino acids", "TREATMENT", 52, 73], ["infection", "PROBLEM", 124, 133], ["hepatic", "ANATOMY", 14, 21], ["amino acids", "OBSERVATION", 62, 73], ["infection", "OBSERVATION", 124, 133]]], ["Differentially expressed metabolic processes were also found in the chronic and resolving phases of infection, although the number of modulated transcripts and proteins were lower (Figures 1G, S1A, and S1B).Identification of Inflammatory-Metabolic Changes in the Liver during Chronic Infection ::: ResultsTo address the effects of virus-induced alterations on the metabolic output of the liver, we performed targeted metabolomics of serum, focusing on amino acids, biogenic amines, sphingolipids, acylcarnitines, and glycerophospholipids.", [["Liver", "ANATOMY", 263, 268], ["liver", "ANATOMY", 388, 393], ["serum", "ANATOMY", 433, 438], ["infection", "DISEASE", 100, 109], ["amino acids", "CHEMICAL", 452, 463], ["amines", "CHEMICAL", 474, 480], ["acylcarnitines", "CHEMICAL", 497, 511], ["glycerophospholipids", "CHEMICAL", 517, 537], ["amino acids", "CHEMICAL", 452, 463], ["biogenic amines", "CHEMICAL", 465, 480], ["sphingolipids", "CHEMICAL", 482, 495], ["acylcarnitines", "CHEMICAL", 497, 511], ["glycerophospholipids", "CHEMICAL", 517, 537], ["S1A", "GENE_OR_GENE_PRODUCT", 193, 196], ["S1B", "GENE_OR_GENE_PRODUCT", 202, 205], ["Liver", "ORGAN", 263, 268], ["liver", "ORGAN", 388, 393], ["serum", "ORGANISM_SUBSTANCE", 433, 438], ["amino acids", "AMINO_ACID", 452, 463], ["biogenic amines", "SIMPLE_CHEMICAL", 465, 480], ["sphingolipids", "SIMPLE_CHEMICAL", 482, 495], ["acylcarnitines", "SIMPLE_CHEMICAL", 497, 511], ["glycerophospholipids", "SIMPLE_CHEMICAL", 517, 537], ["S1A", "PROTEIN", 193, 196], ["S1B", "PROTEIN", 202, 205], ["infection", "PROBLEM", 100, 109], ["proteins", "TEST", 160, 168], ["Figures", "TEST", 181, 188], ["Inflammatory-Metabolic Changes in the Liver", "PROBLEM", 225, 268], ["Chronic Infection", "PROBLEM", 276, 293], ["virus", "PROBLEM", 331, 336], ["induced alterations", "PROBLEM", 337, 356], ["the metabolic output", "TEST", 360, 380], ["serum", "TEST", 433, 438], ["amino acids", "TEST", 452, 463], ["biogenic amines", "TREATMENT", 465, 480], ["sphingolipids", "TREATMENT", 482, 495], ["acylcarnitines", "TREATMENT", 497, 511], ["glycerophospholipids", "TREATMENT", 517, 537], ["metabolic processes", "OBSERVATION", 25, 44], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["resolving", "OBSERVATION_MODIFIER", 80, 89], ["phases", "OBSERVATION_MODIFIER", 90, 96], ["infection", "OBSERVATION", 100, 109], ["Inflammatory", "OBSERVATION", 225, 237], ["Metabolic Changes", "OBSERVATION", 238, 255], ["Liver", "ANATOMY", 263, 268], ["Chronic", "OBSERVATION_MODIFIER", 276, 283], ["Infection", "OBSERVATION", 284, 293], ["metabolic output", "OBSERVATION", 364, 380], ["liver", "ANATOMY", 388, 393]]], ["Downregulation of metabolites on day 2 (Figure S1E) was observed for glycerophospholipids and sphingolipids (Figure 1H; clusters 1 and 3) although acylcarnitines (Figure 1H; cluster 4) were rather upregulated on day 8 after infection (Figure 1H).", [["acylcarnitines", "CHEMICAL", 147, 161], ["infection", "DISEASE", 224, 233], ["glycerophospholipids", "CHEMICAL", 69, 89], ["sphingolipids", "CHEMICAL", 94, 107], ["acylcarnitines", "CHEMICAL", 147, 161], ["1H", "CHEMICAL", 170, 172], ["glycerophospholipids", "SIMPLE_CHEMICAL", 69, 89], ["sphingolipids", "SIMPLE_CHEMICAL", 94, 107], ["acylcarnitines", "SIMPLE_CHEMICAL", 147, 161], ["Downregulation of metabolites", "PROBLEM", 0, 29], ["glycerophospholipids", "TREATMENT", 69, 89], ["sphingolipids", "TEST", 94, 107], ["Figure 1H", "TEST", 109, 118], ["clusters", "TEST", 120, 128], ["acylcarnitines", "TEST", 147, 161], ["infection", "PROBLEM", 224, 233], ["metabolites", "OBSERVATION_MODIFIER", 18, 29]]], ["Systemic amino acids and biogenic amines exhibited a sustained decline from day 2 to day 8 and gradually recovered in the later phases of infection (Figure 1H; cluster 2).", [["amino acids", "CHEMICAL", 9, 20], ["amines", "CHEMICAL", 34, 40], ["infection", "DISEASE", 138, 147], ["amino acids", "CHEMICAL", 9, 20], ["biogenic amines", "CHEMICAL", 25, 40], ["Systemic", "SIMPLE_CHEMICAL", 0, 8], ["amino acids", "AMINO_ACID", 9, 20], ["biogenic amines", "SIMPLE_CHEMICAL", 25, 40], ["Systemic amino acids", "TEST", 0, 20], ["biogenic amines", "TEST", 25, 40], ["a sustained decline", "PROBLEM", 51, 70], ["infection", "PROBLEM", 138, 147], ["amino acids", "OBSERVATION", 9, 20], ["sustained", "OBSERVATION_MODIFIER", 53, 62], ["decline", "OBSERVATION", 63, 70], ["infection", "OBSERVATION", 138, 147]]], ["This affected almost exclusively essential and semi-essential proteinogenic amino acids (His, Ile, Leu, Met, Trp, Val, and Arg; Figure 1H) and coincided with transcriptional regulation of amino-acid-related metabolic pathways on day 8 (Figures 1F\u20131H and S1F; Table S1C).", [["amino acids", "CHEMICAL", 76, 87], ["amino-acid", "CHEMICAL", 188, 198], ["amino acids", "CHEMICAL", 76, 87], ["His", "CHEMICAL", 89, 92], ["Ile", "CHEMICAL", 94, 97], ["Leu", "CHEMICAL", 99, 102], ["Met", "CHEMICAL", 104, 107], ["Trp", "CHEMICAL", 109, 112], ["Val", "CHEMICAL", 114, 117], ["Arg", "CHEMICAL", 123, 126], ["1H", "CHEMICAL", 135, 137], ["amino-acid", "CHEMICAL", 188, 198], ["amino acids", "AMINO_ACID", 76, 87], ["Ile", "AMINO_ACID", 94, 97], ["Leu", "AMINO_ACID", 99, 102], ["Met", "GENE_OR_GENE_PRODUCT", 104, 107], ["Trp", "AMINO_ACID", 109, 112], ["Val", "AMINO_ACID", 114, 117], ["Arg", "AMINO_ACID", 123, 126], ["amino-acid", "AMINO_ACID", 188, 198], ["S1F; Table S1C", "GENE_OR_GENE_PRODUCT", 254, 268], ["S1F", "PROTEIN", 254, 257], ["semi-essential proteinogenic amino acids", "TEST", 47, 87], ["Leu", "TEST", 99, 102], ["Trp", "TEST", 109, 112], ["amino-acid", "TREATMENT", 188, 198], ["Figures", "TEST", 236, 243]]], ["Together, our integrated transcriptomic and proteomic analysis linked changes in the liver with altered systemic metabolite levels during chronic viral infection.Reduced Food Intake during Viral Infection Mildly Affects Gene Expression in the Liver ::: ResultsMice infected with LCMV strain clone 13 develop infection-associated cachexia (Baazim et al., 2019) and display reduced food intake (Figure S2A).", [["liver", "ANATOMY", 85, 90], ["Liver", "ANATOMY", 243, 248], ["cachexia", "ANATOMY", 329, 337], ["chronic viral infection", "DISEASE", 138, 161], ["infection", "DISEASE", 308, 317], ["cachexia", "DISEASE", 329, 337], ["liver", "ORGAN", 85, 90], ["Liver", "ORGAN", 243, 248], ["LCMV strain clone 13", "ORGANISM", 279, 299], ["cachexia", "CANCER", 329, 337], ["proteomic analysis", "TEST", 44, 62], ["changes in the liver", "PROBLEM", 70, 90], ["altered systemic metabolite levels", "PROBLEM", 96, 130], ["chronic viral infection", "PROBLEM", 138, 161], ["Viral Infection", "PROBLEM", 189, 204], ["LCMV strain clone", "PROBLEM", 279, 296], ["infection", "PROBLEM", 308, 317], ["associated cachexia", "PROBLEM", 318, 337], ["liver", "ANATOMY", 85, 90], ["altered", "OBSERVATION_MODIFIER", 96, 103], ["systemic", "OBSERVATION_MODIFIER", 104, 112], ["metabolite levels", "OBSERVATION", 113, 130], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["infection", "OBSERVATION", 152, 161], ["Food Intake", "OBSERVATION", 170, 181], ["Viral", "OBSERVATION_MODIFIER", 189, 194], ["Infection", "OBSERVATION", 195, 204], ["Liver", "ANATOMY", 243, 248], ["LCMV", "OBSERVATION", 279, 283], ["cachexia", "OBSERVATION", 329, 337]]], ["We therefore performed a pair-feeding experiment to investigate the impact of infection-associated changes in food uptake to the metabolic reprogramming of the liver 8 days after infection.", [["liver", "ANATOMY", 160, 165], ["infection", "DISEASE", 78, 87], ["infection", "DISEASE", 179, 188], ["liver", "ORGAN", 160, 165], ["a pair-feeding experiment", "TREATMENT", 23, 48], ["infection", "PROBLEM", 78, 87], ["associated changes in food uptake", "PROBLEM", 88, 121], ["infection", "PROBLEM", 179, 188], ["infection", "OBSERVATION", 78, 87], ["food uptake", "OBSERVATION", 110, 121], ["metabolic reprogramming", "OBSERVATION", 129, 152], ["liver", "ANATOMY", 160, 165], ["infection", "OBSERVATION", 179, 188]]], ["Uninfected mice received restricted amounts of food equivalent to the amounts consumed by infected mice.", [["mice", "ORGANISM", 11, 15], ["mice", "ORGANISM", 99, 103], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 99, 103]]], ["Subsequently, we collected liver tissue of infected, pair-fed, and naive animals and performed transcriptome analyses.", [["liver tissue", "ANATOMY", 27, 39], ["liver tissue", "TISSUE", 27, 39], ["transcriptome analyses", "TEST", 95, 117], ["liver", "ANATOMY", 27, 32], ["infected", "OBSERVATION", 43, 51]]], ["These results indicated that most of the observed transcriptional changes were linked to viral infection and independent of anorexic behavior (Figures 2A, S2B, and S2C).", [["viral infection", "DISEASE", 89, 104], ["anorexic behavior", "DISEASE", 124, 141], ["the observed transcriptional changes", "PROBLEM", 37, 73], ["viral infection", "PROBLEM", 89, 104], ["anorexic behavior", "PROBLEM", 124, 141], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["infection", "OBSERVATION", 95, 104]]], ["Uninfected pair-fed mice showed only minor differential gene expression changes that pertained mainly to lipid metabolism (Figures 2B and 2C; Table S4).", [["mice", "ORGANISM", 20, 24], ["lipid", "SIMPLE_CHEMICAL", 105, 110], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["minor differential gene expression changes", "PROBLEM", 37, 79], ["lipid metabolism", "TEST", 105, 121], ["minor differential", "OBSERVATION_MODIFIER", 37, 55], ["gene expression", "OBSERVATION", 56, 71]]], ["Together, these experiments demonstrated that the majority of the observed virus-induced metabolic changes in the liver, including amino-acid-related pathways, correlated with the infection status of the mice and were independent of altered food intake (Figures 1H and 2D).IFN-I Signaling Reprograms Hepatic Metabolism ::: ResultsThe observed changes of hepatic amino acid metabolism became noticeable as early as 2 days, which coincides with peak serum levels of IFN-\u03b1 and IFN-\u03b2 in mice infected with LCMV (Bhattacharya et al., 2015).", [["liver", "ANATOMY", 114, 119], ["Hepatic", "ANATOMY", 300, 307], ["hepatic", "ANATOMY", 354, 361], ["serum", "ANATOMY", 448, 453], ["infection", "DISEASE", 180, 189], ["amino acid", "CHEMICAL", 362, 372], ["amino-acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 362, 372], ["liver", "ORGAN", 114, 119], ["mice", "ORGANISM", 204, 208], ["IFN-I", "GENE_OR_GENE_PRODUCT", 273, 278], ["hepatic", "MULTI-TISSUE_STRUCTURE", 354, 361], ["amino acid", "AMINO_ACID", 362, 372], ["serum", "ORGANISM_SUBSTANCE", 448, 453], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 464, 469], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 474, 479], ["mice", "ORGANISM", 483, 487], ["LCMV", "ORGANISM", 502, 506], ["IFN", "PROTEIN", 273, 276], ["IFN", "PROTEIN", 464, 467], ["IFN-\u03b2", "PROTEIN", 474, 479], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 483, 487], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 483, 487], ["LCMV", "SPECIES", 502, 506], ["the observed virus", "PROBLEM", 62, 80], ["metabolic changes in the liver", "PROBLEM", 89, 119], ["amino-acid-related pathways", "PROBLEM", 131, 158], ["the infection", "PROBLEM", 176, 189], ["hepatic amino acid metabolism", "PROBLEM", 354, 383], ["peak serum levels", "TEST", 443, 460], ["IFN", "TEST", 464, 467], ["IFN", "TEST", 474, 477], ["virus", "OBSERVATION", 75, 80], ["metabolic changes", "OBSERVATION", 89, 106], ["liver", "ANATOMY", 114, 119], ["infection", "OBSERVATION", 180, 189], ["Hepatic", "ANATOMY", 300, 307], ["hepatic", "ANATOMY", 354, 361], ["amino acid metabolism", "OBSERVATION", 362, 383], ["LCMV", "OBSERVATION", 502, 506]]], ["Thus, we aimed to dissect a potential role of early IFN-I signaling in the observed changes in the liver.", [["liver", "ANATOMY", 99, 104], ["IFN-I", "GENE_OR_GENE_PRODUCT", 52, 57], ["liver", "ORGAN", 99, 104], ["IFN", "PROTEIN", 52, 55], ["the observed changes in the liver", "PROBLEM", 71, 104], ["liver", "ANATOMY", 99, 104]]], ["To measure the impact of IFN-I signaling on liver parenchyma, we performed an extracellular metabolic flux analysis of primary murine hepatocytes upon stimulation with IFN-\u03b2 in vitro.", [["liver parenchyma", "ANATOMY", 44, 60], ["extracellular", "ANATOMY", 78, 91], ["hepatocytes", "ANATOMY", 134, 145], ["IFN-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 44, 60], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["murine", "ORGANISM", 127, 133], ["hepatocytes", "CELL", 134, 145], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 168, 173], ["IFN", "PROTEIN", 25, 28], ["primary murine hepatocytes", "CELL_TYPE", 119, 145], ["IFN", "PROTEIN", 168, 171], ["\u03b2", "PROTEIN", 172, 173], ["murine", "SPECIES", 127, 133], ["an extracellular metabolic flux analysis", "TEST", 75, 115], ["primary murine hepatocytes", "PROBLEM", 119, 145], ["IFN", "TREATMENT", 168, 171], ["liver", "ANATOMY", 44, 49], ["parenchyma", "ANATOMY_MODIFIER", 50, 60], ["metabolic flux", "OBSERVATION", 92, 106], ["primary murine hepatocytes", "OBSERVATION", 119, 145]]], ["IFN-\u03b2 affected proxies for mitochondrial respiration and glycolysis in an IFNAR1-dependent manner (Figures 3A and 3B), indicating that IFN-I signaling affects metabolism of hepatocytes.", [["mitochondrial", "ANATOMY", 27, 40], ["hepatocytes", "ANATOMY", 173, 184], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 27, 40], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 74, 80], ["IFN-I", "GENE_OR_GENE_PRODUCT", 135, 140], ["hepatocytes", "CELL", 173, 184], ["IFN", "PROTEIN", 0, 3], ["\u03b2", "PROTEIN", 4, 5], ["IFNAR1", "PROTEIN", 74, 80], ["IFN", "PROTEIN", 135, 138], ["hepatocytes", "CELL_TYPE", 173, 184], ["affected proxies", "PROBLEM", 6, 22], ["mitochondrial respiration", "PROBLEM", 27, 52], ["glycolysis", "TEST", 57, 67], ["IFN-I signaling affects metabolism of hepatocytes", "PROBLEM", 135, 184], ["hepatocytes", "ANATOMY", 173, 184]]], ["To deconvolute tissue heterogeneity in vivo and to assess the contribution of IFN-I signaling to metabolic reprogramming in the liver, we took advantage of a genetic model of hepatocyte-specific ablation of Ifnar1 (Alb-Cre ERT2 Ifnar1fl/fl [Ifnar1\u0394/\u0394]) and respective littermate controls (Alb-Cre ERT2 Ifnar1+/+ [Ifnar1+/+]).", [["tissue", "ANATOMY", 15, 21], ["liver", "ANATOMY", 128, 133], ["hepatocyte", "ANATOMY", 175, 185], ["tissue", "TISSUE", 15, 21], ["IFN-I", "GENE_OR_GENE_PRODUCT", 78, 83], ["liver", "ORGAN", 128, 133], ["hepatocyte", "CELL", 175, 185], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 207, 213], ["Alb-Cre ERT2 Ifnar1fl/fl", "GENE_OR_GENE_PRODUCT", 215, 239], ["Alb-Cre ERT2 Ifnar1", "GENE_OR_GENE_PRODUCT", 289, 308], ["IFN", "PROTEIN", 78, 81], ["Ifnar1", "PROTEIN", 207, 213], ["Alb", "PROTEIN", 215, 218], ["Cre ERT2", "PROTEIN", 219, 227], ["Ifnar1fl", "PROTEIN", 228, 236], ["fl", "PROTEIN", 237, 239], ["Ifnar1\u0394", "PROTEIN", 241, 248], ["Alb", "PROTEIN", 289, 292], ["Cre ERT2", "PROTEIN", 293, 301], ["Ifnar1", "PROTEIN", 302, 308], ["Ifnar1", "PROTEIN", 313, 319], ["IFN", "PROBLEM", 78, 81], ["Ifnar1", "TEST", 207, 213], ["Alb", "TEST", 215, 218], ["Cre", "TEST", 219, 222], ["ERT2", "TEST", 223, 227], ["Ifnar1fl", "TEST", 228, 236], ["fl", "TEST", 237, 239], ["Ifnar1\u0394", "TEST", 241, 248], ["Alb", "TEST", 289, 292], ["Cre ERT2", "TEST", 293, 301], ["Ifnar1", "TEST", 302, 308], ["Ifnar1", "PROBLEM", 313, 319], ["liver", "ANATOMY", 128, 133], ["hepatocyte", "ANATOMY", 175, 185]]], ["These mice did not reveal any genotype-specific differences in viremia or serum concentration of IFN-\u03b1 1.5 days after infection (Figures S3A\u2013S3C), suggesting that any potential differences seen in expression profiling of liver tissue from Ifnar1\u0394/\u0394 versus Ifnar1+/+ mice is unlikely to be due to altered viral loads and/or systemic IFN-I responses.", [["serum", "ANATOMY", 74, 79], ["liver tissue", "ANATOMY", 221, 233], ["viremia", "DISEASE", 63, 70], ["infection", "DISEASE", 118, 127], ["mice", "ORGANISM", 6, 10], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 97, 102], ["liver tissue", "TISSUE", 221, 233], ["Ifnar1\u0394", "GENE_OR_GENE_PRODUCT", 239, 246], ["\u0394", "GENE_OR_GENE_PRODUCT", 247, 248], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 256, 262], ["IFN-I", "GENE_OR_GENE_PRODUCT", 332, 337], ["IFN", "PROTEIN", 97, 100], ["Ifnar1", "PROTEIN", 256, 262], ["IFN", "PROTEIN", 332, 335], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 266, 270], ["mice", "SPECIES", 6, 10], ["viremia", "PROBLEM", 63, 70], ["serum concentration", "TEST", 74, 93], ["IFN", "TEST", 97, 100], ["infection", "PROBLEM", 118, 127], ["liver tissue", "PROBLEM", 221, 233], ["Ifnar1\u0394", "TEST", 239, 246], ["\u0394", "PROBLEM", 247, 248], ["Ifnar1", "PROBLEM", 256, 262], ["mice", "PROBLEM", 266, 270], ["altered viral loads", "PROBLEM", 296, 315], ["viremia", "OBSERVATION", 63, 70], ["liver", "ANATOMY", 221, 226], ["viral loads", "OBSERVATION", 304, 315]]], ["Moreover, naive and infected Ifnar1\u0394/\u0394 versus Ifnar1+/+ animals displayed comparable abundances of immune-cell-related transcripts, suggesting only minor differences of immune cell infiltration between the genotypes at this early time point after infection (Figure S3D).", [["immune-cell", "ANATOMY", 99, 110], ["immune cell", "ANATOMY", 169, 180], ["infection", "DISEASE", 247, 256], ["Ifnar1\u0394", "GENE_OR_GENE_PRODUCT", 29, 36], ["\u0394", "GENE_OR_GENE_PRODUCT", 37, 38], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 46, 52], ["immune-cell", "CELL", 99, 110], ["immune cell", "CELL", 169, 180], ["Ifnar1", "PROTEIN", 46, 52], ["naive and infected Ifnar1\u0394/\u0394", "PROBLEM", 10, 38], ["Ifnar1", "TEST", 46, 52], ["animals", "PROBLEM", 56, 63], ["immune cell infiltration", "PROBLEM", 169, 193], ["the genotypes", "PROBLEM", 202, 215], ["infection", "PROBLEM", 247, 256], ["infected", "OBSERVATION_MODIFIER", 20, 28], ["cell", "OBSERVATION", 106, 110], ["minor", "OBSERVATION_MODIFIER", 148, 153], ["immune cell infiltration", "OBSERVATION", 169, 193], ["infection", "OBSERVATION", 247, 256]]], ["Next, we analyzed transcriptomic changes of liver tissue taken from uninfected and infected mice of either genotype at the peak of serum IFN-\u03b1 levels and employed a limma (2 \u00d7 2 factorial) interaction model.", [["liver tissue", "ANATOMY", 44, 56], ["serum", "ANATOMY", 131, 136], ["liver tissue", "TISSUE", 44, 56], ["mice", "ORGANISM", 92, 96], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 137, 142], ["IFN", "PROTEIN", 137, 140], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["liver tissue", "PROBLEM", 44, 56], ["serum IFN", "TEST", 131, 140], ["liver", "ANATOMY", 44, 49], ["infected", "OBSERVATION_MODIFIER", 83, 91]]], ["This resulted in a set of 526 hepatocyte-intrinsic IFNAR1-regulated genes, which were found to be associated with both classical ISG responses as well as metabolic processes (Figures 3C, 3D, and S3E; Table S5A).", [["hepatocyte", "ANATOMY", 30, 40], ["hepatocyte", "CELL", 30, 40], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 51, 57], ["Table S5A", "GENE_OR_GENE_PRODUCT", 200, 209], ["IFNAR1", "PROTEIN", 51, 57], ["hepatocyte", "TEST", 30, 40], ["regulated genes", "OBSERVATION", 58, 73], ["ISG", "OBSERVATION", 129, 132]]], ["The regulated genes could be divided into two major classes\u2014IFNAR1-stimulated (cluster 1) and IFNAR1-repressed (cluster 2) genes (Figure 3C; Table S5B).", [["IFNAR1-stimulated (cluster 1", "GENE_OR_GENE_PRODUCT", 60, 88], ["IFNAR1-repressed (cluster 2", "GENE_OR_GENE_PRODUCT", 94, 121], ["Table S5B", "GENE_OR_GENE_PRODUCT", 141, 150], ["regulated genes", "DNA", 4, 19], ["IFNAR1", "PROTEIN", 60, 66], ["IFNAR1-repressed (cluster 2) genes", "DNA", 94, 128], ["Figure 3C", "DNA", 130, 139], ["Table S5B", "DNA", 141, 150], ["IFNAR1", "PROBLEM", 94, 100]]], ["The majority of induced genes were well-known classical ISGs encoding for antiviral effectors (cluster 1; Figure 3D; Table S5C; Schoggins et al., 2011).", [["induced genes", "DNA", 16, 29], ["ISGs", "DNA", 56, 60], ["antiviral effectors", "PROTEIN", 74, 93], ["antiviral effectors", "TREATMENT", 74, 93]]], ["Interferon-repressed genes (IRGs), which are not that well characterized (Mostafavi et al., 2016, Schoggins et al., 2011), were found to be strongly enriched for metabolism-associated processes (cluster 2; Figure 3D; Table S5C).", [["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["IRGs", "GENE_OR_GENE_PRODUCT", 28, 32], ["Interferon-repressed genes", "DNA", 0, 26], ["IRGs", "DNA", 28, 32], ["Interferon", "TREATMENT", 0, 10]]], ["In addition, clusters 3 and 4 contained genes whose maintained expression depended on intact IFNAR1 signaling and were also associated with metabolic processes (Figure 3D; Table S5C).", [["4", "GENE_OR_GENE_PRODUCT", 28, 29], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 93, 99], ["IFNAR1", "PROTEIN", 93, 99]]], ["Hepatocyte-intrinsic IFNAR1 signaling mainly regulated metabolic genes on day 2 after infection.", [["Hepatocyte", "ANATOMY", 0, 10], ["infection", "DISEASE", 86, 95], ["Hepatocyte", "GENE_OR_GENE_PRODUCT", 0, 10], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 21, 27], ["IFNAR1", "PROTEIN", 21, 27], ["metabolic genes", "DNA", 55, 70], ["Hepatocyte", "TEST", 0, 10], ["intrinsic IFNAR1 signaling", "PROBLEM", 11, 37], ["infection", "PROBLEM", 86, 95], ["intrinsic IFNAR1", "OBSERVATION", 11, 27], ["metabolic genes", "OBSERVATION", 55, 70], ["infection", "OBSERVATION", 86, 95]]], ["Notably, a bioinformatic intersection with our longitudinal data obtained from chronically infected wild-type mice suggested that the IFN-I-dependent regulation of many of these genes is maintained beyond these early time points (Figure 3E).", [["mice", "ORGANISM", 110, 114], ["IFN-I", "GENE_OR_GENE_PRODUCT", 134, 139], ["IFN-I", "PROTEIN", 134, 139], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["a bioinformatic intersection", "TEST", 9, 37], ["our longitudinal data", "TEST", 43, 64], ["the IFN", "TREATMENT", 130, 137]]], ["Specifically, virus-induced gene regulation of amino-acid-related pathways (Figure 1) was driven by hepatocyte-intrinsic IFNAR1 signaling (Figure 3E) and corresponded with the differentially regulated metabolites observed in infected wild-type mice (Figure 1H).", [["hepatocyte", "ANATOMY", 100, 110], ["amino-acid", "CHEMICAL", 47, 57], ["amino-acid", "CHEMICAL", 47, 57], ["amino-acid", "AMINO_ACID", 47, 57], ["hepatocyte", "CELL", 100, 110], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 121, 127], ["mice", "ORGANISM", 244, 248], ["IFNAR1", "PROTEIN", 121, 127], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 244, 248], ["virus", "PROBLEM", 14, 19], ["amino-acid", "TEST", 47, 57], ["hepatocyte", "TEST", 100, 110], ["the differentially regulated metabolites", "PROBLEM", 172, 212], ["hepatocyte", "ANATOMY", 100, 110], ["metabolites", "OBSERVATION_MODIFIER", 201, 212], ["infected", "OBSERVATION_MODIFIER", 225, 233]]], ["To investigate whether these metabolic changes depended on hepatocyte-intrinsic IFNAR1 signaling, we performed metabolomics and found that systemic serum levels were indeed regulated by local IFNAR1 signaling of hepatocytes (Figure S3F).", [["hepatocyte", "ANATOMY", 59, 69], ["serum", "ANATOMY", 148, 153], ["hepatocytes", "ANATOMY", 212, 223], ["hepatocyte", "CELL", 59, 69], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 80, 86], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 192, 198], ["hepatocytes", "CELL", 212, 223], ["IFNAR1", "PROTEIN", 80, 86], ["IFNAR1", "PROTEIN", 192, 198], ["hepatocytes", "CELL_TYPE", 212, 223], ["these metabolic changes", "PROBLEM", 23, 46], ["metabolomics", "TEST", 111, 123], ["systemic serum levels", "TEST", 139, 160], ["hepatocytes", "ANATOMY", 212, 223]]], ["In a more stringent analysis using the limma (2 \u00d7 2 factorial) interaction model, we found 15 serum metabolites to be regulated by hepatocyte-intrinsic IFNAR1 signaling, including the semi-essential amino acid arginine and its downstream metabolite ornithine (Figure 3F).", [["serum", "ANATOMY", 94, 99], ["hepatocyte", "ANATOMY", 131, 141], ["amino acid arginine", "CHEMICAL", 199, 218], ["ornithine", "CHEMICAL", 249, 258], ["amino acid", "CHEMICAL", 199, 209], ["arginine", "CHEMICAL", 210, 218], ["ornithine", "CHEMICAL", 249, 258], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["hepatocyte", "CELL", 131, 141], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 152, 158], ["amino acid", "AMINO_ACID", 199, 209], ["arginine", "AMINO_ACID", 210, 218], ["ornithine", "SIMPLE_CHEMICAL", 249, 258], ["IFNAR1", "PROTEIN", 152, 158], ["the limma", "TEST", 35, 44], ["interaction model", "TEST", 63, 80], ["serum metabolites", "TEST", 94, 111], ["hepatocyte", "TEST", 131, 141], ["intrinsic IFNAR1 signaling", "PROBLEM", 142, 168], ["the semi-essential amino acid arginine", "TREATMENT", 180, 218], ["hepatocyte", "ANATOMY", 131, 141], ["IFNAR1 signaling", "OBSERVATION", 152, 168]]], ["In summary, our data indicate that hepatocyte-intrinsic IFNAR1 signaling acts as a transcriptional regulator of liver metabolism and results in changes of circulating metabolites during infection.Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsArginine and ornithine are both key metabolites of the urea cycle.", [["hepatocyte", "ANATOMY", 35, 45], ["liver", "ANATOMY", 112, 117], ["Hepatocyte", "ANATOMY", 196, 206], ["infection", "DISEASE", 186, 195], ["ResultsArginine", "CHEMICAL", 260, 275], ["ornithine", "CHEMICAL", 280, 289], ["urea", "CHEMICAL", 322, 326], ["Urea", "CHEMICAL", 245, 249], ["ResultsArginine", "CHEMICAL", 260, 275], ["ornithine", "CHEMICAL", 280, 289], ["urea", "CHEMICAL", 322, 326], ["hepatocyte", "CELL", 35, 45], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 56, 62], ["liver", "ORGAN", 112, 117], ["Hepatocyte", "CELL", 196, 206], ["ResultsArginine", "SIMPLE_CHEMICAL", 260, 275], ["ornithine", "SIMPLE_CHEMICAL", 280, 289], ["urea", "SIMPLE_CHEMICAL", 322, 326], ["IFNAR1", "PROTEIN", 56, 62], ["Ifnar1", "PROTEIN", 217, 223], ["our data", "TEST", 12, 20], ["hepatocyte", "TEST", 35, 45], ["liver metabolism", "PROBLEM", 112, 128], ["circulating metabolites during infection", "PROBLEM", 155, 195], ["Hepatocyte", "TEST", 196, 206], ["ornithine", "TREATMENT", 280, 289], ["hepatocyte", "ANATOMY", 35, 45], ["liver", "ANATOMY", 112, 117], ["circulating metabolites", "OBSERVATION", 155, 178], ["infection", "OBSERVATION", 186, 195], ["Intrinsic Ifnar1", "OBSERVATION", 207, 223], ["Signaling Breaks", "OBSERVATION", 224, 240]]], ["The involved enzymes are encoded by Arg1, Otc, and Ass1, which are primarily expressed in the liver, as well as Asl, which is ubiquitously expressed (Uhl\u00e9n et al., 2015).", [["liver", "ANATOMY", 94, 99], ["Arg1", "GENE_OR_GENE_PRODUCT", 36, 40], ["Otc", "GENE_OR_GENE_PRODUCT", 42, 45], ["Ass1", "GENE_OR_GENE_PRODUCT", 51, 55], ["liver", "ORGAN", 94, 99], ["Asl", "GENE_OR_GENE_PRODUCT", 112, 115], ["Arg1", "PROTEIN", 36, 40], ["Otc", "PROTEIN", 42, 45], ["Ass1", "PROTEIN", 51, 55], ["Asl", "PROTEIN", 112, 115], ["The involved enzymes", "TEST", 0, 20], ["liver", "ANATOMY", 94, 99]]], ["Expression analysis of liver tissue of uninfected and infected Ifnar1\u0394/\u0394 and Ifnar1+/+ mice highlighted that expression of Otc and Ass1 was repressed in a hepatocyte-intrinsic IFNAR1-dependent manner (Figures 4A, S4A, and S4B).", [["liver tissue", "ANATOMY", 23, 35], ["Ifnar1\u0394/\u0394", "ANATOMY", 63, 72], ["hepatocyte", "ANATOMY", 155, 165], ["liver tissue", "TISSUE", 23, 35], ["Ifnar1\u0394/", "ORGANISM", 63, 71], ["\u0394", "GENE_OR_GENE_PRODUCT", 71, 72], ["Ifnar1", "GENE_OR_GENE_PRODUCT", 77, 83], ["Otc", "GENE_OR_GENE_PRODUCT", 123, 126], ["Ass1", "GENE_OR_GENE_PRODUCT", 131, 135], ["hepatocyte", "CELL", 155, 165], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 176, 182], ["S4A", "GENE_OR_GENE_PRODUCT", 213, 216], ["S4B", "GENE_OR_GENE_PRODUCT", 222, 225], ["Ifnar1", "PROTEIN", 77, 83], ["Otc", "PROTEIN", 123, 126], ["Ass1", "PROTEIN", 131, 135], ["IFNAR1", "PROTEIN", 176, 182], ["S4A", "PROTEIN", 213, 216], ["S4B", "PROTEIN", 222, 225], ["mice", "SPECIES", 87, 91], ["Expression analysis", "TEST", 0, 19], ["liver tissue", "PROBLEM", 23, 35], ["Ifnar1", "TEST", 77, 83], ["a hepatocyte", "TEST", 153, 165], ["S4A", "TEST", 213, 216], ["liver", "ANATOMY", 23, 28], ["uninfected", "OBSERVATION", 39, 49], ["hepatocyte", "ANATOMY", 155, 165], ["IFNAR1", "OBSERVATION", 176, 182]]], ["Arg1 was induced, whereas Asl was repressed upon infection, both independent of hepatocyte-intrinsic IFNAR1 signaling (Figure 4A).", [["hepatocyte", "ANATOMY", 80, 90], ["Asl", "CHEMICAL", 26, 29], ["infection", "DISEASE", 49, 58], ["Arg1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Asl", "GENE_OR_GENE_PRODUCT", 26, 29], ["hepatocyte", "CELL", 80, 90], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 101, 107], ["Arg1", "PROTEIN", 0, 4], ["Asl", "PROTEIN", 26, 29], ["IFNAR1", "PROTEIN", 101, 107], ["infection", "PROBLEM", 49, 58], ["infection", "OBSERVATION", 49, 58], ["hepatocyte", "ANATOMY", 80, 90]]], ["These infection-induced transcriptional changes of the urea cycle genes Otc, Ass1, Asl, and Arg1 were maintained on transcriptomic and proteomic level up to 30 days after infection, with the most pronounced effects seen on days 2 and 8 (Figures S4C\u2013S4F).", [["infection", "DISEASE", 6, 15], ["urea", "CHEMICAL", 55, 59], ["infection", "DISEASE", 171, 180], ["urea", "CHEMICAL", 55, 59], ["urea", "SIMPLE_CHEMICAL", 55, 59], ["Otc", "GENE_OR_GENE_PRODUCT", 72, 75], ["Ass1", "GENE_OR_GENE_PRODUCT", 77, 81], ["Asl", "GENE_OR_GENE_PRODUCT", 83, 86], ["Arg1", "GENE_OR_GENE_PRODUCT", 92, 96], ["urea cycle genes", "DNA", 55, 71], ["Otc", "DNA", 72, 75], ["Ass1", "DNA", 77, 81], ["Asl", "DNA", 83, 86], ["Arg1", "DNA", 92, 96], ["These infection", "PROBLEM", 0, 15], ["transcriptional changes", "PROBLEM", 24, 47], ["the urea cycle genes Otc", "PROBLEM", 51, 75], ["proteomic level", "TEST", 135, 150], ["infection", "PROBLEM", 171, 180], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 171, 180], ["most pronounced", "OBSERVATION_MODIFIER", 191, 206]]], ["Of note, the regulation of Otc and Ass1 was independent of food intake (Figure S4G).Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsTo corroborate the hepatocyte-specific origin of the observed reprogramming of the hepatic urea cycle, we performed single-cell RNA-seq (scRNA-seq) of primary murine hepatocytes isolated from naive or LCMV-infected wild-type mice 2 days after infection.", [["Hepatocyte", "ANATOMY", 84, 94], ["hepatocyte", "ANATOMY", 174, 184], ["hepatic", "ANATOMY", 238, 245], ["hepatocytes", "ANATOMY", 321, 332], ["urea", "CHEMICAL", 246, 250], ["infection", "DISEASE", 398, 407], ["Urea", "CHEMICAL", 133, 137], ["urea", "CHEMICAL", 246, 250], ["Otc", "GENE_OR_GENE_PRODUCT", 27, 30], ["Ass1", "GENE_OR_GENE_PRODUCT", 35, 39], ["food", "ORGANISM_SUBDIVISION", 59, 63], ["Hepatocyte", "CELL", 84, 94], ["hepatocyte", "CELL", 174, 184], ["hepatic", "ORGAN", 238, 245], ["urea", "SIMPLE_CHEMICAL", 246, 250], ["murine", "ORGANISM", 314, 320], ["hepatocytes", "CELL", 321, 332], ["LCMV", "ORGANISM", 356, 360], ["mice", "ORGANISM", 380, 384], ["Otc", "PROTEIN", 27, 30], ["Ass1", "PROTEIN", 35, 39], ["Ifnar1", "PROTEIN", 105, 111], ["primary murine hepatocytes", "CELL_TYPE", 306, 332], ["murine", "SPECIES", 314, 320], ["mice", "SPECIES", 380, 384], ["LCMV", "SPECIES", 356, 360], ["mice", "SPECIES", 380, 384], ["Otc", "TREATMENT", 27, 30], ["Hepatocyte", "TEST", 84, 94], ["the hepatic urea cycle", "TEST", 234, 256], ["single-cell RNA", "TEST", 271, 286], ["scRNA", "TEST", 292, 297], ["primary murine hepatocytes", "PROBLEM", 306, 332], ["LCMV", "PROBLEM", 356, 360], ["infection", "PROBLEM", 398, 407], ["Intrinsic Ifnar1", "OBSERVATION", 95, 111], ["Signaling Breaks", "OBSERVATION", 112, 128], ["hepatocyte", "ANATOMY", 174, 184], ["hepatic", "ANATOMY", 238, 245], ["urea cycle", "OBSERVATION", 246, 256], ["infection", "OBSERVATION", 398, 407]]], ["Both samples showed comparable numbers of reads (uninfected: 1,493.5; infected: 1,429.0) and genes (uninfected: 705.5; infected: 761.0) per cell.", [["samples", "ANATOMY", 5, 12], ["cell", "ANATOMY", 140, 144], ["cell", "CELL", 140, 144], ["Both samples", "TEST", 0, 12]]], ["We identified 348 differentially expressed genes in hepatocytes that correlated well with changes observed in bulk liver tissue (Figures 1, S4H, and S4I).", [["hepatocytes", "ANATOMY", 52, 63], ["liver tissue", "ANATOMY", 115, 127], ["hepatocytes", "CELL", 52, 63], ["liver tissue", "TISSUE", 115, 127], ["S4H", "GENE_OR_GENE_PRODUCT", 140, 143], ["hepatocytes", "CELL_TYPE", 52, 63], ["differentially expressed genes in hepatocytes", "PROBLEM", 18, 63], ["Figures", "TEST", 129, 136], ["hepatocytes", "ANATOMY", 52, 63], ["bulk", "ANATOMY_MODIFIER", 110, 114], ["liver", "ANATOMY", 115, 120], ["tissue", "ANATOMY_MODIFIER", 121, 127]]], ["Accordingly, genes induced in hepatocytes were associated with antiviral innate immune responses, whereas repressed genes were vastly associated with metabolic processes (Figures S4J and S4K).", [["hepatocytes", "ANATOMY", 30, 41], ["hepatocytes", "CELL", 30, 41], ["hepatocytes", "CELL_TYPE", 30, 41], ["repressed genes", "DNA", 106, 121], ["genes induced in hepatocytes", "PROBLEM", 13, 41], ["antiviral innate immune responses", "PROBLEM", 63, 96], ["metabolic processes", "PROBLEM", 150, 169], ["hepatocytes", "ANATOMY", 30, 41]]], ["Hepatocytes clustered by the infection status of the mice (Figure 4B), and we confirmed hepatocyte-intrinsic repression of Ass1 and Otc upon infection, which inversely correlated with expression levels of the ISG Ifit1 on the single-cell level (Figures 4C and 4D).", [["Hepatocytes", "ANATOMY", 0, 11], ["hepatocyte", "ANATOMY", 88, 98], ["cell", "ANATOMY", 233, 237], ["infection", "DISEASE", 29, 38], ["infection", "DISEASE", 141, 150], ["Hepatocytes", "CELL", 0, 11], ["mice", "ORGANISM", 53, 57], ["hepatocyte", "CELL", 88, 98], ["Ass1", "GENE_OR_GENE_PRODUCT", 123, 127], ["Otc", "GENE_OR_GENE_PRODUCT", 132, 135], ["ISG Ifit1", "GENE_OR_GENE_PRODUCT", 209, 218], ["cell", "CELL", 233, 237], ["Ass1", "PROTEIN", 123, 127], ["Otc", "PROTEIN", 132, 135], ["ISG Ifit1", "PROTEIN", 209, 218], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["hepatocyte", "TEST", 88, 98], ["Ass1", "PROBLEM", 123, 127], ["Otc upon infection", "PROBLEM", 132, 150], ["expression levels", "TEST", 184, 201], ["infection", "OBSERVATION", 29, 38], ["hepatocyte", "ANATOMY", 88, 98], ["intrinsic repression", "OBSERVATION", 99, 119], ["infection", "OBSERVATION", 141, 150]]], ["Transcriptional repression of Otc and Ass1 manifested in reduced abundance of OTC and ASS1 proteins in hepatocytes as observed by immunohistochemistry on days 2 and 8 after infection (Figures 4E and 4F).", [["hepatocytes", "ANATOMY", 103, 114], ["infection", "DISEASE", 173, 182], ["Otc", "GENE_OR_GENE_PRODUCT", 30, 33], ["Ass1", "GENE_OR_GENE_PRODUCT", 38, 42], ["OTC", "SIMPLE_CHEMICAL", 78, 81], ["ASS1", "GENE_OR_GENE_PRODUCT", 86, 90], ["hepatocytes", "CELL", 103, 114], ["Otc", "PROTEIN", 30, 33], ["Ass1", "PROTEIN", 38, 42], ["OTC", "PROTEIN", 78, 81], ["ASS1 proteins", "PROTEIN", 86, 99], ["hepatocytes", "CELL_TYPE", 103, 114], ["Transcriptional repression of Otc", "PROBLEM", 0, 33], ["Ass1", "TREATMENT", 38, 42], ["reduced abundance of OTC", "PROBLEM", 57, 81], ["ASS1 proteins in hepatocytes", "PROBLEM", 86, 114], ["immunohistochemistry", "TEST", 130, 150], ["infection", "PROBLEM", 173, 182], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["abundance", "OBSERVATION", 65, 74], ["hepatocytes", "ANATOMY", 103, 114], ["infection", "OBSERVATION", 173, 182]]], ["As expected, STAT1, a master regulator of IFNAR1 downstream signaling, was significantly upregulated in hepatocytes (Figures 4E and 4F).", [["hepatocytes", "ANATOMY", 104, 115], ["STAT1", "GENE_OR_GENE_PRODUCT", 13, 18], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 42, 48], ["hepatocytes", "CELL", 104, 115], ["STAT1", "PROTEIN", 13, 18], ["IFNAR1", "PROTEIN", 42, 48], ["hepatocytes", "CELL_TYPE", 104, 115], ["hepatocytes", "ANATOMY", 104, 115]]], ["The modulation of Otc and Ass1 on day 2 and day 8 after infection was confirmed by real-time PCR in sorted hepatocytes (Figure 4G).Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsIn line with this, liver tissue of infected mice exhibited reduced enzymatic activity of OTC and ASS1, which we measured by the abundance of the 13C-labeled reaction products argininosuccinate (ASS1) or citrulline (OTC) after pulsing with 13C-labeled substrates.", [["hepatocytes", "ANATOMY", 107, 118], ["Hepatocyte", "ANATOMY", 131, 141], ["liver tissue", "ANATOMY", 221, 233], ["infection", "DISEASE", 56, 65], ["citrulline", "CHEMICAL", 405, 415], ["OTC", "CHEMICAL", 417, 420], ["Urea", "CHEMICAL", 180, 184], ["13C", "CHEMICAL", 347, 350], ["argininosuccinate", "CHEMICAL", 377, 394], ["citrulline", "CHEMICAL", 405, 415], ["OTC", "CHEMICAL", 417, 420], ["13C", "CHEMICAL", 441, 444], ["Otc", "GENE_OR_GENE_PRODUCT", 18, 21], ["Ass1", "GENE_OR_GENE_PRODUCT", 26, 30], ["hepatocytes", "CELL", 107, 118], ["Hepatocyte", "CELL", 131, 141], ["liver tissue", "TISSUE", 221, 233], ["mice", "ORGANISM", 246, 250], ["OTC", "SIMPLE_CHEMICAL", 291, 294], ["ASS1", "SIMPLE_CHEMICAL", 299, 303], ["13C", "SIMPLE_CHEMICAL", 347, 350], ["argininosuccinate", "SIMPLE_CHEMICAL", 377, 394], ["ASS1", "SIMPLE_CHEMICAL", 396, 400], ["citrulline", "SIMPLE_CHEMICAL", 405, 415], ["OTC", "SIMPLE_CHEMICAL", 417, 420], ["13C", "SIMPLE_CHEMICAL", 441, 444], ["Otc", "PROTEIN", 18, 21], ["Ass1", "PROTEIN", 26, 30], ["sorted hepatocytes", "CELL_TYPE", 100, 118], ["Ifnar1", "PROTEIN", 152, 158], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 246, 250], ["The modulation of Otc", "TREATMENT", 0, 21], ["infection", "PROBLEM", 56, 65], ["real-time PCR", "TEST", 83, 96], ["Hepatocyte", "TEST", 131, 141], ["infected mice", "PROBLEM", 237, 250], ["reduced enzymatic activity of OTC", "PROBLEM", 261, 294], ["the 13C-labeled reaction products", "TREATMENT", 343, 376], ["argininosuccinate (ASS1)", "TREATMENT", 377, 401], ["citrulline (OTC", "TREATMENT", 405, 420], ["13C-labeled substrates", "TREATMENT", 441, 463], ["infection", "OBSERVATION", 56, 65], ["hepatocytes", "ANATOMY", 107, 118], ["Intrinsic Ifnar1", "OBSERVATION", 142, 158], ["Signaling Breaks", "OBSERVATION", 159, 175], ["liver", "ANATOMY", 221, 226], ["infected", "OBSERVATION", 237, 245], ["reduced", "OBSERVATION_MODIFIER", 261, 268], ["enzymatic activity", "OBSERVATION", 269, 287]]], ["Addition of the ASS1-specific inhibitor \u03b1-methyl-DL-aspartic acid (MDLA) abolished production of argininosuccinate and indicated specificity of the assay (Figure S4L).", [["\u03b1-methyl-DL-aspartic acid", "CHEMICAL", 40, 65], ["MDLA", "CHEMICAL", 67, 71], ["\u03b1-methyl-DL-aspartic acid", "CHEMICAL", 40, 65], ["MDLA", "CHEMICAL", 67, 71], ["argininosuccinate", "CHEMICAL", 97, 114], ["ASS1", "GENE_OR_GENE_PRODUCT", 16, 20], ["\u03b1-methyl-DL-aspartic acid", "SIMPLE_CHEMICAL", 40, 65], ["MDLA", "SIMPLE_CHEMICAL", 67, 71], ["argininosuccinate", "SIMPLE_CHEMICAL", 97, 114], ["ASS1", "PROTEIN", 16, 20], ["the ASS1", "TEST", 12, 20], ["aspartic acid (MDLA)", "TREATMENT", 52, 72], ["argininosuccinate", "TREATMENT", 97, 114], ["the assay", "TEST", 144, 153]]], ["In line with the IFNAR1-dependent increase of systemic ornithine levels upon infection (Figure 4A), these data indicate that IFNAR1 represses the degradation of ornithine via OTC in hepatocytes.", [["hepatocytes", "ANATOMY", 182, 193], ["ornithine", "CHEMICAL", 55, 64], ["infection", "DISEASE", 77, 86], ["ornithine", "CHEMICAL", 161, 170], ["ornithine", "CHEMICAL", 55, 64], ["ornithine", "CHEMICAL", 161, 170], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 17, 23], ["ornithine", "SIMPLE_CHEMICAL", 55, 64], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 125, 131], ["ornithine", "SIMPLE_CHEMICAL", 161, 170], ["OTC", "SIMPLE_CHEMICAL", 175, 178], ["hepatocytes", "CELL", 182, 193], ["IFNAR1", "PROTEIN", 17, 23], ["IFNAR1", "PROTEIN", 125, 131], ["hepatocytes", "CELL_TYPE", 182, 193], ["systemic ornithine levels", "TREATMENT", 46, 71], ["infection", "PROBLEM", 77, 86], ["these data", "TEST", 100, 110], ["IFNAR1", "PROBLEM", 125, 131], ["ornithine via OTC in hepatocytes", "TREATMENT", 161, 193], ["dependent", "OBSERVATION_MODIFIER", 24, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["hepatocytes", "ANATOMY", 182, 193]]], ["The downregulation of Asl expression, together with decreased argininosuccinate, is expected to aggravate the infection-induced break in the urea cycle by limiting arginine re-synthesis (Figure 4A).Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsWe confirmed the aforementioned transcriptional changes of the urea cycle and upregulation of Ifit1 in the viral infection model of coronavirus mouse hepatitis virus (MHV) by real-time PCR (Figure S4M).", [["Hepatocyte", "ANATOMY", 198, 208], ["infection", "DISEASE", 110, 119], ["urea", "CHEMICAL", 141, 145], ["arginine", "CHEMICAL", 164, 172], ["urea", "CHEMICAL", 332, 336], ["viral infection", "DISEASE", 376, 391], ["coronavirus mouse hepatitis virus", "DISEASE", 401, 434], ["argininosuccinate", "CHEMICAL", 62, 79], ["urea", "CHEMICAL", 141, 145], ["arginine", "CHEMICAL", 164, 172], ["Urea", "CHEMICAL", 247, 251], ["urea", "CHEMICAL", 332, 336], ["Asl", "GENE_OR_GENE_PRODUCT", 22, 25], ["argininosuccinate", "SIMPLE_CHEMICAL", 62, 79], ["urea", "SIMPLE_CHEMICAL", 141, 145], ["arginine", "SIMPLE_CHEMICAL", 164, 172], ["Hepatocyte", "CELL", 198, 208], ["urea", "SIMPLE_CHEMICAL", 332, 336], ["Ifit1", "GENE_OR_GENE_PRODUCT", 363, 368], ["coronavirus", "ORGANISM", 401, 412], ["mouse hepatitis virus", "ORGANISM", 413, 434], ["MHV", "ORGANISM", 436, 439], ["Asl", "PROTEIN", 22, 25], ["Ifnar1", "PROTEIN", 219, 225], ["Ifit1", "PROTEIN", 363, 368], ["coronavirus", "SPECIES", 401, 412], ["mouse", "SPECIES", 413, 418], ["hepatitis virus", "SPECIES", 419, 434], ["coronavirus mouse hepatitis virus", "SPECIES", 401, 434], ["MHV", "SPECIES", 436, 439], ["Asl expression", "PROBLEM", 22, 36], ["decreased argininosuccinate", "PROBLEM", 52, 79], ["the infection", "PROBLEM", 106, 119], ["break in the urea cycle", "PROBLEM", 128, 151], ["Hepatocyte", "TEST", 198, 208], ["the urea cycle", "TREATMENT", 328, 342], ["upregulation of Ifit1", "PROBLEM", 347, 368], ["the viral infection", "PROBLEM", 372, 391], ["coronavirus mouse hepatitis virus", "PROBLEM", 401, 434], ["downregulation", "OBSERVATION_MODIFIER", 4, 18], ["Asl expression", "OBSERVATION", 22, 36], ["infection", "OBSERVATION", 110, 119], ["Intrinsic Ifnar1", "OBSERVATION", 209, 225], ["Signaling Breaks", "OBSERVATION", 226, 242], ["viral infection", "OBSERVATION", 376, 391], ["coronavirus mouse hepatitis", "OBSERVATION", 401, 428]]], ["To test whether similar responses in the liver are seen in an inflammatory context, we administered the synthetic viral RNA analog and TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)) intraperitoneally to wild-type mice.", [["liver", "ANATOMY", 41, 46], ["polyinosinic-polycytidylic acid", "CHEMICAL", 148, 179], ["poly(I:C", "CHEMICAL", 181, 189], ["polyinosinic-polycytidylic acid", "CHEMICAL", 148, 179], ["poly(I:C)", "CHEMICAL", 181, 190], ["liver", "ORGAN", 41, 46], ["TLR3", "GENE_OR_GENE_PRODUCT", 135, 139], ["polyinosinic-polycytidylic acid", "SIMPLE_CHEMICAL", 148, 179], ["poly(I:C", "SIMPLE_CHEMICAL", 181, 189], ["mice", "ORGANISM", 223, 227], ["TLR3", "PROTEIN", 135, 139], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 223, 227], ["similar responses in the liver", "PROBLEM", 16, 46], ["the synthetic viral RNA analog", "TREATMENT", 100, 130], ["TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)", "TREATMENT", 135, 190], ["liver", "ANATOMY", 41, 46], ["inflammatory", "OBSERVATION", 62, 74]]], ["Poly(I:C) treatment resulted in strong induction of Ifit1 and corroborated the upregulation of Arg1 and downregulation of Otc and Ass1 in liver tissue by real-time PCR (Figure S4N).", [["liver tissue", "ANATOMY", 138, 150], ["Poly(I:C", "CHEMICAL", 0, 8], ["Poly(I:C", "CHEMICAL", 0, 8], ["Poly(I:C", "SIMPLE_CHEMICAL", 0, 8], ["Ifit1", "GENE_OR_GENE_PRODUCT", 52, 57], ["Arg1", "GENE_OR_GENE_PRODUCT", 95, 99], ["Otc", "GENE_OR_GENE_PRODUCT", 122, 125], ["Ass1", "GENE_OR_GENE_PRODUCT", 130, 134], ["liver tissue", "TISSUE", 138, 150], ["Ifit1", "PROTEIN", 52, 57], ["Arg1", "PROTEIN", 95, 99], ["Otc", "PROTEIN", 122, 125], ["Ass1", "PROTEIN", 130, 134], ["treatment", "TREATMENT", 10, 19], ["Arg1", "PROBLEM", 95, 99], ["downregulation of Otc", "TREATMENT", 104, 125], ["Ass1 in liver tissue", "PROBLEM", 130, 150], ["liver", "ANATOMY", 138, 143]]], ["Treatment with 100 ng recombinant IFN-\u03b1 induced an ISG signature in the liver but did not yield reproducible changes of expression of these genes (data not shown), suggesting that interferon signaling is required, but not sufficient to regulate the urea cycle.Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsNext, we aimed to address whether viral infection leads to hyperammonemia, a hallmark parameter of urea cycle deficiency (UCD).", [["liver", "ANATOMY", 72, 77], ["Hepatocyte", "ANATOMY", 260, 270], ["IFN-\u03b1", "CHEMICAL", 34, 39], ["urea", "CHEMICAL", 249, 253], ["viral infection", "DISEASE", 365, 380], ["hyperammonemia", "DISEASE", 390, 404], ["urea", "CHEMICAL", 430, 434], ["UCD", "DISEASE", 453, 456], ["urea", "CHEMICAL", 249, 253], ["Urea", "CHEMICAL", 309, 313], ["urea", "CHEMICAL", 430, 434], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["liver", "ORGAN", 72, 77], ["interferon", "GENE_OR_GENE_PRODUCT", 180, 190], ["urea", "SIMPLE_CHEMICAL", 249, 253], ["Hepatocyte", "CELL", 260, 270], ["urea", "SIMPLE_CHEMICAL", 430, 434], ["IFN", "PROTEIN", 34, 37], ["\u03b1", "PROTEIN", 38, 39], ["interferon", "PROTEIN", 180, 190], ["Ifnar1", "PROTEIN", 281, 287], ["Treatment", "TREATMENT", 0, 9], ["100 ng recombinant IFN", "TREATMENT", 15, 37], ["an ISG signature in the liver", "PROBLEM", 48, 77], ["interferon signaling", "PROBLEM", 180, 200], ["Hepatocyte", "TEST", 260, 270], ["viral infection", "PROBLEM", 365, 380], ["hyperammonemia", "PROBLEM", 390, 404], ["urea cycle deficiency", "PROBLEM", 430, 451], ["liver", "ANATOMY", 72, 77], ["Intrinsic Ifnar1", "OBSERVATION", 271, 287], ["Signaling Breaks", "OBSERVATION", 288, 304], ["infection", "OBSERVATION", 371, 380]]], ["Indeed, blood ammonia levels were significantly increased from 2 up to 8 days after LCMV infection, correlating with downregulation of the ammonia-fixating enzyme Cps1 (Figures 5A and S5A).", [["blood", "ANATOMY", 8, 13], ["ammonia", "CHEMICAL", 14, 21], ["LCMV infection", "DISEASE", 84, 98], ["ammonia", "CHEMICAL", 139, 146], ["ammonia", "CHEMICAL", 14, 21], ["ammonia", "CHEMICAL", 139, 146], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["ammonia", "SIMPLE_CHEMICAL", 14, 21], ["LCMV", "ORGANISM", 84, 88], ["ammonia", "SIMPLE_CHEMICAL", 139, 146], ["Cps1", "GENE_OR_GENE_PRODUCT", 163, 167], ["S5A", "GENE_OR_GENE_PRODUCT", 184, 187], ["ammonia-fixating enzyme", "PROTEIN", 139, 162], ["Cps1", "PROTEIN", 163, 167], ["Figures 5A", "PROTEIN", 169, 179], ["S5A", "PROTEIN", 184, 187], ["LCMV", "SPECIES", 84, 88], ["blood ammonia levels", "TEST", 8, 28], ["LCMV infection", "PROBLEM", 84, 98], ["the ammonia", "TEST", 135, 146], ["infection", "OBSERVATION", 89, 98]]], ["This prompted us to further characterize the observed urea-cycle-related metabolic changes on a systemic level by in vivo tracing of 13C6 heavy-isotope-labeled arginine (Figure 5B).", [["arginine", "CHEMICAL", 160, 168], ["arginine", "CHEMICAL", 160, 168], ["arginine", "SIMPLE_CHEMICAL", 160, 168], ["the observed urea-cycle", "PROBLEM", 41, 64], ["metabolic changes", "PROBLEM", 73, 90], ["a systemic level", "TEST", 94, 110], ["vivo tracing", "TEST", 117, 129], ["metabolic changes", "OBSERVATION", 73, 90]]], ["Liver tissue of infected mice that received a bolus of 13C6 arginine showed increased concentration of labeled ornithine and citrulline (Figure 5C).", [["Liver tissue", "ANATOMY", 0, 12], ["13C6 arginine", "CHEMICAL", 55, 68], ["ornithine", "CHEMICAL", 111, 120], ["citrulline", "CHEMICAL", 125, 135], ["arginine", "CHEMICAL", 60, 68], ["ornithine", "CHEMICAL", 111, 120], ["citrulline", "CHEMICAL", 125, 135], ["Liver tissue", "TISSUE", 0, 12], ["mice", "ORGANISM", 25, 29], ["13C6 arginine", "SIMPLE_CHEMICAL", 55, 68], ["ornithine", "SIMPLE_CHEMICAL", 111, 120], ["citrulline", "SIMPLE_CHEMICAL", 125, 135], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["a bolus of 13C6 arginine", "TREATMENT", 44, 68], ["labeled ornithine", "TREATMENT", 103, 120], ["citrulline (Figure 5C", "TREATMENT", 125, 146], ["infected", "OBSERVATION", 16, 24]]], ["Arginine was not detected in the liver as reported previously (Wu et al., 2009).", [["liver", "ANATOMY", 33, 38], ["Arginine", "CHEMICAL", 0, 8], ["Arginine", "CHEMICAL", 0, 8], ["Arginine", "AMINO_ACID", 0, 8], ["liver", "ORGAN", 33, 38], ["Arginine", "TREATMENT", 0, 8], ["liver", "ANATOMY", 33, 38]]], ["These local metabolic changes in the liver tissue, together with transcriptomic and proteomic changes in hepatocytes highly correlated with changes in systemic metabolism.", [["liver tissue", "ANATOMY", 37, 49], ["hepatocytes", "ANATOMY", 105, 116], ["liver tissue", "TISSUE", 37, 49], ["hepatocytes", "CELL", 105, 116], ["hepatocytes", "CELL_TYPE", 105, 116], ["These local metabolic changes in the liver tissue", "PROBLEM", 0, 49], ["transcriptomic and proteomic changes in hepatocytes", "PROBLEM", 65, 116], ["changes in systemic metabolism", "PROBLEM", 140, 170], ["local", "OBSERVATION_MODIFIER", 6, 11], ["metabolic changes", "OBSERVATION", 12, 29], ["liver", "ANATOMY", 37, 42], ["tissue", "ANATOMY_MODIFIER", 43, 49], ["hepatocytes", "ANATOMY", 105, 116], ["systemic metabolism", "OBSERVATION", 151, 170]]], ["We detected increased 13C6 arginine degradation in the serum (Figure 5D), which is consistent with the induction of Arg1 (Figures 4A and S4C).", [["serum", "ANATOMY", 55, 60], ["13C6 arginine", "CHEMICAL", 22, 35], ["arginine", "CHEMICAL", 27, 35], ["13C6", "SIMPLE_CHEMICAL", 22, 26], ["arginine", "AMINO_ACID", 27, 35], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["Arg1 (Figures 4A", "GENE_OR_GENE_PRODUCT", 116, 132], ["S4C", "GENE_OR_GENE_PRODUCT", 137, 140], ["Arg1", "PROTEIN", 116, 120], ["S4C", "PROTEIN", 137, 140], ["increased 13C6 arginine degradation", "PROBLEM", 12, 47], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["13C6", "OBSERVATION_MODIFIER", 22, 26], ["arginine degradation", "OBSERVATION", 27, 47], ["consistent with", "UNCERTAINTY", 83, 98]]], ["Together with IFNAR1-dependent repression of Otc and Ass1 (Figures 4A\u20134D), this resulted in the systemic accumulation of 13C5 ornithine and 13C5 citrulline, respectively (Figure 5D).", [["13C5 ornithine", "CHEMICAL", 121, 135], ["13C5 citrulline", "CHEMICAL", 140, 155], ["13C5 ornithine", "CHEMICAL", 121, 135], ["13C5 citrulline", "CHEMICAL", 140, 155], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 14, 20], ["Otc", "GENE_OR_GENE_PRODUCT", 45, 48], ["Ass1", "GENE_OR_GENE_PRODUCT", 53, 57], ["Figures 4A\u20134D", "GENE_OR_GENE_PRODUCT", 59, 72], ["13C5", "SIMPLE_CHEMICAL", 121, 125], ["ornithine", "SIMPLE_CHEMICAL", 126, 135], ["13C5 citrulline", "SIMPLE_CHEMICAL", 140, 155], ["IFNAR1", "PROTEIN", 14, 20], ["Otc", "PROTEIN", 45, 48], ["Ass1", "PROTEIN", 53, 57], ["Figures 4A\u20134D", "PROTEIN", 59, 72], ["Otc", "TEST", 45, 48], ["the systemic accumulation", "TEST", 92, 117], ["ornithine and 13C5 citrulline", "TREATMENT", 126, 155], ["dependent", "OBSERVATION_MODIFIER", 21, 30], ["repression", "OBSERVATION_MODIFIER", 31, 41], ["systemic accumulation", "OBSERVATION", 96, 117]]], ["In accordance with increased arginine degradation and decreased ornithine degradation, we detected elevated levels of 13C1-labeled urea in liver tissue (Figure S5B), whereas 13C1-labeled urea was only mildly elevated in the circulation (Figure S5C).", [["liver tissue", "ANATOMY", 139, 151], ["arginine", "CHEMICAL", 29, 37], ["ornithine", "CHEMICAL", 64, 73], ["urea", "CHEMICAL", 131, 135], ["urea", "CHEMICAL", 187, 191], ["arginine", "CHEMICAL", 29, 37], ["ornithine", "CHEMICAL", 64, 73], ["13C1", "CHEMICAL", 118, 122], ["urea", "CHEMICAL", 131, 135], ["13C1", "CHEMICAL", 174, 178], ["urea", "CHEMICAL", 187, 191], ["arginine", "SIMPLE_CHEMICAL", 29, 37], ["ornithine", "SIMPLE_CHEMICAL", 64, 73], ["13C1", "SIMPLE_CHEMICAL", 118, 122], ["urea", "SIMPLE_CHEMICAL", 131, 135], ["liver tissue", "TISSUE", 139, 151], ["13C1", "SIMPLE_CHEMICAL", 174, 178], ["urea", "SIMPLE_CHEMICAL", 187, 191], ["increased arginine degradation", "PROBLEM", 19, 49], ["decreased ornithine degradation", "PROBLEM", 54, 85], ["elevated levels of 13C1-labeled urea in liver tissue", "PROBLEM", 99, 151], ["Figure S5B", "TEST", 153, 163], ["labeled urea", "TEST", 179, 191], ["mildly elevated", "PROBLEM", 201, 216], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["arginine degradation", "OBSERVATION", 29, 49], ["liver tissue", "ANATOMY", 139, 151], ["mildly", "OBSERVATION_MODIFIER", 201, 207], ["elevated", "OBSERVATION", 208, 216], ["circulation", "ANATOMY", 224, 235]]], ["Together with the reduction of 13C5 arginine, the end product of this pathway, these results support the notion that viral infection initiates a break of the hepatic urea cycle as early as 2 days after infection that persists at least until 8 days after infection and alters levels of metabolites in the circulation (Figure S5D).Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle ::: ResultsConsistently, we observed a significant decrease of the arginine-to-ornithine ratio in the serum of mice infected with LCMV as a result of both reduced arginine and increased ornithine levels (Figures 5E and S5E).", [["hepatic", "ANATOMY", 158, 165], ["Hepatocyte", "ANATOMY", 329, 339], ["serum", "ANATOMY", 491, 496], ["13C5 arginine", "CHEMICAL", 31, 44], ["viral infection", "DISEASE", 117, 132], ["urea", "CHEMICAL", 166, 170], ["infection", "DISEASE", 202, 211], ["infection", "DISEASE", 254, 263], ["arginine", "CHEMICAL", 456, 464], ["ornithine", "CHEMICAL", 468, 477], ["arginine", "CHEMICAL", 552, 560], ["ornithine", "CHEMICAL", 575, 584], ["arginine", "CHEMICAL", 36, 44], ["urea", "CHEMICAL", 166, 170], ["Urea", "CHEMICAL", 378, 382], ["arginine", "CHEMICAL", 456, 464], ["ornithine", "CHEMICAL", 468, 477], ["arginine", "CHEMICAL", 552, 560], ["ornithine", "CHEMICAL", 575, 584], ["13C5 arginine", "GENE_OR_GENE_PRODUCT", 31, 44], ["hepatic", "ORGAN", 158, 165], ["urea", "SIMPLE_CHEMICAL", 166, 170], ["Hepatocyte", "CELL", 329, 339], ["arginine", "SIMPLE_CHEMICAL", 456, 464], ["ornithine", "SIMPLE_CHEMICAL", 468, 477], ["serum", "ORGANISM_SUBSTANCE", 491, 496], ["mice", "ORGANISM", 500, 504], ["LCMV", "ORGANISM", 519, 523], ["arginine", "SIMPLE_CHEMICAL", 552, 560], ["ornithine", "SIMPLE_CHEMICAL", 575, 584], ["Ifnar1", "PROTEIN", 350, 356], ["mice", "SPECIES", 500, 504], ["mice", "SPECIES", 500, 504], ["LCMV", "SPECIES", 519, 523], ["the reduction of 13C5 arginine", "TREATMENT", 14, 44], ["viral infection", "PROBLEM", 117, 132], ["the hepatic urea cycle", "TREATMENT", 154, 176], ["infection", "PROBLEM", 202, 211], ["infection", "PROBLEM", 254, 263], ["alters levels of metabolites", "PROBLEM", 268, 296], ["Hepatocyte", "TEST", 329, 339], ["the arginine", "TEST", 452, 464], ["ornithine ratio", "TEST", 468, 483], ["LCMV", "PROBLEM", 519, 523], ["both reduced arginine", "PROBLEM", 539, 560], ["increased ornithine levels", "PROBLEM", 565, 591], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["infection", "OBSERVATION", 123, 132], ["hepatic", "ANATOMY", 158, 165], ["infection", "OBSERVATION", 202, 211], ["circulation", "ANATOMY", 304, 315], ["Intrinsic Ifnar1", "OBSERVATION", 340, 356], ["Signaling Breaks", "OBSERVATION", 357, 373], ["significant", "OBSERVATION_MODIFIER", 428, 439], ["decrease", "OBSERVATION_MODIFIER", 440, 448], ["LCMV", "OBSERVATION", 519, 523], ["reduced", "OBSERVATION_MODIFIER", 544, 551], ["increased", "OBSERVATION_MODIFIER", 565, 574], ["ornithine levels", "OBSERVATION", 575, 591]]], ["Similar changes in serum concentration of arginine and ornithine were seen upon infection with MHV (Figures S5F and S5G).", [["serum", "ANATOMY", 19, 24], ["arginine", "CHEMICAL", 42, 50], ["ornithine", "CHEMICAL", 55, 64], ["infection", "DISEASE", 80, 89], ["arginine", "CHEMICAL", 42, 50], ["ornithine", "CHEMICAL", 55, 64], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["arginine", "SIMPLE_CHEMICAL", 42, 50], ["ornithine", "SIMPLE_CHEMICAL", 55, 64], ["MHV", "SPECIES", 95, 98], ["Similar changes in serum concentration of arginine and ornithine", "PROBLEM", 0, 64], ["infection", "PROBLEM", 80, 89], ["serum concentration", "OBSERVATION_MODIFIER", 19, 38], ["infection", "OBSERVATION", 80, 89]]], ["Taken altogether, our results derived from different experimental models demonstrate conserved transcriptional and metabolic modulation of the urea cycle upon viral infection.Systemic Arginine-Ornithine Homeostasis Is a Regulator of Antiviral Adaptive Immunity ::: ResultsBecause activated T cells are auxotrophic for arginine (Geiger et al., 2016, Murray, 2016), we hypothesized that an altered arginine-to-ornithine serum ratio might exert immunomodulatory function.", [["T cells", "ANATOMY", 290, 297], ["serum", "ANATOMY", 418, 423], ["urea", "CHEMICAL", 143, 147], ["viral infection", "DISEASE", 159, 174], ["Arginine", "CHEMICAL", 184, 192], ["arginine", "CHEMICAL", 318, 326], ["arginine", "CHEMICAL", 396, 404], ["ornithine", "CHEMICAL", 408, 417], ["urea", "CHEMICAL", 143, 147], ["Arginine", "CHEMICAL", 184, 192], ["arginine", "CHEMICAL", 318, 326], ["arginine", "CHEMICAL", 396, 404], ["ornithine", "CHEMICAL", 408, 417], ["urea", "SIMPLE_CHEMICAL", 143, 147], ["Arginine", "SIMPLE_CHEMICAL", 184, 192], ["Ornithine", "SIMPLE_CHEMICAL", 193, 202], ["T cells", "CELL", 290, 297], ["arginine", "SIMPLE_CHEMICAL", 318, 326], ["arginine", "SIMPLE_CHEMICAL", 396, 404], ["ornithine", "SIMPLE_CHEMICAL", 408, 417], ["serum", "ORGANISM_SUBSTANCE", 418, 423], ["activated T cells", "CELL_TYPE", 280, 297], ["the urea cycle", "PROBLEM", 139, 153], ["viral infection", "PROBLEM", 159, 174], ["Systemic Arginine-Ornithine Homeostasis", "TREATMENT", 175, 214], ["activated T cells", "PROBLEM", 280, 297], ["arginine", "PROBLEM", 318, 326], ["an altered arginine", "PROBLEM", 385, 404], ["ornithine serum ratio", "TEST", 408, 429], ["metabolic modulation", "OBSERVATION", 115, 135], ["viral infection", "OBSERVATION", 159, 174], ["immunomodulatory function", "OBSERVATION", 442, 467]]], ["To test this in vitro, primary naive murine splenic CD8 T cells were activated with anti-CD3/CD28 antibodies for 3 days and IFN-\u03b3 and tumor necrosis factor alpha (TNF-\u03b1) production was assessed by flow cytometry.", [["splenic CD8 T cells", "ANATOMY", 44, 63], ["tumor", "DISEASE", 134, 139], ["murine", "ORGANISM", 37, 43], ["splenic CD8 T cells", "CELL", 44, 63], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 84, 92], ["CD28", "GENE_OR_GENE_PRODUCT", 93, 97], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 124, 129], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 134, 161], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 163, 168], ["primary naive murine splenic CD8 T cells", "CELL_TYPE", 23, 63], ["anti-CD3", "PROTEIN", 84, 92], ["CD28 antibodies", "PROTEIN", 93, 108], ["IFN", "PROTEIN", 124, 127], ["tumor necrosis factor alpha", "PROTEIN", 134, 161], ["TNF", "PROTEIN", 163, 166], ["murine", "SPECIES", 37, 43], ["anti-CD3/CD28 antibodies", "TEST", 84, 108], ["IFN", "TEST", 124, 127], ["\u03b3", "PROBLEM", 128, 129], ["tumor necrosis factor alpha", "PROBLEM", 134, 161], ["TNF", "TEST", 163, 166], ["flow cytometry", "TEST", 197, 211], ["splenic", "ANATOMY", 44, 51], ["CD8", "OBSERVATION", 52, 55], ["tumor", "OBSERVATION_MODIFIER", 134, 139], ["necrosis", "OBSERVATION_MODIFIER", 140, 148]]], ["CD8 T cells cultured in medium with 11.5 \u03bcM arginine, a concentration comparable to the observed changes in vivo, displayed reduced cytokine production compared to standard cell culture medium containing 1,150 \u03bcM arginine (Figure 6A).", [["CD8 T cells", "ANATOMY", 0, 11], ["cell", "ANATOMY", 173, 177], ["arginine", "CHEMICAL", 44, 52], ["arginine", "CHEMICAL", 213, 221], ["arginine", "CHEMICAL", 44, 52], ["arginine", "CHEMICAL", 213, 221], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["arginine", "SIMPLE_CHEMICAL", 44, 52], ["cell", "CELL", 173, 177], ["arginine", "SIMPLE_CHEMICAL", 213, 221], ["CD8 T cells", "CELL_TYPE", 0, 11], ["cytokine", "PROTEIN", 132, 140], ["CD8 T cells", "TEST", 0, 11], ["arginine", "TREATMENT", 44, 52], ["a concentration", "TREATMENT", 54, 69], ["reduced cytokine production", "PROBLEM", 124, 151], ["standard cell culture medium", "TEST", 164, 192]]], ["Addition of ornithine, which is absent in standard cell culture medium, resulted in an additive suppressive effect on cytokine production (Figure 6A).", [["cell", "ANATOMY", 51, 55], ["ornithine", "CHEMICAL", 12, 21], ["ornithine", "CHEMICAL", 12, 21], ["ornithine", "SIMPLE_CHEMICAL", 12, 21], ["cell", "CELL", 51, 55], ["cytokine", "PROTEIN", 118, 126], ["ornithine", "TREATMENT", 12, 21], ["cytokine production", "PROBLEM", 118, 137], ["suppressive", "OBSERVATION_MODIFIER", 96, 107]]], ["This indicated that decreased concentrations of arginine impact CD8 T cell responses and that these effects are aggravated by a simultaneous increase of ornithine.Systemic Arginine-Ornithine Homeostasis Is a Regulator of Antiviral Adaptive Immunity ::: ResultsTo experimentally uncouple the observed changes in the urea cycle from other co-occurring effects in vivo, we treated wild-type mice with recombinant pegylated human arginase 1 (recArg1) (Cheng et al., 2007) to aggravate the observed endogenous regulation of arginine and ornithine in the circulation.", [["CD8 T cell", "ANATOMY", 64, 74], ["arginine", "CHEMICAL", 48, 56], ["ornithine", "CHEMICAL", 153, 162], ["Arginine", "CHEMICAL", 172, 180], ["urea", "CHEMICAL", 315, 319], ["arginine", "CHEMICAL", 519, 527], ["ornithine", "CHEMICAL", 532, 541], ["arginine", "CHEMICAL", 48, 56], ["ornithine", "CHEMICAL", 153, 162], ["Arginine", "CHEMICAL", 172, 180], ["urea", "CHEMICAL", 315, 319], ["arginine", "CHEMICAL", 519, 527], ["ornithine", "CHEMICAL", 532, 541], ["arginine", "SIMPLE_CHEMICAL", 48, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["ornithine", "SIMPLE_CHEMICAL", 153, 162], ["Arginine", "SIMPLE_CHEMICAL", 172, 180], ["Ornithine", "SIMPLE_CHEMICAL", 181, 190], ["urea", "SIMPLE_CHEMICAL", 315, 319], ["mice", "ORGANISM", 388, 392], ["human", "ORGANISM", 420, 425], ["arginase 1", "GENE_OR_GENE_PRODUCT", 426, 436], ["recArg1", "GENE_OR_GENE_PRODUCT", 438, 445], ["arginine", "SIMPLE_CHEMICAL", 519, 527], ["ornithine", "SIMPLE_CHEMICAL", 532, 541], ["recombinant pegylated human arginase 1", "PROTEIN", 398, 436], ["recArg1", "PROTEIN", 438, 445], ["mice", "SPECIES", 388, 392], ["human", "SPECIES", 420, 425], ["mice", "SPECIES", 388, 392], ["human", "SPECIES", 420, 425], ["a simultaneous increase of ornithine", "TREATMENT", 126, 162], ["Systemic Arginine-Ornithine Homeostasis", "TREATMENT", 163, 202], ["the urea cycle", "PROBLEM", 311, 325], ["recombinant pegylated human arginase", "TREATMENT", 398, 434], ["arginine and ornithine", "TREATMENT", 519, 541], ["decreased", "OBSERVATION_MODIFIER", 20, 29], ["concentrations", "OBSERVATION_MODIFIER", 30, 44], ["circulation", "ANATOMY", 549, 560]]], ["As expected, recArg1 converted arginine to ornithine in the serum and closely recapitulated the decreased arginine-to-ornithine ratio seen upon viral infection (Figures 5E and S6A).", [["serum", "ANATOMY", 60, 65], ["arginine", "CHEMICAL", 31, 39], ["ornithine", "CHEMICAL", 43, 52], ["arginine", "CHEMICAL", 106, 114], ["ornithine", "CHEMICAL", 118, 127], ["viral infection", "DISEASE", 144, 159], ["arginine", "CHEMICAL", 31, 39], ["ornithine", "CHEMICAL", 43, 52], ["arginine", "CHEMICAL", 106, 114], ["ornithine", "CHEMICAL", 118, 127], ["recArg1", "SIMPLE_CHEMICAL", 13, 20], ["arginine", "AMINO_ACID", 31, 39], ["ornithine", "SIMPLE_CHEMICAL", 43, 52], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["arginine", "SIMPLE_CHEMICAL", 106, 114], ["ornithine", "SIMPLE_CHEMICAL", 118, 127], ["recArg1", "PROTEIN", 13, 20], ["ornithine in the serum", "TEST", 43, 65], ["the decreased arginine", "PROBLEM", 92, 114], ["ornithine ratio", "PROBLEM", 118, 133], ["viral infection", "PROBLEM", 144, 159], ["decreased", "OBSERVATION", 96, 105], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159]]], ["Administration of recArg1 did not affect the abundance of splenic T cells of infected and uninfected animals on day 8 after infection (Figure S6B).", [["splenic T cells", "ANATOMY", 58, 73], ["recArg1", "CHEMICAL", 18, 25], ["infection", "DISEASE", 124, 133], ["recArg1", "GENE_OR_GENE_PRODUCT", 18, 25], ["splenic T cells", "CELL", 58, 73], ["recArg1", "PROTEIN", 18, 25], ["splenic T cells", "CELL_TYPE", 58, 73], ["recArg1", "TREATMENT", 18, 25], ["splenic T cells", "PROBLEM", 58, 73], ["infection", "PROBLEM", 124, 133], ["splenic", "ANATOMY", 58, 65], ["T cells", "OBSERVATION", 66, 73], ["infected", "OBSERVATION_MODIFIER", 77, 85]]], ["Yet, we recognized an impaired shift from naive (CD62L+CD44\u2212) to effector (CD62L\u2212CD44+) T cells (Figures S6C and S6D).", [["CD62L+CD44\u2212", "ANATOMY", 49, 60], ["effector (CD62L\u2212CD44+) T cells", "ANATOMY", 65, 95], ["CD62L", "GENE_OR_GENE_PRODUCT", 49, 54], ["CD44", "GENE_OR_GENE_PRODUCT", 55, 59], ["CD62L", "GENE_OR_GENE_PRODUCT", 75, 80], ["CD44", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD62L", "PROTEIN", 49, 54], ["CD44", "PROTEIN", 55, 59], ["CD62L", "PROTEIN", 75, 80], ["CD44", "PROTEIN", 81, 85], ["T cells", "CELL_TYPE", 88, 95], ["S6C", "PROTEIN", 105, 108], ["S6D", "PROTEIN", 113, 116], ["an impaired shift", "PROBLEM", 19, 36], ["CD44", "TEST", 81, 85], ["impaired", "OBSERVATION", 22, 30]]], ["Further, the numbers of virus-specific CD8 T cells (Figure 6B) and their ability to produce the cytokines IFN-\u03b3 and TNF-\u03b1 upon peptide re-stimulation (Figures 6C\u20136E) were diminished upon recArg1 treatment.", [["CD8 T cells", "ANATOMY", 39, 50], ["recArg1", "CHEMICAL", 187, 194], ["CD8 T cells", "CELL", 39, 50], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 106, 111], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 116, 121], ["recArg1", "SIMPLE_CHEMICAL", 187, 194], ["CD8 T cells", "CELL_TYPE", 39, 50], ["cytokines", "PROTEIN", 96, 105], ["IFN", "PROTEIN", 106, 109], ["\u03b3", "PROTEIN", 110, 111], ["TNF", "PROTEIN", 116, 119], ["recArg1", "PROTEIN", 187, 194], ["virus", "TEST", 24, 29], ["the cytokines IFN", "TEST", 92, 109], ["TNF", "TEST", 116, 119], ["peptide re-stimulation", "TREATMENT", 127, 149], ["Figures", "TEST", 151, 158], ["recArg1 treatment", "TREATMENT", 187, 204], ["diminished", "OBSERVATION", 171, 181]]], ["Virus-specific CD4 T cells were similarly affected (Figure S6E).", [["CD4 T cells", "ANATOMY", 15, 26], ["Virus", "ORGANISM", 0, 5], ["CD4 T cells", "CELL", 15, 26], ["CD4 T cells", "CELL_TYPE", 15, 26], ["Virus", "TEST", 0, 5], ["specific CD4 T cells", "TEST", 6, 26]]], ["CD8 T cell effector function remained impaired in recArg1-treated animals at least up to 50 days after infection (Figure 6F) and coincided with elevated viral loads in blood (Figure 6G) and organs 8 and 50 days after infection (Figures S6F\u2013S6I).", [["CD8 T cell", "ANATOMY", 0, 10], ["blood", "ANATOMY", 168, 173], ["organs", "ANATOMY", 190, 196], ["recArg1", "CHEMICAL", 50, 57], ["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 217, 226], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["recArg1", "GENE_OR_GENE_PRODUCT", 50, 57], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["organs", "ORGAN", 190, 196], ["CD8", "PROTEIN", 0, 3], ["recArg1", "PROTEIN", 50, 57], ["CD8 T cell effector function", "TEST", 0, 28], ["infection", "PROBLEM", 103, 112], ["elevated viral loads in blood", "PROBLEM", 144, 173], ["infection", "PROBLEM", 217, 226], ["elevated", "OBSERVATION_MODIFIER", 144, 152], ["viral loads", "OBSERVATION", 153, 164], ["organs", "ANATOMY", 190, 196], ["infection", "OBSERVATION", 217, 226]]], ["To investigate whether impaired cytokine production of CD8 T cells upon recArg1 treatment coincides with exhaustion, we analyzed PD1 expression on virus-specific CD8 T cells in the blood of mice 30 days after infection.", [["CD8 T cells", "ANATOMY", 55, 66], ["CD8 T cells", "ANATOMY", 162, 173], ["blood", "ANATOMY", 181, 186], ["recArg1", "CHEMICAL", 72, 79], ["infection", "DISEASE", 209, 218], ["CD8 T", "GENE_OR_GENE_PRODUCT", 55, 60], ["recArg1", "GENE_OR_GENE_PRODUCT", 72, 79], ["PD1", "GENE_OR_GENE_PRODUCT", 129, 132], ["CD8 T cells", "CELL", 162, 173], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["mice", "ORGANISM", 190, 194], ["cytokine", "PROTEIN", 32, 40], ["CD8 T cells", "CELL_TYPE", 55, 66], ["recArg1", "PROTEIN", 72, 79], ["PD1", "PROTEIN", 129, 132], ["CD8 T cells", "CELL_TYPE", 162, 173], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 190, 194], ["impaired cytokine production", "PROBLEM", 23, 51], ["CD8 T cells", "PROBLEM", 55, 66], ["recArg1 treatment", "TREATMENT", 72, 89], ["exhaustion", "PROBLEM", 105, 115], ["virus", "TEST", 147, 152], ["infection", "PROBLEM", 209, 218], ["infection", "OBSERVATION", 209, 218]]], ["This did not reveal any obvious differences for PD1 upon treatment with recArg1 (Figure S6J).", [["PD1", "GENE_OR_GENE_PRODUCT", 48, 51], ["recArg1", "GENE_OR_GENE_PRODUCT", 72, 79], ["PD1", "PROTEIN", 48, 51], ["recArg1", "PROTEIN", 72, 79], ["treatment", "TREATMENT", 57, 66], ["recArg1", "TREATMENT", 72, 79]]], ["Strikingly, treatment with recArg1 significantly ameliorated virus-induced CD8 T-cell-mediated tissue damage as determined by reduced serum concentration of ALT and AST (Figures 6H and 6I).", [["CD8 T-cell", "ANATOMY", 75, 85], ["tissue", "ANATOMY", 95, 101], ["serum", "ANATOMY", 134, 139], ["recArg1", "CHEMICAL", 27, 34], ["recArg1", "SIMPLE_CHEMICAL", 27, 34], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["tissue", "TISSUE", 95, 101], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["ALT", "SIMPLE_CHEMICAL", 157, 160], ["AST", "SIMPLE_CHEMICAL", 165, 168], ["recArg1", "PROTEIN", 27, 34], ["CD8 T-cell", "CELL_TYPE", 75, 85], ["ALT", "PROTEIN", 157, 160], ["AST", "PROTEIN", 165, 168], ["treatment", "TREATMENT", 12, 21], ["recArg1", "TREATMENT", 27, 34], ["significantly ameliorated virus", "PROBLEM", 35, 66], ["mediated tissue damage", "PROBLEM", 86, 108], ["reduced serum concentration", "PROBLEM", 126, 153], ["ALT", "TEST", 157, 160], ["AST", "TEST", 165, 168], ["Figures", "TEST", 170, 177], ["tissue", "ANATOMY", 95, 101], ["damage", "OBSERVATION", 102, 108]]], ["We conclude that modulation of the systemic arginine-to-ornithine ratio regulates antiviral T cell responses to ameliorate virus-induced tissue damage.DiscussionMetabolic adjustments are crucial for activation and differentiation of immune cells (Jha et al., 2015, Pearce and Pearce, 2013, Pearce et al., 2009).", [["T cell", "ANATOMY", 92, 98], ["tissue", "ANATOMY", 137, 143], ["immune cells", "ANATOMY", 233, 245], ["arginine", "CHEMICAL", 44, 52], ["ornithine", "CHEMICAL", 56, 65], ["tissue damage", "DISEASE", 137, 150], ["arginine", "CHEMICAL", 44, 52], ["ornithine", "CHEMICAL", 56, 65], ["arginine", "SIMPLE_CHEMICAL", 44, 52], ["ornithine", "SIMPLE_CHEMICAL", 56, 65], ["T cell", "CELL", 92, 98], ["tissue", "TISSUE", 137, 143], ["immune cells", "CELL", 233, 245], ["immune cells", "CELL_TYPE", 233, 245], ["the systemic arginine", "TEST", 31, 52], ["ornithine ratio", "TEST", 56, 71], ["antiviral T cell responses", "TREATMENT", 82, 108], ["ameliorate virus", "PROBLEM", 112, 128], ["tissue damage", "PROBLEM", 137, 150], ["DiscussionMetabolic adjustments", "TREATMENT", 151, 182], ["tissue", "ANATOMY", 137, 143], ["damage", "OBSERVATION", 144, 150]]], ["Our study identified an IFNAR1-dependent mechanism whereby hepatocytes receive instructions to repress the transcription of genes with metabolic function.", [["hepatocytes", "ANATOMY", 59, 70], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 24, 30], ["hepatocytes", "CELL", 59, 70], ["IFNAR1", "PROTEIN", 24, 30], ["hepatocytes", "CELL_TYPE", 59, 70], ["Our study", "TEST", 0, 9], ["an IFNAR1-dependent mechanism", "PROBLEM", 21, 50], ["IFNAR1", "OBSERVATION", 24, 30], ["hepatocytes", "ANATOMY", 59, 70], ["metabolic function", "OBSERVATION", 135, 153]]], ["The role of IFN-repressed genes in disease and homeostasis is still poorly understood.", [["IFN", "GENE_OR_GENE_PRODUCT", 12, 15], ["IFN-repressed genes", "DNA", 12, 31], ["disease", "PROBLEM", 35, 42]]], ["Yet it is noticeable that IFN-I-driven expression signatures from other organs and cell types do not appear to feature similar global repressive gene regulation (Mostafavi et al., 2016, Schoggins et al., 2011).", [["organs", "ANATOMY", 72, 78], ["cell", "ANATOMY", 83, 87], ["IFN-I", "GENE_OR_GENE_PRODUCT", 26, 31], ["organs", "ORGAN", 72, 78], ["cell", "CELL", 83, 87], ["IFN-I", "PROTEIN", 26, 31]]], ["This potentially highlights a unique feature of the liver, which rapidly integrates inflammatory cues from the environment to modulate its intrinsic metabolism and, as a consequence, its systemic metabolic output to peripheral organs.", [["liver", "ANATOMY", 52, 57], ["peripheral organs", "ANATOMY", 216, 233], ["liver", "ORGAN", 52, 57], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 216, 233], ["liver", "ANATOMY", 52, 57], ["inflammatory", "OBSERVATION", 84, 96], ["metabolism", "OBSERVATION_MODIFIER", 149, 159], ["metabolic output", "OBSERVATION", 196, 212], ["peripheral", "ANATOMY_MODIFIER", 216, 226], ["organs", "ANATOMY", 227, 233]]], ["This IFNAR1-mediated metabolic reprogramming of the liver may give rise to an unfavorable environment for pathogens (Sanchez et al., 2018), optimize the metabolic milieu for mounting adaptive immune responses (Ma et al., 2017), or instruct tissue repair and regeneration to prevent extensive tissue pathology.", [["liver", "ANATOMY", 52, 57], ["tissue", "ANATOMY", 240, 246], ["tissue", "ANATOMY", 292, 298], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 5, 11], ["liver", "ORGAN", 52, 57], ["tissue", "TISSUE", 240, 246], ["tissue", "TISSUE", 292, 298], ["IFNAR1", "PROTEIN", 5, 11], ["pathogens", "PROBLEM", 106, 115], ["instruct tissue repair", "TREATMENT", 231, 253], ["regeneration", "TREATMENT", 258, 270], ["extensive tissue pathology", "PROBLEM", 282, 308], ["metabolic reprogramming", "OBSERVATION", 21, 44], ["liver", "ANATOMY", 52, 57], ["extensive tissue", "OBSERVATION_MODIFIER", 282, 298], ["pathology", "OBSERVATION", 299, 308]]], ["None of these options are mutually exclusive, and host damage control may be achieved by modulating disease tolerance and/or reducing immune effectors (Medzhitov, 2008).DiscussionNext to other metabolic changes, we identified a regulatory effect of IFNAR1 signaling on the urea cycle, a central metabolic pathway that is primarily expressed in the liver.", [["liver", "ANATOMY", 348, 353], ["urea", "CHEMICAL", 273, 277], ["urea", "CHEMICAL", 273, 277], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 249, 255], ["urea", "SIMPLE_CHEMICAL", 273, 277], ["liver", "ORGAN", 348, 353], ["IFNAR1", "PROTEIN", 249, 255], ["host damage control", "TREATMENT", 50, 69], ["modulating disease tolerance", "PROBLEM", 89, 117], ["IFNAR1 signaling on the urea cycle", "PROBLEM", 249, 283], ["central", "ANATOMY_MODIFIER", 287, 294], ["metabolic pathway", "OBSERVATION", 295, 312], ["liver", "ANATOMY", 348, 353]]], ["Its primary function is the conversion of circulating toxic ammonia into non-toxic urea with a fumarate shunt connecting the urea cycle to the TCA cycle (Meijer et al., 1990).", [["ammonia", "CHEMICAL", 60, 67], ["urea", "CHEMICAL", 83, 87], ["fumarate", "CHEMICAL", 95, 103], ["urea", "CHEMICAL", 125, 129], ["ammonia", "CHEMICAL", 60, 67], ["urea", "CHEMICAL", 83, 87], ["fumarate", "CHEMICAL", 95, 103], ["urea", "CHEMICAL", 125, 129], ["TCA", "CHEMICAL", 143, 146], ["ammonia", "SIMPLE_CHEMICAL", 60, 67], ["urea", "SIMPLE_CHEMICAL", 83, 87], ["fumarate", "SIMPLE_CHEMICAL", 95, 103], ["urea", "SIMPLE_CHEMICAL", 125, 129], ["TCA", "SIMPLE_CHEMICAL", 143, 146], ["circulating toxic ammonia into non-toxic urea", "PROBLEM", 42, 87], ["a fumarate shunt", "TREATMENT", 93, 109]]], ["Fumarate can subsequently be metabolized to aspartate and \u03b1-ketoglutarate, two major precursors of de novo amino acid synthesis.", [["Fumarate", "CHEMICAL", 0, 8], ["aspartate", "CHEMICAL", 44, 53], ["\u03b1-ketoglutarate", "CHEMICAL", 58, 73], ["amino acid", "CHEMICAL", 107, 117], ["Fumarate", "CHEMICAL", 0, 8], ["aspartate", "CHEMICAL", 44, 53], ["\u03b1-ketoglutarate", "CHEMICAL", 58, 73], ["amino acid", "CHEMICAL", 107, 117], ["Fumarate", "SIMPLE_CHEMICAL", 0, 8], ["aspartate", "SIMPLE_CHEMICAL", 44, 53], ["\u03b1-ketoglutarate", "SIMPLE_CHEMICAL", 58, 73], ["amino acid", "AMINO_ACID", 107, 117], ["Fumarate", "TREATMENT", 0, 8], ["aspartate and \u03b1-ketoglutarate", "PROBLEM", 44, 73], ["de novo amino acid synthesis", "TREATMENT", 99, 127], ["amino acid", "OBSERVATION", 107, 117]]], ["Hence, the urea cycle is a central metabolic pathway that is crucial for both detoxication as well as cellular proliferation (Watford, 2003).DiscussionWe modeled the altered levels of serum arginine and ornithine upon viral infection by administration of recombinant arginase and demonstrate a suppressive effect on virus-specific CD8 T cell responses.", [["cellular", "ANATOMY", 102, 110], ["serum", "ANATOMY", 184, 189], ["CD8 T cell", "ANATOMY", 331, 341], ["urea", "CHEMICAL", 11, 15], ["arginine", "CHEMICAL", 190, 198], ["ornithine", "CHEMICAL", 203, 212], ["viral infection", "DISEASE", 218, 233], ["urea", "CHEMICAL", 11, 15], ["arginine", "CHEMICAL", 190, 198], ["ornithine", "CHEMICAL", 203, 212], ["urea", "SIMPLE_CHEMICAL", 11, 15], ["cellular", "CELL", 102, 110], ["serum", "ORGANISM_SUBSTANCE", 184, 189], ["arginine", "SIMPLE_CHEMICAL", 190, 198], ["ornithine", "SIMPLE_CHEMICAL", 203, 212], ["arginase", "GENE_OR_GENE_PRODUCT", 267, 275], ["CD8 T cell", "CELL", 331, 341], ["recombinant arginase", "PROTEIN", 255, 275], ["CD8", "PROTEIN", 331, 334], ["the urea cycle", "TEST", 7, 21], ["serum arginine", "TREATMENT", 184, 198], ["ornithine upon viral infection", "PROBLEM", 203, 233], ["recombinant arginase", "TREATMENT", 255, 275], ["a suppressive effect on virus", "PROBLEM", 292, 321], ["cellular proliferation", "OBSERVATION", 102, 124], ["viral infection", "OBSERVATION", 218, 233]]], ["This is in line with nutrient availability as an important factor that may either boost or dampen effector functions of T cells (Chang et al., 2015, Geiger et al., 2016, Johnson et al., 2018, Ma et al., 2017, Sinclair et al., 2013, Van de Velde and Murray, 2016).", [["T cells", "ANATOMY", 120, 127], ["T cells", "CELL", 120, 127], ["T cells", "CELL_TYPE", 120, 127]]], ["A recent study identified that T cells may actively shape serum metabolite levels themselves, thereby creating potential functional feedback loops between systemic metabolism and T cell activation (Miyajima et al., 2017).", [["T cells", "ANATOMY", 31, 38], ["serum", "ANATOMY", 58, 63], ["T cell", "ANATOMY", 179, 185], ["T cells", "CELL", 31, 38], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["T cell", "CELL", 179, 185], ["T cells", "CELL_TYPE", 31, 38], ["A recent study", "TEST", 0, 14], ["T cells", "PROBLEM", 31, 38], ["serum metabolite levels", "TEST", 58, 81], ["systemic metabolism", "PROBLEM", 155, 174], ["feedback loops", "OBSERVATION", 132, 146]]], ["This study adds another regulatory layer next to well-established mechanisms, including T cell exhaustion, of how the host may fine-tune adaptive immunity during chronic infection (Wherry and Kurachi, 2015).DiscussionThe urea cycle is linked to amino acid, polyamine, and nucleotide metabolic pathways and represents a major hub of systemic nitrogen metabolism, which contributes to the formation of advanced liver disease (Li et al., 2019).", [["T cell", "ANATOMY", 88, 94], ["liver", "ANATOMY", 409, 414], ["chronic infection", "DISEASE", 162, 179], ["urea", "CHEMICAL", 221, 225], ["amino acid", "CHEMICAL", 245, 255], ["polyamine", "CHEMICAL", 257, 266], ["nucleotide", "CHEMICAL", 272, 282], ["nitrogen", "CHEMICAL", 341, 349], ["liver disease", "DISEASE", 409, 422], ["urea", "CHEMICAL", 221, 225], ["amino acid", "CHEMICAL", 245, 255], ["polyamine", "CHEMICAL", 257, 266], ["nucleotide", "CHEMICAL", 272, 282], ["nitrogen", "CHEMICAL", 341, 349], ["T cell", "CELL", 88, 94], ["urea", "SIMPLE_CHEMICAL", 221, 225], ["amino acid", "AMINO_ACID", 245, 255], ["polyamine", "SIMPLE_CHEMICAL", 257, 266], ["nucleotide", "SIMPLE_CHEMICAL", 272, 282], ["nitrogen", "SIMPLE_CHEMICAL", 341, 349], ["liver", "ORGAN", 409, 414], ["This study", "TEST", 0, 10], ["T cell exhaustion", "PROBLEM", 88, 105], ["chronic infection", "PROBLEM", 162, 179], ["The urea cycle", "TEST", 217, 231], ["amino acid", "TEST", 245, 255], ["polyamine", "TREATMENT", 257, 266], ["nucleotide metabolic pathways", "TREATMENT", 272, 301], ["systemic nitrogen metabolism", "PROBLEM", 332, 360], ["advanced liver disease", "PROBLEM", 400, 422], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["infection", "OBSERVATION", 170, 179], ["systemic", "OBSERVATION", 332, 340], ["nitrogen metabolism", "OBSERVATION", 341, 360], ["advanced", "OBSERVATION_MODIFIER", 400, 408], ["liver", "ANATOMY", 409, 414], ["disease", "OBSERVATION", 415, 422]]], ["Accordingly, inherited urea cycle disorders (UCDs) and the resulting hyperammonemia with altered serum levels of the associated metabolites display severe health threats (Mew et al., 2003).", [["serum", "ANATOMY", 97, 102], ["urea", "CHEMICAL", 23, 27], ["UCDs", "DISEASE", 45, 49], ["hyperammonemia", "DISEASE", 69, 83], ["urea", "CHEMICAL", 23, 27], ["urea", "SIMPLE_CHEMICAL", 23, 27], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["inherited urea cycle disorders", "PROBLEM", 13, 43], ["UCDs", "TEST", 45, 49], ["the resulting hyperammonemia", "PROBLEM", 55, 83], ["altered serum levels", "PROBLEM", 89, 109], ["severe health threats", "PROBLEM", 148, 169], ["urea cycle", "OBSERVATION_MODIFIER", 23, 33], ["hyperammonemia", "OBSERVATION", 69, 83], ["severe", "OBSERVATION_MODIFIER", 148, 154]]], ["We found that mice infected with LCMV display hyperammonemia, a hallmark of hepatic encephalopathy (Tranah et al., 2013).", [["hepatic", "ANATOMY", 76, 83], ["hyperammonemia", "DISEASE", 46, 60], ["hepatic encephalopathy", "DISEASE", 76, 98], ["mice", "ORGANISM", 14, 18], ["LCMV", "ORGANISM", 33, 37], ["hepatic", "ORGAN", 76, 83], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["LCMV", "SPECIES", 33, 37], ["LCMV", "PROBLEM", 33, 37], ["hyperammonemia", "PROBLEM", 46, 60], ["hepatic encephalopathy", "PROBLEM", 76, 98], ["LCMV", "OBSERVATION", 33, 37], ["hyperammonemia", "OBSERVATION", 46, 60], ["hallmark", "OBSERVATION_MODIFIER", 64, 72], ["hepatic", "ANATOMY", 76, 83], ["encephalopathy", "OBSERVATION", 84, 98]]], ["Additional investigations will be required to address whether infection-associated hyperammonemia may modulate sickness behavior and influence disease progression (Dantzer et al., 2008, Wang et al., 2019).DiscussionDownregulation or even loss of Otc and Ass1 are common features of many cancers, limiting aspartate consumption by the urea cycle and instead feeding into de novo nucleotide synthesis associated with tumor growth (Feun et al., 2012, Lam et al., 2011, Lee et al., 2018, Rabinovich et al., 2015).", [["cancers", "ANATOMY", 287, 294], ["tumor", "ANATOMY", 415, 420], ["infection", "DISEASE", 62, 71], ["hyperammonemia", "DISEASE", 83, 97], ["sickness behavior", "DISEASE", 111, 128], ["cancers", "DISEASE", 287, 294], ["aspartate", "CHEMICAL", 305, 314], ["urea", "CHEMICAL", 334, 338], ["nucleotide", "CHEMICAL", 378, 388], ["tumor", "DISEASE", 415, 420], ["aspartate", "CHEMICAL", 305, 314], ["urea", "CHEMICAL", 334, 338], ["nucleotide", "CHEMICAL", 378, 388], ["Otc", "GENE_OR_GENE_PRODUCT", 246, 249], ["Ass1", "GENE_OR_GENE_PRODUCT", 254, 258], ["cancers", "CANCER", 287, 294], ["aspartate", "SIMPLE_CHEMICAL", 305, 314], ["urea", "SIMPLE_CHEMICAL", 334, 338], ["nucleotide", "SIMPLE_CHEMICAL", 378, 388], ["tumor", "CANCER", 415, 420], ["Otc", "PROTEIN", 246, 249], ["Ass1", "PROTEIN", 254, 258], ["Additional investigations", "TEST", 0, 25], ["infection", "PROBLEM", 62, 71], ["hyperammonemia", "PROBLEM", 83, 97], ["modulate sickness behavior", "PROBLEM", 102, 128], ["influence disease progression", "PROBLEM", 133, 162], ["DiscussionDownregulation", "TREATMENT", 205, 229], ["even loss of Otc", "PROBLEM", 233, 249], ["many cancers", "PROBLEM", 282, 294], ["the urea cycle", "TREATMENT", 330, 344], ["novo nucleotide synthesis", "TREATMENT", 373, 398], ["tumor growth", "PROBLEM", 415, 427], ["hyperammonemia", "OBSERVATION", 83, 97], ["many", "OBSERVATION_MODIFIER", 282, 286], ["cancers", "OBSERVATION", 287, 294]]], ["Otc and Ass1 are also crucial for de novo arginine synthesis.", [["arginine", "CHEMICAL", 42, 50], ["arginine", "CHEMICAL", 42, 50], ["Otc", "GENE_OR_GENE_PRODUCT", 0, 3], ["Ass1", "GENE_OR_GENE_PRODUCT", 8, 12], ["arginine", "SIMPLE_CHEMICAL", 42, 50], ["Otc", "PROTEIN", 0, 3], ["Ass1", "PROTEIN", 8, 12], ["de novo arginine synthesis", "PROBLEM", 34, 60]]], ["As a result, many tumors are auxotrophic for arginine, which renders arginine a metabolic vulnerability that is currently therapeutically exploited by recArg1 treatment of cancer patients (De Santo et al., 2018).", [["tumors", "ANATOMY", 18, 24], ["cancer", "ANATOMY", 172, 178], ["tumors", "DISEASE", 18, 24], ["arginine", "CHEMICAL", 45, 53], ["arginine", "CHEMICAL", 69, 77], ["recArg1", "CHEMICAL", 151, 158], ["cancer", "DISEASE", 172, 178], ["arginine", "CHEMICAL", 45, 53], ["arginine", "CHEMICAL", 69, 77], ["tumors", "CANCER", 18, 24], ["arginine", "AMINO_ACID", 45, 53], ["arginine", "AMINO_ACID", 69, 77], ["recArg1", "SIMPLE_CHEMICAL", 151, 158], ["cancer", "CANCER", 172, 178], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["many tumors", "PROBLEM", 13, 24], ["arginine", "PROBLEM", 45, 53], ["cancer", "PROBLEM", 172, 178], ["tumors", "OBSERVATION", 18, 24], ["metabolic vulnerability", "OBSERVATION", 80, 103]]], ["In line, UCDs and in particular Ass1 deficiency of tumors potentially synergize with checkpoint blockade treatment in tumors (Lee et al., 2018).", [["UCDs", "ANATOMY", 9, 13], ["tumors", "ANATOMY", 51, 57], ["tumors", "ANATOMY", 118, 124], ["tumors", "DISEASE", 51, 57], ["tumors", "DISEASE", 118, 124], ["UCDs", "CANCER", 9, 13], ["Ass1", "GENE_OR_GENE_PRODUCT", 32, 36], ["tumors", "CANCER", 51, 57], ["tumors", "CANCER", 118, 124], ["Ass1", "PROTEIN", 32, 36], ["UCDs", "TEST", 9, 13], ["Ass1 deficiency of tumors", "PROBLEM", 32, 57], ["checkpoint blockade treatment", "TREATMENT", 85, 114], ["tumors", "PROBLEM", 118, 124], ["tumors", "OBSERVATION", 51, 57]]], ["Interestingly, reduced serum levels of arginine are associated with less liver tissue damage in chronic HBV infection although increased serum levels of arginine and arginine derivatives have been associated with non-alcoholic fatty liver disease (Dumas et al., 2014, Li et al., 2011, Pallett et al., 2015, Soga et al., 2011).", [["serum", "ANATOMY", 23, 28], ["liver tissue", "ANATOMY", 73, 85], ["serum", "ANATOMY", 137, 142], ["non-alcoholic fatty liver", "ANATOMY", 213, 238], ["arginine", "CHEMICAL", 39, 47], ["liver tissue damage", "DISEASE", 73, 92], ["HBV infection", "DISEASE", 104, 117], ["arginine", "CHEMICAL", 153, 161], ["arginine", "CHEMICAL", 166, 174], ["non-alcoholic fatty liver disease", "DISEASE", 213, 246], ["arginine", "CHEMICAL", 39, 47], ["arginine", "CHEMICAL", 153, 161], ["arginine", "CHEMICAL", 166, 174], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["arginine", "SIMPLE_CHEMICAL", 39, 47], ["liver tissue", "TISSUE", 73, 85], ["HBV", "ORGANISM", 104, 107], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["arginine", "SIMPLE_CHEMICAL", 153, 161], ["arginine derivatives", "SIMPLE_CHEMICAL", 166, 186], ["liver", "ORGAN", 233, 238], ["HBV", "SPECIES", 104, 107], ["reduced serum levels of arginine", "PROBLEM", 15, 47], ["less liver tissue damage", "PROBLEM", 68, 92], ["chronic HBV infection", "PROBLEM", 96, 117], ["increased serum levels of arginine", "PROBLEM", 127, 161], ["arginine derivatives", "TREATMENT", 166, 186], ["non-alcoholic fatty liver disease", "PROBLEM", 213, 246], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["serum levels", "OBSERVATION_MODIFIER", 23, 35], ["liver", "ANATOMY", 73, 78], ["tissue", "OBSERVATION_MODIFIER", 79, 85], ["damage", "OBSERVATION", 86, 92], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["HBV", "OBSERVATION_MODIFIER", 104, 107], ["infection", "OBSERVATION", 108, 117], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["associated with", "UNCERTAINTY", 197, 212], ["non-alcoholic", "OBSERVATION_MODIFIER", 213, 226], ["fatty", "OBSERVATION", 227, 232], ["liver", "ANATOMY", 233, 238]]], ["Finally, deregulated ornithine metabolism and increased synthesis of polyamines may also impact cellular proliferation as well as the replication of diverse groups of viruses, potentially impacting on infection-associated cancer formation and progression (Casero et al., 2018, Mounce et al., 2016).DiscussionUsing different approaches, we demonstrate that virus-induced IFNAR1 signaling in hepatocytes leads to downregulation of Otc and Ass1.", [["cellular", "ANATOMY", 96, 104], ["cancer", "ANATOMY", 222, 228], ["hepatocytes", "ANATOMY", 390, 401], ["ornithine", "CHEMICAL", 21, 30], ["polyamines", "CHEMICAL", 69, 79], ["infection", "DISEASE", 201, 210], ["cancer", "DISEASE", 222, 228], ["ornithine", "CHEMICAL", 21, 30], ["polyamines", "CHEMICAL", 69, 79], ["ornithine", "SIMPLE_CHEMICAL", 21, 30], ["polyamines", "SIMPLE_CHEMICAL", 69, 79], ["cellular", "CELL", 96, 104], ["cancer", "CANCER", 222, 228], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 370, 376], ["hepatocytes", "CELL", 390, 401], ["Otc", "GENE_OR_GENE_PRODUCT", 429, 432], ["Ass1", "GENE_OR_GENE_PRODUCT", 437, 441], ["IFNAR1", "PROTEIN", 370, 376], ["hepatocytes", "CELL_TYPE", 390, 401], ["Otc", "PROTEIN", 429, 432], ["Ass1", "PROTEIN", 437, 441], ["deregulated ornithine metabolism", "PROBLEM", 9, 41], ["increased synthesis of polyamines", "PROBLEM", 46, 79], ["cellular proliferation", "PROBLEM", 96, 118], ["diverse groups of viruses", "PROBLEM", 149, 174], ["infection", "PROBLEM", 201, 210], ["cancer formation", "PROBLEM", 222, 238], ["virus", "PROBLEM", 356, 361], ["IFNAR1 signaling in hepatocytes", "PROBLEM", 370, 401], ["downregulation of Otc", "TREATMENT", 411, 432], ["ornithine metabolism", "OBSERVATION", 21, 41], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["cellular proliferation", "OBSERVATION", 96, 118], ["diverse", "OBSERVATION_MODIFIER", 149, 156], ["viruses", "OBSERVATION", 167, 174], ["infection", "OBSERVATION", 201, 210], ["cancer", "OBSERVATION", 222, 228], ["progression", "OBSERVATION_MODIFIER", 243, 254], ["hepatocytes", "ANATOMY", 390, 401]]], ["The simultaneous upregulation of Arg1 during viral infection of the liver suggests that, during infection, hepatocytes are reprogrammed toward increased arginine degradation and ornithine accumulation.", [["liver", "ANATOMY", 68, 73], ["hepatocytes", "ANATOMY", 107, 118], ["Arg1", "CHEMICAL", 33, 37], ["viral infection", "DISEASE", 45, 60], ["infection", "DISEASE", 96, 105], ["arginine", "CHEMICAL", 153, 161], ["ornithine", "CHEMICAL", 178, 187], ["arginine", "CHEMICAL", 153, 161], ["ornithine", "CHEMICAL", 178, 187], ["Arg1", "GENE_OR_GENE_PRODUCT", 33, 37], ["liver", "ORGAN", 68, 73], ["hepatocytes", "CELL", 107, 118], ["arginine", "SIMPLE_CHEMICAL", 153, 161], ["ornithine", "SIMPLE_CHEMICAL", 178, 187], ["Arg1", "PROTEIN", 33, 37], ["hepatocytes", "CELL_TYPE", 107, 118], ["Arg1", "PROBLEM", 33, 37], ["viral infection of the liver", "PROBLEM", 45, 73], ["infection", "PROBLEM", 96, 105], ["increased arginine degradation", "PROBLEM", 143, 173], ["ornithine accumulation", "PROBLEM", 178, 200], ["Arg1", "OBSERVATION", 33, 37], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["liver", "ANATOMY", 68, 73], ["infection", "OBSERVATION", 96, 105], ["hepatocytes", "ANATOMY", 107, 118], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["arginine degradation", "OBSERVATION", 153, 173], ["ornithine accumulation", "OBSERVATION", 178, 200]]], ["However, we cannot exclude the possibility that infiltrating immune cells, including myeloid-derived suppressor cells (MDSCs), may contribute to increased Arg1 expression in the liver (Gabrilovich, 2017).", [["infiltrating immune cells", "ANATOMY", 48, 73], ["myeloid-derived suppressor cells", "ANATOMY", 85, 117], ["MDSCs", "ANATOMY", 119, 124], ["liver", "ANATOMY", 178, 183], ["infiltrating immune cells", "CELL", 48, 73], ["myeloid-derived suppressor cells", "CELL", 85, 117], ["MDSCs", "CELL", 119, 124], ["Arg1", "GENE_OR_GENE_PRODUCT", 155, 159], ["liver", "ORGAN", 178, 183], ["infiltrating immune cells", "CELL_TYPE", 48, 73], ["myeloid-derived suppressor cells", "CELL_TYPE", 85, 117], ["MDSCs", "CELL_TYPE", 119, 124], ["Arg1", "PROTEIN", 155, 159], ["infiltrating immune cells", "PROBLEM", 48, 73], ["myeloid-derived suppressor cells", "PROBLEM", 85, 117], ["increased Arg1 expression in the liver", "PROBLEM", 145, 183], ["cannot exclude the possibility", "UNCERTAINTY", 12, 42], ["infiltrating", "OBSERVATION_MODIFIER", 48, 60], ["immune cells", "OBSERVATION", 61, 73], ["suppressor cells", "OBSERVATION", 101, 117], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["Arg1 expression", "OBSERVATION", 155, 170], ["liver", "ANATOMY", 178, 183]]], ["In line with this, our 13C6 heavy-isotope-labeling experiments confirmed that viral infection increases the hepatic conversion of arginine to ornithine and correlates with systemic accumulation of ornithine and citrulline.", [["hepatic", "ANATOMY", 108, 115], ["viral infection", "DISEASE", 78, 93], ["arginine", "CHEMICAL", 130, 138], ["ornithine", "CHEMICAL", 142, 151], ["ornithine", "CHEMICAL", 197, 206], ["citrulline", "CHEMICAL", 211, 221], ["arginine", "CHEMICAL", 130, 138], ["ornithine", "CHEMICAL", 142, 151], ["ornithine", "CHEMICAL", 197, 206], ["citrulline", "CHEMICAL", 211, 221], ["hepatic", "MULTI-TISSUE_STRUCTURE", 108, 115], ["arginine", "AMINO_ACID", 130, 138], ["ornithine", "SIMPLE_CHEMICAL", 142, 151], ["ornithine", "SIMPLE_CHEMICAL", 197, 206], ["citrulline", "SIMPLE_CHEMICAL", 211, 221], ["viral infection", "PROBLEM", 78, 93], ["arginine to ornithine", "TREATMENT", 130, 151], ["systemic accumulation of ornithine", "TREATMENT", 172, 206], ["citrulline", "TREATMENT", 211, 221], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["infection", "OBSERVATION", 84, 93], ["hepatic", "ANATOMY", 108, 115]]], ["The observed infection-dependent reduction of the urea cycle end product 13C5 arginine further supported the notion of an IFNAR1-mediated break of the urea cycle.", [["infection", "DISEASE", 13, 22], ["urea", "CHEMICAL", 50, 54], ["13C5 arginine", "CHEMICAL", 73, 86], ["urea", "CHEMICAL", 151, 155], ["urea", "CHEMICAL", 50, 54], ["13C5 arginine", "CHEMICAL", 73, 86], ["urea", "CHEMICAL", 151, 155], ["urea", "SIMPLE_CHEMICAL", 50, 54], ["13C5", "SIMPLE_CHEMICAL", 73, 77], ["arginine", "AMINO_ACID", 78, 86], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 122, 128], ["urea", "SIMPLE_CHEMICAL", 151, 155], ["IFNAR1", "PROTEIN", 122, 128], ["The observed infection", "PROBLEM", 0, 22], ["dependent reduction", "PROBLEM", 23, 42], ["the urea cycle", "TREATMENT", 46, 60], ["infection", "OBSERVATION", 13, 22], ["dependent", "OBSERVATION_MODIFIER", 23, 32], ["reduction", "OBSERVATION_MODIFIER", 33, 42]]], ["Still, these results do not rule out the potential additional contributions of extrahepatic events, as changes in the endocrine system are likely co-occurring with systemic metabolic reprogramming and/or sickness behavior during infection.", [["extrahepatic", "ANATOMY", 79, 91], ["endocrine system", "ANATOMY", 118, 134], ["sickness behavior", "DISEASE", 204, 221], ["infection", "DISEASE", 229, 238], ["extrahepatic", "ORGAN", 79, 91], ["endocrine system", "ANATOMICAL_SYSTEM", 118, 134], ["extrahepatic events", "PROBLEM", 79, 98], ["changes in the endocrine system", "PROBLEM", 103, 134], ["systemic metabolic reprogramming", "PROBLEM", 164, 196], ["sickness behavior", "PROBLEM", 204, 221], ["infection", "PROBLEM", 229, 238], ["extrahepatic", "ANATOMY", 79, 91], ["metabolic reprogramming", "OBSERVATION", 173, 196], ["infection", "OBSERVATION", 229, 238]]], ["Previous studies also established a link between hepatic autophagy, hepatocyte-derived circulating ARG1, and the systemic arginine-to-ornithine ratio, leading to reduced tumor growth in mice (Poillet-Perez et al., 2018).", [["hepatic", "ANATOMY", 49, 56], ["hepatocyte", "ANATOMY", 68, 78], ["tumor", "ANATOMY", 170, 175], ["arginine", "CHEMICAL", 122, 130], ["ornithine", "CHEMICAL", 134, 143], ["tumor", "DISEASE", 170, 175], ["arginine", "CHEMICAL", 122, 130], ["ornithine", "CHEMICAL", 134, 143], ["hepatic", "MULTI-TISSUE_STRUCTURE", 49, 56], ["hepatocyte", "CELL", 68, 78], ["ARG1", "GENE_OR_GENE_PRODUCT", 99, 103], ["arginine", "SIMPLE_CHEMICAL", 122, 130], ["ornithine", "SIMPLE_CHEMICAL", 134, 143], ["tumor", "CANCER", 170, 175], ["mice", "ORGANISM", 186, 190], ["ARG1", "PROTEIN", 99, 103], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["Previous studies", "TEST", 0, 16], ["hepatic autophagy", "TEST", 49, 66], ["hepatocyte", "TEST", 68, 78], ["the systemic arginine", "TEST", 109, 130], ["ornithine ratio", "TEST", 134, 149], ["reduced tumor growth", "PROBLEM", 162, 182], ["hepatic", "ANATOMY", 49, 56], ["autophagy", "OBSERVATION", 57, 66], ["hepatocyte", "ANATOMY", 68, 78], ["reduced", "OBSERVATION_MODIFIER", 162, 169], ["tumor", "OBSERVATION", 170, 175], ["growth", "OBSERVATION_MODIFIER", 176, 182]]], ["These lines of evidence suggest that endogenous metabolic reprogramming of the urea cycle modulates the pathophysiology during infectious disease.", [["urea", "CHEMICAL", 79, 83], ["infectious disease", "DISEASE", 127, 145], ["urea", "CHEMICAL", 79, 83], ["urea", "SIMPLE_CHEMICAL", 79, 83], ["the urea cycle", "PROBLEM", 75, 89], ["infectious disease", "PROBLEM", 127, 145], ["endogenous", "OBSERVATION_MODIFIER", 37, 47], ["metabolic reprogramming", "OBSERVATION", 48, 71], ["infectious", "OBSERVATION_MODIFIER", 127, 137]]], ["Our results may also provide a potential explanation for why many non-hepatotropic infections result in concomitant hepatitis (Adams and Hubscher, 2006, Lalazar and Ilan, 2014).", [["infections", "DISEASE", 83, 93], ["hepatitis", "DISEASE", 116, 125], ["many non-hepatotropic infections", "PROBLEM", 61, 93], ["concomitant hepatitis", "PROBLEM", 104, 125], ["infections", "OBSERVATION", 83, 93], ["hepatitis", "OBSERVATION", 116, 125]]], ["Taken together, our study provides evidence for an infection-induced reprogramming of the urea cycle in hepatocytes, a central metabolic pathway in the liver, leading to hyperammonemia alongside with the deregulation of systemic metabolism.", [["hepatocytes", "ANATOMY", 104, 115], ["liver", "ANATOMY", 152, 157], ["infection", "DISEASE", 51, 60], ["urea", "CHEMICAL", 90, 94], ["hyperammonemia", "DISEASE", 170, 184], ["urea", "CHEMICAL", 90, 94], ["urea", "SIMPLE_CHEMICAL", 90, 94], ["hepatocytes", "CELL", 104, 115], ["liver", "ORGAN", 152, 157], ["hepatocytes", "CELL_TYPE", 104, 115], ["our study", "TEST", 16, 25], ["an infection", "PROBLEM", 48, 60], ["the urea cycle in hepatocytes", "PROBLEM", 86, 115], ["a central metabolic pathway in the liver", "PROBLEM", 117, 157], ["hyperammonemia", "PROBLEM", 170, 184], ["systemic metabolism", "PROBLEM", 220, 239], ["evidence for", "UNCERTAINTY", 35, 47], ["infection", "OBSERVATION", 51, 60], ["hepatocytes", "ANATOMY", 104, 115], ["central", "ANATOMY_MODIFIER", 119, 126], ["metabolic pathway", "OBSERVATION", 127, 144], ["liver", "ANATOMY", 152, 157], ["hyperammonemia", "OBSERVATION", 170, 184], ["systemic metabolism", "OBSERVATION", 220, 239]]], ["We identified hepatocyte-intrinsic IFNAR1 signaling as a key regulator of circulating levels of arginine and ornithine to fine-tune adaptive immunity.", [["hepatocyte", "ANATOMY", 14, 24], ["arginine", "CHEMICAL", 96, 104], ["ornithine", "CHEMICAL", 109, 118], ["arginine", "CHEMICAL", 96, 104], ["ornithine", "CHEMICAL", 109, 118], ["hepatocyte", "CELL", 14, 24], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 35, 41], ["arginine", "SIMPLE_CHEMICAL", 96, 104], ["ornithine", "SIMPLE_CHEMICAL", 109, 118], ["IFNAR1", "PROTEIN", 35, 41], ["hepatocyte", "TEST", 14, 24], ["intrinsic IFNAR1 signaling", "PROBLEM", 25, 51], ["arginine and ornithine", "TREATMENT", 96, 118], ["hepatocyte", "ANATOMY", 14, 24], ["intrinsic IFNAR1", "OBSERVATION", 25, 41]]], ["This endogenous cytokine-driven mechanism of immunomodulation and host protection across organs could be targeted to ameliorate tissue pathology in infectious and inflammatory diseases.Key Resources Table ::: STAR\u2605Methods", [["organs", "ANATOMY", 89, 95], ["tissue", "ANATOMY", 128, 134], ["infectious and inflammatory diseases", "DISEASE", 148, 184], ["organs", "ORGAN", 89, 95], ["tissue", "TISSUE", 128, 134], ["endogenous cytokine", "PROTEIN", 5, 24], ["This endogenous cytokine", "TREATMENT", 0, 24], ["immunomodulation", "TREATMENT", 45, 61], ["host protection across organs", "TREATMENT", 66, 95], ["tissue pathology", "PROBLEM", 128, 144], ["infectious and inflammatory diseases", "PROBLEM", 148, 184], ["immunomodulation", "OBSERVATION", 45, 61], ["infectious", "OBSERVATION_MODIFIER", 148, 158], ["inflammatory", "OBSERVATION_MODIFIER", 163, 175]]]], "PMC7167216": [["IntroductionThe impact of the novel \u201csevere acute respiratory syndrome coronavirus-2\u201d (SARS-CoV-2) and the associated infection, Coronavirus Disease-2019 (COVID-2019), on all aspects of humanity and our healthcare workers cannot be overstated [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 44, 82], ["SARS-CoV-2", "CHEMICAL", 87, 97], ["infection", "DISEASE", 118, 127], ["Coronavirus Disease", "DISEASE", 129, 148], ["SARS-CoV-2", "SPECIES", 87, 97], ["the novel \u201csevere acute respiratory syndrome coronavirus", "PROBLEM", 26, 82], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["the associated infection", "PROBLEM", 103, 127], ["Coronavirus Disease", "PROBLEM", 129, 148], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["respiratory syndrome coronavirus", "OBSERVATION", 50, 82], ["infection", "OBSERVATION", 118, 127], ["Coronavirus Disease", "OBSERVATION", 129, 148]]], ["Nevertheless, as the number of positive cases continue to grow \u2013 with the associated morbidity and mortality, it is critical to control further spread via implementation and strict compliance with isolation precautions, as healthcare workers and other patients are at significant risk for exposure [2].", [["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260], ["the associated morbidity", "PROBLEM", 70, 94], ["isolation precautions", "TREATMENT", 197, 218]]], ["SARS-CoV-2 is a respiratory pathogen that is spread predominately through large droplets and contact (i.e. fomites such as surfaces) transmission [3].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV-2", "SPECIES", 0, 10], ["a respiratory pathogen", "PROBLEM", 14, 36], ["respiratory", "ANATOMY", 16, 27], ["pathogen", "OBSERVATION", 28, 36], ["large", "OBSERVATION_MODIFIER", 74, 79], ["droplets", "OBSERVATION", 80, 88]]], ["As such, respiratory and contact isolation precautions are paramount in limiting further exposure.", [["respiratory", "ANATOMY", 9, 20], ["respiratory and contact isolation precautions", "TREATMENT", 9, 54], ["respiratory", "ANATOMY", 9, 20]]], ["Because of the highly contagious nature of SARS-CoV-2 and its case fatality rate, much of which is still under investigation, additional precautions are recommended beyond what is typically used for limiting the spread of routine respiratory pathogens [4].", [["respiratory", "ANATOMY", 230, 241], ["SARS", "DISEASE", 43, 47], ["respiratory pathogens", "DISEASE", 230, 251], ["SARS-CoV-2", "ORGANISM", 43, 53], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["additional precautions", "TREATMENT", 126, 148], ["routine respiratory pathogens", "PROBLEM", 222, 251], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["contagious", "OBSERVATION_MODIFIER", 22, 32]]], ["Unfortunately, as the numbers of cases increase, some of the presumptively infected or confirmed SARS-CoV-2 patients will present with concomitant problems that might require surgical intervention.IntroductionFew specific guidelines are available to outline the steps necessary to adequately maintain appropriate isolation precautions in patients who require emergent surgical interventions and who are either confirmed SARS-CoV2 or who are awaiting the results of testing.", [["SARS", "DISEASE", 97, 101], ["SARS-CoV-2", "ORGANISM", 97, 107], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 338, 346], ["SARS-CoV", "SPECIES", 97, 105], ["SARS", "PROBLEM", 97, 101], ["concomitant problems", "PROBLEM", 135, 155], ["surgical intervention", "TREATMENT", 175, 196], ["appropriate isolation precautions", "TREATMENT", 301, 334], ["emergent surgical interventions", "TREATMENT", 359, 390], ["testing", "TEST", 465, 472]]], ["The purpose of this discussion is to outline the steps our U.S. institution undertook in managing a patient who required emergent cardiac surgery for an acute aortic syndrome who was presumptively infected, and did test positive on post-operative day two.", [["cardiac", "ANATOMY", 130, 137], ["aortic", "ANATOMY", 159, 165], ["acute aortic syndrome", "DISEASE", 153, 174], ["patient", "ORGANISM", 100, 107], ["cardiac", "ORGAN", 130, 137], ["aortic", "ORGAN", 159, 165], ["patient", "SPECIES", 100, 107], ["emergent cardiac surgery", "TREATMENT", 121, 145], ["an acute aortic syndrome", "PROBLEM", 150, 174], ["cardiac", "ANATOMY", 130, 137], ["surgery", "OBSERVATION", 138, 145], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["aortic", "ANATOMY", 159, 165], ["syndrome", "OBSERVATION", 166, 174]]], ["This is particularly important due to reports of the virus still being found on un-sanitized surfaces for up to 17 days [3].Preparing for surgery ::: Case presentation", [["the virus", "PROBLEM", 49, 58], ["un-sanitized surfaces", "TREATMENT", 80, 101]]]], "PMC7446142": [["EinleitungIn allen deutschen Bundesl\u00e4ndern wurden im M\u00e4rz 2020 Ma\u00dfnahmen (Kontakt- und Mobilit\u00e4tseinschr\u00e4nkungen, Schlie\u00dfung von Kindertagesst\u00e4tten und Schulen etc.) ergriffen, um die Ausbreitung von COVID-19 zu verhindern.", [["EinleitungIn allen deutschen Bundesl\u00e4ndern wurden im M\u00e4rz 2020 Ma\u00dfnahmen (Kontakt- und Mobilit\u00e4tseinschr\u00e4nkungen, Schlie\u00dfung von Kindertagesst\u00e4tten und Schulen etc.) ergriffen, um die Ausbreitung von COVID-19 zu verhindern", "SPECIES", 0, 222]]], ["Insbesondere zur Infektion, zum klinischen Verlauf und zur Infektiosit\u00e4t bei Kindern gibt es bislang wenig verl\u00e4ssliche Daten, die zur Entscheidung \u00fcber die Wiederer\u00f6ffnung von Kinderbetreuungseinrichtungen beitragen.Einleitung", [["Einleitung", "CHEMICAL", 217, 227], ["Einleitung", "CHEMICAL", 217, 227], ["Insbesondere zur Infektion, zum klinischen Verlauf und zur Infektiosit\u00e4t bei Kindern gibt es bislang wenig verl\u00e4ssliche Daten, die zur Entscheidung \u00fcber die Wiederer\u00f6ffnung von Kinderbetreuungseinrichtungen beitragen", "SPECIES", 0, 216], ["zum klinischen Verlauf", "TREATMENT", 28, 50]]]], "PMC7443554": [["On March 11, 2020, the World Health Organization announced that the coronavirus disease (COVID-19) is a pandemic crisis.", [["coronavirus disease", "DISEASE", 68, 87], ["COVID-19", "CHEMICAL", 89, 97], ["pandemic", "DISEASE", 104, 112], ["coronavirus", "ORGANISM", 68, 79], ["the coronavirus disease", "PROBLEM", 64, 87], ["COVID", "TEST", 89, 94], ["a pandemic crisis", "PROBLEM", 102, 119], ["coronavirus disease", "OBSERVATION", 68, 87], ["pandemic crisis", "OBSERVATION", 104, 119]]], ["Besides the disease itself, the fear from COVID-19 has a high psychological burden (eg, psychological distress, anxiety, and depression) on patients and their families, medical staff, health care workers, and the general population.1 These days, we are faced with a lot of information regarding COVID-19 from different sources.", [["anxiety", "DISEASE", 112, 119], ["depression", "DISEASE", 125, 135], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["the disease itself", "PROBLEM", 8, 26], ["COVID", "TEST", 42, 47], ["a high psychological burden (eg", "PROBLEM", 55, 86], ["psychological distress", "PROBLEM", 88, 110], ["anxiety", "PROBLEM", 112, 119], ["depression", "PROBLEM", 125, 135], ["COVID", "TREATMENT", 295, 300], ["disease", "OBSERVATION", 12, 19]]], ["However, fake information, gossip, and rumors seem to be more common than factual information about this disease.", [["this disease", "PROBLEM", 100, 112]]]], "77be754c1f757d4fc481c3a4062d5c76ba744fa4": [["Further, as we attempt to preserve personal protective equipment (PPE) in the face of a critical nationwide shortage, many EDs have moved to use telephone and video technology to interview, reassess, and educate our patients; and therefore, even the comfort provided by the doctor \"walking in\" may be lost.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["personal protective equipment", "TREATMENT", 35, 64]]], ["This may serve -explicitly or implicitly -to increase a patient's sense of isolation and even stigmatization.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["isolation", "TREATMENT", 75, 84]]], ["And the interpersonal isolation experienced by our patients is even more pronounced outside the walls of the ED.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["the interpersonal isolation", "TREATMENT", 4, 31], ["walls", "ANATOMY_MODIFIER", 96, 101]]]], "PMC7194558": [["The study by Kiesha Prem and colleagues1 in The Lancet Public Health is crucial for policy makers everywhere, as it indicates the effects of extending or relaxing physical distancing control measures on the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China.", [["coronavirus disease", "DISEASE", 207, 226], ["coronavirus", "ORGANISM", 207, 218], ["The study", "TEST", 0, 9], ["relaxing physical distancing control measures", "TREATMENT", 154, 199], ["the coronavirus disease", "PROBLEM", 203, 226]]], ["Prem and colleagues1 use observed data on COVID-19 spread from Wuhan and finely detailed empirical data from China on the number of contacts per day by age group at home, school, work, and other locations.2 Their model indicates that if the physical distancing measures begun in late January, 2020, in Wuhan are gradually relaxed in March, the virus could start to resurge 3 months later in June, and generate a second peak 5 months later at the end of August, 2020.", [["COVID", "TEST", 42, 47], ["the virus", "PROBLEM", 340, 349]]], ["Their projections suggest that an additional month of physical distancing measures (or other methods, such as widespread testing) could buy 2 additional months before such measures would have to be reinstated to prevent the resurgence of the epidemic toward health-care system overload.", [["physical distancing measures", "TREATMENT", 54, 82], ["overload", "PROBLEM", 277, 285]]]], "PMC7255735": [["IntroductionAn outbreak of pneumonia of unknown origin was first reported in Wuhan, China, on Dec 31, 2019.", [["pneumonia", "DISEASE", 27, 36], ["pneumonia", "PROBLEM", 27, 36], ["pneumonia", "OBSERVATION", 27, 36], ["unknown origin", "OBSERVATION_MODIFIER", 40, 54]]], ["After a week, the cause had been identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 With a persistently increasing number of cases of COVID-19 worldwide, WHO declared a pandemic on March 11, 2020.2 Spain has been one of the most affected countries worldwide with 203 715 confirmed cases as of April 30, 2020.3 Particularly, the Community of Madrid has documented the highest number of cases within the country.4", [["acute respiratory syndrome coronavirus", "DISEASE", 54, 92], ["severe acute respiratory syndrome coronavirus", "SPECIES", 47, 92], ["SARS-CoV", "SPECIES", 96, 104], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 47, 92], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["COVID", "TREATMENT", 160, 165], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome", "OBSERVATION", 60, 80], ["persistently", "OBSERVATION_MODIFIER", 117, 129], ["increasing", "OBSERVATION_MODIFIER", 130, 140]]]], "ae8ab88c9d7d891f5bd4927ef0a1ca51a6175acd": [["IntroductionMarine natural products research is a dynamic and constantly changing field that has evolved and adapted new technologies with cutting-edge molecular and cell biology.", [["cell", "ANATOMY", 166, 170], ["cell", "CELL", 166, 170]]], ["Modern high-field multidimensional nuclear magnetic resonance (NMR) methods facilitate the rapid structure elucidation of minute quantities of pharmacologically active natural products.", [["high", "OBSERVATION_MODIFIER", 7, 11], ["pharmacologically", "OBSERVATION_MODIFIER", 143, 160], ["active", "OBSERVATION_MODIFIER", 161, 167], ["natural products", "OBSERVATION", 168, 184]]], ["Advances in microbial sourcing have yielded exciting new biological diversity.", [["new", "OBSERVATION_MODIFIER", 53, 56], ["biological diversity", "OBSERVATION", 57, 77]]], ["This is especially true in the field of marine natural products, where marine bacteria and fungi have began to eclipse sponges and other invertebrates as important sources of novel chemistry (see \u25b6 Chap.", [["marine bacteria", "PROBLEM", 71, 86], ["fungi", "PROBLEM", 91, 96], ["novel chemistry", "TEST", 175, 190]]], ["3) [1] [2] [3] [4] [5] .IntroductionThe activation of oncogenes and/or the inactivation of tumor suppressor genes plays an important role in the etiology and progression of cancer, an assemblage of diseases that result from accumulated mutations.", [["tumor", "ANATOMY", 91, 96], ["cancer", "ANATOMY", 173, 179], ["tumor", "DISEASE", 91, 96], ["cancer", "DISEASE", 173, 179], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 3, 22], ["tumor", "CANCER", 91, 96], ["cancer", "CANCER", 173, 179], ["oncogenes", "DNA", 54, 63], ["tumor suppressor genes", "DNA", 91, 113], ["The activation of oncogenes", "TREATMENT", 36, 63], ["the inactivation of tumor suppressor genes", "TREATMENT", 71, 113], ["cancer", "PROBLEM", 173, 179], ["diseases", "PROBLEM", 198, 206], ["accumulated mutations", "PROBLEM", 224, 245], ["tumor", "OBSERVATION", 91, 96], ["cancer", "OBSERVATION", 173, 179], ["accumulated mutations", "OBSERVATION", 224, 245]]], ["Our knowledge of cancer genetics has expanded rapidly during the past few decades.", [["cancer", "ANATOMY", 17, 23], ["cancer", "DISEASE", 17, 23], ["cancer", "CANCER", 17, 23], ["cancer", "OBSERVATION", 17, 23], ["expanded", "OBSERVATION_MODIFIER", 37, 45], ["rapidly", "OBSERVATION_MODIFIER", 46, 53]]], ["Since the initial discovery of oncogenes, the field of cancer biology has grown to include the elucidation of the molecular mechanisms that underlie tumorigenesis, tumor growth, progression, metastasis, tumor cell death, and treatment resistance.", [["cancer", "ANATOMY", 55, 61], ["tumor", "ANATOMY", 164, 169], ["tumor cell", "ANATOMY", 203, 213], ["cancer", "DISEASE", 55, 61], ["tumor", "DISEASE", 164, 169], ["metastasis", "DISEASE", 191, 201], ["tumor", "DISEASE", 203, 208], ["death", "DISEASE", 214, 219], ["cancer", "CANCER", 55, 61], ["tumor", "CANCER", 164, 169], ["tumor cell", "CELL", 203, 213], ["oncogenes", "DNA", 31, 40], ["tumor growth", "PROBLEM", 164, 176], ["progression", "PROBLEM", 178, 189], ["metastasis", "PROBLEM", 191, 201], ["tumor cell death", "PROBLEM", 203, 219], ["treatment resistance", "TREATMENT", 225, 245], ["cancer", "OBSERVATION", 55, 61], ["tumorigenesis", "OBSERVATION", 149, 162], ["tumor", "OBSERVATION_MODIFIER", 164, 169], ["growth", "OBSERVATION_MODIFIER", 170, 176], ["progression", "OBSERVATION_MODIFIER", 178, 189], ["metastasis", "OBSERVATION", 191, 201], ["tumor cell death", "OBSERVATION", 203, 219]]], ["As a result, mechanismbased drug discovery efforts have prospered and molecular-targeted agents (i.e., trastuzumab) are in clinical use.", [["trastuzumab", "CHEMICAL", 103, 114], ["trastuzumab", "SIMPLE_CHEMICAL", 103, 114], ["molecular-targeted agents", "TREATMENT", 70, 95], ["trastuzumab", "TREATMENT", 103, 114]]], ["By integrating critical technological advancements with a growing number of important molecular mechanism-based antitumor targets, marine natural products research currently plays a vital role in anticancer drug discovery [6, 7] .", [["antitumor", "ANATOMY", 112, 121], ["anticancer", "ANATOMY", 196, 206], ["antitumor", "CANCER", 112, 121], ["anticancer", "CANCER", 196, 206], ["marine natural products", "TREATMENT", 131, 154], ["molecular mechanism", "OBSERVATION", 86, 105], ["antitumor targets", "OBSERVATION", 112, 129]]], ["In addition, newly developed strategies aim to alter the genetic regulation of secondary metabolite biosynthesis.", [["secondary metabolite biosynthesis", "PROBLEM", 79, 112], ["secondary", "OBSERVATION", 79, 88], ["metabolite biosynthesis", "OBSERVATION", 89, 112]]], ["Taken together, these advances show great promise to increase the structural diversity of natural products for drug discovery.IntroductionWhile the face of natural products chemistry has dramatically changed, the therapeutic potential of compounds identified in anticancer marine natural product programs remains inexorably tied to the quality of the bioassay methods used to direct the discovery efforts.", [["anticancer", "ANATOMY", 262, 272], ["anticancer", "CANCER", 262, 272], ["natural products", "TREATMENT", 90, 106], ["the bioassay methods", "TREATMENT", 347, 367], ["great", "OBSERVATION_MODIFIER", 36, 41], ["structural", "OBSERVATION_MODIFIER", 66, 76], ["diversity", "OBSERVATION_MODIFIER", 77, 86], ["natural products", "OBSERVATION", 90, 106]]], ["In this respect, there is a fundamental need for cuttingedge molecular and biomedical research to support nearly all aspects of contemporary antitumor drug discovery.", [["antitumor", "ANATOMY", 141, 150], ["antitumor", "CANCER", 141, 150], ["cuttingedge molecular", "TREATMENT", 49, 70]]], ["Yet, few chemists are specifically trained to critically evaluate the cell biology that supports the potential significance of anticancer targets or the molecular biology involved in the design of molecular-targeted antitumor bioassay methods.", [["cell", "ANATOMY", 70, 74], ["anticancer", "ANATOMY", 127, 137], ["antitumor", "ANATOMY", 216, 225], ["cell", "CELL", 70, 74], ["anticancer", "CANCER", 127, 137], ["antitumor", "CANCER", 216, 225], ["anticancer targets", "PROBLEM", 127, 145], ["targeted antitumor bioassay methods", "TREATMENT", 207, 242]]], ["To ensure the quality of these efforts, the most successful programs usually depend on strong collaborative research efforts with molecular and tumor cell biologists, pharmacologists, and experts in the design of high-throughput bioassay systems.IntroductionImportant factors that must be considered when using modern molecular-targeted antitumor bioassay methods comprise a relatively short list of drug target-associated, bioassay method-dependent, and test sample source-specific factors.", [["tumor cell", "ANATOMY", 144, 154], ["antitumor", "ANATOMY", 337, 346], ["tumor", "DISEASE", 144, 149], ["tumor cell", "CELL", 144, 154], ["antitumor", "CANCER", 337, 346], ["IntroductionImportant factors", "PROBLEM", 246, 275], ["test sample source", "TEST", 455, 473], ["tumor cell", "OBSERVATION", 144, 154]]], ["These may include, but are not limited to, the following list of points that require careful consideration: (a) identification of a molecular target; (b) validation of the antitumor target; (c) selection of a measurable biochemical, chemical, or biological process for the assay; (d) methods used to acquire or measure the data; (e) use of experimental controls; (f) bioassay validation and the application of appropriate statistical methods; (g) possible experimental artifacts; (h) active compound identification; and (i) nuisance compounds and methods for chemical dereplication.", [["antitumor", "ANATOMY", 172, 181], ["antitumor", "CANCER", 172, 181], ["a molecular target", "PROBLEM", 130, 148], ["the assay", "TEST", 269, 278], ["experimental controls", "TREATMENT", 340, 361], ["bioassay validation", "TREATMENT", 367, 386], ["experimental artifacts", "PROBLEM", 456, 478], ["chemical dereplication", "TREATMENT", 559, 581]]], ["It may not be feasible to expect all natural products chemists to become experts in bioassay systems.", [["may not be", "UNCERTAINTY", 3, 13]]], ["Nonetheless, a general appreciation for these important assay components is critical to the success of every molecular-targeted antitumor drug discovery process.IntroductionThe transcription factor hypoxia-inducible factor-1 (HIF-1) has emerged as an important target for anticancer drug discovery [8] [9] [10] [11] [12] .", [["antitumor", "ANATOMY", 128, 137], ["anticancer", "ANATOMY", 272, 282], ["antitumor", "CANCER", 128, 137], ["hypoxia-inducible factor-1", "GENE_OR_GENE_PRODUCT", 198, 224], ["HIF-1", "GENE_OR_GENE_PRODUCT", 226, 231], ["anticancer", "CANCER", 272, 282], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 298, 320], ["transcription factor", "PROTEIN", 177, 197], ["hypoxia-inducible factor-1 (HIF-1", "PROTEIN", 198, 231], ["these important assay components", "PROBLEM", 40, 72], ["The transcription factor hypoxia-inducible factor", "PROBLEM", 173, 222]]], ["Hypoxic conditions (decreased oxygen tension) that are present within actively growing tumor masses activate HIF-1.", [["tumor masses", "ANATOMY", 87, 99], ["oxygen", "CHEMICAL", 30, 36], ["tumor", "DISEASE", 87, 92], ["oxygen", "CHEMICAL", 30, 36], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["tumor masses", "CANCER", 87, 99], ["HIF-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["HIF-1", "PROTEIN", 109, 114], ["Hypoxic conditions", "PROBLEM", 0, 18], ["decreased oxygen tension", "PROBLEM", 20, 44], ["actively growing tumor masses", "PROBLEM", 70, 99], ["decreased", "OBSERVATION_MODIFIER", 20, 29], ["oxygen tension", "OBSERVATION", 30, 44], ["growing", "OBSERVATION_MODIFIER", 79, 86], ["tumor", "OBSERVATION_MODIFIER", 87, 92], ["masses", "OBSERVATION", 93, 99]]], ["The heterodimeric protein complex known collectively as HIF-1 then regulates the transcriptional response to tumor hypoxia [13] .", [["tumor", "ANATOMY", 109, 114], ["tumor", "DISEASE", 109, 114], ["hypoxia", "DISEASE", 115, 122], ["HIF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["tumor", "CANCER", 109, 114], ["heterodimeric protein complex", "PROTEIN", 4, 33], ["HIF-1", "PROTEIN", 56, 61], ["The heterodimeric protein complex", "PROBLEM", 0, 33], ["tumor hypoxia", "PROBLEM", 109, 122], ["protein complex", "OBSERVATION", 18, 33], ["tumor", "OBSERVATION", 109, 114]]], ["Numerous natural products have been identified that regulate HIF-1 activation and suppress tumorrelated HIF-1 target genes [14] [15] [16] .", [["HIF-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["HIF-1", "GENE_OR_GENE_PRODUCT", 104, 109], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 123, 137], ["HIF", "PROTEIN", 61, 64], ["HIF-1 target genes", "DNA", 104, 122], ["Numerous natural products", "TREATMENT", 0, 25]]], ["Because of its current distinction in the drug discovery process, HIF-1 has been selected as a representative example to demonstrate the importance of the previously outlined points that must be considered in the design and implementation of molecular-targeted bioassays used in the discovery of antitumor natural products.", [["antitumor", "ANATOMY", 296, 305], ["HIF-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["antitumor", "CANCER", 296, 305], ["HIF-1", "PROTEIN", 66, 71], ["molecular-targeted bioassays", "TREATMENT", 242, 270], ["antitumor natural products", "TREATMENT", 296, 322]]], ["Screening efforts have shown the marine invertebrate and algal extracts in the U.S. National Cancer Institute's Open Repository to be a valuable source of new regulators of HIF-1 signaling [14] .", [["extracts", "ANATOMY", 63, 71], ["Cancer", "DISEASE", 93, 99], ["algal extracts", "ORGANISM_SUBSTANCE", 57, 71], ["HIF-1", "GENE_OR_GENE_PRODUCT", 173, 178], ["HIF", "PROTEIN", 173, 176]]], ["Compounds isolated from marine organisms appear to either inhibit or promote HIF-1 activation.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["HIF", "PROTEIN", 77, 80], ["marine organisms", "PROBLEM", 24, 40]]], ["In addition to its coverage of basic concepts in molecular-targeted antitumor drug discovery, this chapter highlights the emerging role of marine natural products as potential regulators of HIF-mediated hypoxic signaling.Bioassay Target SelectionPerhaps, nowhere in natural product-based drug discovery is bioassay target selection more important than in the field of molecular-targeted antitumor drug discovery.", [["antitumor", "ANATOMY", 68, 77], ["antitumor", "ANATOMY", 387, 396], ["antitumor", "CANCER", 68, 77], ["HIF", "GENE_OR_GENE_PRODUCT", 190, 193], ["antitumor", "CANCER", 387, 396], ["HIF", "PROTEIN", 190, 193], ["marine natural products", "TREATMENT", 139, 162], ["hypoxic signaling", "PROBLEM", 203, 220], ["natural product", "TREATMENT", 266, 281], ["antitumor drug", "OBSERVATION", 68, 82], ["hypoxic signaling", "OBSERVATION", 203, 220], ["antitumor drug", "OBSERVATION", 387, 401]]], ["Traditional antitumor drug discovery has relied heavily on tumor cell viability assays for the identification of new natural product-based anticancer compounds [17] [18] [19] .", [["antitumor", "ANATOMY", 12, 21], ["tumor cell", "ANATOMY", 59, 69], ["anticancer", "ANATOMY", 139, 149], ["tumor", "DISEASE", 59, 64], ["[17] [18] [19]", "CHEMICAL", 160, 174], ["antitumor", "CANCER", 12, 21], ["tumor cell", "CELL", 59, 69], ["anticancer", "CANCER", 139, 149], ["[17] [18] [19]", "SIMPLE_CHEMICAL", 160, 174], ["Traditional antitumor drug discovery", "TREATMENT", 0, 36], ["tumor cell viability assays", "TEST", 59, 86], ["new natural product-based anticancer compounds", "PROBLEM", 113, 159], ["new", "OBSERVATION_MODIFIER", 113, 116]]], ["Assay target selection consisted mainly of a choice in tumor cell lines and/or in the design of specific assays to discriminate between agents that produce either a cytostatic or cytotoxic effect.", [["tumor cell lines", "ANATOMY", 55, 71], ["tumor", "DISEASE", 55, 60], ["tumor cell lines", "CELL", 55, 71], ["tumor cell lines", "CELL_LINE", 55, 71], ["Assay target selection", "TEST", 0, 22], ["tumor cell lines", "TREATMENT", 55, 71], ["agents", "TREATMENT", 136, 142], ["a cytostatic or cytotoxic effect", "PROBLEM", 163, 195], ["tumor cell lines", "OBSERVATION", 55, 71], ["cytostatic", "OBSERVATION_MODIFIER", 165, 175], ["cytotoxic effect", "OBSERVATION", 179, 195]]], ["In these cases, the bioassay target can be considered the tumor class, which is equated to the tumor cell line tissue source.", [["tumor", "ANATOMY", 58, 63], ["tumor cell line tissue", "ANATOMY", 95, 117], ["tumor", "DISEASE", 58, 63], ["tumor", "DISEASE", 95, 100], ["tumor", "CANCER", 58, 63], ["tumor cell line", "CELL", 95, 110], ["tissue", "TISSUE", 111, 117], ["the tumor class", "PROBLEM", 54, 69], ["the tumor cell line tissue source", "PROBLEM", 91, 124], ["tumor", "OBSERVATION", 58, 63], ["tumor cell line tissue", "OBSERVATION", 95, 117]]], ["Although this strategy may currently be considered less fashionable, it continues to produce some of the most promising anticancer marine natural products (salinosporamide [20, 21] and Yondelis/ET-743/trabectedin [22, 23] ).", [["anticancer", "ANATOMY", 120, 130], ["salinosporamide [20, 21] and Yondelis/ET-743", "CHEMICAL", 156, 200], ["trabectedin", "CHEMICAL", 201, 212], ["salinosporamide", "CHEMICAL", 156, 171], ["ET-743", "CHEMICAL", 194, 200], ["trabectedin", "CHEMICAL", 201, 212], ["anticancer", "CANCER", 120, 130], ["salinosporamide", "SIMPLE_CHEMICAL", 156, 171], ["Yondelis/ET-743", "SIMPLE_CHEMICAL", 185, 200], ["trabectedin", "SIMPLE_CHEMICAL", 201, 212]]], ["Marine natural products researchers have taken advantage of modern high-throughput bioassays to identify new compounds that function through an assorted array of antitumor molecular targets [14] .Bioassay Target SelectionThe definition of an antitumor molecular target is somewhat subjective.", [["antitumor", "ANATOMY", 162, 171], ["antitumor", "ANATOMY", 242, 251], ["antitumor", "CANCER", 162, 171], ["antitumor", "CANCER", 242, 251], ["Marine natural products", "TREATMENT", 0, 23], ["modern high-throughput bioassays", "TREATMENT", 60, 92], ["new compounds", "PROBLEM", 105, 118], ["an antitumor molecular target", "PROBLEM", 239, 268], ["antitumor molecular target", "OBSERVATION", 242, 268]]], ["One investigator may consider an enzyme/enzymatic activity, protein-protein interaction, or protein-DNA interaction as the molecular target.", [["DNA", "CELLULAR_COMPONENT", 100, 103], ["enzyme", "PROTEIN", 33, 39], ["an enzyme", "TEST", 30, 39], ["protein", "TEST", 92, 99]]], ["Superficially, enzymes such as receptor protein kinases, cyclin-dependent kinases, checkpoint kinases, topoisomerases, DNA polymerases, and other proteins that mediate important reactions can be thought of in this way.", [["cyclin-dependent kinases", "GENE_OR_GENE_PRODUCT", 57, 81], ["topoisomerases", "GENE_OR_GENE_PRODUCT", 103, 117], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["receptor protein kinases", "PROTEIN", 31, 55], ["cyclin-dependent kinases", "PROTEIN", 57, 81], ["checkpoint kinases", "PROTEIN", 83, 101], ["topoisomerases", "PROTEIN", 103, 117], ["DNA polymerases", "PROTEIN", 119, 134], ["enzymes", "TEST", 15, 22], ["receptor protein kinases", "TEST", 31, 55], ["cyclin-dependent kinases", "TEST", 57, 81], ["checkpoint kinases", "TEST", 83, 101], ["topoisomerases", "PROBLEM", 103, 117], ["DNA polymerases", "PROBLEM", 119, 134]]], ["In this case, an antitumor molecular target is something as conceptually straightforward as a specific protein or proteinmediated biochemical reaction.", [["antitumor", "ANATOMY", 17, 26], ["antitumor", "CANCER", 17, 26], ["a specific protein or proteinmediated biochemical reaction", "PROBLEM", 92, 150]]], ["However, another drug discovery group may consider the disruption of a genetically controlled process as the molecular target, even though many individual steps may be involved in regulating the control of the overall process.", [["a genetically controlled process", "PROBLEM", 69, 101]]], ["In this case, the molecular target is viewed more as a complex set of biochemical and genetic events that may involve many proteins or other macromolecules.", [["biochemical and genetic events", "PROBLEM", 70, 100]]], ["Under this broader definition, antitumor molecular targets include such occurrences as apoptosis-related cellular signaling, mammalian target of rapamycin (mTOR)-regulated protein expression, proteasome-mediated protein degradation, heat shock protein-dependent protein stability, etc. This broader view also includes the targeting of specific genes and the transcriptional or translational events involved in protein-mediated processes.", [["antitumor", "ANATOMY", 31, 40], ["cellular", "ANATOMY", 105, 113], ["rapamycin", "CHEMICAL", 145, 154], ["rapamycin", "CHEMICAL", 145, 154], ["antitumor", "CANCER", 31, 40], ["cellular", "CELL", 105, 113], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 125, 154], ["mTOR", "GENE_OR_GENE_PRODUCT", 156, 160], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 233, 251], ["mTOR", "PROTEIN", 156, 160], ["proteasome", "PROTEIN", 192, 202], ["heat shock protein", "PROTEIN", 233, 251], ["antitumor molecular targets", "TREATMENT", 31, 58], ["apoptosis", "PROBLEM", 87, 96], ["cellular signaling", "PROBLEM", 105, 123], ["rapamycin (mTOR", "TREATMENT", 145, 160], ["regulated protein expression", "PROBLEM", 162, 190], ["proteasome-mediated protein degradation", "TREATMENT", 192, 231], ["heat shock protein", "TEST", 233, 251], ["dependent protein stability", "PROBLEM", 252, 279], ["This broader view", "TEST", 286, 303], ["translational events", "PROBLEM", 377, 397], ["cellular signaling", "OBSERVATION", 105, 123], ["protein stability", "OBSERVATION", 262, 279]]], ["According to this broader definition, drug discovery groups may employ assays that specifically examine the effects of small molecules on the multistep processes that regulate the expression or function of genes that are considered to be important in tumorigenesis, tumor progression, or metastasis.", [["tumor", "ANATOMY", 266, 271], ["tumor", "DISEASE", 266, 271], ["metastasis", "DISEASE", 288, 298], ["tumor", "CANCER", 266, 271], ["small molecules", "PROBLEM", 119, 134], ["tumor progression", "PROBLEM", 266, 283], ["metastasis", "PROBLEM", 288, 298], ["small", "OBSERVATION_MODIFIER", 119, 124], ["molecules", "OBSERVATION", 125, 134], ["tumor", "OBSERVATION", 266, 271], ["metastasis", "OBSERVATION", 288, 298]]], ["In this light, oncogenic gene transcription and the proteins involved in regulating tumor-associated gene transcription have emerged as major targets for anticancer drug discovery programs that focus on the regulation of specific tumorspecific gene function [24] .Bioassay Target SelectionThe distinctions between various molecular target definitions quickly blur when one considers the interactions between the systems involved in each class of antitumor molecular target.", [["tumor", "ANATOMY", 84, 89], ["anticancer", "ANATOMY", 154, 164], ["antitumor", "ANATOMY", 446, 455], ["tumor", "DISEASE", 84, 89], ["tumor", "CANCER", 84, 89], ["anticancer", "CANCER", 154, 164], ["antitumor", "CANCER", 446, 455], ["oncogenic gene transcription", "TREATMENT", 15, 43], ["the proteins", "PROBLEM", 48, 60], ["regulating tumor", "PROBLEM", 73, 89], ["gene transcription", "TREATMENT", 101, 119], ["anticancer drug discovery programs", "TREATMENT", 154, 188], ["tumor", "OBSERVATION", 84, 89], ["various", "OBSERVATION_MODIFIER", 314, 321], ["molecular", "OBSERVATION_MODIFIER", 322, 331], ["target definitions", "OBSERVATION", 332, 350]]], ["Enzymes may be considered biochemical targets, but enzymes can regulate the synthesis of proteins that control gene expression.", [["enzymes", "PROTEIN", 51, 58], ["Enzymes", "TEST", 0, 7], ["biochemical targets", "TEST", 26, 45], ["enzymes", "TEST", 51, 58], ["the synthesis of proteins", "PROBLEM", 72, 97]]], ["Similarly, oncogenes may code for the production of enzymes or other proteins that play an important role in biochemical processes that enhance the growth and spread of tumors.", [["tumors", "ANATOMY", 169, 175], ["tumors", "DISEASE", 169, 175], ["tumors", "CANCER", 169, 175], ["oncogenes", "DNA", 11, 20], ["enzymes", "PROTEIN", 52, 59], ["the production of enzymes", "TEST", 34, 59], ["other proteins", "PROBLEM", 63, 77], ["tumors", "PROBLEM", 169, 175], ["growth", "OBSERVATION_MODIFIER", 148, 154], ["tumors", "OBSERVATION", 169, 175]]], ["Oncogenes may also code for transcription factors that regulate the expression of other genes involved in tumorigenesis.", [["Oncogenes", "GENE_OR_GENE_PRODUCT", 0, 9], ["Oncogenes", "PROTEIN", 0, 9], ["transcription factors", "PROTEIN", 28, 49], ["transcription factors", "TREATMENT", 28, 49]]], ["In such cases, each specific step in the process of DNA replication, transcription, translation, and protein function may represent a potentially druggable step within a single molecular target.Bioassay Target SelectionHypoxia is one of the signature features of the tumor microenvironment.", [["tumor", "ANATOMY", 267, 272], ["tumor", "DISEASE", 267, 272], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["tumor", "CANCER", 267, 272], ["DNA replication", "TREATMENT", 52, 67], ["tumor", "OBSERVATION", 267, 272]]], ["The rapid growth of tumor cells outstrips the capacity of tumor blood vessels to supply oxygen.", [["tumor cells", "ANATOMY", 20, 31], ["tumor blood vessels", "ANATOMY", 58, 77], ["tumor", "DISEASE", 20, 25], ["tumor", "DISEASE", 58, 63], ["oxygen", "CHEMICAL", 88, 94], ["oxygen", "CHEMICAL", 88, 94], ["tumor cells", "CELL", 20, 31], ["tumor blood vessels", "MULTI-TISSUE_STRUCTURE", 58, 77], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["tumor cells", "CELL_TYPE", 20, 31], ["The rapid growth of tumor cells", "PROBLEM", 0, 31], ["tumor blood vessels", "PROBLEM", 58, 77], ["oxygen", "TREATMENT", 88, 94], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["tumor cells", "OBSERVATION", 20, 31], ["capacity", "OBSERVATION_MODIFIER", 46, 54], ["tumor", "OBSERVATION", 58, 63], ["vessels", "ANATOMY", 70, 77], ["oxygen", "OBSERVATION_MODIFIER", 88, 94]]], ["Newly formed tumor blood vessels often fail to mature, and the tumor blood flow is sluggish and irregular [25] .", [["tumor blood vessels", "ANATOMY", 13, 32], ["tumor blood", "ANATOMY", 63, 74], ["tumor", "DISEASE", 13, 18], ["tumor", "DISEASE", 63, 68], ["tumor blood vessels", "MULTI-TISSUE_STRUCTURE", 13, 32], ["tumor", "CANCER", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["Newly formed tumor blood vessels", "PROBLEM", 0, 32], ["the tumor blood flow", "TEST", 59, 79], ["tumor", "OBSERVATION", 13, 18], ["vessels", "ANATOMY", 25, 32], ["mature", "OBSERVATION_MODIFIER", 47, 53], ["tumor", "OBSERVATION", 63, 68], ["flow", "OBSERVATION_MODIFIER", 75, 79], ["sluggish", "OBSERVATION_MODIFIER", 83, 91], ["irregular", "OBSERVATION_MODIFIER", 96, 105]]], ["The combination of increased oxygen demand and insufficient oxygen delivery yields hypoxic regions that are commonly found in solid tumors.", [["solid tumors", "ANATOMY", 126, 138], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 60, 66], ["tumors", "DISEASE", 132, 138], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 60, 66], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["oxygen", "SIMPLE_CHEMICAL", 60, 66], ["solid tumors", "CANCER", 126, 138], ["increased oxygen demand", "PROBLEM", 19, 42], ["insufficient oxygen delivery", "TREATMENT", 47, 75], ["hypoxic regions", "PROBLEM", 83, 98], ["solid tumors", "PROBLEM", 126, 138], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["oxygen demand", "OBSERVATION", 29, 42], ["insufficient", "OBSERVATION_MODIFIER", 47, 59], ["oxygen", "OBSERVATION_MODIFIER", 60, 66], ["solid", "OBSERVATION_MODIFIER", 126, 131], ["tumors", "OBSERVATION", 132, 138]]], ["Clinical studies indicate that the extent of tumor hypoxia correlates with advanced disease stages and poor prognosis.", [["tumor", "ANATOMY", 45, 50], ["tumor", "DISEASE", 45, 50], ["hypoxia", "DISEASE", 51, 58], ["tumor", "CANCER", 45, 50], ["Clinical studies", "TEST", 0, 16], ["tumor hypoxia", "PROBLEM", 45, 58], ["advanced disease stages", "PROBLEM", 75, 98], ["tumor", "OBSERVATION", 45, 50], ["advanced", "OBSERVATION_MODIFIER", 75, 83], ["disease", "OBSERVATION", 84, 91]]], ["Unlike normal cells from the same tissue, tumor cells are often chronically hypoxic [26] .", [["cells", "ANATOMY", 14, 19], ["tissue", "ANATOMY", 34, 40], ["tumor cells", "ANATOMY", 42, 53], ["tumor", "DISEASE", 42, 47], ["cells", "CELL", 14, 19], ["tissue", "TISSUE", 34, 40], ["tumor cells", "CELL", 42, 53], ["normal cells", "CELL_TYPE", 7, 19], ["tumor cells", "CELL_TYPE", 42, 53], ["tumor cells", "PROBLEM", 42, 53], ["chronically hypoxic", "PROBLEM", 64, 83], ["normal cells", "OBSERVATION", 7, 19], ["tumor cells", "OBSERVATION", 42, 53]]], ["Since hypoxia can activate both survival and death programs, it serves as a form of physiological pressure that selects for the oncogenically transformed cells with diminished apoptotic potential [27] .", [["cells", "ANATOMY", 154, 159], ["hypoxia", "DISEASE", 6, 13], ["death", "DISEASE", 45, 50], ["cells", "CELL", 154, 159], ["oncogenically transformed cells", "CELL_LINE", 128, 159], ["hypoxia", "PROBLEM", 6, 13], ["physiological pressure", "TREATMENT", 84, 106], ["diminished apoptotic potential", "PROBLEM", 165, 195], ["diminished", "OBSERVATION_MODIFIER", 165, 175], ["apoptotic", "OBSERVATION_MODIFIER", 176, 185]]], ["The tumor cells that have adapted to a hypoxic environment are more aggressive [25, 26, 28] .", [["tumor cells", "ANATOMY", 4, 15], ["tumor", "DISEASE", 4, 9], ["tumor cells", "CELL", 4, 15], ["tumor cells", "CELL_TYPE", 4, 15], ["The tumor cells", "PROBLEM", 0, 15], ["a hypoxic environment", "PROBLEM", 37, 58], ["tumor cells", "OBSERVATION", 4, 15]]], ["Because of hypoxia-associated resistance to radiation treatment and chemotherapy, hypoxic tumor cells are considered an important contributor to malignant progression and disease relapse [25, 26] .", [["hypoxic tumor cells", "ANATOMY", 82, 101], ["tumor", "DISEASE", 90, 95], ["hypoxic tumor cells", "CELL", 82, 101], ["hypoxic tumor cells", "CELL_TYPE", 82, 101], ["hypoxia-associated resistance", "PROBLEM", 11, 40], ["radiation treatment", "TREATMENT", 44, 63], ["chemotherapy", "TREATMENT", 68, 80], ["hypoxic tumor cells", "PROBLEM", 82, 101], ["malignant progression", "PROBLEM", 145, 166], ["disease relapse", "PROBLEM", 171, 186], ["resistance", "OBSERVATION_MODIFIER", 30, 40], ["radiation treatment", "OBSERVATION", 44, 63], ["hypoxic", "OBSERVATION_MODIFIER", 82, 89], ["tumor cells", "OBSERVATION", 90, 101], ["malignant", "OBSERVATION_MODIFIER", 145, 154]]], ["Approaches such as breathing carbogen (95% O 2 , 5% CO 2 ) have been employed to overcome tumor hypoxia by increasing tumor oxygenation.", [["tumor", "ANATOMY", 90, 95], ["tumor", "ANATOMY", 118, 123], ["carbogen", "CHEMICAL", 29, 37], ["tumor", "DISEASE", 90, 95], ["hypoxia", "DISEASE", 96, 103], ["tumor", "DISEASE", 118, 123], ["carbogen", "CHEMICAL", 29, 37], ["O 2", "CHEMICAL", 43, 46], ["CO 2", "CHEMICAL", 52, 56], ["carbogen", "SIMPLE_CHEMICAL", 29, 37], ["tumor", "CANCER", 90, 95], ["tumor", "CANCER", 118, 123], ["breathing carbogen", "TREATMENT", 19, 37], ["tumor hypoxia", "PROBLEM", 90, 103], ["increasing tumor oxygenation", "PROBLEM", 107, 135], ["tumor", "OBSERVATION", 90, 95], ["increasing", "OBSERVATION_MODIFIER", 107, 117], ["tumor", "OBSERVATION", 118, 123]]], ["Most of the initial drug discovery efforts target the direct effects of hypoxia -lack of cellular oxygenby either discovering chemical sensitizers that improve the outcome of radiation or developing hypoxic cytotoxins that selectively kill hypoxic cells [25, 26] .", [["cellular", "ANATOMY", 89, 97], ["hypoxic cells", "ANATOMY", 240, 253], ["hypoxia", "DISEASE", 72, 79], ["cellular", "CELL", 89, 97], ["cells", "CELL", 248, 253], ["hypoxic cells", "CELL_TYPE", 240, 253], ["hypoxia", "PROBLEM", 72, 79], ["cellular oxygenby", "PROBLEM", 89, 106], ["radiation", "TREATMENT", 175, 184], ["developing hypoxic cytotoxins", "PROBLEM", 188, 217], ["hypoxic cells", "PROBLEM", 240, 253], ["hypoxic cytotoxins", "OBSERVATION", 199, 217]]], ["No hypoxic cytotoxin is currently approved, and there is only one bioreductive drug (tirapazamine) in clinical trials [29] .", [["tirapazamine", "CHEMICAL", 85, 97], ["tirapazamine", "CHEMICAL", 85, 97], ["tirapazamine", "SIMPLE_CHEMICAL", 85, 97], ["hypoxic cytotoxin", "PROBLEM", 3, 20], ["one bioreductive drug (tirapazamine", "TREATMENT", 62, 97], ["hypoxic", "OBSERVATION_MODIFIER", 3, 10], ["cytotoxin", "OBSERVATION", 11, 20]]], ["Although mixed results have been reported from clinical trials with tirapazamine, it is undeniable that drugs that target tumor hypoxia have significant therapeutic potential as part of a combination therapy [30] .", [["tumor", "ANATOMY", 122, 127], ["tirapazamine", "CHEMICAL", 68, 80], ["tumor", "DISEASE", 122, 127], ["hypoxia", "DISEASE", 128, 135], ["tirapazamine", "CHEMICAL", 68, 80], ["tirapazamine", "SIMPLE_CHEMICAL", 68, 80], ["tumor", "CANCER", 122, 127], ["tirapazamine", "TREATMENT", 68, 80], ["drugs", "TREATMENT", 104, 109], ["target tumor hypoxia", "PROBLEM", 115, 135], ["a combination therapy", "TREATMENT", 186, 207], ["tumor", "OBSERVATION", 122, 127]]], ["Clearly, tumor hypoxia represents an important unmet therapeutic need, and molecular-targeted drug discovery efforts should be directed at this target.Bioassay Target SelectionHypoxia-inducible factor-1 is an important molecular target for anticancer drug discovery that targets tumor hypoxia.", [["tumor", "ANATOMY", 9, 14], ["anticancer", "ANATOMY", 240, 250], ["tumor", "ANATOMY", 279, 284], ["tumor", "DISEASE", 9, 14], ["hypoxia", "DISEASE", 15, 22], ["tumor", "DISEASE", 279, 284], ["hypoxia", "DISEASE", 285, 292], ["tumor", "CANCER", 9, 14], ["Hypoxia-inducible factor-1", "GENE_OR_GENE_PRODUCT", 176, 202], ["anticancer", "CANCER", 240, 250], ["tumor", "CANCER", 279, 284], ["Hypoxia-inducible factor-1", "PROTEIN", 176, 202], ["tumor hypoxia", "PROBLEM", 9, 22], ["Bioassay", "TEST", 151, 159], ["Hypoxia", "PROBLEM", 176, 183], ["inducible factor", "PROBLEM", 184, 200], ["tumor hypoxia", "PROBLEM", 279, 292], ["tumor", "OBSERVATION", 9, 14], ["tumor", "OBSERVATION", 279, 284]]], ["First discovered as the transcriptional activator that binds to the promoter of human erythropoietin (EPO) gene and activates transcription under hypoxic conditions [31] , HIF-1 was later shown to regulate the expression of genes that promote cellular adaptation and survival under hypoxic conditions [32, 33] .", [["cellular", "ANATOMY", 243, 251], ["human", "ORGANISM", 80, 85], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 86, 100], ["EPO", "GENE_OR_GENE_PRODUCT", 102, 105], ["HIF-1", "GENE_OR_GENE_PRODUCT", 172, 177], ["cellular", "CELL", 243, 251], ["transcriptional activator", "PROTEIN", 24, 49], ["promoter", "DNA", 68, 76], ["human erythropoietin (EPO) gene", "DNA", 80, 111], ["HIF-1", "PROTEIN", 172, 177], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["the transcriptional activator", "TREATMENT", 20, 49], ["human erythropoietin (EPO) gene", "TREATMENT", 80, 111], ["hypoxic conditions", "PROBLEM", 146, 164]]], ["For example, Semenza and coworkers [32, 33] have generally classified the HIF-1 target genes that enhance the survival of hypoxic tumor cells into the following major functional groups: (1) those that increase oxygen delivery by promoting erythropoiesis [erythropoietin (EPO), transferrin, etc.], angiogenesis [vascular endothelial growth factor (VEGF), etc.], and vasodilatation (heme oxygenase, nitric oxide synthase II, etc.); (2) those that decrease oxygen consumption by switching to anaerobic metabolism (glucose transporter 1, glycolytic enzymes that include hexokinase 1, hexokinase 2, aldolase A, enolase 1, lactate dehydrogenase A, etc.); and (3) those that promote autocrine growth/survival (insulin-like growth factor II, etc.).", [["hypoxic tumor cells", "ANATOMY", 122, 141], ["tumor", "DISEASE", 130, 135], ["oxygen", "CHEMICAL", 210, 216], ["nitric oxide", "CHEMICAL", 397, 409], ["oxygen", "CHEMICAL", 454, 460], ["glucose", "CHEMICAL", 511, 518], ["lactate", "CHEMICAL", 617, 624], ["oxygen", "CHEMICAL", 210, 216], ["nitric oxide", "CHEMICAL", 397, 409], ["oxygen", "CHEMICAL", 454, 460], ["glucose", "CHEMICAL", 511, 518], ["lactate", "CHEMICAL", 617, 624], ["HIF-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["hypoxic tumor cells", "CELL", 122, 141], ["oxygen", "SIMPLE_CHEMICAL", 210, 216], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 255, 269], ["EPO", "GENE_OR_GENE_PRODUCT", 271, 274], ["transferrin", "GENE_OR_GENE_PRODUCT", 277, 288], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 311, 345], ["VEGF", "GENE_OR_GENE_PRODUCT", 347, 351], ["heme oxygenase", "GENE_OR_GENE_PRODUCT", 381, 395], ["nitric oxide synthase II", "GENE_OR_GENE_PRODUCT", 397, 421], ["oxygen", "SIMPLE_CHEMICAL", 454, 460], ["glucose transporter 1", "GENE_OR_GENE_PRODUCT", 511, 532], ["glycolytic enzymes", "GENE_OR_GENE_PRODUCT", 534, 552], ["hexokinase 1", "GENE_OR_GENE_PRODUCT", 566, 578], ["hexokinase 2", "GENE_OR_GENE_PRODUCT", 580, 592], ["aldolase A", "GENE_OR_GENE_PRODUCT", 594, 604], ["enolase 1", "GENE_OR_GENE_PRODUCT", 606, 615], ["lactate dehydrogenase A", "GENE_OR_GENE_PRODUCT", 617, 640], ["insulin-like growth factor II", "GENE_OR_GENE_PRODUCT", 703, 732], ["HIF-1 target genes", "DNA", 74, 92], ["hypoxic tumor cells", "CELL_TYPE", 122, 141], ["erythropoietin", "PROTEIN", 255, 269], ["EPO", "PROTEIN", 271, 274], ["transferrin", "PROTEIN", 277, 288], ["vascular endothelial growth factor", "PROTEIN", 311, 345], ["VEGF", "PROTEIN", 347, 351], ["heme oxygenase", "PROTEIN", 381, 395], ["nitric oxide synthase II", "PROTEIN", 397, 421], ["glucose transporter 1", "PROTEIN", 511, 532], ["glycolytic enzymes", "PROTEIN", 534, 552], ["hexokinase 1", "PROTEIN", 566, 578], ["hexokinase 2", "PROTEIN", 580, 592], ["aldolase A", "PROTEIN", 594, 604], ["enolase 1", "PROTEIN", 606, 615], ["lactate dehydrogenase A", "PROTEIN", 617, 640], ["insulin-like growth factor II", "PROTEIN", 703, 732], ["hypoxic tumor cells", "PROBLEM", 122, 141], ["oxygen delivery", "TREATMENT", 210, 225], ["promoting erythropoiesis", "PROBLEM", 229, 253], ["erythropoietin (EPO)", "TREATMENT", 255, 275], ["transferrin", "TREATMENT", 277, 288], ["angiogenesis", "PROBLEM", 297, 309], ["vascular endothelial growth factor (VEGF)", "PROBLEM", 311, 352], ["vasodilatation (heme oxygenase", "TREATMENT", 365, 395], ["nitric oxide synthase II", "TREATMENT", 397, 421], ["oxygen consumption", "TREATMENT", 454, 472], ["anaerobic metabolism", "TEST", 489, 509], ["glucose transporter", "TEST", 511, 530], ["glycolytic enzymes", "TEST", 534, 552], ["hexokinase", "TEST", 566, 576], ["hexokinase", "TEST", 580, 590], ["aldolase A, enolase", "TEST", 594, 613], ["lactate dehydrogenase A", "TEST", 617, 640], ["survival (insulin", "TREATMENT", 693, 710], ["hypoxic tumor cells", "OBSERVATION", 122, 141], ["erythropoiesis", "OBSERVATION", 239, 253], ["vascular endothelial", "ANATOMY", 311, 331], ["oxygen consumption", "OBSERVATION", 454, 472]]], ["Recent studies indicate that HIF-1 also regulates the expression of genes that are involved in processes ranging from tumor cell immortalization, genetic instability, dedifferentiation, invasion, metastasis, to treatment resistance [32] [33] [34] .", [["tumor cell", "ANATOMY", 118, 128], ["tumor", "DISEASE", 118, 123], ["genetic instability", "DISEASE", 146, 165], ["metastasis", "DISEASE", 196, 206], ["HIF-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["tumor cell", "CELL", 118, 128], ["HIF-1", "PROTEIN", 29, 34], ["Recent studies", "TEST", 0, 14], ["tumor cell immortalization", "PROBLEM", 118, 144], ["genetic instability", "PROBLEM", 146, 165], ["invasion", "PROBLEM", 186, 194], ["metastasis", "PROBLEM", 196, 206], ["treatment resistance", "TEST", 211, 231], ["tumor cell immortalization", "OBSERVATION", 118, 144], ["dedifferentiation", "OBSERVATION_MODIFIER", 167, 184], ["invasion", "OBSERVATION_MODIFIER", 186, 194], ["metastasis", "OBSERVATION", 196, 206]]], ["These observations suggest that HIF-1 plays an important role in the etiology and malignant progression of cancers.Molecular Target ValidationMolecular target validation is the process of establishing that a potential molecular target is essential for a disease process and that inhibition (or dysregulation) of that specific target can produce a potential therapeutic benefit.", [["cancers", "ANATOMY", 107, 114], ["cancers", "DISEASE", 107, 114], ["HIF-1", "GENE_OR_GENE_PRODUCT", 32, 37], ["cancers", "CANCER", 107, 114], ["HIF-1", "PROTEIN", 32, 37], ["malignant progression of cancers", "PROBLEM", 82, 114], ["a disease process", "PROBLEM", 252, 269], ["malignant", "OBSERVATION_MODIFIER", 82, 91], ["progression", "OBSERVATION_MODIFIER", 92, 103], ["cancers", "OBSERVATION", 107, 114]]], ["Screening efforts that use poorly validated antitumor molecular targets can be extremely expensive and time consuming in identifing active compounds that may fail to produce a significant antitumor effect in living cells.", [["antitumor", "ANATOMY", 44, 53], ["antitumor", "ANATOMY", 188, 197], ["cells", "ANATOMY", 215, 220], ["antitumor", "CANCER", 44, 53], ["antitumor", "CANCER", 188, 197], ["cells", "CELL", 215, 220], ["living cells", "CELL_TYPE", 208, 220], ["a significant antitumor effect in living cells", "PROBLEM", 174, 220], ["significant", "OBSERVATION_MODIFIER", 176, 187], ["antitumor", "OBSERVATION", 188, 197]]], ["Demonstrating that a drug or other representative inhibitor of the molecular target produces the desired therapeutic outcome in patients may be the ultimate form of target validation.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["a drug", "TREATMENT", 19, 25]]], ["For example, the validation of antitumor targets such as tubulin/microtubules or topoisomerases may be considered solidly validated as druggable molecular targets by the therapeutic efficacy of the microtubule-targeted anticancer drugs vincristine and paclitaxel and by the topoisomerase inhibitors topotecan and etoposide, respectively.", [["antitumor", "ANATOMY", 31, 40], ["microtubules", "ANATOMY", 65, 77], ["microtubule", "ANATOMY", 198, 209], ["anticancer", "ANATOMY", 219, 229], ["vincristine", "CHEMICAL", 236, 247], ["paclitaxel", "CHEMICAL", 252, 262], ["topotecan", "CHEMICAL", 299, 308], ["etoposide", "CHEMICAL", 313, 322], ["vincristine", "CHEMICAL", 236, 247], ["paclitaxel", "CHEMICAL", 252, 262], ["topotecan", "CHEMICAL", 299, 308], ["etoposide", "CHEMICAL", 313, 322], ["antitumor", "CANCER", 31, 40], ["tubulin", "GENE_OR_GENE_PRODUCT", 57, 64], ["microtubules", "CELLULAR_COMPONENT", 65, 77], ["topoisomerases", "GENE_OR_GENE_PRODUCT", 81, 95], ["microtubule", "CELLULAR_COMPONENT", 198, 209], ["anticancer", "CANCER", 219, 229], ["vincristine", "SIMPLE_CHEMICAL", 236, 247], ["paclitaxel", "SIMPLE_CHEMICAL", 252, 262], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 274, 287], ["topotecan", "SIMPLE_CHEMICAL", 299, 308], ["etoposide", "SIMPLE_CHEMICAL", 313, 322], ["tubulin", "PROTEIN", 57, 64], ["microtubules", "PROTEIN", 65, 77], ["topoisomerases", "PROTEIN", 81, 95], ["microtubule", "PROTEIN", 198, 209], ["topoisomerase", "PROTEIN", 274, 287], ["antitumor targets", "TREATMENT", 31, 48], ["tubulin/microtubules", "TREATMENT", 57, 77], ["topoisomerases", "TREATMENT", 81, 95], ["the microtubule", "TREATMENT", 194, 209], ["targeted anticancer drugs vincristine", "TREATMENT", 210, 247], ["paclitaxel", "TREATMENT", 252, 262], ["the topoisomerase inhibitors topotecan", "TREATMENT", 270, 308], ["etoposide", "TREATMENT", 313, 322]]], ["Under these conditions, molecular target validation can be considered the construction of an evidence-based case to support the essential nature and causative role of the target to a specific disease.", [["a specific disease", "PROBLEM", 181, 199]]], ["Evidence to validate the target can come from clinical studies, but is most often derived from a combination of in vitro and preclinical animal-based experimental results.Molecular Target ValidationDrugs often fail in clinical studies because they either do not produce the desired therapeutic effect or because they exhibit severe side effects, or toxicities, that render them unsafe for patient use [35] .", [["toxicities", "DISEASE", 349, 359], ["patient", "ORGANISM", 389, 396], ["patient", "SPECIES", 389, 396], ["clinical studies", "TEST", 46, 62], ["clinical studies", "TEST", 218, 234], ["severe side effects", "PROBLEM", 325, 344], ["toxicities", "PROBLEM", 349, 359]]], ["Both reasons for the clinical failure of new drugs have been attributed to a lack of thorough target validation [35] .", [["the clinical failure", "PROBLEM", 17, 37], ["new drugs", "TREATMENT", 41, 50]]], ["Therefore, it is essential to design a strategy for target validation that not only evaluates the therapeutic relevance of the target but that will also examine the specificity of the molecular target for the biochemical or physiological processes that contribute to the disease process.", [["the biochemical or physiological processes", "PROBLEM", 205, 247], ["the disease process", "PROBLEM", 267, 286], ["disease", "OBSERVATION", 271, 278]]], ["This is crucial in order to discriminate between disease-specific activity and off-target-related effects.", [["disease", "PROBLEM", 49, 56]]], ["While many in vitro cell-based methods (e.g., DNA-microarray or proteomic-based systems) are widely used in target validation, the most convincing data usually come from those models that more closely represent the disease condition in humans [36] .", [["cell", "ANATOMY", 20, 24], ["cell", "CELL", 20, 24], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["humans", "ORGANISM", 236, 242], ["humans", "SPECIES", 236, 242], ["humans", "SPECIES", 236, 242], ["DNA", "TEST", 46, 49], ["proteomic-based systems", "TREATMENT", 64, 87], ["the disease condition", "PROBLEM", 211, 232], ["disease", "OBSERVATION", 215, 222]]], ["Various forms of gene/ target knockout models are used to examine the physiological relationship between a specific gene, or gene product protein, and a particular disease phenotype.", [["gene product protein", "PROTEIN", 125, 145], ["gene/ target knockout models", "TREATMENT", 17, 45], ["gene product protein", "PROBLEM", 125, 145], ["a particular disease phenotype", "PROBLEM", 151, 181]]], ["Traditional gene knockout methods (e.g., homologous recombination-based methods) and alternative gene knockdown or silencing methods (e.g., RNA interference) have proven invaluable as in vivo means to validate the critical role of a selected molecular target for a specific disease process [37] .", [["Traditional gene knockout methods", "TREATMENT", 0, 33], ["homologous recombination-based methods", "TREATMENT", 41, 79], ["alternative gene knockdown", "TREATMENT", 85, 111], ["silencing methods", "TREATMENT", 115, 132], ["a specific disease process", "PROBLEM", 263, 289]]], ["Data from animal-based models that include physiological, genomic, or proteomic results from in vivo models are generally considered important for reliable target validation [35] .Molecular Target ValidationAs a model for a validated antitumor drug target, multiple lines of evidence support the critical involvement of HIF-1 in the growth, progression, and metastatic spread of various forms of cancer [8] [9] [10] [11] [12] .", [["antitumor", "ANATOMY", 234, 243], ["cancer", "ANATOMY", 396, 402], ["cancer", "DISEASE", 396, 402], ["antitumor", "CANCER", 234, 243], ["HIF-1", "GENE_OR_GENE_PRODUCT", 320, 325], ["cancer", "CANCER", 396, 402], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 403, 425], ["HIF-1", "PROTEIN", 320, 325], ["a validated antitumor drug target", "TREATMENT", 222, 255], ["metastatic spread of various forms of cancer", "PROBLEM", 358, 402], ["progression", "OBSERVATION_MODIFIER", 341, 352], ["metastatic", "OBSERVATION_MODIFIER", 358, 368]]], ["In line with the laboratory findings, clinical studies indicate that overexpression of the oxygen-regulated HIF-1a protein correlates with advanced disease stages, treatment resistance, and poor prognosis among patients with tumors derived from tissues that range from brain to breast [25, 26] .", [["tumors", "ANATOMY", 225, 231], ["tissues", "ANATOMY", 245, 252], ["brain", "ANATOMY", 269, 274], ["breast", "ANATOMY", 278, 284], ["oxygen", "CHEMICAL", 91, 97], ["tumors", "DISEASE", 225, 231], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 108, 114], ["patients", "ORGANISM", 211, 219], ["tumors", "CANCER", 225, 231], ["tissues", "TISSUE", 245, 252], ["brain", "ORGAN", 269, 274], ["breast", "ORGAN", 278, 284], ["oxygen-regulated HIF-1a protein", "PROTEIN", 91, 122], ["patients", "SPECIES", 211, 219], ["clinical studies", "TEST", 38, 54], ["the oxygen", "TEST", 87, 97], ["advanced disease stages", "PROBLEM", 139, 162], ["treatment resistance", "TREATMENT", 164, 184], ["tumors", "PROBLEM", 225, 231], ["breast", "ANATOMY", 278, 284]]], ["In general, the availability and activity of the oxygen-regulated HIF-1a subunit determines the activity of HIF-1, a heterodimer of the bHLH-PAS (basic helix-loop-helix-PER-ARNT-SIMM) proteins HIF-1a and HIF-1b/ARNT (aryl hydrocarbon receptor nuclear translocator).", [["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 49, 55], ["aryl hydrocarbon", "CHEMICAL", 217, 233], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 66, 72], ["HIF-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["bHLH-PAS", "GENE_OR_GENE_PRODUCT", 136, 144], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 193, 199], ["HIF-1b", "GENE_OR_GENE_PRODUCT", 204, 210], ["ARNT", "GENE_OR_GENE_PRODUCT", 211, 215], ["aryl hydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 217, 242], ["oxygen-regulated HIF-1a subunit", "PROTEIN", 49, 80], ["HIF-1", "PROTEIN", 108, 113], ["bHLH", "PROTEIN", 136, 140], ["PAS", "PROTEIN", 141, 144], ["basic helix-loop-helix-PER-ARNT-SIMM) proteins", "PROTEIN", 146, 192], ["HIF-1a and HIF-1b", "PROTEIN", 193, 210], ["ARNT", "PROTEIN", 211, 215], ["aryl hydrocarbon receptor nuclear translocator", "PROTEIN", 217, 263], ["the oxygen", "TEST", 45, 55], ["the bHLH", "TEST", 132, 140], ["helix", "TEST", 163, 168], ["HIF", "TEST", 193, 196], ["HIF", "TEST", 204, 207], ["1b/ARNT (aryl hydrocarbon receptor nuclear translocator", "TREATMENT", 208, 263]]], ["Under normoxic conditions, HIF-1a protein is degraded rapidly (protein half-life <5 min) while HIF-1b protein is constitutively expressed.", [["HIF-1a", "GENE_OR_GENE_PRODUCT", 27, 33], ["HIF-1b", "GENE_OR_GENE_PRODUCT", 95, 101], ["HIF-1a protein", "PROTEIN", 27, 41], ["HIF-1b protein", "PROTEIN", 95, 109], ["HIF-1a protein", "TEST", 27, 41], ["normoxic conditions", "OBSERVATION", 6, 25]]], ["In many of the clinical specimens examined, the expression of HIF-1a protein is directly linked to the extent of tumor hypoxia.", [["specimens", "ANATOMY", 24, 33], ["tumor", "ANATOMY", 113, 118], ["tumor", "DISEASE", 113, 118], ["hypoxia", "DISEASE", 119, 126], ["specimens", "CANCER", 24, 33], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 62, 68], ["tumor", "CANCER", 113, 118], ["HIF-1a protein", "PROTEIN", 62, 76], ["the clinical specimens", "TEST", 11, 33], ["tumor hypoxia", "PROBLEM", 113, 126], ["tumor", "OBSERVATION", 113, 118]]], ["The decrease in oxygen tension inhibits the hydroxylases that tag HIF-1a protein for degradation and inactivation.", [["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 66, 72], ["hydroxylases", "PROTEIN", 44, 56], ["HIF-1a protein", "PROTEIN", 66, 80], ["The decrease in oxygen tension", "PROBLEM", 0, 30], ["the hydroxylases", "TREATMENT", 40, 56], ["tag HIF", "TEST", 62, 69], ["degradation", "PROBLEM", 85, 96], ["inactivation", "PROBLEM", 101, 113], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["oxygen tension", "OBSERVATION", 16, 30]]], ["The stabilized HIF-1a protein then translocates into the nucleus, heterodimerizes with HIF-1b protein, binds to the hypoxia response elements (HREs), and activates transcription of HIF-1 target genes ( Fig. 22.1) .", [["nucleus", "ANATOMY", 57, 64], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 15, 21], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["HIF-1b", "GENE_OR_GENE_PRODUCT", 87, 93], ["HIF-1", "GENE_OR_GENE_PRODUCT", 181, 186], ["HIF-1a protein", "PROTEIN", 15, 29], ["HIF-1b protein", "PROTEIN", 87, 101], ["hypoxia response elements", "DNA", 116, 141], ["HREs", "DNA", 143, 147], ["HIF-1 target genes", "DNA", 181, 199], ["the hypoxia response elements", "PROBLEM", 112, 141], ["HIF", "TEST", 181, 184], ["nucleus", "ANATOMY", 57, 64], ["hypoxia", "OBSERVATION", 116, 123], ["response elements", "OBSERVATION", 124, 141]]], ["In other cases such as renal clear cell carcinoma, HIF-1a protein is expressed at high levels even under well-oxygenated conditions [38] .", [["renal clear cell carcinoma", "ANATOMY", 23, 49], ["renal clear cell carcinoma", "DISEASE", 23, 49], ["renal clear cell carcinoma", "CANCER", 23, 49], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 51, 57], ["HIF-1a protein", "PROTEIN", 51, 65], ["renal clear cell carcinoma", "PROBLEM", 23, 49], ["1a protein", "TEST", 55, 65], ["renal", "ANATOMY", 23, 28], ["clear cell carcinoma", "OBSERVATION", 29, 49]]], ["One of the molecular mechanisms for hypoxia-independent induction of HIF-1a protein is the loss of function of the tumor suppressor von Hippel-Lindau gene (VHL).", [["tumor", "ANATOMY", 115, 120], ["hypoxia", "DISEASE", 36, 43], ["tumor", "DISEASE", 115, 120], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 69, 75], ["tumor", "CANCER", 115, 120], ["HIF-1a protein", "PROTEIN", 69, 83], ["tumor suppressor von Hippel-Lindau gene", "DNA", 115, 154], ["VHL", "DNA", 156, 159], ["hypoxia", "PROBLEM", 36, 43], ["the tumor suppressor", "TREATMENT", 111, 131], ["hypoxia", "OBSERVATION", 36, 43], ["tumor", "OBSERVATION", 115, 120]]], ["The VHL gene product pVHL mediates the degradation of HIF-1a protein by proteasome.", [["pVHL", "GENE_OR_GENE_PRODUCT", 21, 25], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 54, 60], ["VHL gene product", "PROTEIN", 4, 20], ["pVHL", "PROTEIN", 21, 25], ["HIF-1a protein", "PROTEIN", 54, 68], ["proteasome", "PROTEIN", 72, 82], ["proteasome", "TREATMENT", 72, 82]]], ["In the presence of oxygen and iron, HIF-1a proteins are modified posttranslationally by prolyl hydroxylases [39] [40] [41] .", [["oxygen", "CHEMICAL", 19, 25], ["iron", "CHEMICAL", 30, 34], ["oxygen", "CHEMICAL", 19, 25], ["iron", "CHEMICAL", 30, 34], ["prolyl", "CHEMICAL", 88, 94], ["oxygen", "SIMPLE_CHEMICAL", 19, 25], ["iron", "SIMPLE_CHEMICAL", 30, 34], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 36, 42], ["prolyl hydroxylases [39] [40] [41]", "SIMPLE_CHEMICAL", 88, 122], ["HIF-1a proteins", "PROTEIN", 36, 51], ["prolyl hydroxylases", "PROTEIN", 88, 107], ["oxygen and iron", "TREATMENT", 19, 34], ["HIF-1a proteins", "TREATMENT", 36, 51]]], ["The prolyl hydroxylated HIF-1a proteins are then recognized by pVHL, polyubiquitinized by the pVHL-associated E3 ubiquitin ligase complex, and degraded by the proteasome.", [["prolyl", "CHEMICAL", 4, 10], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 24, 30], ["pVHL", "GENE_OR_GENE_PRODUCT", 63, 67], ["pVHL", "GENE_OR_GENE_PRODUCT", 94, 98], ["E3", "GENE_OR_GENE_PRODUCT", 110, 112], ["prolyl hydroxylated HIF-1a proteins", "PROTEIN", 4, 39], ["pVHL", "PROTEIN", 63, 67], ["pVHL", "PROTEIN", 94, 98], ["E3 ubiquitin ligase complex", "PROTEIN", 110, 137], ["proteasome", "PROTEIN", 159, 169], ["The prolyl hydroxylated HIF", "TREATMENT", 0, 27], ["1a proteins", "TREATMENT", 28, 39], ["pVHL", "OBSERVATION", 63, 67], ["ubiquitin ligase complex", "OBSERVATION", 113, 137]]], ["Inactivation of pVHL due to loss of function prevents the degradation of HIF-1a protein.", [["pVHL", "GENE_OR_GENE_PRODUCT", 16, 20], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 73, 79], ["pVHL", "PROTEIN", 16, 20], ["HIF-1a protein", "PROTEIN", 73, 87], ["pVHL", "PROBLEM", 16, 20], ["loss of function", "PROBLEM", 28, 44], ["pVHL", "OBSERVATION", 16, 20]]], ["As a result, HIF-1 is activated under normoxic conditions and the HIF-1 regulated pathways such as angiogenic processes are highly active.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["HIF-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["HIF-1", "PROTEIN", 13, 18], ["HIF-1", "PROTEIN", 66, 71], ["normoxic conditions", "TREATMENT", 38, 57], ["highly", "OBSERVATION_MODIFIER", 124, 130], ["active", "OBSERVATION_MODIFIER", 131, 137]]], ["In addition to the loss of function of VHL, other tumorspecific mechanisms that induce HIF-1a protein and activate HIF-1 in a hypoxiaindependent manner include the activation of oncogenes such as ras (rat sarcoma viral oncogene homolog), src (avian sarcoma viral oncogene), myc (avian myelocytomatosis viral oncogene homolog), and the loss of tumor suppressor genes such as PTEN (phosphatase and tensin homolog) [42, 43] .Molecular Target ValidationResults from numerous animal-based studies further support the notion that HIF-1 is an important molecular target for anticancer drug discovery [44, 45] .", [["tumor", "ANATOMY", 343, 348], ["anticancer", "ANATOMY", 567, 577], ["VHL", "DISEASE", 39, 42], ["avian sarcoma", "DISEASE", 243, 256], ["tumor", "DISEASE", 343, 348], ["VHL", "GENE_OR_GENE_PRODUCT", 39, 42], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 87, 93], ["HIF-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["ras", "GENE_OR_GENE_PRODUCT", 196, 199], ["rat sarcoma viral oncogene homolog", "GENE_OR_GENE_PRODUCT", 201, 235], ["src", "GENE_OR_GENE_PRODUCT", 238, 241], ["avian sarcoma viral", "ORGANISM", 243, 262], ["myc", "GENE_OR_GENE_PRODUCT", 274, 277], ["avian myelocytomatosis viral oncogene homolog", "GENE_OR_GENE_PRODUCT", 279, 324], ["tumor", "CANCER", 343, 348], ["PTEN", "GENE_OR_GENE_PRODUCT", 374, 378], ["phosphatase and tensin homolog", "GENE_OR_GENE_PRODUCT", 380, 410], ["HIF-1", "GENE_OR_GENE_PRODUCT", 524, 529], ["anticancer", "CANCER", 567, 577], ["VHL", "DNA", 39, 42], ["HIF-1a protein", "PROTEIN", 87, 101], ["HIF-1", "PROTEIN", 115, 120], ["oncogenes", "DNA", 178, 187], ["ras", "DNA", 196, 199], ["rat sarcoma viral oncogene homolog", "DNA", 201, 235], ["src", "DNA", 238, 241], ["avian sarcoma viral oncogene", "DNA", 243, 271], ["myc", "DNA", 274, 277], ["avian myelocytomatosis viral oncogene homolog", "DNA", 279, 324], ["tumor suppressor genes", "DNA", 343, 365], ["PTEN", "DNA", 374, 378], ["phosphatase and tensin homolog", "PROTEIN", 380, 410], ["HIF-1", "PROTEIN", 524, 529], ["rat", "SPECIES", 201, 204], ["the loss of function of VHL", "PROBLEM", 15, 42], ["other tumorspecific mechanisms", "PROBLEM", 44, 74], ["HIF", "TEST", 87, 90], ["a hypoxiaindependent manner", "TREATMENT", 124, 151], ["the activation of oncogenes", "TREATMENT", 160, 187], ["ras (rat sarcoma viral oncogene homolog", "TREATMENT", 196, 235], ["src (avian sarcoma viral oncogene)", "PROBLEM", 238, 272], ["myc (avian myelocytomatosis viral oncogene homolog", "TREATMENT", 274, 324], ["the loss of tumor suppressor genes", "PROBLEM", 331, 365], ["PTEN (phosphatase and tensin homolog", "TEST", 374, 410], ["based studies", "TEST", 478, 491], ["VHL", "OBSERVATION", 39, 42], ["tumor suppressor", "OBSERVATION", 343, 359]]], ["In general, overexpression of a gene product in tumor cells does not necessarily support the role of that particular gene as a molecular target for cancer therapeutics.", [["tumor cells", "ANATOMY", 48, 59], ["cancer", "ANATOMY", 148, 154], ["tumor", "DISEASE", 48, 53], ["cancer", "DISEASE", 148, 154], ["tumor cells", "CELL", 48, 59], ["cancer", "CANCER", 148, 154], ["tumor cells", "CELL_TYPE", 48, 59], ["a gene product in tumor cells", "PROBLEM", 30, 59], ["cancer therapeutics", "TREATMENT", 148, 167], ["tumor", "OBSERVATION", 48, 53]]], ["It is anticipated that the inhibition of a true molecular target will suppress tumor progression, while the activation of a molecular target will promote tumor progression in animal-based models.", [["tumor", "ANATOMY", 79, 84], ["tumor", "ANATOMY", 154, 159], ["tumor", "DISEASE", 79, 84], ["tumor", "DISEASE", 154, 159], ["tumor", "CANCER", 79, 84], ["tumor", "CANCER", 154, 159], ["a true molecular target", "PROBLEM", 41, 64], ["tumor progression", "PROBLEM", 79, 96], ["tumor progression", "PROBLEM", 154, 171], ["tumor", "OBSERVATION", 79, 84], ["tumor", "OBSERVATION", 154, 159]]], ["Most of the animal-based studies that substantiate HIF-1 as a target for molecular-based therapeutics focus on the HIF-1A gene. .", [["HIF-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["HIF-1A", "GENE_OR_GENE_PRODUCT", 115, 121], ["HIF-1", "PROTEIN", 51, 56], ["HIF-1A gene", "DNA", 115, 126]]], ["The transcription factor HIF-1 is a heterodimer composed of an HIF-1a subunit that is regulated by cellular oxygen levels and an HIF-1b subunit (also known as ARNT) that is constitutively expressed.", [["cellular", "ANATOMY", 99, 107], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 108, 114], ["HIF-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 63, 69], ["cellular", "CELL", 99, 107], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["HIF-1b", "GENE_OR_GENE_PRODUCT", 129, 135], ["ARNT", "GENE_OR_GENE_PRODUCT", 159, 163], ["transcription factor", "PROTEIN", 4, 24], ["HIF-1", "PROTEIN", 25, 30], ["HIF-1a subunit", "PROTEIN", 63, 77], ["HIF-1b subunit", "PROTEIN", 129, 143], ["ARNT", "PROTEIN", 159, 163], ["The transcription factor HIF", "TEST", 0, 28], ["cellular oxygen levels", "TEST", 99, 121], ["cellular", "OBSERVATION", 99, 107], ["oxygen levels", "OBSERVATION", 108, 121]]], ["Under normoxic conditions, HIF-1a protein is hydroxylated at specific proline residues by Fe 2+ /2-oxoglutarate/ O 2 -dependent prolyl hydroxylase enzymes (e.g., PHD2).", [["proline", "CHEMICAL", 70, 77], ["Fe", "CHEMICAL", 90, 92], ["2-oxoglutarate", "CHEMICAL", 97, 111], ["proline", "CHEMICAL", 70, 77], ["Fe 2+", "CHEMICAL", 90, 95], ["2-oxoglutarate", "CHEMICAL", 97, 111], ["O 2", "CHEMICAL", 113, 116], ["prolyl", "CHEMICAL", 128, 134], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 27, 33], ["proline", "AMINO_ACID", 70, 77], ["Fe 2+", "SIMPLE_CHEMICAL", 90, 95], ["2-oxoglutarate", "SIMPLE_CHEMICAL", 97, 111], ["O 2", "SIMPLE_CHEMICAL", 113, 116], ["prolyl hydroxylase", "GENE_OR_GENE_PRODUCT", 128, 146], ["PHD2", "GENE_OR_GENE_PRODUCT", 162, 166], ["HIF-1a protein", "PROTEIN", 27, 41], ["Fe 2+ /2-oxoglutarate/ O 2 -dependent prolyl hydroxylase enzymes", "PROTEIN", 90, 154], ["PHD2", "PROTEIN", 162, 166], ["HIF", "TEST", 27, 30], ["hydroxylated", "TREATMENT", 45, 57], ["Fe", "TEST", 90, 92], ["dependent prolyl hydroxylase enzymes", "TEST", 118, 154], ["normoxic conditions", "OBSERVATION", 6, 25]]], ["This prolyl-hydroxylation \"tags\" HIF-1a protein for von Hippel-Lindau tumor suppressor protein (pVHL)-E3 ubiquitin ligase-mediated polyubiquitination.", [["tumor", "DISEASE", 70, 75], ["prolyl", "CHEMICAL", 5, 11], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 33, 39], ["von Hippel-Lindau tumor suppressor protein", "GENE_OR_GENE_PRODUCT", 52, 94], ["pVHL)-E3", "GENE_OR_GENE_PRODUCT", 96, 104], ["HIF-1a protein", "PROTEIN", 33, 47], ["von Hippel-Lindau tumor suppressor protein", "PROTEIN", 52, 94], ["pVHL", "PROTEIN", 96, 100], ["E3 ubiquitin ligase", "PROTEIN", 102, 121], ["This prolyl", "TREATMENT", 0, 11], ["HIF", "TEST", 33, 36], ["von Hippel", "TEST", 52, 62], ["Lindau tumor suppressor protein", "TREATMENT", 63, 94], ["pVHL", "TEST", 96, 100], ["E3 ubiquitin ligase", "TREATMENT", 102, 121], ["ubiquitin ligase", "OBSERVATION", 105, 121], ["polyubiquitination", "OBSERVATION", 131, 149]]], ["The \"ubiquitn-tagged\" HIF-1a protein is then rapidly degraded by the 26S proteasome.", [["HIF-1a", "GENE_OR_GENE_PRODUCT", 22, 28], ["26S", "GENE_OR_GENE_PRODUCT", 69, 72], ["ubiquitn-tagged\" HIF-1a protein", "PROTEIN", 5, 36], ["26S proteasome", "PROTEIN", 69, 83], ["1a protein", "TEST", 26, 36], ["26S proteasome", "OBSERVATION", 69, 83]]], ["Hydroxylation of an asparagine residue in the C-terminal transcriptional activation domain (CTD) contributes another level of oxygen-dependent regulation by inactivating HIF-1a protein.", [["asparagine", "CHEMICAL", 20, 30], ["oxygen", "CHEMICAL", 126, 132], ["asparagine", "CHEMICAL", 20, 30], ["C", "CHEMICAL", 46, 47], ["oxygen", "CHEMICAL", 126, 132], ["asparagine", "AMINO_ACID", 20, 30], ["oxygen", "SIMPLE_CHEMICAL", 126, 132], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 170, 176], ["C-terminal transcriptional activation domain", "PROTEIN", 46, 90], ["CTD", "PROTEIN", 92, 95], ["HIF-1a protein", "PROTEIN", 170, 184], ["Hydroxylation", "TREATMENT", 0, 13], ["an asparagine residue", "TREATMENT", 17, 38], ["the C-terminal transcriptional activation domain", "TREATMENT", 42, 90], ["oxygen-dependent regulation", "TREATMENT", 126, 153], ["asparagine residue", "OBSERVATION", 20, 38]]], ["Like PHD2, this asparaginyl hydroxylase [\"factor inhibiting HIF\" (FIH)] is also an Fe 2+ / 2-oxoglutarate/O 2 -dependent hydroxylase that modifies the asparagine residue in the CTD region of HIF-1a protein.", [["Fe", "CHEMICAL", 83, 85], ["2-oxoglutarate", "CHEMICAL", 91, 105], ["asparagine", "CHEMICAL", 151, 161], ["asparaginyl", "CHEMICAL", 16, 27], ["Fe 2+", "CHEMICAL", 83, 88], ["2-oxoglutarate", "CHEMICAL", 91, 105], ["O 2", "CHEMICAL", 106, 109], ["asparagine", "CHEMICAL", 151, 161], ["PHD2", "GENE_OR_GENE_PRODUCT", 5, 9], ["asparaginyl hydroxylase", "GENE_OR_GENE_PRODUCT", 16, 39], ["HIF", "GENE_OR_GENE_PRODUCT", 60, 63], ["FIH", "GENE_OR_GENE_PRODUCT", 66, 69], ["Fe 2+", "SIMPLE_CHEMICAL", 83, 88], ["2-oxoglutarate", "SIMPLE_CHEMICAL", 91, 105], ["O 2", "SIMPLE_CHEMICAL", 106, 109], ["asparagine", "AMINO_ACID", 151, 161], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 191, 197], ["PHD2", "PROTEIN", 5, 9], ["asparaginyl hydroxylase", "PROTEIN", 16, 39], ["HIF", "PROTEIN", 60, 63], ["FIH", "PROTEIN", 66, 69], ["Fe 2+ / 2-oxoglutarate/O 2 -dependent hydroxylase", "PROTEIN", 83, 132], ["CTD region", "PROTEIN", 177, 187], ["HIF-1a protein", "PROTEIN", 191, 205], ["this asparaginyl hydroxylase", "PROBLEM", 11, 39], ["an Fe", "TEST", 80, 85], ["oxoglutarate/O 2 -dependent hydroxylase", "TREATMENT", 93, 132], ["the asparagine residue", "PROBLEM", 147, 169]]], ["Once hydroxylated, the interaction between HIF-1 and the coactivator CBP/ p300 is disrupted and transcriptional activation is blocked.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["CBP", "GENE_OR_GENE_PRODUCT", 69, 72], ["p300", "GENE_OR_GENE_PRODUCT", 74, 78], ["HIF-1", "PROTEIN", 43, 48], ["CBP", "PROTEIN", 69, 72], ["p300", "PROTEIN", 74, 78], ["hydroxylated", "TREATMENT", 5, 17], ["the coactivator CBP/ p300", "TEST", 53, 78]]], ["Besides hypoxic conditions, HIF-1a protein can be stabilized by addition of iron chelators, transition metals, nitric oxide radical (NO\u00b7), or inhibitors of PHDs [e.g., dimethyloxaloylglycine (DMOG)].", [["iron", "CHEMICAL", 76, 80], ["nitric oxide", "CHEMICAL", 111, 123], ["NO\u00b7", "CHEMICAL", 133, 136], ["dimethyloxaloylglycine", "CHEMICAL", 168, 190], ["DMOG", "CHEMICAL", 192, 196], ["iron", "CHEMICAL", 76, 80], ["nitric oxide", "CHEMICAL", 111, 123], ["NO\u00b7", "CHEMICAL", 133, 136], ["dimethyloxaloylglycine", "CHEMICAL", 168, 190], ["DMOG", "CHEMICAL", 192, 196], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 28, 34], ["iron chelators", "SIMPLE_CHEMICAL", 76, 90], ["transition metals", "SIMPLE_CHEMICAL", 92, 109], ["nitric oxide radical", "SIMPLE_CHEMICAL", 111, 131], ["NO\u00b7", "SIMPLE_CHEMICAL", 133, 136], ["PHDs", "SIMPLE_CHEMICAL", 156, 160], ["dimethyloxaloylglycine", "SIMPLE_CHEMICAL", 168, 190], ["DMOG", "SIMPLE_CHEMICAL", 192, 196], ["HIF-1a protein", "PROTEIN", 28, 42], ["hypoxic conditions", "PROBLEM", 8, 26], ["iron chelators", "TREATMENT", 76, 90], ["transition metals", "TREATMENT", 92, 109], ["nitric oxide radical (NO\u00b7)", "TREATMENT", 111, 137], ["inhibitors of PHDs", "TREATMENT", 142, 160], ["dimethyloxaloylglycine (DMOG", "TREATMENT", 168, 196], ["hypoxic conditions", "OBSERVATION", 8, 26]]], ["Such inducing conditions inactivate the prolyl hydroxylases that tag HIF-1a protein for ubiquitination and proteasomal degradation, and suppress the asparaginyl hydroxylase that normally inactivates the transcriptional activity of HIF-1.", [["asparaginyl", "CHEMICAL", 149, 160], ["prolyl", "CHEMICAL", 40, 46], ["asparaginyl", "CHEMICAL", 149, 160], ["prolyl hydroxylases", "GENE_OR_GENE_PRODUCT", 40, 59], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 69, 75], ["asparaginyl hydroxylase", "GENE_OR_GENE_PRODUCT", 149, 172], ["HIF-1", "GENE_OR_GENE_PRODUCT", 231, 236], ["prolyl hydroxylases", "PROTEIN", 40, 59], ["HIF-1a protein", "PROTEIN", 69, 83], ["asparaginyl hydroxylase", "PROTEIN", 149, 172], ["HIF-1", "PROTEIN", 231, 236], ["Such inducing conditions", "PROBLEM", 0, 24], ["the prolyl hydroxylases", "TREATMENT", 36, 59], ["tag HIF", "TEST", 65, 72], ["ubiquitination", "PROBLEM", 88, 102], ["proteasomal degradation", "PROBLEM", 107, 130], ["the asparaginyl hydroxylase", "PROBLEM", 145, 172], ["proteasomal degradation", "OBSERVATION", 107, 130]]], ["In addition, binding between HIF-1 and CBP/p300 can be enhanced by direct nitrosylation of a sulfhydryl moiety in HIF-1a.", [["sulfhydryl", "CHEMICAL", 93, 103], ["sulfhydryl", "CHEMICAL", 93, 103], ["HIF-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["CBP", "GENE_OR_GENE_PRODUCT", 39, 42], ["p300", "GENE_OR_GENE_PRODUCT", 43, 47], ["sulfhydryl", "SIMPLE_CHEMICAL", 93, 103], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 114, 120], ["HIF-1", "PROTEIN", 29, 34], ["CBP", "PROTEIN", 39, 42], ["p300", "PROTEIN", 43, 47], ["HIF-1a", "PROTEIN", 114, 120], ["HIF", "TEST", 29, 32], ["CBP/p300", "TEST", 39, 47], ["a sulfhydryl moiety", "TREATMENT", 91, 110]]], ["When the level of O 2 decreases to a level below a certain threshold, reactive oxygen species (ROS) generated by hypoxic mitochondria inhibit PHD2 and FIH by oxidizing the Fe 2+ in their catalytic sites.", [["mitochondria", "ANATOMY", 121, 133], ["oxygen", "CHEMICAL", 79, 85], ["ROS", "CHEMICAL", 95, 98], ["Fe", "CHEMICAL", 172, 174], ["O 2", "CHEMICAL", 18, 21], ["oxygen", "CHEMICAL", 79, 85], ["Fe 2+", "CHEMICAL", 172, 177], ["O 2", "GENE_OR_GENE_PRODUCT", 18, 21], ["reactive oxygen species", "SIMPLE_CHEMICAL", 70, 93], ["ROS", "SIMPLE_CHEMICAL", 95, 98], ["mitochondria", "CELLULAR_COMPONENT", 121, 133], ["PHD2", "GENE_OR_GENE_PRODUCT", 142, 146], ["FIH", "GENE_OR_GENE_PRODUCT", 151, 154], ["Fe 2+", "SIMPLE_CHEMICAL", 172, 177], ["O 2", "PROTEIN", 18, 21], ["PHD2", "PROTEIN", 142, 146], ["FIH", "PROTEIN", 151, 154], ["Fe 2", "PROTEIN", 172, 176], ["catalytic sites", "PROTEIN", 187, 202], ["reactive oxygen species", "PROBLEM", 70, 93], ["hypoxic mitochondria inhibit PHD2", "PROBLEM", 113, 146], ["reactive", "OBSERVATION_MODIFIER", 70, 78], ["oxygen species", "OBSERVATION", 79, 93]]], ["Natural products that inhibit the mitochondrial electron transport chain (e.g., rotenone) block HIF-1 activation by suppressing the hypoxia-induced increase in ROS production by mitochondria.", [["mitochondrial", "ANATOMY", 34, 47], ["mitochondria", "ANATOMY", 178, 190], ["rotenone", "CHEMICAL", 80, 88], ["hypoxia", "DISEASE", 132, 139], ["ROS", "CHEMICAL", 160, 163], ["rotenone", "CHEMICAL", 80, 88], ["mitochondrial", "CELLULAR_COMPONENT", 34, 47], ["rotenone", "SIMPLE_CHEMICAL", 80, 88], ["HIF-1", "GENE_OR_GENE_PRODUCT", 96, 101], ["ROS", "SIMPLE_CHEMICAL", 160, 163], ["mitochondria", "CELLULAR_COMPONENT", 178, 190], ["HIF", "PROTEIN", 96, 99], ["Natural products", "TREATMENT", 0, 16], ["rotenone) block HIF", "TREATMENT", 80, 99], ["the hypoxia", "PROBLEM", 128, 139], ["hypoxia", "OBSERVATION", 132, 139], ["increase", "OBSERVATION_MODIFIER", 148, 156], ["ROS production", "OBSERVATION", 160, 174]]], ["This promotes the PHD2-mediated degradation and FIH-facilitated inactivation of the HIF-1a subunit (Selection of Measurable Biochemical Processes Suitable for Bioassay DevelopmentSince HIF-1 is a transcription factor, a cell-based reporter assay should be selected as the method to monitor the activity of HIF-1.", [["cell", "ANATOMY", 220, 224], ["PHD2", "GENE_OR_GENE_PRODUCT", 18, 22], ["FIH", "GENE_OR_GENE_PRODUCT", 48, 51], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 84, 90], ["HIF-1", "GENE_OR_GENE_PRODUCT", 185, 190], ["cell", "CELL", 220, 224], ["HIF-1", "GENE_OR_GENE_PRODUCT", 306, 311], ["PHD2", "PROTEIN", 18, 22], ["FIH", "PROTEIN", 48, 51], ["HIF-1a subunit", "PROTEIN", 84, 98], ["HIF", "PROTEIN", 185, 188], ["transcription factor", "PROTEIN", 196, 216], ["HIF-1", "PROTEIN", 306, 311], ["the HIF-1a subunit", "TREATMENT", 80, 98]]], ["Upon induction and activation, HIF-1 binds to the HRE present in the promoter region and activates transcription of the reporter gene [45, 46] .", [["HIF-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["HIF-1", "PROTEIN", 31, 36], ["HRE", "DNA", 50, 53], ["promoter region", "DNA", 69, 84], ["reporter gene", "DNA", 120, 133]]], ["In general, the reporter gene may encode an enzyme such as luciferase, whose activity can be easily measured in a high-throughput format.", [["luciferase", "GENE_OR_GENE_PRODUCT", 59, 69], ["reporter gene", "DNA", 16, 29], ["luciferase", "PROTEIN", 59, 69], ["an enzyme", "TEST", 41, 50]]], ["The activity of the reporter (e.g., luciferase) correlates with the expression of the reporter gene that serves as an indicator of HIF-1 activity.", [["luciferase", "GENE_OR_GENE_PRODUCT", 36, 46], ["HIF-1", "GENE_OR_GENE_PRODUCT", 131, 136], ["luciferase", "PROTEIN", 36, 46], ["reporter gene", "DNA", 86, 99], ["HIF", "PROTEIN", 131, 134]]], ["It is anticipated that compounds/extracts that activate HIF-1 will increase the activity of the reporter, while HIF-1 inhibitory compounds/extracts will decrease the reporter activity.", [["extracts", "ANATOMY", 33, 41], ["extracts", "ANATOMY", 139, 147], ["extracts", "ORGANISM_SUBSTANCE", 33, 41], ["HIF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["HIF-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["extracts", "ORGANISM_SUBSTANCE", 139, 147], ["HIF-1", "PROTEIN", 56, 61], ["HIF", "PROTEIN", 112, 115], ["compounds/extracts", "TREATMENT", 23, 41]]], ["The advantage of such a cell-based reporter assay is that it will detect a wide range of chemicals with dissimilar mechanisms of action.", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28]]], ["The challenge is that it may take considerable effort to resolve the mechanism(s) of action once the active compounds are identified.", [["the active compounds", "PROBLEM", 97, 117], ["active", "OBSERVATION_MODIFIER", 101, 107], ["compounds", "OBSERVATION", 108, 117]]], ["In the event that the active compound(s) has been well characterized, the compound may serve as a molecular probe to further investigate the crosstalk between signaling pathways.", [["a molecular probe", "TREATMENT", 96, 113], ["active", "OBSERVATION_MODIFIER", 22, 28], ["compound", "OBSERVATION_MODIFIER", 29, 37]]], ["For example, an assay measuring the activity of a particular kinase can be used to identify inhibitors of that particular kinase.", [["kinase", "PROTEIN", 61, 67], ["kinase", "PROTEIN", 122, 128], ["an assay", "TEST", 13, 21]]], ["Among the approaches used to discover HIF-1 inhibitors, one is to identify compounds that can disrupt the interaction between HIF-1 and the coactivator CBP/p300 [(cAMP-response element-binding protein)-binding protein/E1A-binding protein, 300 kD] [47] .", [["AMP", "CHEMICAL", 164, 167], ["AMP", "CHEMICAL", 164, 167], ["HIF-1", "GENE_OR_GENE_PRODUCT", 38, 43], ["HIF-1", "GENE_OR_GENE_PRODUCT", 126, 131], ["CBP", "GENE_OR_GENE_PRODUCT", 152, 155], ["p300", "GENE_OR_GENE_PRODUCT", 156, 160], ["cAMP-response element-binding protein)-binding protein", "GENE_OR_GENE_PRODUCT", 163, 217], ["E1A", "GENE_OR_GENE_PRODUCT", 218, 221], ["HIF", "PROTEIN", 38, 41], ["HIF-1", "PROTEIN", 126, 131], ["CBP", "PROTEIN", 152, 155], ["p300 [(cAMP-response element-binding protein)-binding protein", "PROTEIN", 156, 217], ["E1A-binding protein", "PROTEIN", 218, 237], ["HIF-1 inhibitors", "TREATMENT", 38, 54], ["HIF", "TEST", 126, 129], ["the coactivator CBP", "TEST", 136, 155], ["p300", "TEST", 156, 160], ["AMP", "TEST", 164, 167], ["binding protein", "TEST", 185, 200], ["binding protein/E1A", "TEST", 202, 221], ["binding protein", "TEST", 222, 237]]], ["In general, the activity of HIF-1 is determined by the availability and activity of the oxygen-regulated HIF-1a subunit ( Fig. 22.1 ).", [["oxygen", "CHEMICAL", 88, 94], ["oxygen", "CHEMICAL", 88, 94], ["HIF-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 105, 111], ["HIF-1", "PROTEIN", 28, 33], ["oxygen-regulated HIF-1a subunit", "PROTEIN", 88, 119], ["the oxygen", "TREATMENT", 84, 94]]], ["In the presence of oxygen and iron(II), the HIF-1a subunits are hydroxylated by prolyl hydroxylases, and this posttranslational modification triggers pVHL-mediated proteasome degradation of HIF-1a proteins [39] [40] [41] .", [["oxygen", "CHEMICAL", 19, 25], ["iron", "CHEMICAL", 30, 34], ["oxygen", "CHEMICAL", 19, 25], ["iron(II)", "CHEMICAL", 30, 38], ["prolyl", "CHEMICAL", 80, 86], ["oxygen", "SIMPLE_CHEMICAL", 19, 25], ["iron(II", "SIMPLE_CHEMICAL", 30, 37], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 44, 50], ["prolyl hydroxylases", "GENE_OR_GENE_PRODUCT", 80, 99], ["pVHL", "GENE_OR_GENE_PRODUCT", 150, 154], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 190, 196], ["[39] [40] [41]", "SIMPLE_CHEMICAL", 206, 220], ["HIF-1a subunits", "PROTEIN", 44, 59], ["prolyl hydroxylases", "PROTEIN", 80, 99], ["pVHL", "PROTEIN", 150, 154], ["proteasome", "PROTEIN", 164, 174], ["HIF-1a proteins", "PROTEIN", 190, 205], ["oxygen and iron(II)", "TREATMENT", 19, 38], ["the HIF-1a subunits", "TREATMENT", 40, 59], ["hydroxylated by prolyl hydroxylases", "TREATMENT", 64, 99], ["this posttranslational modification", "TREATMENT", 105, 140], ["pVHL", "TEST", 150, 154], ["oxygen", "OBSERVATION_MODIFIER", 19, 25]]], ["Upon a reduction in cellular oxygen levels or in the presence of iron chelators, the hydroxylation reaction is inhibited and the stabilized HIF-1a proteins translocate into the nucleus, heterodimerize with HIF-1b subunits, and activate gene transcription.", [["cellular", "ANATOMY", 20, 28], ["nucleus", "ANATOMY", 177, 184], ["oxygen", "CHEMICAL", 29, 35], ["iron", "CHEMICAL", 65, 69], ["oxygen", "CHEMICAL", 29, 35], ["iron", "CHEMICAL", 65, 69], ["cellular", "CELL", 20, 28], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["iron chelators", "SIMPLE_CHEMICAL", 65, 79], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 140, 146], ["nucleus", "CELLULAR_COMPONENT", 177, 184], ["HIF-1b", "GENE_OR_GENE_PRODUCT", 206, 212], ["HIF-1a proteins", "PROTEIN", 140, 155], ["HIF-1b subunits", "PROTEIN", 206, 221], ["a reduction in cellular oxygen levels", "PROBLEM", 5, 42], ["iron chelators", "TREATMENT", 65, 79], ["the hydroxylation reaction", "PROBLEM", 81, 107], ["HIF-1b subunits", "TREATMENT", 206, 221], ["activate gene transcription", "TREATMENT", 227, 254], ["reduction", "OBSERVATION_MODIFIER", 7, 16], ["cellular", "OBSERVATION_MODIFIER", 20, 28], ["oxygen levels", "OBSERVATION", 29, 42], ["nucleus", "ANATOMY", 177, 184]]], ["The interaction between HIF-1 and CBP/p300 enhances the formation of the transcriptional initiation complex and increases the transcription of target genes.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["CBP", "GENE_OR_GENE_PRODUCT", 34, 37], ["p300", "GENE_OR_GENE_PRODUCT", 38, 42], ["HIF-1", "PROTEIN", 24, 29], ["CBP", "PROTEIN", 34, 37], ["p300", "PROTEIN", 38, 42], ["transcriptional initiation complex", "PROTEIN", 73, 107], ["target genes", "DNA", 143, 155], ["HIF", "TEST", 24, 27], ["CBP/p300", "TEST", 34, 42]]], ["Oxygen-dependent asparaginyl hydroxylation of HIF-1a protein (Asn803) by factor inhibiting HIF (FIH) abrogates the interaction between HIF-1 and CBP/p300.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["asparaginyl", "CHEMICAL", 17, 28], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["asparaginyl", "SIMPLE_CHEMICAL", 17, 28], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 46, 52], ["Asn803", "GENE_OR_GENE_PRODUCT", 62, 68], ["HIF", "GENE_OR_GENE_PRODUCT", 91, 94], ["FIH", "GENE_OR_GENE_PRODUCT", 96, 99], ["HIF-1", "GENE_OR_GENE_PRODUCT", 135, 140], ["CBP/p300", "GENE_OR_GENE_PRODUCT", 145, 153], ["HIF-1a protein", "PROTEIN", 46, 60], ["Asn803", "PROTEIN", 62, 68], ["HIF", "PROTEIN", 91, 94], ["FIH", "PROTEIN", 96, 99], ["HIF", "PROTEIN", 135, 138], ["CBP", "PROTEIN", 145, 148], ["p300", "PROTEIN", 149, 153], ["Oxygen", "TREATMENT", 0, 6], ["dependent asparaginyl hydroxylation", "TREATMENT", 7, 42], ["HIF-1a protein (Asn803)", "TREATMENT", 46, 69], ["HIF", "TEST", 135, 138], ["CBP", "TEST", 145, 148]]], ["To discover disruptors of HIF-1a/p300 interaction, Kung and colleagues employed a time-resolved fluorescence high-throughput screening assay to detect the binding between a 41-amino-acid HIF-1a-derived polypeptide representing the minimal p300/CBP binding domain and a glutathione-Stransferase (GST) fusion protein that contains the 122-amino-acid minimal HIF-1a-binding domain from p300 (GST-CH1) [47] .", [["41-amino-acid", "CHEMICAL", 173, 186], ["glutathione", "CHEMICAL", 269, 280], ["amino-acid", "CHEMICAL", 337, 347], ["41-amino-acid", "CHEMICAL", 173, 186], ["glutathione", "CHEMICAL", 269, 280], ["amino-acid", "CHEMICAL", 337, 347], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 26, 32], ["p300", "GENE_OR_GENE_PRODUCT", 33, 37], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 187, 193], ["p300", "GENE_OR_GENE_PRODUCT", 239, 243], ["CBP", "GENE_OR_GENE_PRODUCT", 244, 247], ["glutathione-Stransferase", "GENE_OR_GENE_PRODUCT", 269, 293], ["GST", "GENE_OR_GENE_PRODUCT", 295, 298], ["HIF-1a-", "GENE_OR_GENE_PRODUCT", 356, 363], ["p300", "GENE_OR_GENE_PRODUCT", 383, 387], ["GST-CH1", "GENE_OR_GENE_PRODUCT", 389, 396], ["HIF", "PROTEIN", 26, 29], ["p300", "PROTEIN", 33, 37], ["41-amino-acid HIF-1a", "PROTEIN", 173, 193], ["p300", "PROTEIN", 239, 243], ["CBP binding domain", "PROTEIN", 244, 262], ["glutathione-Stransferase (GST) fusion protein", "PROTEIN", 269, 314], ["122-amino-acid minimal HIF-1a-binding domain", "PROTEIN", 333, 377], ["p300", "PROTEIN", 383, 387], ["GST", "PROTEIN", 389, 392], ["CH1", "PROTEIN", 393, 396], ["fluorescence", "TEST", 96, 108], ["screening assay", "TEST", 125, 140], ["derived polypeptide", "TREATMENT", 194, 213], ["the minimal p300/CBP binding domain", "PROBLEM", 227, 262], ["a glutathione", "TEST", 267, 280], ["fusion protein", "TEST", 300, 314]]], ["The biotinylated HIF-1a-derived polypeptide was immobilized onto streptavidin-coated plates.", [["HIF-1a", "GENE_OR_GENE_PRODUCT", 17, 23], ["streptavidin", "SIMPLE_CHEMICAL", 65, 77], ["biotinylated HIF-1a-derived polypeptide", "PROTEIN", 4, 43], ["streptavidin", "PROTEIN", 65, 77], ["The biotinylated HIF", "TEST", 0, 20], ["1a-derived polypeptide", "TREATMENT", 21, 43], ["streptavidin-coated plates", "TREATMENT", 65, 91]]], ["The interactions between the HIF-1a polypeptide and the GST-CH1 fusion protein were examined using time-resolved fluorescence to monitor a europium-conjugated anti-GST antibody probe.", [["europium", "CHEMICAL", 139, 147], ["europium", "CHEMICAL", 139, 147], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 29, 35], ["GST-CH1", "GENE_OR_GENE_PRODUCT", 56, 63], ["HIF-1a polypeptide", "PROTEIN", 29, 47], ["GST", "PROTEIN", 56, 59], ["CH1 fusion protein", "PROTEIN", 60, 78], ["europium-conjugated anti-GST antibody probe", "PROTEIN", 139, 182], ["1a polypeptide", "TREATMENT", 33, 47], ["the GST", "TEST", 52, 59], ["CH1 fusion protein", "TREATMENT", 60, 78], ["a europium-conjugated anti-GST antibody probe", "TREATMENT", 137, 182]]], ["A library of >600,000 natural products and synthetic compounds was evaluated, and the dithiodiketopiperazine metabolite chetomin was identified as a submicromolar inhibitor of HIF-1a/p300 interaction.", [["dithiodiketopiperazine", "CHEMICAL", 86, 108], ["chetomin", "CHEMICAL", 120, 128], ["dithiodiketopiperazine", "CHEMICAL", 86, 108], ["chetomin", "CHEMICAL", 120, 128], ["dithiodiketopiperazine", "SIMPLE_CHEMICAL", 86, 108], ["chetomin", "SIMPLE_CHEMICAL", 120, 128], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 176, 182], ["p300", "GENE_OR_GENE_PRODUCT", 183, 187], ["HIF", "PROTEIN", 176, 179], ["p300", "PROTEIN", 183, 187], ["A library", "TEST", 0, 9], ["synthetic compounds", "TREATMENT", 43, 62], ["the dithiodiketopiperazine metabolite chetomin", "TREATMENT", 82, 128], ["a submicromolar inhibitor", "TREATMENT", 147, 172]]], ["The advantage of such a biochemical process-based assay is that it can be used to discover active compounds that selectively target a specific predetermined mechanism.", [["a biochemical process", "TREATMENT", 22, 43], ["active compounds", "PROBLEM", 91, 107]]], ["However, some of the active compounds identified in this type of in vitro assays may not be further pursued if they fail to demonstrate efficacy in cell-based systems.", [["cell", "ANATOMY", 148, 152], ["cell", "CELL", 148, 152], ["the active compounds", "PROBLEM", 17, 37], ["vitro assays", "TEST", 68, 80], ["active", "OBSERVATION_MODIFIER", 21, 27], ["compounds", "OBSERVATION", 28, 37]]], ["In the case of chetomin, it exhibited anticancer efficacy in vivo.", [["anticancer", "ANATOMY", 38, 48], ["chetomin", "CHEMICAL", 15, 23], ["chetomin", "CHEMICAL", 15, 23], ["chetomin", "SIMPLE_CHEMICAL", 15, 23], ["anticancer", "CANCER", 38, 48], ["chetomin", "TREATMENT", 15, 23], ["anticancer efficacy", "OBSERVATION", 38, 57]]], ["Since the CH1 domain is also required for CBP/p300 to serve as a coactivator to other transcriptional activators, the relative \"nonspecificity\" and subsequent toxicity prevented the further development of chetomin as a chemotherapeutic drug.Selection of Measurable Biochemical Processes Suitable for Bioassay DevelopmentSmall-molecule HIF-1 inhibitors have also been identified using other approaches such as an ELISA (enzyme-linked immunosorbent assay)-based assay that detects the interaction between the HIF-1a and HIF-1b PAS A domains [48] .", [["toxicity", "DISEASE", 159, 167], ["chetomin", "CHEMICAL", 205, 213], ["chetomin", "CHEMICAL", 205, 213], ["CBP", "GENE_OR_GENE_PRODUCT", 42, 45], ["p300", "GENE_OR_GENE_PRODUCT", 46, 50], ["chetomin", "SIMPLE_CHEMICAL", 205, 213], ["HIF-1", "GENE_OR_GENE_PRODUCT", 335, 340], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 507, 513], ["HIF-1", "GENE_OR_GENE_PRODUCT", 518, 523], ["CH1 domain", "PROTEIN", 10, 20], ["CBP", "PROTEIN", 42, 45], ["p300", "PROTEIN", 46, 50], ["HIF", "PROTEIN", 335, 338], ["HIF", "PROTEIN", 507, 510], ["HIF", "PROTEIN", 518, 521], ["CBP/p300", "TREATMENT", 42, 50], ["subsequent toxicity", "PROBLEM", 148, 167], ["chetomin", "TREATMENT", 205, 213], ["a chemotherapeutic drug", "TREATMENT", 217, 240], ["Measurable Biochemical Processes", "PROBLEM", 254, 286], ["Bioassay", "TEST", 300, 308], ["an ELISA", "TEST", 409, 417], ["enzyme", "TEST", 419, 425], ["immunosorbent assay", "TEST", 433, 452]]], ["As previously discussed, biochemical process-based in vitro assays may facilitate the discovery of HIF inhibitors that target one specific mechanism or process.", [["HIF", "GENE_OR_GENE_PRODUCT", 99, 102], ["HIF", "PROTEIN", 99, 102], ["biochemical process", "PROBLEM", 25, 44], ["vitro assays", "TEST", 54, 66], ["HIF inhibitors", "TREATMENT", 99, 113]]], ["For enzyme-based assays, the recombinant protein should retain the native and active conformation.", [["recombinant protein", "PROTEIN", 29, 48], ["enzyme", "TEST", 4, 10], ["the recombinant protein", "TEST", 25, 48], ["active conformation", "OBSERVATION", 78, 97]]], ["Active compounds identified from the screening effort may have a higher possibility of being active in cell-based assays, if they can penetrate the host cells.", [["cell", "ANATOMY", 103, 107], ["cells", "ANATOMY", 153, 158], ["cell", "CELL", 103, 107], ["cells", "CELL", 153, 158], ["host cells", "CELL_TYPE", 148, 158], ["Active compounds", "PROBLEM", 0, 16], ["host cells", "OBSERVATION", 148, 158]]], ["In the case of in vitro assays that monitor protein interactions, the proteins used are often only polypeptides or otherwise truncated proteins that contain the domain(s) of interest.", [["truncated proteins", "PROTEIN", 125, 143], ["vitro assays", "TEST", 18, 30], ["protein interactions", "PROBLEM", 44, 64], ["the proteins", "TREATMENT", 66, 78], ["otherwise truncated proteins", "PROBLEM", 115, 143]]], ["These \"protein\" reagents may not retain the native conformation that is required for proper binding.", [["These \"protein\" reagents", "TREATMENT", 0, 24]]], ["As such, a large percentage of the actives from the primary screening efforts with such biochemical assays may fall out of the \"hit list\" when evaluated in cell-based systems.", [["cell", "ANATOMY", 156, 160], ["cell", "CELL", 156, 160], ["the primary screening efforts", "TEST", 48, 77], ["biochemical assays", "TEST", 88, 106], ["large", "OBSERVATION_MODIFIER", 11, 16], ["percentage", "OBSERVATION_MODIFIER", 17, 27]]], ["In addition, further studies are still required to discern the specificity and the bioavailability of active compounds before the agent can be advanced to animal-based studies.Techniques Used to Acquire or Measure the Bioassay DataFollowing rapid advances in molecular techniques, most of the assay-related reagents are available from commercial sources.", [["further studies", "TEST", 13, 28], ["active compounds", "PROBLEM", 102, 118], ["the agent", "TREATMENT", 126, 135], ["animal-based studies", "TEST", 155, 175], ["the assay-related reagents", "TREATMENT", 289, 315]]], ["For screening purposes, it is important to select the method(s) that is suitable for a high-throughput format as well as cost effective.", [["screening purposes", "TEST", 4, 22]]], ["In the case of discovering small-molecule HIF-1 inhibitors, we have chosen a cell-based luciferase assay as the format for primary screening [49] .", [["cell", "ANATOMY", 77, 81], ["HIF-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["cell", "CELL", 77, 81], ["luciferase", "GENE_OR_GENE_PRODUCT", 88, 98], ["HIF", "PROTEIN", 42, 45], ["luciferase", "PROTEIN", 88, 98], ["small-molecule HIF", "TREATMENT", 27, 45], ["primary screening", "TEST", 123, 140], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["In this cell-based assay, the activity of HIF-1 correlates with the enzymatic activity of the luciferase reporter.", [["cell", "ANATOMY", 8, 12], ["cell", "CELL", 8, 12], ["HIF-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["luciferase", "GENE_OR_GENE_PRODUCT", 94, 104], ["HIF-1", "PROTEIN", 42, 47], ["luciferase reporter", "DNA", 94, 113]]], ["The luciferase assay itself is straightforward, and the reagents are readily available from commercial sources.", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["luciferase", "PROTEIN", 4, 14], ["The luciferase assay", "TEST", 0, 20]]], ["In addition, other accessories such as cell culture plates and plate readers are available in both 96-and 384-well format for the purpose of screening.", [["cell", "ANATOMY", 39, 43], ["cell", "CELL", 39, 43], ["cell culture plates", "TEST", 39, 58], ["plate readers", "TEST", 63, 76], ["screening", "TEST", 141, 150]]], ["Cell-based reporter assays require cellular uptake of the reporter constructs by either transient or stable transfection.", [["Cell", "ANATOMY", 0, 4], ["cellular", "ANATOMY", 35, 43], ["Cell", "CELL", 0, 4], ["cellular", "CELL", 35, 43], ["reporter constructs", "DNA", 58, 77], ["Cell-based reporter assays", "TEST", 0, 26], ["transient", "OBSERVATION_MODIFIER", 88, 97], ["stable", "OBSERVATION_MODIFIER", 101, 107], ["transfection", "OBSERVATION", 108, 120]]], ["The transient transfection method is relatively fast, but the cells need to be transfected every time the assay is performed.", [["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["The transient transfection method", "PROBLEM", 0, 33], ["the cells", "PROBLEM", 58, 67], ["the assay", "TEST", 102, 111], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["transfection method", "OBSERVATION", 14, 33]]], ["The stable transfection approach is relatively time consuming in regard to the initial effort to establish a genetically modified cell line that has incorporated the reporter construct into its genome.", [["cell line", "ANATOMY", 130, 139], ["cell line", "CELL", 130, 139], ["genetically modified cell line", "CELL_LINE", 109, 139], ["a genetically modified cell line", "TREATMENT", 107, 139], ["stable", "OBSERVATION_MODIFIER", 4, 10], ["transfection", "OBSERVATION", 11, 23], ["cell line", "OBSERVATION", 130, 139]]], ["However, once a stable cell line is established, the cells can be directly assayed without transfection.Techniques Used to Acquire or Measure the Bioassay DataUpon selecting a transient transfection approach for our HIF-1 inhibitor discovery efforts, the initial studies were directed at identifying the optimal model system for the cell-based reporter assay.", [["cell line", "ANATOMY", 23, 32], ["cells", "ANATOMY", 53, 58], ["cell", "ANATOMY", 333, 337], ["cell line", "CELL", 23, 32], ["cells", "CELL", 53, 58], ["HIF-1", "GENE_OR_GENE_PRODUCT", 216, 221], ["cell", "CELL", 333, 337], ["stable cell line", "CELL_LINE", 16, 32], ["HIF", "PROTEIN", 216, 219], ["a stable cell line", "TREATMENT", 14, 32], ["a transient transfection approach", "TREATMENT", 174, 207], ["the initial studies", "TEST", 251, 270], ["stable", "OBSERVATION_MODIFIER", 16, 22], ["cell line", "OBSERVATION", 23, 32]]], ["A panel of human breast tumor cell lines that represent different disease stages and malignant progression were selected as in vitro models (early stage estrogen dependent: T47D and MCF-7; highly metastatic estrogen independent: MDA-MB-231).", [["breast tumor cell lines", "ANATOMY", 17, 40], ["T47D", "ANATOMY", 173, 177], ["MCF-7", "ANATOMY", 182, 187], ["MDA-MB-231", "ANATOMY", 229, 239], ["breast tumor", "DISEASE", 17, 29], ["estrogen", "CHEMICAL", 153, 161], ["estrogen", "CHEMICAL", 207, 215], ["MDA-MB-231", "CHEMICAL", 229, 239], ["estrogen", "CHEMICAL", 153, 161], ["estrogen", "CHEMICAL", 207, 215], ["human", "ORGANISM", 11, 16], ["breast tumor cell lines", "CELL", 17, 40], ["estrogen", "SIMPLE_CHEMICAL", 153, 161], ["T47D", "CELL", 173, 177], ["MCF-7", "CANCER", 182, 187], ["estrogen", "SIMPLE_CHEMICAL", 207, 215], ["MDA-MB-231", "CANCER", 229, 239], ["human breast tumor cell lines", "CELL_LINE", 11, 40], ["T47D", "CELL_LINE", 173, 177], ["MCF-7", "CELL_LINE", 182, 187], ["highly metastatic estrogen independent: MDA-MB-231", "CELL_LINE", 189, 239], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["A panel", "TEST", 0, 7], ["human breast tumor cell lines", "PROBLEM", 11, 40], ["different disease stages", "PROBLEM", 56, 80], ["malignant progression", "PROBLEM", 85, 106], ["vitro models", "TEST", 127, 139], ["early stage estrogen dependent", "PROBLEM", 141, 171], ["T47D", "TEST", 173, 177], ["MCF", "TEST", 182, 185], ["MDA-MB", "TEST", 229, 235], ["breast", "ANATOMY", 17, 23], ["tumor cell lines", "OBSERVATION", 24, 40], ["different", "OBSERVATION_MODIFIER", 56, 65], ["disease", "OBSERVATION", 66, 73], ["malignant", "OBSERVATION_MODIFIER", 85, 94], ["metastatic", "OBSERVATION_MODIFIER", 196, 206]]], ["First, the conditions for transient transfection were optimized in each cell line using a control construct (pGL3control, Promega) that expresses luciferase under the control of a constitutively active promoter.", [["cell line", "ANATOMY", 72, 81], ["cell line", "CELL", 72, 81], ["Promega", "GENE_OR_GENE_PRODUCT", 122, 129], ["luciferase", "GENE_OR_GENE_PRODUCT", 146, 156], ["cell line", "CELL_LINE", 72, 81], ["pGL3control", "DNA", 109, 120], ["luciferase", "PROTEIN", 146, 156], ["constitutively active promoter", "DNA", 180, 210], ["transient transfection", "TREATMENT", 26, 48], ["a control construct (pGL3control, Promega)", "TREATMENT", 88, 130]]], ["Second, a cell-based reporter assay for HIF-1 activity was performed in each cell line.", [["cell", "ANATOMY", 10, 14], ["cell line", "ANATOMY", 77, 86], ["cell", "CELL", 10, 14], ["HIF-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["cell line", "CELL", 77, 86], ["HIF", "PROTEIN", 40, 43], ["a cell", "TEST", 8, 14], ["HIF", "TEST", 40, 43], ["cell line", "OBSERVATION", 77, 86]]], ["The objective was to identify the cell line with the highest level of HIF activation.", [["cell line", "ANATOMY", 34, 43], ["cell line", "CELL", 34, 43], ["HIF", "GENE_OR_GENE_PRODUCT", 70, 73], ["HIF", "PROTEIN", 70, 73], ["the cell line", "TREATMENT", 30, 43], ["cell line", "OBSERVATION", 34, 43], ["HIF activation", "OBSERVATION", 70, 84]]], ["In order to improve screening efficiency, a robust assay with a high level of induction was sought to provide a low rate of background noise-associated false-positive experimental artifacts.", [["a robust assay", "TEST", 42, 56], ["a low rate of background noise", "PROBLEM", 110, 140], ["positive experimental artifacts", "PROBLEM", 158, 189], ["positive", "OBSERVATION_MODIFIER", 158, 166], ["experimental artifacts", "OBSERVATION", 167, 189]]], ["The cells were transiently transfected with the pHRE3-TK-luc reporter to monitor HIF-1 activity and exposed to inducing conditions that activate HIF-1.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["pHRE3", "GENE_OR_GENE_PRODUCT", 48, 53], ["HIF-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["HIF-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["pHRE3-TK-luc reporter", "DNA", 48, 69], ["HIF", "PROTEIN", 81, 84], ["HIF-1", "PROTEIN", 145, 150], ["HIF", "TEST", 81, 84]]], ["The conditions that activate HIF-1 range from hypoxia (decreased oxygen tension), iron chelators, transition metals (Co 2+ , Ni 2+ , etc.), to oncogenic mutations (activation of oncogenes and/or inactivation of tumor suppressor genes).", [["tumor", "ANATOMY", 211, 216], ["hypoxia", "DISEASE", 46, 53], ["oxygen", "CHEMICAL", 65, 71], ["iron", "CHEMICAL", 82, 86], ["tumor", "DISEASE", 211, 216], ["oxygen", "CHEMICAL", 65, 71], ["iron", "CHEMICAL", 82, 86], ["Co 2+", "CHEMICAL", 117, 122], ["Ni 2+", "CHEMICAL", 125, 130], ["HIF-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["iron chelators", "SIMPLE_CHEMICAL", 82, 96], ["Co 2+", "SIMPLE_CHEMICAL", 117, 122], ["Ni 2+", "SIMPLE_CHEMICAL", 125, 130], ["tumor", "CANCER", 211, 216], ["HIF-1", "PROTEIN", 29, 34], ["oncogenes", "DNA", 178, 187], ["tumor suppressor genes", "DNA", 211, 233], ["HIF", "TEST", 29, 32], ["hypoxia", "PROBLEM", 46, 53], ["decreased oxygen tension", "PROBLEM", 55, 79], ["iron chelators", "TREATMENT", 82, 96], ["transition metals", "PROBLEM", 98, 115], ["Co", "TEST", 117, 119], ["Ni", "TEST", 125, 127], ["oncogenic mutations", "PROBLEM", 143, 162], ["activation of oncogenes", "TREATMENT", 164, 187], ["tumor suppressor genes", "TREATMENT", 211, 233], ["decreased", "OBSERVATION_MODIFIER", 55, 64], ["oxygen tension", "OBSERVATION", 65, 79]]], ["In solid tumors, hypoxia is a common pathophysiological condition and the extent of tumor hypoxia correlates with advanced disease stages and poor prognosis.", [["solid tumors", "ANATOMY", 3, 15], ["tumor", "ANATOMY", 84, 89], ["tumors", "DISEASE", 9, 15], ["hypoxia", "DISEASE", 17, 24], ["tumor", "DISEASE", 84, 89], ["hypoxia", "DISEASE", 90, 97], ["solid tumors", "CANCER", 3, 15], ["tumor", "CANCER", 84, 89], ["solid tumors", "PROBLEM", 3, 15], ["hypoxia", "PROBLEM", 17, 24], ["a common pathophysiological condition", "PROBLEM", 28, 65], ["tumor hypoxia", "PROBLEM", 84, 97], ["advanced disease stages", "PROBLEM", 114, 137], ["solid", "OBSERVATION_MODIFIER", 3, 8], ["tumors", "OBSERVATION", 9, 15], ["hypoxia", "OBSERVATION", 17, 24], ["tumor", "OBSERVATION", 84, 89], ["advanced", "OBSERVATION_MODIFIER", 114, 122], ["disease", "OBSERVATION", 123, 130]]], ["Since HIF-1 is a key regulator of hypoxia-regulated gene expression that promotes tumor cell adaptation to hypoxia and overall treatment resistance, compounds that inhibit hypoxic activation of HIF-1 represent potential drug leads that selectively target tumor hypoxia.", [["tumor cell", "ANATOMY", 82, 92], ["tumor", "ANATOMY", 255, 260], ["tumor", "DISEASE", 82, 87], ["hypoxia", "DISEASE", 107, 114], ["tumor", "DISEASE", 255, 260], ["hypoxia", "DISEASE", 261, 268], ["HIF-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["tumor cell", "CELL", 82, 92], ["HIF-1", "GENE_OR_GENE_PRODUCT", 194, 199], ["tumor", "CANCER", 255, 260], ["HIF-1", "PROTEIN", 6, 11], ["HIF-1", "PROTEIN", 194, 199], ["hypoxia", "PROBLEM", 34, 41], ["tumor cell adaptation", "PROBLEM", 82, 103], ["hypoxia", "PROBLEM", 107, 114], ["overall treatment resistance", "TREATMENT", 119, 147], ["hypoxic activation of HIF", "PROBLEM", 172, 197], ["selectively target tumor hypoxia", "PROBLEM", 236, 268], ["hypoxia", "OBSERVATION", 34, 41], ["tumor cell", "OBSERVATION", 82, 92], ["treatment resistance", "OBSERVATION", 127, 147], ["tumor", "OBSERVATION", 255, 260]]], ["The focus of our discovery project was the identification of small molecules that inhibit HIF-1 activation by hypoxia.", [["hypoxia", "DISEASE", 110, 117], ["HIF-1", "GENE_OR_GENE_PRODUCT", 90, 95], ["HIF-1", "PROTEIN", 90, 95], ["small molecules", "PROBLEM", 61, 76], ["hypoxia", "PROBLEM", 110, 117], ["small", "OBSERVATION_MODIFIER", 61, 66], ["molecules", "OBSERVATION", 67, 76], ["hypoxia", "OBSERVATION", 110, 117]]], ["Among the cell lines examined (Fig. 22.", [["cell lines", "ANATOMY", 10, 20], ["cell lines", "CELL", 10, 20], ["cell lines", "CELL_LINE", 10, 20], ["the cell lines", "TEST", 6, 20], ["cell lines", "OBSERVATION", 10, 20]]], ["2), T47D breast tumor cells exhibited the highest level of HIF-1 induction upon hypoxic exposure (1% O 2 /5% CO 2 /94% N 2 , 16 h).", [["T47D breast tumor cells", "ANATOMY", 4, 27], ["breast tumor", "DISEASE", 9, 21], ["CO", "CHEMICAL", 109, 111], ["T47D breast tumor cells", "CELL", 4, 27], ["HIF-1", "GENE_OR_GENE_PRODUCT", 59, 64], ["T47D breast tumor cells", "CELL_LINE", 4, 27], ["HIF", "PROTEIN", 59, 62], ["T47D breast tumor cells", "PROBLEM", 4, 27], ["hypoxic exposure", "PROBLEM", 80, 96], ["CO", "TEST", 109, 111], ["breast", "ANATOMY", 9, 15], ["tumor", "OBSERVATION", 16, 21], ["highest", "OBSERVATION_MODIFIER", 42, 49]]], ["This T47D cell-based HIF-1 reporter assay produced the greatest signal to noise (background) ratio.", [["T47D cell", "ANATOMY", 5, 14], ["T47D cell", "CELL", 5, 14], ["HIF-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["T47D cell", "CELL_LINE", 5, 14], ["HIF", "PROTEIN", 21, 24], ["This T47D cell", "TEST", 0, 14], ["reporter assay", "TEST", 27, 41]]], ["The effectiveness of the cell-based reporter assay for detecting HIF-1 inhibitors was examined with a known HIF-1 inhibitor, MEK1 (meiosis-specific serine/threonine protein kinase) inhibitor PD98059.", [["cell", "ANATOMY", 25, 29], ["PD98059", "CHEMICAL", 191, 198], ["serine", "CHEMICAL", 148, 154], ["threonine", "CHEMICAL", 155, 164], ["PD98059", "CHEMICAL", 191, 198], ["cell", "CELL", 25, 29], ["HIF-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["HIF-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["MEK1", "GENE_OR_GENE_PRODUCT", 125, 129], ["meiosis-specific serine/threonine protein kinase", "GENE_OR_GENE_PRODUCT", 131, 179], ["PD98059", "SIMPLE_CHEMICAL", 191, 198], ["HIF", "PROTEIN", 65, 68], ["HIF", "PROTEIN", 108, 111], ["MEK1", "PROTEIN", 125, 129], ["HIF", "TEST", 65, 68], ["a known HIF", "TEST", 100, 111], ["MEK1 (meiosis", "TREATMENT", 125, 138], ["specific serine/threonine protein kinase) inhibitor PD98059", "TREATMENT", 139, 198]]], ["In MCF-7, MDA-MB-231, and T47D cells, PD98059 inhibited HIF-1 activation by hypoxia with comparable potencies (Fig. 22.3) .", [["MCF-7", "ANATOMY", 3, 8], ["MDA-MB-231", "ANATOMY", 10, 20], ["T47D cells", "ANATOMY", 26, 36], ["PD98059", "CHEMICAL", 38, 45], ["hypoxia", "DISEASE", 76, 83], ["PD98059", "CHEMICAL", 38, 45], ["MCF-7", "CELL", 3, 8], ["MDA-MB-231", "CELL", 10, 20], ["T47D cells", "CELL", 26, 36], ["PD98059", "SIMPLE_CHEMICAL", 38, 45], ["HIF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["MCF-7", "CELL_LINE", 3, 8], ["MDA-MB-231", "CELL_LINE", 10, 20], ["T47D cells", "CELL_LINE", 26, 36], ["HIF-1", "PROTEIN", 56, 61], ["MCF", "TEST", 3, 6], ["MDA-MB", "TEST", 10, 16], ["T47D cells", "TEST", 26, 36], ["PD98059", "TEST", 38, 45], ["HIF", "TEST", 56, 59], ["hypoxia", "PROBLEM", 76, 83], ["hypoxia", "OBSERVATION", 76, 83]]], ["Further cell viability studies in T47D cells excluded the possibility of false positives due to cytotoxicity.Design and Use of Proper Experimental ControlsIn an ideal situation, all molecular-targeted screening efforts should be conducted in a statistically significant way (N ! 3) to achieve accuracy and reliability.", [["cell", "ANATOMY", 8, 12], ["T47D cells", "ANATOMY", 34, 44], ["cell", "CELL", 8, 12], ["T47D cells", "CELL", 34, 44], ["T47D cells", "CELL_LINE", 34, 44], ["Further cell viability studies", "TEST", 0, 30], ["T47D cells", "TEST", 34, 44], ["false positives", "PROBLEM", 73, 88], ["cytotoxicity", "PROBLEM", 96, 108], ["cell viability", "OBSERVATION", 8, 22], ["false positives", "OBSERVATION", 73, 88]]], ["However, it is time consuming and not feasible for many small academic laboratories with limited resources to examine tens of thousands of samples in triplicate.Design and Use of Proper Experimental ControlsTo meet this challenge, one approach is to include some element of replication and proper experimental controls to ensure the effectiveness of the bioassays.", [["samples", "CANCER", 139, 146], ["Proper Experimental Controls", "TREATMENT", 179, 207], ["this challenge", "TREATMENT", 215, 229], ["replication", "TREATMENT", 274, 285], ["proper experimental controls", "TREATMENT", 290, 318]]], ["If an assay is deemed effective, then we can assume that the results obtained with the samples will have a higher probability of accuracy.", [["an assay", "TEST", 3, 11], ["the samples", "TEST", 83, 94]]], ["In the T47D cell-based reporter assay for HIF-1 activity, the ratio of luciferase activity under hypoxic conditions versus that under normoxic conditions serves as an indicator for the extent of HIF-1 activation.", [["T47D cell", "ANATOMY", 7, 16], ["T47D cell", "CELL", 7, 16], ["HIF-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["luciferase", "GENE_OR_GENE_PRODUCT", 71, 81], ["HIF-1", "GENE_OR_GENE_PRODUCT", 195, 200], ["T47D cell", "CELL_LINE", 7, 16], ["HIF", "PROTEIN", 42, 45], ["luciferase", "PROTEIN", 71, 81], ["HIF", "PROTEIN", 195, 198], ["HIF", "TEST", 42, 45], ["luciferase activity", "PROBLEM", 71, 90], ["hypoxic conditions", "PROBLEM", 97, 115]]], ["The inhibition of HIF-1 activity observed in the presence of an HIF-1 inhibitor (e.g., cycloheximide) (1) indicates the effectiveness of the assay for detecting HIF-1 inhibitors [50] .", [["cycloheximide", "CHEMICAL", 87, 100], ["cycloheximide", "CHEMICAL", 87, 100], ["HIF-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["HIF-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["cycloheximide", "SIMPLE_CHEMICAL", 87, 100], ["HIF-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["HIF-1", "PROTEIN", 18, 23], ["HIF", "PROTEIN", 64, 67], ["HIF", "PROTEIN", 161, 164], ["an HIF-1 inhibitor", "TREATMENT", 61, 79], ["cycloheximide", "TREATMENT", 87, 100], ["the assay", "TEST", 137, 146], ["HIF", "TEST", 161, 164]]], ["Other HIF-1 inhibitors have also been used as positive controls in HIF-1 bioassays.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["HIF-1", "GENE_OR_GENE_PRODUCT", 67, 72], ["HIF", "PROTEIN", 6, 9], ["HIF", "PROTEIN", 67, 70], ["Other HIF-1 inhibitors", "TREATMENT", 0, 22]]], ["These positive controls include the nonselective alkaloid-based protein synthesis inhibitor emetine (2)Design and Use of Proper Experimental ControlsO NH Upon identification of the proper controls, another factor that impacts the screening outcome is the final concentration of the test sample.", [["emetine", "CHEMICAL", 92, 99], ["emetine", "CHEMICAL", 92, 99], ["emetine", "SIMPLE_CHEMICAL", 92, 99], ["These positive controls", "PROBLEM", 0, 23], ["the nonselective alkaloid-based protein synthesis inhibitor emetine", "TREATMENT", 32, 99], ["the test sample", "TEST", 278, 293]]], ["When the sample concentration is too high, nonspecific and/or less potent inhibitors will appear as positives in the assay, and this will lead to an unmanageably high hit rate.", [["sample", "ANATOMY", 9, 15], ["the sample concentration", "TEST", 5, 29], ["nonspecific and/or less potent inhibitors", "PROBLEM", 43, 84], ["an unmanageably high hit rate", "PROBLEM", 146, 175]]], ["As shown in Fig. 22 .4a, approximately 78% of the extracts on a 96-well sample plate inhibited HIF-1 activation by >50% when tested at the concentration of 50 mg/mL.", [["extracts", "ANATOMY", 50, 58], ["extracts", "ORGANISM_SUBSTANCE", 50, 58], ["HIF-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["HIF", "PROTEIN", 95, 98]]], ["In contrast, the hit rate in the primary assay was reduced to 2% when the same samples were examined at 5 mg/mL (Fig. 22.4b ).Bioassay Validation and the Application of Appropriate Statistical MethodsThe results of molecular-targeted antitumor assays can only be considered reliable if the experiments are properly controlled, the bioassay methods have been rigorously validated, and the results are analyzed using suitable statistical methods for the particular bioassay design.", [["samples", "ANATOMY", 79, 86], ["antitumor", "ANATOMY", 234, 243], ["antitumor", "CANCER", 234, 243], ["the hit rate", "TEST", 13, 25], ["the primary assay", "TEST", 29, 46], ["the bioassay methods", "TEST", 327, 347]]], ["Despite the fact that these criteria are necessary for the publication of manuscripts that specifically describe new bioassay methods, such standards are seldom given sufficient attention in publications that describe the biological activities associated with either marine or terrestrial natural products.", [["new bioassay methods", "TEST", 113, 133], ["terrestrial natural products", "TREATMENT", 277, 305], ["terrestrial natural products", "OBSERVATION", 277, 305]]], ["It is relatively common to see publications that combine the isolation and structure elucidation, total synthesis, and other aspects of medicinal chemistry with biological testing results.", [["total synthesis", "TREATMENT", 98, 113], ["medicinal chemistry", "TEST", 136, 155], ["biological testing", "TEST", 161, 179]]], ["All too often these reports focus on the natural products chemistry but fall short in respect to their standards for the bioassay acquisition methods and statistical data analysis.", [["the natural products chemistry", "TEST", 37, 67], ["the bioassay acquisition methods", "TEST", 117, 149], ["statistical data analysis", "TEST", 154, 179]]], ["Experimental results are commonly reported The cells were lysed, and luciferase activity was determined and presented as percent inhibition relative to a nontreated hypoxic control. (a) Approximately 78% of the extracts on a 96-well sample plate of chemically diverse plant extracts inhibited HIF-1 activation by >50% when tested at the concentration of 50 mg/mL. (b) When the identical 96-well plate of extracts was evaluated at a final concentration of 5 mg/mL, the corresponding hit rate in the primary assay was reduced to only 2% without including the data for positive or negative experimental controls, IC 50 values are frequently reported without any indication of experimental replication, and structure-activity relationship studies are sometimes supported by tables of results that do not specify the magnitude of the observed experimental error or if the differences in bioactivity between structurally related compounds have statistical significance.", [["cells", "ANATOMY", 47, 52], ["extracts", "ANATOMY", 211, 219], ["extracts", "ANATOMY", 274, 282], ["extracts", "ANATOMY", 404, 412], ["cells", "CELL", 47, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 69, 79], ["extracts", "ORGANISM_SUBSTANCE", 211, 219], ["extracts", "ORGANISM_SUBSTANCE", 274, 282], ["HIF-1", "GENE_OR_GENE_PRODUCT", 293, 298], ["extracts", "ORGANISM_SUBSTANCE", 404, 412], ["luciferase", "PROTEIN", 69, 79], ["HIF", "PROTEIN", 293, 296], ["luciferase activity", "TEST", 69, 88], ["a nontreated hypoxic control", "TREATMENT", 152, 180], ["the primary assay", "TEST", 494, 511], ["the data", "TEST", 553, 561], ["experimental replication", "PROBLEM", 673, 697], ["hypoxic control", "OBSERVATION", 165, 180], ["replication", "OBSERVATION", 686, 697]]], ["However, recent articles, reviews, and texts provide a detailed perspective of statistical methods used to analyze and evaluate bioassay data [55] [56] [57] [58] [59] .Bioassay Validation and the Application of Appropriate Statistical MethodsIn order to ensure the reliability of bioassays used to screen extracts, active chromatographic fractions, and purified natural products from marine organisms, these assays must be validated with respect to an array of assay parameters (robustness, linearity, accuracy, precision, sensitivity, and specificity).", [["extracts", "ANATOMY", 305, 313], ["[55] [56] [57] [58] [59]", "CHEMICAL", 142, 166], ["[55] [56] [57] [58] [59]", "SIMPLE_CHEMICAL", 142, 166], ["extracts", "ORGANISM_SUBSTANCE", 305, 313], ["bioassay data", "TEST", 128, 141], ["Appropriate Statistical Methods", "TREATMENT", 211, 242], ["bioassays", "TEST", 280, 289], ["active chromatographic fractions", "PROBLEM", 315, 347], ["marine organisms", "PROBLEM", 384, 400], ["these assays", "TEST", 402, 414], ["an array of assay parameters", "TEST", 449, 477], ["accuracy", "TEST", 502, 510], ["sensitivity", "TEST", 523, 534]]], ["For our screening purposes, we define these bioassay validation terms in a similar manner to the \"Guidelines for Industry\" text on Validation of Analytical Procedures of the International Conference on Harmonisation (ICH) [60-62]: \u2022 Assay \"robustness\" is a measure of an assay's tendency to be susceptible to minor background variation in responses and is reflected by the magnitude of response (or signal) relative to background variation (or noise).", [["ICH", "DISEASE", 217, 220], ["our screening purposes", "TEST", 4, 26], ["an assay's tendency", "PROBLEM", 268, 287]]], ["Robust bioassays are generally more sensitive and require fewer replicates to observe statistical significance. \u2022 Assay \"linearity\" is the ability of the assay to obtain test results that are uniformly proportional (within a specific range) to either the molecular/biochemical process evaluated or, in the case of analytical procedures, directly proportional to the concentration of sample. \u2022 Assay \"accuracy\" is a measure of how close the results of the assay are relative to accepted reference or control values. \u2022 Assay \"precision\" is the variation between multiple replicates and is generally expressed in terms of standard deviation, coefficient of variation, etc. Bioassay precision is a measure of experiment to experiment repeatability (intra-assay precision within a given laboratory), intermediate variation (between various equipment, personnel, etc.), and assay reproducibility between different laboratories.", [["Robust bioassays", "TEST", 0, 16], ["analytical procedures", "TREATMENT", 314, 335], ["the concentration of sample", "TREATMENT", 362, 389], ["the assay", "TEST", 451, 460], ["standard deviation", "PROBLEM", 619, 637]]], ["The sensitivity is a measure of the minimum detection limits of a bioassay method. \u2022 Assay \"specificity\" is determined by the ability of the assay method to specifically respond to the desired molecular or biochemical process, relative to the bioassay's susceptibility to false positives due to off-target effects produced by test substances.", [["false positives", "DISEASE", 272, 287], ["a bioassay method", "TEST", 64, 81], ["the bioassay's susceptibility", "TEST", 239, 268], ["false positives", "PROBLEM", 272, 287]]], ["Shen and colleagues took an siRNA (small interfering RNA)-based loss-offunction screening approach to identify potential druggable targets that control the HIF-1 pathway [63] .", [["HIF-1", "GENE_OR_GENE_PRODUCT", 156, 161], ["HIF", "PROTEIN", 156, 159], ["an siRNA (small interfering RNA", "PROBLEM", 25, 56], ["based loss", "PROBLEM", 58, 68], ["screening approach", "TEST", 80, 98]]], ["A non-small-cell lung carcinoma H1299 cell-derived stable HIF-1 reporter cell line (H1299_HRE) was established.", [["non-small-cell lung carcinoma H1299 cell", "ANATOMY", 2, 42], ["HIF-1 reporter cell line", "ANATOMY", 58, 82], ["H1299_HRE", "ANATOMY", 84, 93], ["non-small-cell lung carcinoma", "DISEASE", 2, 31], ["non-small-cell lung carcinoma H1299 cell", "CELL", 2, 42], ["HIF-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["cell line", "CELL", 73, 82], ["H1299_HRE", "CELL", 84, 93], ["non-small-cell lung carcinoma H1299 cell-derived stable HIF-1 reporter cell line", "CELL_LINE", 2, 82], ["H1299_HRE", "CELL_LINE", 84, 93], ["A non-small-cell lung carcinoma", "PROBLEM", 0, 31], ["1 reporter cell line", "TREATMENT", 62, 82], ["non-small-cell", "OBSERVATION", 2, 16], ["lung", "ANATOMY", 17, 21], ["carcinoma", "OBSERVATION", 22, 31], ["H1299 cell", "OBSERVATION", 32, 42], ["stable", "OBSERVATION_MODIFIER", 51, 57], ["cell line", "OBSERVATION", 73, 82]]], ["Expression of this luciferase reporter was under the control of the HRE from the enolase promoter and hypoxic exposure increased luciferase activity by three-to fivefold.", [["luciferase", "GENE_OR_GENE_PRODUCT", 19, 29], ["enolase", "GENE_OR_GENE_PRODUCT", 81, 88], ["luciferase", "GENE_OR_GENE_PRODUCT", 129, 139], ["luciferase reporter", "DNA", 19, 38], ["HRE", "DNA", 68, 71], ["enolase promoter", "DNA", 81, 97], ["luciferase", "PROTEIN", 129, 139], ["this luciferase reporter", "PROBLEM", 14, 38], ["the enolase promoter", "TREATMENT", 77, 97], ["hypoxic exposure increased luciferase activity", "PROBLEM", 102, 148], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["luciferase activity", "OBSERVATION", 129, 148]]], ["For assay validation, H1299_HRE cells were transfected with an HIF-1A siRNA as a positive control and a scramble siRNA as a negative control.", [["H1299_HRE cells", "ANATOMY", 22, 37], ["H1299_HRE cells", "CELL", 22, 37], ["HIF-1A", "GENE_OR_GENE_PRODUCT", 63, 69], ["H1299_HRE cells", "CELL_LINE", 22, 37], ["HIF", "PROTEIN", 63, 66], ["assay validation", "TEST", 4, 20], ["H1299_HRE cells", "PROBLEM", 22, 37], ["an HIF", "TEST", 60, 66], ["1A siRNA", "TREATMENT", 67, 75], ["a positive control", "TREATMENT", 79, 97], ["a scramble siRNA", "TREATMENT", 102, 118]]], ["The transfected cells were exposed to hypoxic conditions and the luciferase activities determined.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["luciferase", "GENE_OR_GENE_PRODUCT", 65, 75], ["transfected cells", "CELL_LINE", 4, 21], ["luciferase", "PROTEIN", 65, 75], ["The transfected cells", "PROBLEM", 0, 21], ["hypoxic conditions", "PROBLEM", 38, 56], ["the luciferase activities", "TEST", 61, 86], ["transfected cells", "OBSERVATION", 4, 21], ["hypoxic conditions", "OBSERVATION", 38, 56]]], ["The assay used in this initial screening had Z-factor values that were greater than 0.5.", [["Z-factor", "GENE_OR_GENE_PRODUCT", 45, 53], ["The assay", "TEST", 0, 9], ["this initial screening", "TEST", 18, 40], ["Z-factor values", "TEST", 45, 60]]], ["This indicated that the H1299_HRE-based reporter assay was suitable for highthroughput screening.", [["H1299_HRE", "GENE_OR_GENE_PRODUCT", 24, 33], ["H1299_HRE", "DNA", 24, 33], ["the H1299_HRE-based reporter assay", "TEST", 20, 54], ["highthroughput screening", "TEST", 72, 96]]], ["The Z-factor is a simple statistical parameter used to assess assay quality, defined as Z-factor \u00bc 1 \u00c0 [3 \u00c2 (s p + s n )]/jm p \u00c0 m n j [64] .", [["Z-factor", "GENE_OR_GENE_PRODUCT", 4, 12], ["Z-factor", "PROTEIN", 4, 12], ["Z-factor", "PROTEIN", 88, 96], ["assay quality", "TEST", 62, 75], ["Z", "TEST", 88, 89]]], ["The four parameters are the means (m) and the standard deviations (s) of the controls [positive (p) and negative (n)].", [["the controls", "TEST", 73, 85]]], ["An ideal assay will yield a Z-factor of 1, an excellent assay Z-factor between 0.5 and 1.0, a marginal assay Z-factor between 0 and 0.5, and a highly variable assay will produce a Z-factor less than 0.Bioassay Validation and the Application of Appropriate Statistical MethodsBased on the Z-factor analysis, the H1299_HRE-based reporter assay was considered suitable for high-throughput screening (HTS) and was used to examine an siRNA library against approximately 4,000 druggable targets.", [["Z-factor", "PROTEIN", 62, 70], ["Z-factor", "PROTEIN", 180, 188], ["H1299_HRE", "DNA", 311, 320], ["An ideal assay", "TEST", 0, 14], ["a Z-factor", "TEST", 26, 36], ["a marginal assay Z-factor", "TEST", 92, 117], ["a highly variable assay", "PROBLEM", 141, 164], ["a Z-factor", "TEST", 178, 188], ["the Z-factor analysis", "TEST", 284, 305], ["the H1299_HRE-based reporter assay", "TEST", 307, 341], ["an siRNA library", "TREATMENT", 426, 442]]], ["However, confirmation studies revealed that the hits identified in the primary assay were caused by siRNA-mediated off-target gene silencing that nonspecifically inhibited HIF-1.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 172, 177], ["HIF-1", "PROTEIN", 172, 177], ["confirmation studies", "TEST", 9, 29], ["the hits", "PROBLEM", 44, 52], ["the primary assay", "TEST", 67, 84], ["siRNA", "PROBLEM", 100, 105]]], ["The H1299_HRE cells were used to establish a 384-well-based reporter assay for HIF-1 activity.", [["H1299_HRE cells", "ANATOMY", 4, 19], ["H1299_HRE cells", "CELL", 4, 19], ["HIF-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["H1299_HRE cells", "CELL_LINE", 4, 19], ["HIF", "PROTEIN", 79, 82], ["The H1299_HRE cells", "TEST", 0, 19], ["reporter assay", "TEST", 60, 74]]], ["A library of 691,200 small molecules was examined in this assay (Z-factor 0.18), and this chemical genomics approach led to the identification of alkyliminophenylacetate compounds as potent HIF-1 inhibitors.", [["alkyliminophenylacetate", "CHEMICAL", 146, 169], ["alkyliminophenylacetate", "CHEMICAL", 146, 169], ["alkyliminophenylacetate", "SIMPLE_CHEMICAL", 146, 169], ["HIF-1", "GENE_OR_GENE_PRODUCT", 190, 195], ["HIF", "PROTEIN", 190, 193], ["A library", "TEST", 0, 9], ["small molecules", "PROBLEM", 21, 36], ["this assay", "TEST", 53, 63], ["Z-factor", "TEST", 65, 73], ["alkyliminophenylacetate compounds", "TREATMENT", 146, 179], ["potent HIF", "TREATMENT", 183, 193]]], ["The low Z-factor indicates that this latter HTS assay would have only marginal reliability.Bioassay Method-Specific Experimental ArtifactsEvery assay format has method-specific advantages and disadvantages.", [["Z-factor", "PROTEIN", 8, 16], ["The low Z-factor", "PROBLEM", 0, 16], ["this latter HTS assay", "TEST", 32, 53], ["Bioassay", "TEST", 91, 99], ["low Z", "OBSERVATION_MODIFIER", 4, 9], ["marginal", "OBSERVATION_MODIFIER", 70, 78]]], ["For the purpose of HTS screening, most bioassays employ colorimetric, fluorescent, or luminescent methods to measure the outcomes.", [["HTS screening", "TEST", 19, 32], ["luminescent methods", "TREATMENT", 86, 105]]], ["In the case of marine organism extracts, many substances in the crude extracts can potentially interfere with fluorescence-or luminescence-based methods due to autofluorescence or quenching of the fluorescent and/or luminescent signals.", [["extracts", "ANATOMY", 31, 39], ["extracts", "ANATOMY", 70, 78], ["extracts", "ORGANISM_SUBSTANCE", 31, 39], ["extracts", "ORGANISM_SUBSTANCE", 70, 78], ["marine organism extracts", "PROBLEM", 15, 39], ["many substances in the crude extracts", "PROBLEM", 41, 78], ["fluorescence", "TEST", 110, 122], ["autofluorescence", "PROBLEM", 160, 176], ["the fluorescent and/or luminescent signals", "TEST", 193, 235]]], ["To reduce the rate of false positives associated with method-related experimental artifacts, the active samples should be first evaluated in a secondary screening system that acts as a control for substances that particularly interfere with the selected bioassay method.", [["samples", "ANATOMY", 104, 111], ["samples", "CANCER", 104, 111], ["false positives", "PROBLEM", 22, 37], ["method-related experimental artifacts", "PROBLEM", 54, 91], ["a secondary screening system", "TEST", 141, 169], ["false positives", "OBSERVATION", 22, 37], ["experimental artifacts", "OBSERVATION", 69, 91]]], ["For example, active extracts that inhibit HIF-1 activation in our previously described T47D cell-based reporter assay are then examined in T47D cells that are transfected with a control construct (pGL3-control) [49, 65] .", [["extracts", "ANATOMY", 20, 28], ["T47D cell", "ANATOMY", 87, 96], ["T47D cells", "ANATOMY", 139, 149], ["extracts", "ORGANISM_SUBSTANCE", 20, 28], ["HIF-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["T47D cell", "CELL", 87, 96], ["T47D cells", "CELL", 139, 149], ["pGL3", "GENE_OR_GENE_PRODUCT", 197, 201], ["HIF-1", "PROTEIN", 42, 47], ["T47D cell", "CELL_LINE", 87, 96], ["T47D cells", "CELL_LINE", 139, 149], ["pGL3", "DNA", 197, 201], ["active extracts", "PROBLEM", 13, 28], ["reporter assay", "TEST", 103, 117], ["a control construct (pGL3-control", "TREATMENT", 176, 209], ["active", "OBSERVATION_MODIFIER", 13, 19]]], ["The pGL3-control construct contains a simian virus 40 (SV40) promoter and enhancer sequences that strongly express a modified firefly luciferase reporter gene (luc+) in many mammalian cell lines.", [["cell lines", "ANATOMY", 184, 194], ["pGL3", "GENE_OR_GENE_PRODUCT", 4, 8], ["simian virus 40", "ORGANISM", 38, 53], ["SV40", "ORGANISM", 55, 59], ["luciferase", "GENE_OR_GENE_PRODUCT", 134, 144], ["luc", "GENE_OR_GENE_PRODUCT", 160, 163], ["mammalian cell lines", "CELL", 174, 194], ["pGL3-control construct", "DNA", 4, 26], ["simian virus 40 (SV40) promoter", "DNA", 38, 69], ["enhancer sequences", "DNA", 74, 92], ["firefly luciferase reporter gene", "DNA", 126, 158], ["luc", "DNA", 160, 163], ["mammalian cell lines", "CELL_LINE", 174, 194], ["simian virus", "SPECIES", 38, 50], ["simian virus", "SPECIES", 38, 50], ["The pGL3-control construct", "TREATMENT", 0, 26], ["a simian virus 40 (SV40) promoter", "TREATMENT", 36, 69], ["mammalian cell lines", "TREATMENT", 174, 194], ["mammalian cell lines", "OBSERVATION", 174, 194]]], ["A false positive that inhibits the luciferase reaction and/or expression will also suppress luciferase activity in the tumor cells that have been transfected with the control construct.", [["tumor cells", "ANATOMY", 119, 130], ["tumor", "DISEASE", 119, 124], ["luciferase", "GENE_OR_GENE_PRODUCT", 35, 45], ["luciferase", "GENE_OR_GENE_PRODUCT", 92, 102], ["tumor cells", "CELL", 119, 130], ["luciferase", "PROTEIN", 35, 45], ["luciferase", "PROTEIN", 92, 102], ["tumor cells", "CELL_TYPE", 119, 130], ["A false positive", "PROBLEM", 0, 16], ["the luciferase reaction", "PROBLEM", 31, 54], ["luciferase activity in the tumor cells", "PROBLEM", 92, 130], ["false positive", "OBSERVATION", 2, 16], ["tumor cells", "OBSERVATION", 119, 130]]], ["Similarly, active samples identified using a fluorescence-based method can be evaluated in a separate fluorescencebased assay for an unrelated target.", [["samples", "ANATOMY", 18, 25], ["a fluorescence-based method", "TREATMENT", 43, 70], ["active", "OBSERVATION_MODIFIER", 11, 17]]], ["In general, false positives associated with a specific method will inhibit all similar assays that examine unrelated targets using the same assay method.", [["false positives", "PROBLEM", 12, 27], ["false positives", "OBSERVATION", 12, 27]]], ["In this respect, it is critical to establish a screening protocol that incorporates procedures that remove method-related experimental artifacts.Identification of Active Marine Natural ProductsJust as demonstrating clinical efficacy results is the most definitive form of target validation, the identification of therapeutically effective compounds that regulate the selected molecular target can be considered strong practical proof of bioassay validation.", [["a screening protocol", "TEST", 45, 65], ["procedures", "TREATMENT", 84, 94], ["experimental artifacts", "PROBLEM", 122, 144], ["Active Marine Natural Products", "TREATMENT", 163, 193], ["therapeutically effective compounds", "PROBLEM", 313, 348], ["bioassay validation", "TEST", 437, 456], ["experimental artifacts", "OBSERVATION", 122, 144], ["Active", "OBSERVATION_MODIFIER", 163, 169], ["Marine Natural Products", "OBSERVATION", 170, 193]]], ["The subject of molecular-targeted anticancer marine natural product discovery has been reviewed with respect to antitumor compounds that were specifically identified through the use of molecular-targeted bioassays [6] .Identification of Active Marine Natural ProductsTo date, only a relatively small number of marine natural products have been found to inhibit HIF-1 activation in various tumor cell lines (reviewed in 14) .", [["anticancer", "ANATOMY", 34, 44], ["antitumor", "ANATOMY", 112, 121], ["tumor cell lines", "ANATOMY", 389, 405], ["tumor", "DISEASE", 389, 394], ["anticancer", "CANCER", 34, 44], ["antitumor", "CANCER", 112, 121], ["HIF-1", "GENE_OR_GENE_PRODUCT", 361, 366], ["tumor cell lines", "CELL", 389, 405], ["HIF", "PROTEIN", 361, 364], ["tumor cell lines", "CELL_LINE", 389, 405], ["Active Marine Natural Products", "TREATMENT", 237, 267], ["marine natural products", "TREATMENT", 310, 333], ["various tumor cell lines", "TREATMENT", 381, 405], ["Active", "OBSERVATION_MODIFIER", 237, 243], ["Marine", "OBSERVATION_MODIFIER", 244, 250], ["Natural Products", "OBSERVATION", 251, 267], ["small", "OBSERVATION_MODIFIER", 294, 299], ["tumor cell lines", "OBSERVATION", 389, 405]]], ["The University of Mississippi HIF discovery program identified most of these marinederived HIF-1 inhibitors [66] .", [["HIF", "GENE_OR_GENE_PRODUCT", 30, 33], ["HIF-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["HIF", "PROTEIN", 30, 33], ["HIF", "PROTEIN", 91, 94], ["these marinederived HIF", "TREATMENT", 71, 94]]], ["Over 10,560 lipid extracts of marine invertebrates and algae crude extracts have been evaluated in the primary T47D human breast tumor cell-based reporter assay for the ability to inhibit hypoxia-induced HIF-1 activation [49] .", [["extracts", "ANATOMY", 18, 26], ["extracts", "ANATOMY", 67, 75], ["T47D", "ANATOMY", 111, 115], ["breast tumor cell", "ANATOMY", 122, 139], ["breast tumor", "DISEASE", 122, 134], ["hypoxia", "DISEASE", 188, 195], ["lipid extracts", "ORGANISM_SUBSTANCE", 12, 26], ["algae crude extracts", "ORGANISM_SUBSTANCE", 55, 75], ["T47D", "CELL", 111, 115], ["human", "ORGANISM", 116, 121], ["breast tumor cell", "CELL", 122, 139], ["HIF-1", "GENE_OR_GENE_PRODUCT", 204, 209], ["primary T47D human breast tumor cell", "CELL_LINE", 103, 139], ["HIF", "PROTEIN", 204, 207], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["marine invertebrates", "TREATMENT", 30, 50], ["algae crude extracts", "TREATMENT", 55, 75], ["reporter assay", "TEST", 146, 160], ["hypoxia", "PROBLEM", 188, 195], ["breast", "ANATOMY", 122, 128], ["tumor", "OBSERVATION", 129, 134]]], ["As previously described, the extracts were examined in the T47D cell-based reporter assay (5 mg/mL \u00bc 5 ppm) and the threshold for actives was set at !70% inhibition.", [["extracts", "ANATOMY", 29, 37], ["T47D cell", "ANATOMY", 59, 68], ["extracts", "ORGANISM_SUBSTANCE", 29, 37], ["T47D cell", "CELL", 59, 68], ["T47D cell", "CELL_LINE", 59, 68]]], ["Actives from the primary screen were subjected to a panel of additional bioassays designed to aid in the confirmation, prioritization, deselection, and dereplication process (Fig. 22.5) .Actives in the primary assays (\u2265 70% inhibition of HIF-1 activity) 1 st set of confirmatory bioassays (in both T47D and PC-3 cells) 2 nd set of confirmatory bioassays (in both T47D and PC-3 cells)Hypoxia-Activated HIF-1 T47D cell-based reporter assay (1% O 2 )Non-specifically inhibits luciferase expression or luciferase activity (inhibit pHRE-luc and pGL3-control to the same degree) 2.", [["T47D", "ANATOMY", 298, 302], ["PC-3 cells", "ANATOMY", 307, 317], ["T47D", "ANATOMY", 363, 367], ["PC-3 cells", "ANATOMY", 372, 382], ["T47D cell", "ANATOMY", 407, 416], ["HIF-1", "GENE_OR_GENE_PRODUCT", 238, 243], ["T47D", "CELL", 298, 302], ["PC-3 cells", "CELL", 307, 317], ["T47D", "CELL", 363, 367], ["PC-3 cells", "CELL", 372, 382], ["HIF-1", "GENE_OR_GENE_PRODUCT", 401, 406], ["luciferase", "GENE_OR_GENE_PRODUCT", 473, 483], ["luciferase", "GENE_OR_GENE_PRODUCT", 498, 508], ["pHRE-luc", "GENE_OR_GENE_PRODUCT", 527, 535], ["pGL3", "GENE_OR_GENE_PRODUCT", 540, 544], ["HIF", "PROTEIN", 238, 241], ["T47D", "CELL_LINE", 298, 302], ["T47D", "CELL_LINE", 363, 367], ["HIF", "PROTEIN", 401, 404], ["luciferase", "PROTEIN", 473, 483], ["luciferase", "PROTEIN", 498, 508], ["pHRE", "PROTEIN", 527, 531], ["luc", "DNA", 532, 535], ["pGL3", "DNA", 540, 544], ["the primary screen", "TEST", 13, 31], ["additional bioassays", "TEST", 61, 81], ["the confirmation", "TEST", 101, 117], ["deselection", "TEST", 135, 146], ["the primary assays", "TEST", 198, 216], ["HIF", "TEST", 238, 241], ["confirmatory bioassays", "TEST", 266, 288], ["PC", "TEST", 307, 309], ["confirmatory bioassays", "TEST", 331, 353], ["PC", "TEST", 372, 374], ["Hypoxia", "PROBLEM", 383, 390], ["T47D cell", "TEST", 407, 416], ["reporter assay", "TEST", 423, 437], ["Non-specifically inhibits luciferase expression", "PROBLEM", 447, 494], ["luciferase activity", "TEST", 498, 517], ["pHRE", "TEST", 527, 531], ["pGL3-control", "TREATMENT", 540, 552]]], ["HIF-1 inhibition due to cytotoxicityFalse positives (to be deselected) b Fig. 22 .5 Flow diagrams depicting representative bioassays used in HIF-1 inhibitor confirmation, prioritization, deselection, and dereplication process. (a) General flow diagram outlining HIF-1 bioassay evaluation system; (b) specific experimental protocols used to confirm, prioritize, deselect, and dereplicate extracts, fractions, and purified compounds detected in primary HIF-1 luciferase reporter assay system Since the number of samples in the NCI Open Repository of marine invertebrate and algae extracts [67] was relatively large (10,560 lipid extracts), screening results from this large group of samples were analyzed and summarized in the following synopsis.", [["extracts", "ANATOMY", 387, 395], ["samples", "ANATOMY", 510, 517], ["extracts", "ANATOMY", 578, 586], ["extracts", "ANATOMY", 627, 635], ["samples", "ANATOMY", 681, 688], ["HIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIF-1", "GENE_OR_GENE_PRODUCT", 141, 146], ["HIF-1", "GENE_OR_GENE_PRODUCT", 262, 267], ["extracts", "ORGANISM_SUBSTANCE", 387, 395], ["HIF-1 luciferase", "GENE_OR_GENE_PRODUCT", 451, 467], ["algae extracts", "ORGANISM_SUBSTANCE", 572, 586], ["lipid extracts", "ORGANISM_SUBSTANCE", 621, 635], ["samples", "CANCER", 681, 688], ["HIF", "PROTEIN", 0, 3], ["HIF", "PROTEIN", 141, 144], ["HIF", "PROTEIN", 262, 265], ["HIF", "PROTEIN", 451, 454], ["HIF", "TEST", 0, 3], ["cytotoxicityFalse positives", "PROBLEM", 24, 51], ["b Fig.", "TEST", 71, 77], ["Flow diagrams", "TEST", 84, 97], ["representative bioassays", "TEST", 108, 132], ["deselection", "PROBLEM", 187, 198], ["General flow diagram", "TEST", 231, 251], ["1 bioassay evaluation system", "TEST", 266, 294], ["specific experimental protocols", "TEST", 300, 331], ["algae extracts", "TEST", 572, 586], ["screening", "TEST", 638, 647], ["large", "OBSERVATION_MODIFIER", 607, 612]]], ["A total of 109 active extracts (1% hit rate) were identified in the primary screen ( Fig. 22.6a) .", [["extracts", "ANATOMY", 22, 30], ["extracts", "ORGANISM_SUBSTANCE", 22, 30], ["hit rate", "TEST", 35, 43], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Over one-half of the active samples were lipid extracts of marine sponges (57 out of 109) .", [["samples", "ANATOMY", 28, 35], ["extracts", "ANATOMY", 47, 55], ["samples", "CANCER", 28, 35], ["lipid extracts", "ORGANISM_SUBSTANCE", 41, 55], ["marine sponges", "TREATMENT", 59, 73], ["marine sponges", "OBSERVATION", 59, 73]]], ["Although, a broad range of organisms were shown to have HIF-1 inhibitory activity (sea hares, algae, echinoderms, bryozoans, nudibranchs, and cnidarians).", [["echinoderms", "ANATOMY", 101, 112], ["bryozoans", "ANATOMY", 114, 123], ["nudibranchs", "ANATOMY", 125, 136], ["HIF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["HIF", "PROTEIN", 56, 59], ["a broad range of organisms", "PROBLEM", 10, 36], ["HIF", "TEST", 56, 59]]], ["Active extracts were subjected to additional bioassays that include the following: (1) a pNip3-luc reporter assay for detecting substances that inhibit HIF-1 activation [68] ; (2) a pGL3-control (Promega) reporter assay to deselect false positives that inhibit luciferase expression/activity [49, 65] ; (3) a cell proliferation/viability assay to exclude cytotoxic extracts; and (4) a pHRE-TK-Luc reporter assay to confirm the initial results and discern the specificity toward the inhibition of low-oxygen (1% O 2 ) hypoxia-induced HIF-1 activation relative to the ability of chemical hypoxia [1,10-phenanthroline (10 mM)] to induce HIF-1 activation.", [["extracts", "ANATOMY", 7, 15], ["cell", "ANATOMY", 309, 313], ["extracts", "ANATOMY", 365, 373], ["oxygen", "CHEMICAL", 500, 506], ["hypoxia", "DISEASE", 517, 524], ["1,10-phenanthroline", "CHEMICAL", 595, 614], ["oxygen", "CHEMICAL", 500, 506], ["1,10-phenanthroline", "CHEMICAL", 595, 614], ["extracts", "ORGANISM_SUBSTANCE", 7, 15], ["pNip3", "GENE_OR_GENE_PRODUCT", 89, 94], ["HIF-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["pGL3", "GENE_OR_GENE_PRODUCT", 182, 186], ["luciferase", "GENE_OR_GENE_PRODUCT", 261, 271], ["cell", "CELL", 309, 313], ["extracts", "ORGANISM_SUBSTANCE", 365, 373], ["oxygen", "SIMPLE_CHEMICAL", 500, 506], ["HIF-1", "GENE_OR_GENE_PRODUCT", 533, 538], ["1,10-phenanthroline", "SIMPLE_CHEMICAL", 595, 614], ["HIF-1", "GENE_OR_GENE_PRODUCT", 634, 639], ["HIF", "PROTEIN", 152, 155], ["pGL3-control (Promega) reporter", "DNA", 182, 213], ["luciferase", "PROTEIN", 261, 271], ["HIF", "PROTEIN", 533, 536], ["HIF", "PROTEIN", 634, 637], ["Active extracts", "PROBLEM", 0, 15], ["a pGL3-control (Promega)", "TREATMENT", 180, 204], ["false positives", "PROBLEM", 232, 247], ["luciferase expression", "TEST", 261, 282], ["a cell proliferation/viability assay", "TEST", 307, 343], ["cytotoxic extracts", "PROBLEM", 355, 373], ["a pHRE-TK-Luc reporter assay", "TEST", 383, 411], ["hypoxia", "PROBLEM", 517, 524], ["chemical hypoxia", "PROBLEM", 577, 593], ["phenanthroline", "TREATMENT", 600, 614]]], ["Between 80% and 90% of the active extracts were confirmed upon retesting.", [["extracts", "ANATOMY", 34, 42], ["extracts", "ORGANISM_SUBSTANCE", 34, 42]]], ["Less than one-half of the samples suppressed tumor cell proliferation/viability by more than 50%.", [["samples", "ANATOMY", 26, 33], ["tumor cell", "ANATOMY", 45, 55], ["tumor", "DISEASE", 45, 50], ["tumor cell", "CELL", 45, 55], ["the samples suppressed tumor cell proliferation", "PROBLEM", 22, 69], ["tumor cell proliferation", "OBSERVATION", 45, 69], ["viability", "OBSERVATION_MODIFIER", 70, 79]]], ["Over 50% of the active extracts showed selectivity for inhibiting hypoxia-induced HIF-1 activation over chemical hypoxiainduced HIF-1 activation.", [["extracts", "ANATOMY", 23, 31], ["hypoxia", "DISEASE", 66, 73], ["extracts", "ORGANISM_SUBSTANCE", 23, 31], ["HIF-1", "GENE_OR_GENE_PRODUCT", 82, 87], ["HIF-1", "GENE_OR_GENE_PRODUCT", 128, 133], ["HIF", "PROTEIN", 82, 85], ["HIF", "PROTEIN", 128, 131], ["inhibiting hypoxia", "PROBLEM", 55, 73]]], ["From the original 109 extracts that were active in the primary T47D cell-based reporter assay, 40 extracts (0.38% of the 10,560 extracts examined) withstood confirmatory secondary testing and were prioritized for further study (Fig. 22.6b) .", [["extracts", "ANATOMY", 22, 30], ["T47D cell", "ANATOMY", 63, 72], ["extracts", "ANATOMY", 98, 106], ["extracts", "ANATOMY", 128, 136], ["extracts", "ORGANISM_SUBSTANCE", 22, 30], ["T47D cell", "CELL", 63, 72], ["extracts", "ORGANISM_SUBSTANCE", 98, 106], ["primary T47D cell", "CELL_LINE", 55, 72], ["confirmatory secondary testing", "TEST", 157, 187], ["further study", "TEST", 213, 226], ["active", "OBSERVATION_MODIFIER", 41, 47]]], ["Samples from the NCI Open Repository are available on a first-come-first-serve basis, and the availability of many extracts is extremely limited.", [["extracts", "ANATOMY", 115, 123], ["extracts", "ORGANISM_SUBSTANCE", 115, 123], ["Samples", "TEST", 0, 7]]], ["Supply-based prioritization suggested that only 33 extracts (out of the original 109 active extracts) were available from the NCI-Developmental Therapeutics Program (NCI-DTP) in sufficient quantity (typically 2-4 g) to guarantee any probability of successful bioassay-guided isolation and structure elucidation efforts, to ensure that the quantities of active pure compounds isolated would be adequate for in vitro mechanistic studies, and/or to evaluate for efficacy in vivo.", [["extracts", "ANATOMY", 51, 59], ["extracts", "ANATOMY", 92, 100], ["NCI-DTP", "CHEMICAL", 166, 173], ["extracts", "ORGANISM_SUBSTANCE", 51, 59], ["extracts", "ORGANISM_SUBSTANCE", 92, 100], ["successful bioassay", "TREATMENT", 248, 267], ["guided isolation", "TREATMENT", 268, 284], ["active pure compounds", "PROBLEM", 353, 374], ["vitro mechanistic studies", "TEST", 409, 434]]], ["Based on results from the biological confirmatory studies and the quantity of samples available, about one-third of the samples were assigned as \"high-priority\" for isolation efforts.Non-specifically inhibits luciferase expression or luciferase activity (inhibit pHRE-luc and pGL3-control to the same degree) 2.", [["luciferase", "GENE_OR_GENE_PRODUCT", 209, 219], ["luciferase", "GENE_OR_GENE_PRODUCT", 234, 244], ["pHRE-luc", "GENE_OR_GENE_PRODUCT", 263, 271], ["pGL3", "GENE_OR_GENE_PRODUCT", 276, 280], ["luciferase", "PROTEIN", 209, 219], ["luciferase", "PROTEIN", 234, 244], ["pHRE", "PROTEIN", 263, 267], ["luc", "DNA", 268, 271], ["pGL3", "DNA", 276, 280], ["the biological confirmatory studies", "TEST", 22, 57], ["isolation efforts", "TREATMENT", 165, 182], ["Non-specifically inhibits luciferase expression", "PROBLEM", 183, 230], ["luciferase activity", "PROBLEM", 234, 253], ["pHRE", "TEST", 263, 267], ["pGL3-control", "TREATMENT", 276, 288], ["luciferase expression", "OBSERVATION", 209, 230], ["luciferase activity", "OBSERVATION", 234, 253]]], ["HIF-1 inhibition due to cytotoxicityThis synopsis exemplified several of the advantages of sourcing the NCI Open Repository -the large number of samples available for HTS assays, low-cost access to chemical diversity, logistical ease relative to investigator-initiated collection efforts and intellectual property negotiations, and the ability to identify new pharmacological activities even for \"known\" natural products.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIF", "PROTEIN", 0, 3], ["cytotoxicity", "PROBLEM", 24, 36], ["HTS assays", "TEST", 167, 177], ["collection efforts", "TREATMENT", 269, 287], ["intellectual property negotiations", "TREATMENT", 292, 326], ["large", "OBSERVATION_MODIFIER", 129, 134]]], ["Efforts to source NCI samples are also associated with a number of disadvantages.", [["NCI samples", "ANATOMY", 18, 29], ["NCI samples", "CANCER", 18, 29], ["source NCI samples", "TEST", 11, 29]]], ["Despite these possible disadvantages, a variety seahares (3) sponges (57) sponges (15) red algae (7) brown algae (11) green algae (3) nudibranchs (2) echinoderms (4) ascidians (6) bryozoans (2) \"not known\" (4) cnidarians (10) (1) ascidians (4) red algae (4) brown algae (1) green algae (1) \"not known\" (2) seahares (2) cnidarians (4) Fig. 22 .6 Charts illustrating numbers and distribution of marine organism extracts found to inhibit HIF-1 activation in a cell-based reporter assay.", [["extracts", "ANATOMY", 409, 417], ["cell", "ANATOMY", 457, 461], ["extracts", "ORGANISM_SUBSTANCE", 409, 417], ["HIF-1", "GENE_OR_GENE_PRODUCT", 435, 440], ["cell", "CELL", 457, 461], ["HIF", "PROTEIN", 435, 438], ["a variety seahares (3) sponges (57) sponges", "TREATMENT", 38, 81], ["red algae", "TREATMENT", 87, 96], ["green algae (3) nudibranchs (2) echinoderms", "TREATMENT", 118, 161], ["red algae", "TEST", 244, 253], ["Fig.", "TEST", 334, 338], ["marine organism extracts", "PROBLEM", 393, 417], ["possible", "UNCERTAINTY", 14, 22]]], ["Lipid extracts (10,560) from the NCI Open Repository of marine invertebrate and algae extracts were examined for the ability to inhibit hypoxia-induced HIF-1 activation in a T47D breast tumor cell line-based luciferase reporter assay. (a) Primary screening revealed 109 extracts strongly inhibited HIF-1 activation in the primary assay (a !70% decrease in pTK-HRE3-Luc). (b) Only 40 extracts remained following secondary evaluation in assays designed to confirm and prioritize the samples that were shown to be active in the primary reporter assay.", [["extracts", "ANATOMY", 6, 14], ["algae extracts", "ANATOMY", 80, 94], ["T47D breast tumor cell line", "ANATOMY", 174, 201], ["extracts", "ANATOMY", 270, 278], ["extracts", "ANATOMY", 383, 391], ["samples", "ANATOMY", 481, 488], ["hypoxia", "DISEASE", 136, 143], ["breast tumor", "DISEASE", 179, 191], ["Lipid extracts", "ORGANISM_SUBSTANCE", 0, 14], ["algae extracts", "ORGANISM_SUBSTANCE", 80, 94], ["HIF-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["T47D breast tumor cell line", "CELL", 174, 201], ["luciferase", "GENE_OR_GENE_PRODUCT", 208, 218], ["extracts", "ORGANISM_SUBSTANCE", 270, 278], ["HIF-1", "GENE_OR_GENE_PRODUCT", 298, 303], ["extracts", "ORGANISM_SUBSTANCE", 383, 391], ["HIF", "PROTEIN", 152, 155], ["T47D breast tumor cell line", "CELL_LINE", 174, 201], ["luciferase", "PROTEIN", 208, 218], ["HIF", "PROTEIN", 298, 301], ["pTK", "PROTEIN", 356, 359], ["HRE3", "PROTEIN", 360, 364], ["Luc", "PROTEIN", 365, 368], ["Lipid extracts", "TEST", 0, 14], ["algae extracts", "TREATMENT", 80, 94], ["hypoxia", "PROBLEM", 136, 143], ["a T47D breast tumor cell line", "TREATMENT", 172, 201], ["Primary screening", "TEST", 239, 256], ["pTK", "TEST", 356, 359], ["secondary evaluation", "TEST", 411, 431], ["assays", "TEST", 435, 441], ["the samples", "TEST", 477, 488], ["breast", "ANATOMY", 179, 185], ["tumor cell line", "OBSERVATION", 186, 201]]], ["Extracts from a variety of marine organisms were found to contain substances that potently inhibited hypoxic-induced HIF-1 activation (Figures and caption reproduced with the of novel HIF-1 inhibitors were discovered from the available samples, and some of these were described in two recent reviews on natural product-derived inhibitors of HIF-1 (Table 22 .1) [14, 69] .Non-specifically inhibits luciferase expression or luciferase activity (inhibit pHRE-luc and pGL3-control to the same degree) 2.", [["Extracts", "ANATOMY", 0, 8], ["samples", "ANATOMY", 236, 243], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["HIF-1", "GENE_OR_GENE_PRODUCT", 117, 122], ["HIF-1", "GENE_OR_GENE_PRODUCT", 184, 189], ["HIF-1", "GENE_OR_GENE_PRODUCT", 341, 346], ["luciferase", "GENE_OR_GENE_PRODUCT", 397, 407], ["luciferase", "GENE_OR_GENE_PRODUCT", 422, 432], ["pHRE-luc", "GENE_OR_GENE_PRODUCT", 451, 459], ["pGL3", "GENE_OR_GENE_PRODUCT", 464, 468], ["HIF", "PROTEIN", 117, 120], ["HIF", "PROTEIN", 184, 187], ["HIF", "PROTEIN", 341, 344], ["luciferase", "PROTEIN", 397, 407], ["luciferase", "PROTEIN", 422, 432], ["pHRE", "PROTEIN", 451, 455], ["luc", "DNA", 456, 459], ["pGL3", "DNA", 464, 468], ["Extracts", "TREATMENT", 0, 8], ["marine organisms", "PROBLEM", 27, 43], ["hypoxic-induced HIF", "PROBLEM", 101, 120], ["novel HIF-1 inhibitors", "TREATMENT", 178, 200], ["natural product", "TREATMENT", 303, 318], ["HIF", "TEST", 341, 344], ["Non-specifically inhibits luciferase expression", "PROBLEM", 371, 418], ["luciferase activity", "PROBLEM", 422, 441], ["pHRE", "TEST", 451, 455], ["pGL3-control", "TREATMENT", 464, 476], ["luciferase expression", "OBSERVATION", 397, 418], ["luciferase activity", "OBSERVATION", 422, 441]]], ["HIF-1 inhibition due to cytotoxicityOnce the active compounds were isolated, a combination of spectroscopic and spectrometric methods including multidimensional NMR spectroscopy and highresolution mass spectrometry (HRMS) were employed to elucidate the structures of active compounds.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIF", "PROTEIN", 0, 3], ["cytotoxicity", "PROBLEM", 24, 36], ["spectroscopic and spectrometric methods", "TREATMENT", 94, 133], ["multidimensional NMR spectroscopy", "TEST", 144, 177], ["highresolution mass spectrometry", "TEST", 182, 214], ["HRMS", "TEST", 216, 220], ["active compounds", "PROBLEM", 267, 283], ["active", "OBSERVATION_MODIFIER", 45, 51], ["active", "OBSERVATION_MODIFIER", 267, 273], ["compounds", "OBSERVATION", 274, 283]]], ["This unique HIF-1 inhibitor discovery effort that combined the chemical diversity offered by natural products with effective and reliable bioassays has resulted in the identification of some of the most potent HIF-1 inhibitors known [16] .", [["HIF-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["HIF-1", "GENE_OR_GENE_PRODUCT", 210, 215], ["HIF", "PROTEIN", 12, 15], ["HIF", "PROTEIN", 210, 213], ["natural products", "TREATMENT", 93, 109]]], ["The first marine natural product found to inhibit hypoxia-induced HIF-1 activation in tumor cells was from the lipid extract of a Jamaican collection of the red alga Laurencia intricata Lamouroux (Rhodomelaceae).", [["tumor cells", "ANATOMY", 86, 97], ["lipid extract", "ANATOMY", 111, 124], ["hypoxia", "DISEASE", 50, 57], ["tumor", "DISEASE", 86, 91], ["HIF-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["tumor cells", "CELL", 86, 97], ["red alga", "ORGANISM", 157, 165], ["Laurencia intricata Lamouroux", "ORGANISM", 166, 195], ["Rhodomelaceae", "CANCER", 197, 210], ["HIF-1", "PROTEIN", 66, 71], ["tumor cells", "CELL_TYPE", 86, 97], ["Laurencia intricata", "SPECIES", 166, 185], ["red alga", "SPECIES", 157, 165], ["Laurencia intricata", "SPECIES", 166, 185], ["hypoxia", "PROBLEM", 50, 57], ["induced HIF", "PROBLEM", 58, 69], ["1 activation in tumor cells", "PROBLEM", 70, 97], ["a Jamaican collection", "PROBLEM", 128, 149], ["the red alga Laurencia", "PROBLEM", 153, 175], ["tumor cells", "OBSERVATION", 86, 97], ["Jamaican collection", "OBSERVATION", 130, 149], ["red alga Laurencia", "OBSERVATION", 157, 175]]], ["Laurenditerpenol (4), a novel bicyclic diterpene, was found to be the active constituent of the alga.", [["alga", "ANATOMY", 96, 100], ["Laurenditerpenol", "CHEMICAL", 0, 16], ["bicyclic diterpene", "CHEMICAL", 30, 48], ["Laurenditerpenol", "CHEMICAL", 0, 16], ["bicyclic diterpene", "CHEMICAL", 30, 48], ["Laurenditerpenol (4)", "SIMPLE_CHEMICAL", 0, 20], ["bicyclic diterpene", "SIMPLE_CHEMICAL", 30, 48], ["alga", "ORGANISM_SUBDIVISION", 96, 100], ["Laurenditerpenol", "TREATMENT", 0, 16], ["a novel bicyclic diterpene", "TREATMENT", 22, 48], ["active", "OBSERVATION", 70, 76]]], ["Compound 4 inhibited hypoxia (1% O 2 )-induced HIF-1 activation in T47D cells at submicromolar concentrations (Table 22 .1) [70] .", [["T47D cells", "ANATOMY", 67, 77], ["hypoxia", "DISEASE", 21, 28], ["O 2", "CHEMICAL", 33, 36], ["HIF-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["T47D cells", "CELL", 67, 77], ["HIF", "PROTEIN", 47, 50], ["T47D cells", "CELL_LINE", 67, 77], ["Compound 4 inhibited hypoxia", "PROBLEM", 0, 28], ["T47D cells", "TREATMENT", 67, 77], ["submicromolar concentrations", "TEST", 81, 109]]], ["The absolute configuration of 4 50 values for hypoxia (1% O 2 )-induced HIF-1 activation in a T47D cell-based reporter assay, unless otherwise noted b EC 50 values for hypoxia (1% O 2 )-induced HIF-1 activation in a U251 cell-based reporter assay has recently been defined by total synthesis [71] .", [["T47D cell", "ANATOMY", 94, 103], ["EC", "ANATOMY", 151, 153], ["U251 cell", "ANATOMY", 216, 225], ["hypoxia", "DISEASE", 46, 53], ["hypoxia", "DISEASE", 168, 175], ["O 2", "CHEMICAL", 180, 183], ["HIF-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["T47D cell", "CELL", 94, 103], ["EC", "CELL", 151, 153], ["HIF-1", "GENE_OR_GENE_PRODUCT", 194, 199], ["U251 cell", "CELL", 216, 225], ["HIF", "PROTEIN", 72, 75], ["T47D cell", "CELL_LINE", 94, 103], ["HIF", "PROTEIN", 194, 197], ["U251 cell", "CELL_LINE", 216, 225], ["The absolute configuration", "TEST", 0, 26], ["hypoxia", "PROBLEM", 46, 53], ["reporter assay", "TEST", 110, 124], ["hypoxia", "PROBLEM", 168, 175], ["a U251 cell", "TEST", 214, 225], ["reporter assay", "TEST", 232, 246], ["absolute", "OBSERVATION_MODIFIER", 4, 12], ["configuration", "OBSERVATION_MODIFIER", 13, 26]]], ["Total synthesis may also afford sufficient quantities of 4 and various related isomers for further biological evaluation and a study of structure-activity relationships (SARs). furospongolide (6) sodwanone V (7)Non-specifically inhibits luciferase expression or luciferase activity (inhibit pHRE-luc and pGL3-control to the same degree) 2.", [["furospongolide", "CHEMICAL", 177, 191], ["furospongolide", "CHEMICAL", 177, 191], ["sodwanone V", "CHEMICAL", 196, 207], ["luciferase", "GENE_OR_GENE_PRODUCT", 237, 247], ["luciferase", "GENE_OR_GENE_PRODUCT", 262, 272], ["pHRE-luc", "GENE_OR_GENE_PRODUCT", 291, 299], ["pGL3", "GENE_OR_GENE_PRODUCT", 304, 308], ["luciferase", "PROTEIN", 237, 247], ["luciferase", "PROTEIN", 262, 272], ["pHRE", "PROTEIN", 291, 295], ["luc", "DNA", 296, 299], ["pGL3", "DNA", 304, 308], ["Total synthesis", "TREATMENT", 0, 15], ["further biological evaluation", "TEST", 91, 120], ["a study", "TEST", 125, 132], ["furospongolide", "TREATMENT", 177, 191], ["Non-specifically inhibits luciferase expression", "PROBLEM", 211, 258], ["luciferase activity", "PROBLEM", 262, 281], ["pHRE", "TEST", 291, 295], ["pGL3-control", "TREATMENT", 304, 316]]], ["HIF-1 inhibition due to cytotoxicityThe NCI Open Repository of marine invertebrate and algae extracts has proven to be a valuable source of small-molecule inhibitors of HIF-1 activation.", [["algae extracts", "ANATOMY", 87, 101], ["HIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["algae extracts", "ORGANISM_SUBSTANCE", 87, 101], ["HIF-1", "GENE_OR_GENE_PRODUCT", 169, 174], ["HIF", "PROTEIN", 0, 3], ["HIF", "PROTEIN", 169, 172], ["cytotoxicity", "PROBLEM", 24, 36], ["algae extracts", "TREATMENT", 87, 101], ["small", "OBSERVATION_MODIFIER", 140, 145]]], ["These marine natural product-based HIF-1 inhibitors include the sponge metabolites 7-hydroxyneolamellarin (5) [53] , furospongolide (6) [72] , and a series of sodwanone and yardenone triterpenoids [i.e., sodwanone V (7)] [73] .", [["7-hydroxyneolamellarin", "CHEMICAL", 83, 105], ["5) [53] , furospongolide (6) [72]", "CHEMICAL", 107, 140], ["sodwanone", "CHEMICAL", 159, 168], ["yardenone", "CHEMICAL", 173, 182], ["7-hydroxyneolamellarin", "CHEMICAL", 83, 105], ["furospongolide", "CHEMICAL", 117, 131], ["sodwanone", "CHEMICAL", 159, 168], ["yardenone", "CHEMICAL", 173, 182], ["triterpenoids", "CHEMICAL", 183, 196], ["sodwanone V", "CHEMICAL", 204, 215], ["HIF-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["7-hydroxyneolamellarin (5) [53]", "SIMPLE_CHEMICAL", 83, 114], ["furospongolide (6) [72]", "SIMPLE_CHEMICAL", 117, 140], ["sodwanone", "SIMPLE_CHEMICAL", 159, 168], ["yardenone triterpenoids", "SIMPLE_CHEMICAL", 173, 196], ["sodwanone V (7)] [73]", "SIMPLE_CHEMICAL", 204, 225], ["HIF", "PROTEIN", 35, 38], ["These marine natural product", "TREATMENT", 0, 28], ["HIF-1 inhibitors", "TREATMENT", 35, 51], ["the sponge metabolites", "TREATMENT", 60, 82], ["hydroxyneolamellarin", "TREATMENT", 85, 105], ["furospongolide", "TREATMENT", 117, 131], ["sodwanone and yardenone triterpenoids", "TREATMENT", 159, 196]]], ["Similarly, benzo[g]chromen-4-one and benzo[h]chromen-4-one pigments (8) (9) (10) (11) (12) (13) (14) from a tropical marine crinoid (Comasteridae) were also found to inhibit hypoxiainduced activation of HIF-1 [65] .", [["benzo[g]chromen-4-one", "CHEMICAL", 11, 32], ["benzo[h]chromen-4-one pigments", "CHEMICAL", 37, 67], ["Comasteridae", "CHEMICAL", 133, 145], ["benzo[g]chromen-4-one", "CHEMICAL", 11, 32], ["benzo[h]chromen-4-one", "CHEMICAL", 37, 58], ["benzo[g]chromen-4-one", "SIMPLE_CHEMICAL", 11, 32], ["benzo[h]chromen-4-one pigments (8) (9) (10) (11) (12) (13)", "SIMPLE_CHEMICAL", 37, 95], ["Comasteridae", "SIMPLE_CHEMICAL", 133, 145], ["HIF-1", "GENE_OR_GENE_PRODUCT", 203, 208], ["HIF", "PROTEIN", 203, 206], ["benzo", "TEST", 11, 16], ["chromen", "TEST", 19, 26], ["a tropical marine crinoid", "TREATMENT", 106, 131]]], ["However, these benzochromenones were not further pursued because their ability to inhibit HIF-1 activation did not translate into a significant effect on the HIF-1 target genes examined (i.e., secreted VEGF) and, for all practical purposes, these crinoid pigments are now considered possible nuisance compounds.", [["benzochromenones", "CHEMICAL", 15, 31], ["benzochromenones", "CHEMICAL", 15, 31], ["benzochromenones", "SIMPLE_CHEMICAL", 15, 31], ["HIF-1", "GENE_OR_GENE_PRODUCT", 90, 95], ["HIF-1", "GENE_OR_GENE_PRODUCT", 158, 163], ["VEGF", "GENE_OR_GENE_PRODUCT", 202, 206], ["crinoid pigments", "SIMPLE_CHEMICAL", 247, 263], ["HIF", "PROTEIN", 90, 93], ["HIF-1 target genes", "DNA", 158, 176], ["VEGF", "PROTEIN", 202, 206], ["the HIF", "TEST", 154, 161], ["these crinoid pigments", "TREATMENT", 241, 263], ["nuisance compounds", "PROBLEM", 292, 310]]], ["Recently, bioassay-guided fractionation of an active extract of a Mycale sp. sponge yielded 18 new and 8 previously reported lipophilic 2,5-disubstituted pyrroles, collectively known as mycalenitriles and mycalazals [e.g., mycalenitrile-6 (15) and mycalenitrile-7 (16) ] [74] .", [["2,5-disubstituted pyrroles", "CHEMICAL", 136, 162], ["mycalenitriles", "CHEMICAL", 186, 200], ["mycalazals", "CHEMICAL", 205, 215], ["mycalenitrile-6 (15) and mycalenitrile-7 (16)", "CHEMICAL", 223, 268], ["2,5-disubstituted pyrroles", "CHEMICAL", 136, 162], ["mycalenitriles", "CHEMICAL", 186, 200], ["mycalazals", "CHEMICAL", 205, 215], ["mycalenitrile", "CHEMICAL", 223, 236], ["mycalenitrile", "CHEMICAL", 248, 261], ["Mycale sp", "ORGANISM", 66, 75], ["lipophilic 2,5-disubstituted pyrroles", "SIMPLE_CHEMICAL", 125, 162], ["mycalenitriles", "SIMPLE_CHEMICAL", 186, 200], ["mycalazals", "SIMPLE_CHEMICAL", 205, 215], ["mycalenitrile-6 (15)", "SIMPLE_CHEMICAL", 223, 243], ["mycalenitrile-7 (16) ] [74]", "SIMPLE_CHEMICAL", 248, 275], ["bioassay", "TEST", 10, 18], ["guided fractionation", "TREATMENT", 19, 39], ["sponge", "TEST", 77, 83], ["lipophilic", "TEST", 125, 135], ["disubstituted pyrroles", "TREATMENT", 140, 162], ["mycalenitriles", "TREATMENT", 186, 200], ["mycalazals", "TREATMENT", 205, 215], ["mycalenitrile", "TREATMENT", 223, 236], ["mycalenitrile", "TREATMENT", 248, 261], ["active", "OBSERVATION_MODIFIER", 46, 52], ["extract", "OBSERVATION", 53, 60], ["18 new", "OBSERVATION_MODIFIER", 92, 98]]], ["The red pigment caulerpin (17) was first isolated from green algae of the genus Caulerpa [75] .Non-specifically inhibits luciferase expression or luciferase activity (inhibit pHRE-luc and pGL3-control to the same degree) 2.", [["caulerpin", "CHEMICAL", 16, 25], ["caulerpin", "CHEMICAL", 16, 25], ["red pigment caulerpin (17)", "GENE_OR_GENE_PRODUCT", 4, 30], ["luciferase", "GENE_OR_GENE_PRODUCT", 121, 131], ["luciferase", "GENE_OR_GENE_PRODUCT", 146, 156], ["pHRE-luc", "GENE_OR_GENE_PRODUCT", 175, 183], ["pGL3", "GENE_OR_GENE_PRODUCT", 188, 192], ["luciferase", "PROTEIN", 121, 131], ["luciferase", "PROTEIN", 146, 156], ["pHRE", "PROTEIN", 175, 179], ["luc", "DNA", 180, 183], ["pGL3", "DNA", 188, 192], ["The red pigment caulerpin", "TEST", 0, 25], ["Non-specifically inhibits luciferase expression", "PROBLEM", 95, 142], ["luciferase activity", "PROBLEM", 146, 165], ["pHRE", "TEST", 175, 179], ["pGL3-control", "TREATMENT", 188, 200], ["red", "OBSERVATION_MODIFIER", 4, 7], ["pigment", "OBSERVATION_MODIFIER", 8, 15], ["caulerpin", "OBSERVATION_MODIFIER", 16, 25], ["luciferase expression", "OBSERVATION", 121, 142], ["luciferase activity", "OBSERVATION", 146, 165]]], ["HIF-1 inhibition due to cytotoxicityCaulerpin (17) inhibited hypoxia-induced and 1,10-phenanthroline-induced HIF-1 activation [51] .", [["Caulerpin", "CHEMICAL", 36, 45], ["hypoxia-", "CHEMICAL", 61, 69], ["1,10-phenanthroline", "CHEMICAL", 81, 100], ["Caulerpin", "CHEMICAL", 36, 45], ["1,10-phenanthroline", "CHEMICAL", 81, 100], ["HIF-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Caulerpin (17)", "SIMPLE_CHEMICAL", 36, 50], ["hypoxia-", "SIMPLE_CHEMICAL", 61, 69], ["1,10-phenanthroline", "SIMPLE_CHEMICAL", 81, 100], ["HIF-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["HIF", "PROTEIN", 0, 3], ["HIF", "PROTEIN", 109, 112], ["HIF", "TEST", 0, 3], ["cytotoxicityCaulerpin", "PROBLEM", 24, 45], ["hypoxia-", "PROBLEM", 61, 69], ["phenanthroline", "TREATMENT", 86, 100]]], ["The angiogenic factor VEGF is regulated by HIF-1.", [["VEGF", "GENE_OR_GENE_PRODUCT", 22, 26], ["HIF-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["angiogenic factor", "PROTEIN", 4, 21], ["VEGF", "PROTEIN", 22, 26], ["HIF-1", "PROTEIN", 43, 48], ["The angiogenic factor VEGF", "PROBLEM", 0, 26], ["VEGF", "OBSERVATION", 22, 26]]], ["Caulerpin (10 mM) suppressed hypoxic induction of secreted VEGF protein and the ability of hypoxic T47D cell-conditioned media to promote tumor angiogenesis in vitro.", [["T47D cell", "ANATOMY", 99, 108], ["tumor", "ANATOMY", 138, 143], ["Caulerpin", "CHEMICAL", 0, 9], ["tumor", "DISEASE", 138, 143], ["Caulerpin", "CHEMICAL", 0, 9], ["Caulerpin", "SIMPLE_CHEMICAL", 0, 9], ["VEGF", "GENE_OR_GENE_PRODUCT", 59, 63], ["hypoxic T47D cell", "CELL", 91, 108], ["tumor", "CANCER", 138, 143], ["VEGF protein", "PROTEIN", 59, 71], ["hypoxic T47D cell", "CELL_LINE", 91, 108], ["Caulerpin", "TREATMENT", 0, 9], ["secreted VEGF protein", "TEST", 50, 71], ["hypoxic T47D cell-conditioned media", "TREATMENT", 91, 126], ["tumor angiogenesis", "PROBLEM", 138, 156], ["tumor", "OBSERVATION", 138, 143]]], ["In addition to sourcing from the NCI Open Repository, several laboratories have reported the isolation and identification of HIF-1 inhibitors from their field collections of marine organism extracts.", [["extracts", "ANATOMY", 190, 198], ["HIF-1", "GENE_OR_GENE_PRODUCT", 125, 130], ["extracts", "ORGANISM_SUBSTANCE", 190, 198], ["HIF", "PROTEIN", 125, 128], ["several laboratories", "TEST", 54, 74], ["the isolation", "TEST", 89, 102], ["HIF", "TEST", 125, 128], ["marine organism extracts", "PROBLEM", 174, 198], ["marine organism", "OBSERVATION", 174, 189]]], ["Ireland and coworkers recently found that an extract from a Papua New Guinea collection of the sponge Petrosia (Strongylophora) strongylata significantly inhibited HIF-1 activation at 1 mg/mL [76] .", [["Petrosia", "CHEMICAL", 102, 110], ["Strongylophora) strongylata", "ORGANISM", 112, 139], ["HIF-1", "GENE_OR_GENE_PRODUCT", 164, 169], ["HIF", "PROTEIN", 164, 167], ["Strongylophora) strongylata", "SPECIES", 112, 139], ["Strongylophora) strongylata", "SPECIES", 112, 139], ["an extract", "PROBLEM", 42, 52], ["a Papua New Guinea collection", "PROBLEM", 58, 87], ["the sponge Petrosia (Strongylophora) strongylata", "PROBLEM", 91, 139], ["sponge Petrosia", "OBSERVATION", 95, 110]]], ["Through a process of bioassay-guided isolation, three previously reported strongylophorine meroditerpenoids were identified to be responsible for the observed HIF-1 inhibition.", [["strongylophorine", "CHEMICAL", 74, 90], ["strongylophorine meroditerpenoids", "CHEMICAL", 74, 107], ["strongylophorine meroditerpenoids", "SIMPLE_CHEMICAL", 74, 107], ["HIF-1", "GENE_OR_GENE_PRODUCT", 159, 164], ["HIF", "PROTEIN", 159, 162], ["bioassay", "TEST", 21, 29], ["isolation", "TREATMENT", 37, 46], ["strongylophorine meroditerpenoids", "TREATMENT", 74, 107]]], ["Strongylophorines 2 (18), 3 (19) , and 8 (20) inhibited hypoxia-induced HIF-1 activation in a genetically engineered U251 human glioma cell-based luciferase reporter assay [76] .", [["U251", "ANATOMY", 117, 121], ["glioma cell", "ANATOMY", 128, 139], ["hypoxia", "DISEASE", 56, 63], ["Strongylophorines 2", "CHEMICAL", 0, 19], ["8 (20)", "SIMPLE_CHEMICAL", 39, 45], ["HIF-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["U251", "CELL", 117, 121], ["human", "ORGANISM", 122, 127], ["glioma cell", "CELL", 128, 139], ["luciferase", "GENE_OR_GENE_PRODUCT", 146, 156], ["HIF", "PROTEIN", 72, 75], ["genetically engineered U251 human glioma cell", "CELL_LINE", 94, 139], ["luciferase", "PROTEIN", 146, 156], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["Strongylophorines", "TEST", 0, 17], ["hypoxia", "PROBLEM", 56, 63], ["glioma cell", "TEST", 128, 139]]], ["The Red Sea sponge macrolide latrunculin A (21) disrupts actin polymerization and inhibits microfilament formation by reversibly binding to actin monomers [77] [78] [79] .", [["microfilament", "ANATOMY", 91, 104], ["macrolide", "CHEMICAL", 19, 28], ["latrunculin A", "CHEMICAL", 29, 42], ["macrolide", "CHEMICAL", 19, 28], ["latrunculin A", "CHEMICAL", 29, 42], ["latrunculin A (21)", "SIMPLE_CHEMICAL", 29, 47], ["actin", "GENE_OR_GENE_PRODUCT", 57, 62], ["microfilament", "CELLULAR_COMPONENT", 91, 104], ["actin", "GENE_OR_GENE_PRODUCT", 140, 145], ["actin", "PROTEIN", 57, 62], ["actin", "PROTEIN", 140, 145], ["The Red Sea sponge macrolide latrunculin A", "TREATMENT", 0, 42], ["actin polymerization", "TREATMENT", 57, 77], ["microfilament formation", "PROBLEM", 91, 114], ["Sea sponge", "OBSERVATION", 8, 18], ["macrolide latrunculin", "OBSERVATION", 19, 40]]], ["This sponge-derived actin inhibitor has recently been shown to inhibit hypoxia-induced HIF-1 activation in T47D cells [52] .", [["T47D cells", "ANATOMY", 107, 117], ["hypoxia", "DISEASE", 71, 78], ["actin", "GENE_OR_GENE_PRODUCT", 20, 25], ["HIF-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["T47D cells", "CELL", 107, 117], ["actin", "PROTEIN", 20, 25], ["HIF", "PROTEIN", 87, 90], ["T47D cells", "CELL_LINE", 107, 117], ["This sponge-derived actin inhibitor", "TREATMENT", 0, 35], ["hypoxia", "PROBLEM", 71, 78]]], ["Not only are these marine natural products inhibitors of HIF-1 activation in tumor cells, but many appear to function through mechanisms that have not yet been recognized to regulate HIF-1 activity.", [["tumor cells", "ANATOMY", 77, 88], ["tumor", "DISEASE", 77, 82], ["HIF-1", "GENE_OR_GENE_PRODUCT", 57, 62], ["tumor cells", "CELL", 77, 88], ["HIF-1", "GENE_OR_GENE_PRODUCT", 183, 188], ["HIF-1", "PROTEIN", 57, 62], ["tumor cells", "CELL_TYPE", 77, 88], ["HIF", "PROTEIN", 183, 186], ["natural products inhibitors", "TREATMENT", 26, 53], ["1 activation in tumor cells", "PROBLEM", 61, 88], ["tumor cells", "OBSERVATION", 77, 88]]], ["A summary of the marine-derived HIF-1 inhibitors discovered in this program is provided inDereplication of Nuisance CompoundsThe concept of \"nuisance\" compounds is highly subjective and depends on the focus of the individual antitumor discovery group.", [["antitumor", "ANATOMY", 225, 234], ["HIF-1", "GENE_OR_GENE_PRODUCT", 32, 37], ["antitumor", "CANCER", 225, 234], ["HIF", "PROTEIN", 32, 35], ["HIF-1 inhibitors", "TREATMENT", 32, 48]]], ["In high-throughput screening, nonselective compounds that exert a variety of effects on various assay systems are typically considered nuisance compounds.", [["nonselective compounds", "PROBLEM", 30, 52], ["various assay systems", "TREATMENT", 88, 109], ["high", "OBSERVATION_MODIFIER", 3, 7]]], ["Similarly, if the research program is solely interested in the discovery of novel chemical entities with a particular pharmacological activity, the researchers may consider all previously identified known compounds that show activity in other systems to be nuisance compounds.", [["activity in other systems", "PROBLEM", 225, 250]]], ["Each particular type of bioassay method is associated with assay-specific nuisance compounds.", [["bioassay method", "TREATMENT", 24, 39]]], ["Chemically reactive compounds, including certain phenolic compounds, may nonselectively bind to proteins and inhibit enzyme-based assays [80, 81] .", [["enzyme", "PROTEIN", 117, 123], ["Chemically reactive compounds", "PROBLEM", 0, 29], ["certain phenolic compounds", "PROBLEM", 41, 67], ["enzyme", "TEST", 117, 123], ["assays", "TEST", 130, 136], ["reactive compounds", "OBSERVATION", 11, 29], ["phenolic compounds", "OBSERVATION", 49, 67]]], ["Pigments and other colored natural products can interfere with colorimetric assays.", [["Pigments and other colored natural products", "PROBLEM", 0, 43], ["colorimetric assays", "TEST", 63, 82]]], ["It is widely known that fluorescence-based assays may be susceptible to interference by fluorescent natural products [e.g., curcumin (22) ] or compounds such as the flavonoid quercetin (23) that acts to quench the fluorescence [82] .", [["curcumin", "CHEMICAL", 124, 132], ["quercetin", "CHEMICAL", 175, 184], ["curcumin", "CHEMICAL", 124, 132], ["flavonoid", "CHEMICAL", 165, 174], ["quercetin", "CHEMICAL", 175, 184], ["fluorescent natural products", "SIMPLE_CHEMICAL", 88, 116], ["curcumin (22) ]", "SIMPLE_CHEMICAL", 124, 139], ["flavonoid quercetin (23)", "SIMPLE_CHEMICAL", 165, 189], ["fluorescence-based assays", "TEST", 24, 49], ["fluorescent natural products", "TREATMENT", 88, 116], ["the flavonoid quercetin", "TREATMENT", 161, 184]]], ["Poorly controlled fluorescence-based bioassays have been used to support the premise that these natural products regulate a plethora of diverse molecular targets.", [["Poorly controlled fluorescence", "PROBLEM", 0, 30], ["these natural products", "TREATMENT", 90, 112]]], ["Although less appreciated, pigmented and fluorescent natural products may also interfere with luciferase reporter gene assays that rely on fluorescent reagent formulations to enhance their light readouts.", [["luciferase", "GENE_OR_GENE_PRODUCT", 94, 104], ["luciferase reporter gene", "DNA", 94, 118], ["luciferase reporter gene assays", "PROBLEM", 94, 125], ["fluorescent reagent formulations", "TREATMENT", 139, 171], ["their light readouts", "TEST", 183, 203], ["less", "OBSERVATION_MODIFIER", 9, 13], ["pigmented", "OBSERVATION_MODIFIER", 27, 36]]], ["Cytotoxic natural products may be considered nuisance compounds when observed in cell-based bioassays that screen for inhibitors of a tumor cell selective molecular target.", [["cell", "ANATOMY", 81, 85], ["tumor cell", "ANATOMY", 134, 144], ["tumor", "DISEASE", 134, 139], ["cell", "CELL", 81, 85], ["tumor cell", "CELL", 134, 144], ["Cytotoxic natural products", "TREATMENT", 0, 26], ["inhibitors", "TREATMENT", 118, 128], ["a tumor cell selective molecular target", "PROBLEM", 132, 171], ["may be considered", "UNCERTAINTY", 27, 44]]], ["Similarly, compounds that do not penetrate cell membranes may be regarded as nuisance compounds in solution-based enzyme/protein-based in vitro assays.", [["cell membranes", "ANATOMY", 43, 57], ["cell membranes", "CELLULAR_COMPONENT", 43, 57], ["enzyme", "PROTEIN", 114, 120], ["based enzyme/protein", "TEST", 108, 128], ["vitro assays", "TEST", 138, 150]]], ["(22) quercetin (23) Just as in other forms of natural product screening, molecular-targeted drug discovery programs that aim to identify marine natural product-derived anticancer agents must avoid the unnecessary replication of previously identified inhibitors (or activators) of the selected molecular target and common substances that exert nonselective effects on biological systems.", [["anticancer", "ANATOMY", 168, 178], ["quercetin", "CHEMICAL", 5, 14], ["(22) quercetin", "CHEMICAL", 0, 14], ["(22) quercetin", "SIMPLE_CHEMICAL", 0, 14], ["anticancer", "CANCER", 168, 178], ["quercetin", "TREATMENT", 5, 14], ["natural product screening", "TEST", 46, 71], ["anticancer agents", "TREATMENT", 168, 185], ["previously identified inhibitors", "TREATMENT", 228, 260], ["nonselective effects on biological systems", "PROBLEM", 343, 385]]], ["One of the most powerful and inexpensive means to reduce the replication of chemical isolation and structure elucidation efforts in marine natural products is the use of chemotaxonomic literature related to the particular marine organism.", [["chemical isolation", "TREATMENT", 76, 94], ["chemotaxonomic literature", "TREATMENT", 170, 195], ["chemical isolation", "OBSERVATION", 76, 94]]], ["Highly specialized marine natural product databases (Marinlit [85] ) that include searchable NMR and other spectroscopic data are also available and can greatly enhance chemical dereplication efforts.", [["searchable NMR", "TEST", 82, 96], ["other spectroscopic data", "TEST", 101, 125]]], ["These databases can be used to identify known compounds and to distinguish previously reported redundant biological activities that may be associated with a particular marine natural product.", [["redundant biological activities", "PROBLEM", 95, 126], ["biological activities", "OBSERVATION", 105, 126]]], ["Dereplication with chemotaxonomic data from chemical and biological literature databases is most efficient when examining well-characterized species of marine invertebrates and algae, but may be only of limited utility in screening programs that focus on poorly characterized new species of cultured marine microbes.", [["chemotaxonomic data", "TEST", 19, 38], ["biological literature databases", "TEST", 57, 88], ["screening programs", "TEST", 222, 240], ["poorly characterized", "OBSERVATION_MODIFIER", 255, 275], ["new", "OBSERVATION_MODIFIER", 276, 279]]], ["One potential limitation of the use of chemotaxonomic literature for chemical dereplication efforts is that many species of marine organisms are poorly characterized chemically as well as taxonomically [2, 86] .", [["chemotaxonomic literature", "TREATMENT", 39, 64], ["chemical dereplication efforts", "TREATMENT", 69, 99], ["many species of marine organisms", "PROBLEM", 108, 140]]], ["Since most marine natural products chemists are not in the habit of regularly reporting known compounds when they are found to occur in new species, estimates of the potential chemical diversity of many readily collectible species may be significantly underestimated.", [["chemical diversity", "OBSERVATION", 176, 194], ["may be", "UNCERTAINTY", 231, 237], ["significantly", "OBSERVATION_MODIFIER", 238, 251], ["underestimated", "OBSERVATION", 252, 266]]], ["Chemical and biological dereplication for many of these species is often achievable by analysis of the chemotaxonomic and pharmacological literature related to other members of the same genera or taxonomic family.", [["biological dereplication", "TREATMENT", 13, 37], ["these species", "PROBLEM", 50, 63]]], ["While practical limitations exist, the importance of chemical and biological databases in reducing the need for unnecessary marine natural product isolation and structure elucidation efforts cannot be overstated.Dereplication of Nuisance CompoundsThe subject of natural product dereplication has been the subject of recent reviews [87] .", [["biological databases", "TEST", 66, 86], ["unnecessary marine natural product isolation", "TREATMENT", 112, 156], ["natural product dereplication", "TREATMENT", 262, 291]]], ["Compound dereplication strategies also commonly include various libraries of compound data sets that are used with a \"hyphenated\" technique that combines a purification method with a spectroscopic or spectrometric detection system.", [["Compound dereplication strategies", "TREATMENT", 0, 33], ["a \"hyphenated\" technique", "TREATMENT", 115, 139]]], ["Sarker and Nahar have recently reviewed the field of hyphenated separation and spectroscopic/spectrometric techniques with respect to various classes of natural products [88] .", [["hyphenated separation", "TREATMENT", 53, 74], ["spectroscopic/spectrometric techniques", "TREATMENT", 79, 117]]], ["Typical examples may include traditional methods such as high-performance liquid chromatography (HPLC) coupled with ultraviolet (UV) photodiode detection.", [["traditional methods", "TEST", 29, 48], ["high-performance liquid chromatography", "TREATMENT", 57, 95], ["ultraviolet (UV) photodiode detection", "TREATMENT", 116, 153]]], ["Dereplication efforts have more recently come to rely on methods that combine liquid chromatography (LC) and mass spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy.", [["combine liquid chromatography", "TEST", 70, 99], ["mass spectrometry", "TEST", 109, 126], ["nuclear magnetic resonance (NMR) spectroscopy", "TEST", 135, 180]]], ["Tandem LC-MS and LC-MS-MS methods are among the most sensitive means to dereplicate known compounds.", [["Tandem LC", "TEST", 0, 9], ["LC", "TEST", 17, 19], ["MS", "PROBLEM", 20, 22], ["MS methods", "PROBLEM", 23, 33], ["known compounds", "PROBLEM", 84, 99]]], ["While inherently less sensitive, coupled LC-NMR methods have the advantage that they can be simultaneously used for dereplication and the structure elucidation of new natural products.", [["dereplication", "TREATMENT", 116, 129], ["new", "OBSERVATION_MODIFIER", 163, 166], ["natural products", "OBSERVATION", 167, 183]]], ["Hyphenated techniques and their use in the dereplication of natural products are further described in recent reviews [87] .Dereplication of Nuisance CompoundsThe expenditure of unnecessary efforts due to the occurrence of natural products that act by relatively general means to produce numerous nonspecific effects in bioassay systems must also be reduced.", [["Hyphenated techniques", "TREATMENT", 0, 21], ["natural products", "TREATMENT", 60, 76], ["unnecessary efforts", "TREATMENT", 177, 196], ["natural products", "TREATMENT", 222, 238], ["numerous nonspecific effects in bioassay systems", "PROBLEM", 287, 335], ["natural products", "OBSERVATION", 60, 76], ["numerous", "OBSERVATION_MODIFIER", 287, 295], ["nonspecific", "OBSERVATION", 296, 307], ["reduced", "OBSERVATION_MODIFIER", 349, 356]]], ["The previously described methods of compound dereplication can be used to identify known compounds that exert nonselective effects on assay systems.", [["compound dereplication", "TREATMENT", 36, 58], ["known compounds", "PROBLEM", 83, 98], ["assay systems", "TEST", 134, 147]]], ["Alternatively, experimental procedures with appropriate controls can be designed directly into the assay systems to dramatically cut the number of bioassay \"hits\" that result from active compounds with no selectivity for the molecular target.", [["experimental procedures", "TREATMENT", 15, 38], ["the assay systems", "TEST", 95, 112], ["active compounds", "PROBLEM", 180, 196]]], ["This strategy can readily deselect nuisance compounds without requiring any sample purification, chemical analysis, or other dereplication procedure.", [["any sample purification", "TEST", 72, 95], ["chemical analysis", "TEST", 97, 114], ["other dereplication procedure", "TREATMENT", 119, 148]]], ["Examples of this type of bioassay design-based nuisance compound dereplication include the use of alternative isoforms of a particular enzyme in a parallel screening platform [89] and the concurrent measurement of cell viability with cell-based bioassays for a molecular target that should not produce a cytotoxic effect on certain cell types.Dereplication of Nuisance CompoundsThe need to dereplicate known marine natural product HIF-1 inhibitors has only recently emerged as several groups have begun to identify marine invertebrate and algae compounds that inhibit HIF-1 activation (reviewed in 14) .", [["cell", "ANATOMY", 214, 218], ["cell", "ANATOMY", 234, 238], ["cell", "ANATOMY", 332, 336], ["cell", "CELL", 214, 218], ["cell", "CELL", 234, 238], ["cell", "CELL", 332, 336], ["HIF-1", "GENE_OR_GENE_PRODUCT", 431, 436], ["HIF-1", "GENE_OR_GENE_PRODUCT", 568, 573], ["HIF", "PROTEIN", 431, 434], ["HIF", "PROTEIN", 568, 571], ["a particular enzyme", "TEST", 122, 141], ["a parallel screening platform", "TEST", 145, 174], ["cell viability", "PROBLEM", 214, 228], ["a molecular target", "PROBLEM", 259, 277], ["a cytotoxic effect", "PROBLEM", 302, 320], ["algae compounds", "PROBLEM", 539, 554], ["cell viability", "OBSERVATION", 214, 228], ["cytotoxic effect", "OBSERVATION", 304, 320], ["certain cell types", "OBSERVATION", 324, 342]]], ["The marine natural product-based HIF-1 inhibitors described in Table 22 .1 include algal metabolites, crinoid benzochromenone pigments, latrunculin actin inhibitors, terpenes, and various lipids from marine sponges.", [["benzochromenone", "CHEMICAL", 110, 125], ["latrunculin", "CHEMICAL", 136, 147], ["benzochromenone", "CHEMICAL", 110, 125], ["terpenes", "CHEMICAL", 166, 174], ["HIF-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["algal metabolites", "SIMPLE_CHEMICAL", 83, 100], ["crinoid benzochromenone pigments", "SIMPLE_CHEMICAL", 102, 134], ["latrunculin actin inhibitors", "SIMPLE_CHEMICAL", 136, 164], ["terpenes", "SIMPLE_CHEMICAL", 166, 174], ["lipids", "SIMPLE_CHEMICAL", 188, 194], ["HIF", "PROTEIN", 33, 36], ["The marine natural product", "TREATMENT", 0, 26], ["HIF-1 inhibitors", "TREATMENT", 33, 49], ["algal metabolites", "TEST", 83, 100], ["crinoid benzochromenone pigments", "TREATMENT", 102, 134], ["latrunculin actin inhibitors", "TREATMENT", 136, 164], ["terpenes", "TREATMENT", 166, 174], ["various lipids", "TREATMENT", 180, 194], ["marine sponges", "TREATMENT", 200, 214], ["marine sponges", "OBSERVATION", 200, 214]]], ["In addition, various HIF-1 discovery groups have examined terrestrial natural products [15, 16] and synthetic pure compound libraries [63] and have reported that compounds that regulate certain central cellular biochemical processes may also suppress HIF-1 activation.", [["cellular", "ANATOMY", 202, 210], ["HIF-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["15, 16]", "SIMPLE_CHEMICAL", 88, 95], ["cellular", "CELL", 202, 210], ["HIF-1", "GENE_OR_GENE_PRODUCT", 251, 256], ["HIF", "PROTEIN", 21, 24], ["HIF", "PROTEIN", 251, 254], ["central cellular", "OBSERVATION", 194, 210], ["biochemical processes", "OBSERVATION", 211, 232]]], ["Both academic and industrial HIF-1 screening efforts have found that mitochondrial electron transport chain (ETC) inhibitors suppress HIF-1 activation by hypoxia [63, 70] , presumably by interfering with mitochondrial reactive oxygen species (ROS)-mediated signaling and destabilizing HIF-1a protein under hypoxic conditions.", [["mitochondrial", "ANATOMY", 69, 82], ["mitochondrial", "ANATOMY", 204, 217], ["hypoxia", "DISEASE", 154, 161], ["oxygen", "CHEMICAL", 227, 233], ["ROS", "CHEMICAL", 243, 246], ["oxygen", "CHEMICAL", 227, 233], ["HIF-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["mitochondrial", "CELLULAR_COMPONENT", 69, 82], ["electron transport chain", "GENE_OR_GENE_PRODUCT", 83, 107], ["ETC", "GENE_OR_GENE_PRODUCT", 109, 112], ["HIF-1", "GENE_OR_GENE_PRODUCT", 134, 139], ["mitochondrial", "CELLULAR_COMPONENT", 204, 217], ["reactive oxygen species", "SIMPLE_CHEMICAL", 218, 241], ["ROS", "SIMPLE_CHEMICAL", 243, 246], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 285, 291], ["HIF", "PROTEIN", 29, 32], ["HIF-1", "PROTEIN", 134, 139], ["HIF-1a protein", "PROTEIN", 285, 299], ["mitochondrial electron transport chain (ETC) inhibitors", "TREATMENT", 69, 124], ["hypoxia", "PROBLEM", 154, 161], ["mitochondrial reactive oxygen species", "PROBLEM", 204, 241], ["hypoxic conditions", "PROBLEM", 306, 324], ["reactive", "OBSERVATION_MODIFIER", 218, 226], ["oxygen species", "OBSERVATION", 227, 241], ["hypoxic conditions", "OBSERVATION", 306, 324]]], ["The emerging role of mitochondrial reactive oxygen species (ROS) on the regulation of HIF-mediated hypoxic signaling is highlighted by a recent review by Hamanaka and Chandel [90] .", [["mitochondrial", "ANATOMY", 21, 34], ["oxygen", "CHEMICAL", 44, 50], ["ROS", "CHEMICAL", 60, 63], ["oxygen", "CHEMICAL", 44, 50], ["mitochondrial", "CELLULAR_COMPONENT", 21, 34], ["reactive oxygen species", "SIMPLE_CHEMICAL", 35, 58], ["ROS", "SIMPLE_CHEMICAL", 60, 63], ["HIF", "GENE_OR_GENE_PRODUCT", 86, 89], ["HIF", "PROTEIN", 86, 89], ["mitochondrial reactive oxygen species", "PROBLEM", 21, 58], ["hypoxic signaling", "PROBLEM", 99, 116], ["reactive", "OBSERVATION_MODIFIER", 35, 43], ["oxygen species", "OBSERVATION", 44, 58]]], ["New classes of unique ETC inhibitors have been identified that may prove to be pharmacological leads or valuable probes of HIF-1 signaling and mitochondrial function.", [["mitochondrial", "ANATOMY", 143, 156], ["ETC", "GENE_OR_GENE_PRODUCT", 22, 25], ["HIF-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["mitochondrial", "CELLULAR_COMPONENT", 143, 156], ["HIF", "PROTEIN", 123, 126], ["unique ETC inhibitors", "TREATMENT", 15, 36], ["mitochondrial function", "OBSERVATION", 143, 165]]], ["However, at some point, these terrestrial and marine mitochondrial ETC inhibitors may be deemed biochemically active nuisance compounds, for the purpose of HIF-1 inhibitor drug discovery.", [["mitochondrial", "ANATOMY", 53, 66], ["mitochondrial", "CELLULAR_COMPONENT", 53, 66], ["HIF-1", "GENE_OR_GENE_PRODUCT", 156, 161], ["HIF", "PROTEIN", 156, 159], ["these terrestrial", "TREATMENT", 24, 41], ["marine mitochondrial ETC inhibitors", "TREATMENT", 46, 81]]], ["Similarly, the expression of HIF-1a protein and subsequent activation of HIF-1 can be strongly suppressed by pharmacologically active compounds that inhibit eukaryotic protein translation [15, 50, 91, 92] .", [["HIF-1a", "GENE_OR_GENE_PRODUCT", 29, 35], ["HIF-1", "GENE_OR_GENE_PRODUCT", 73, 78], ["HIF-1a protein", "PROTEIN", 29, 43], ["HIF-1", "PROTEIN", 73, 78], ["pharmacologically active compounds", "PROBLEM", 109, 143]]], ["While translation inhibitors have been found to inhibit HIF-1 signaling in tumor cells, the off-target effects associated with the generalized inhibition of protein synthesis may limit the therapeutic potential of these compounds and render such agents to be essentially nuisance compounds, at least for the purpose of bioassay dereplication.Concluding RemarksThe field of antitumor marine natural products research has evolved over the years to incorporate an emphasis on molecular-targeted drug discovery.", [["tumor cells", "ANATOMY", 75, 86], ["antitumor", "ANATOMY", 373, 382], ["tumor", "DISEASE", 75, 80], ["HIF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["tumor cells", "CELL", 75, 86], ["antitumor", "CANCER", 373, 382], ["HIF-1", "PROTEIN", 56, 61], ["tumor cells", "CELL_TYPE", 75, 86], ["translation inhibitors", "TREATMENT", 6, 28], ["HIF", "TEST", 56, 59], ["tumor cells", "PROBLEM", 75, 86], ["the generalized inhibition of protein synthesis", "PROBLEM", 127, 174], ["these compounds", "TREATMENT", 214, 229], ["such agents", "TREATMENT", 241, 252], ["bioassay dereplication", "TREATMENT", 319, 341], ["tumor cells", "OBSERVATION", 75, 86]]], ["These changes have dramatically increased the appreciation among most natural products chemists for molecular and cell biology in natural product-based drug discovery.", [["cell", "ANATOMY", 114, 118], ["cell", "CELL", 114, 118], ["dramatically", "OBSERVATION_MODIFIER", 19, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["natural product", "OBSERVATION", 130, 145], ["drug discovery", "OBSERVATION", 152, 166]]], ["This shift in focus has also spurred a similar need for a general understanding of the factors that must be considered when using modern molecular-targeted antitumor bioassays.", [["antitumor", "ANATOMY", 156, 165], ["antitumor", "CANCER", 156, 165]]], ["Researchers working in natural products must be acutely aware of the nature and validity of their selected molecular target, consider what particular methods their assays will use to measure the target processes, make sure appropriate controls are used, appreciate how the data will be analyzed, understand how the assay method will be validated, and establish suitable means for chemical dereplication.", [["chemical dereplication", "TREATMENT", 380, 402]]], ["The scientific validity and clinical potential of any newly discovered antitumor natural product are only as solid as the reliability of the biological data that support its potential activity.", [["antitumor", "ANATOMY", 71, 80], ["antitumor", "CANCER", 71, 80]]], ["If manuscripts and grant proposals that involve molecular-targeted natural products research are not held to acceptable standards, the value of this discipline to the broader drug discovery community will be diminished.", [["diminished", "PROBLEM", 208, 218]]], ["Therefore, an appreciation for all of these factors is essential for modern molecular-targeted antitumor drug discovery.", [["antitumor", "ANATOMY", 95, 104], ["antitumor", "CANCER", 95, 104], ["antitumor drug", "OBSERVATION", 95, 109]]], ["Through mechanism-based drug discovery efforts, marine natural products have been identified that potently inhibit the hypoxiainduced activation of HIF-1 in tumor cells.", [["tumor cells", "ANATOMY", 157, 168], ["tumor", "DISEASE", 157, 162], ["HIF-1", "GENE_OR_GENE_PRODUCT", 148, 153], ["tumor cells", "CELL", 157, 168], ["HIF-1", "PROTEIN", 148, 153], ["tumor cells", "CELL_TYPE", 157, 168], ["marine natural products", "TREATMENT", 48, 71], ["tumor cells", "OBSERVATION", 157, 168]]], ["As an important antitumor molecular target, the bioassay systems used in the identification of new HIF-1 inhibitors provide compelling examples to illustrate the various components of moleculartargeted bioassay design and analysis that are essential for the discovery of antitumor marine natural products.Study Questions1.", [["antitumor", "ANATOMY", 16, 25], ["antitumor", "ANATOMY", 271, 280], ["antitumor", "CANCER", 16, 25], ["HIF-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["antitumor", "CANCER", 271, 280], ["HIF", "PROTEIN", 99, 102], ["the bioassay systems", "TEST", 44, 64], ["new HIF-1 inhibitors", "TREATMENT", 95, 115], ["moleculartargeted bioassay design and analysis", "TEST", 184, 230], ["antitumor marine natural products", "TREATMENT", 271, 304]]], ["Why is the mere overexpression of a particular gene (or protein) in a disease condition insufficient to validate the gene (or protein) as a disease-specific molecular target? 4.", [["a disease condition", "PROBLEM", 68, 87], ["a disease", "PROBLEM", 138, 147]]], ["What are the potential consequences of poor or inadequate molecular target validation in the drug discovery and development process? 5.", [["poor or inadequate molecular target validation", "PROBLEM", 39, 85], ["development process", "PROBLEM", 112, 131]]], ["What features of the transcription factor hypoxia-inducible factor-1 (HIF-1) make it a suitable representative molecular target to illustrate each of the principles involved in quality bioassay design and analysis? 6.", [["hypoxia-inducible factor-1", "GENE_OR_GENE_PRODUCT", 42, 68], ["HIF-1", "GENE_OR_GENE_PRODUCT", 70, 75], ["transcription factor", "PROTEIN", 21, 41], ["hypoxia-inducible factor-1 (HIF-1", "PROTEIN", 42, 75], ["the transcription factor hypoxia-inducible factor", "PROBLEM", 17, 66]]], ["What is the difference between bioassay validation and target validation? 7.", [["bioassay validation", "TEST", 31, 50], ["target validation", "TEST", 55, 72]]], ["Why is it critical for bioassay method validation to include both positive and negative control compounds? 8.", [["bioassay method validation", "TEST", 23, 49]]], ["Why is compound dereplication so vital to a successful high-throughput screening assay-based drug discovery effort? 10.", [["screening assay", "TEST", 71, 86]]], ["Chemical and biological literature databases are among the most economical sources of compound information regarding the production of specific natural products by any given species of organism.", [["specific natural products", "TREATMENT", 135, 160], ["organism", "PROBLEM", 185, 193]]], ["What are the practical limitations of literature databases in regard to the marine natural product dereplication efforts?", [["literature databases", "TEST", 38, 58]]]], "PMC6947998": [["BackgroundZoonoses are those complications which are transmissible between human and animal populations [1].", [["BackgroundZoonoses", "DISEASE", 0, 18], ["human", "ORGANISM", 75, 80], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["those complications", "PROBLEM", 23, 42]]], ["In this regard dogs and cats are considered as a public health concern, as they may harbor various pathogens such as zoonotic helminths including Toxocara species [2].", [["zoonotic helminths", "DISEASE", 117, 135], ["Toxocara species", "DISEASE", 146, 162], ["dogs", "ORGANISM", 15, 19], ["cats", "ORGANISM", 24, 28], ["dogs", "SPECIES", 15, 19], ["cats", "SPECIES", 24, 28], ["various pathogens", "PROBLEM", 91, 108], ["Toxocara species", "PROBLEM", 146, 162]]], ["Toxocariasis is a worldwide parasitic infection, primarily rendered by T. canis in dogs, T. cati in cats and foxes and T. leonina in a wide range of carnivores [3].", [["Toxocariasis", "DISEASE", 0, 12], ["parasitic infection", "DISEASE", 28, 47], ["T. canis", "DISEASE", 71, 79], ["T. canis", "ORGANISM", 71, 79], ["dogs", "ORGANISM", 83, 87], ["T. cati", "ORGANISM", 89, 96], ["cats", "ORGANISM", 100, 104], ["foxes", "ORGANISM", 109, 114], ["T. leonina", "ORGANISM", 119, 129], ["T. canis", "SPECIES", 71, 79], ["dogs", "SPECIES", 83, 87], ["T. cati", "SPECIES", 89, 96], ["cats", "SPECIES", 100, 104], ["T. leonina", "SPECIES", 119, 129], ["T. canis", "SPECIES", 71, 79], ["T. cati", "SPECIES", 89, 96], ["T. leonina", "SPECIES", 119, 129], ["Toxocariasis", "PROBLEM", 0, 12], ["a worldwide parasitic infection", "PROBLEM", 16, 47], ["worldwide", "OBSERVATION_MODIFIER", 18, 27], ["parasitic", "OBSERVATION_MODIFIER", 28, 37], ["infection", "OBSERVATION", 38, 47]]], ["Mature worms lay eggs in the intestinal lumen of their host, which are excreted into the environment via defecation and pass their developmental stages in optimum soil and climate conditions.", [["worms", "ANATOMY", 7, 12], ["eggs", "ANATOMY", 17, 21], ["intestinal lumen", "ANATOMY", 29, 45], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 17, 21], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 29, 45], ["worms", "SPECIES", 7, 12], ["Mature worms", "PROBLEM", 0, 12], ["worms", "OBSERVATION", 7, 12], ["intestinal", "ANATOMY", 29, 39], ["lumen", "ANATOMY_MODIFIER", 40, 45]]], ["Upon ingestion of embryonated eggs by another host, the larvae would emerge and invade the intestinal mucosa, then migrate through viscera such as lungs, liver, and kidneys.", [["eggs", "ANATOMY", 30, 34], ["intestinal mucosa", "ANATOMY", 91, 108], ["viscera", "ANATOMY", 131, 138], ["lungs", "ANATOMY", 147, 152], ["liver", "ANATOMY", 154, 159], ["kidneys", "ANATOMY", 165, 172], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 30, 34], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 91, 108], ["viscera", "ORGAN", 131, 138], ["lungs", "ORGAN", 147, 152], ["liver", "ORGAN", 154, 159], ["kidneys", "ORGAN", 165, 172], ["embryonated eggs", "TREATMENT", 18, 34], ["the larvae", "TREATMENT", 52, 62], ["intestinal mucosa", "ANATOMY", 91, 108], ["viscera", "ANATOMY", 131, 138], ["lungs", "ANATOMY", 147, 152], ["liver", "ANATOMY", 154, 159], ["kidneys", "ANATOMY", 165, 172]]], ["In addition, transplacental and transmammary transmission to puppies and kittens are important routes of infection.", [["infection", "DISEASE", 105, 114], ["puppies", "ORGANISM", 61, 68], ["kittens", "ORGANISM", 73, 80], ["transplacental and transmammary transmission", "TREATMENT", 13, 57], ["infection", "PROBLEM", 105, 114], ["infection", "OBSERVATION", 105, 114]]], ["In an epidemiological perspective, animal hosts parasitized by adult worms in their gut can disseminate infection by shedding parasite eggs into environment [4].", [["gut", "ANATOMY", 84, 87], ["eggs", "ANATOMY", 135, 139], ["infection", "DISEASE", 104, 113], ["adult worms", "ORGANISM", 63, 74], ["gut", "ORGANISM_SUBDIVISION", 84, 87], ["worms", "SPECIES", 69, 74], ["gut", "ANATOMY", 84, 87], ["infection", "OBSERVATION", 104, 113]]], ["In an epidemiological perspective, animal hosts parasitized by adult worms in their gut, can shed parasite eggs, hence considered as a source for dissemination of the infection [5].", [["gut", "ANATOMY", 84, 87], ["eggs", "ANATOMY", 107, 111], ["infection", "DISEASE", 167, 176], ["adult worms", "ORGANISM", 63, 74], ["gut", "ORGANISM_SUBDIVISION", 84, 87], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 107, 111], ["worms", "SPECIES", 69, 74], ["parasite eggs", "PROBLEM", 98, 111], ["the infection", "PROBLEM", 163, 176], ["gut", "ANATOMY", 84, 87], ["infection", "OBSERVATION", 167, 176]]], ["Human infection occurs by accidental ingestion of eggs, and, to a lesser extent, via pica and devouring on the paratenic hosts, including chicken, cattle, lamb, pig, and earthworms [4, 6].", [["eggs", "ANATOMY", 50, 54], ["infection", "DISEASE", 6, 15], ["pica", "DISEASE", 85, 89], ["Human", "ORGANISM", 0, 5], ["chicken", "ORGANISM", 138, 145], ["cattle", "ORGANISM", 147, 153], ["lamb", "ORGANISM_SUBDIVISION", 155, 159], ["pig", "ORGANISM", 161, 164], ["Human", "SPECIES", 0, 5], ["chicken", "SPECIES", 138, 145], ["cattle", "SPECIES", 147, 153], ["lamb", "SPECIES", 155, 159], ["pig", "SPECIES", 161, 164], ["Human", "SPECIES", 0, 5], ["chicken", "SPECIES", 138, 145], ["cattle", "SPECIES", 147, 153], ["lamb", "SPECIES", 155, 159], ["pig", "SPECIES", 161, 164], ["Human infection", "PROBLEM", 0, 15], ["the paratenic hosts", "TREATMENT", 107, 126], ["infection", "OBSERVATION", 6, 15], ["lesser extent", "OBSERVATION_MODIFIER", 66, 79], ["pica", "OBSERVATION", 85, 89]]], ["Consequently, developmentally-arrested larvae migrate through body organs, but don\u2019t develop into mature worms; hence, they provoke an array of syndromes enclosing VLM, NLM, and OLM as well as covert infection and asymptomatic toxocariasis [7\u20139].", [["larvae", "ANATOMY", 39, 45], ["body organs", "ANATOMY", 62, 73], ["covert infection", "DISEASE", 193, 209], ["toxocariasis", "DISEASE", 227, 239], ["larvae", "ORGANISM", 39, 45], ["body organs", "ORGAN", 62, 73], ["worms", "SPECIES", 105, 110], ["syndromes enclosing VLM", "PROBLEM", 144, 167], ["covert infection", "PROBLEM", 193, 209], ["asymptomatic toxocariasis", "PROBLEM", 214, 239], ["infection", "OBSERVATION", 200, 209]]], ["Although rare, cardiac-associated toxocariasis is a serious, life-threatening complication due to VLM which has recently been emphasized [10].BackgroundMost of the infected individuals manifest nonspecific symptoms such as a cough, rhonchus, dyspnea and pyrexia along with hepatomegaly and eosinophilic granuloma, which implicates diagnosis of the infection using more sensitive approaches such as immunological assays i.e., ELISA for screening and Western blot for confirmation, rather than histological or parasitological methods [4, 11].BackgroundToxocariasis cause by T. cati and T. canis frequently impacts young cats and dogs from birth to 1 year old, entailing respiratory signs (coughing due to pulmonary larval migration), general failure to thrive (retarded growth, emaciation, debilitated body coat and arthralgia) and intestinal disorders (alternating diarrhea and constipation, pot-belly and vomiting).", [["cardiac", "ANATOMY", 15, 22], ["eosinophilic granuloma", "ANATOMY", 290, 312], ["respiratory", "ANATOMY", 668, 679], ["pulmonary", "ANATOMY", 703, 712], ["body", "ANATOMY", 800, 804], ["intestinal", "ANATOMY", 830, 840], ["cardiac-associated toxocariasis", "DISEASE", 15, 46], ["cough", "DISEASE", 225, 230], ["rhonchus", "DISEASE", 232, 240], ["dyspnea", "DISEASE", 242, 249], ["pyrexia", "DISEASE", 254, 261], ["hepatomegaly", "DISEASE", 273, 285], ["granuloma", "DISEASE", 303, 312], ["infection", "DISEASE", 348, 357], ["T. canis", "DISEASE", 584, 592], ["respiratory signs", "DISEASE", 668, 685], ["coughing", "DISEASE", 687, 695], ["pulmonary larval migration", "DISEASE", 703, 729], ["failure to thrive", "DISEASE", 740, 757], ["emaciation", "DISEASE", 776, 786], ["arthralgia", "DISEASE", 814, 824], ["intestinal disorders", "DISEASE", 830, 850], ["diarrhea", "DISEASE", 864, 872], ["constipation", "DISEASE", 877, 889], ["vomiting", "DISEASE", 905, 913], ["cardiac", "ORGAN", 15, 22], ["individuals", "ORGANISM", 173, 184], ["eosinophilic granuloma", "PATHOLOGICAL_FORMATION", 290, 312], ["T. cati", "ORGANISM", 572, 579], ["T. canis", "ORGANISM", 584, 592], ["cats", "ORGANISM", 618, 622], ["dogs", "ORGANISM", 627, 631], ["pulmonary", "ORGAN", 703, 712], ["body", "ORGANISM_SUBDIVISION", 800, 804], ["intestinal", "ORGAN", 830, 840], ["T. cati", "SPECIES", 572, 579], ["T. canis", "SPECIES", 584, 592], ["cats", "SPECIES", 618, 622], ["dogs", "SPECIES", 627, 631], ["T. cati", "SPECIES", 572, 579], ["T. canis", "SPECIES", 584, 592], ["toxocariasis", "PROBLEM", 34, 46], ["life-threatening complication", "PROBLEM", 61, 90], ["VLM", "PROBLEM", 98, 101], ["the infected individuals", "PROBLEM", 160, 184], ["nonspecific symptoms", "PROBLEM", 194, 214], ["a cough", "PROBLEM", 223, 230], ["rhonchus", "PROBLEM", 232, 240], ["dyspnea", "PROBLEM", 242, 249], ["pyrexia", "PROBLEM", 254, 261], ["hepatomegaly", "PROBLEM", 273, 285], ["eosinophilic granuloma", "PROBLEM", 290, 312], ["the infection", "PROBLEM", 344, 357], ["immunological assays", "TEST", 398, 418], ["screening", "TEST", 435, 444], ["Western blot", "TEST", 449, 461], ["confirmation", "TEST", 466, 478], ["entailing respiratory signs", "PROBLEM", 658, 685], ["coughing", "PROBLEM", 687, 695], ["pulmonary larval migration", "PROBLEM", 703, 729], ["general failure to thrive", "PROBLEM", 732, 757], ["retarded growth", "PROBLEM", 759, 774], ["emaciation", "PROBLEM", 776, 786], ["debilitated body coat", "PROBLEM", 788, 809], ["arthralgia", "PROBLEM", 814, 824], ["intestinal disorders", "PROBLEM", 830, 850], ["alternating diarrhea", "PROBLEM", 852, 872], ["constipation", "PROBLEM", 877, 889], ["pot-belly", "PROBLEM", 891, 900], ["vomiting", "PROBLEM", 905, 913], ["cardiac", "ANATOMY", 15, 22], ["toxocariasis", "OBSERVATION", 34, 46], ["VLM", "ANATOMY", 98, 101], ["infected", "OBSERVATION", 164, 172], ["cough", "OBSERVATION", 225, 230], ["dyspnea", "OBSERVATION", 242, 249], ["pyrexia", "OBSERVATION", 254, 261], ["hepatomegaly", "OBSERVATION", 273, 285], ["eosinophilic", "OBSERVATION_MODIFIER", 290, 302], ["granuloma", "OBSERVATION", 303, 312], ["infection", "OBSERVATION", 348, 357], ["respiratory", "ANATOMY", 668, 679], ["pulmonary", "ANATOMY", 703, 712], ["larval migration", "OBSERVATION", 713, 729], ["failure", "OBSERVATION", 740, 747], ["arthralgia", "OBSERVATION", 814, 824], ["intestinal", "ANATOMY", 830, 840], ["belly", "ANATOMY", 895, 900]]], ["No remarkable trait is seen following Toxascaris infection in dogs and/or cats and it is usually well-tolerated [3\u20135].BackgroundOne of the characteristic of helminthic parasites is the stimulation of the immune system that leads to increased Th2 response and high production of IL-4, IL-5, IL-9, IL-10, IL-13, eosinophils, and IgE.", [["immune system", "ANATOMY", 204, 217], ["eosinophils", "ANATOMY", 310, 321], ["Toxascaris infection", "DISEASE", 38, 58], ["helminthic parasites", "DISEASE", 157, 177], ["Toxascaris", "SIMPLE_CHEMICAL", 38, 48], ["dogs", "ORGANISM", 62, 66], ["cats", "ORGANISM", 74, 78], ["IL-4", "GENE_OR_GENE_PRODUCT", 278, 282], ["IL-5", "GENE_OR_GENE_PRODUCT", 284, 288], ["IL-9", "GENE_OR_GENE_PRODUCT", 290, 294], ["IL-10", "GENE_OR_GENE_PRODUCT", 296, 301], ["IL-13", "GENE_OR_GENE_PRODUCT", 303, 308], ["eosinophils", "CELL", 310, 321], ["IgE.", "GENE_OR_GENE_PRODUCT", 327, 331], ["eosinophils", "CELL_TYPE", 310, 321], ["dogs", "SPECIES", 62, 66], ["cats", "SPECIES", 74, 78], ["remarkable trait", "PROBLEM", 3, 19], ["Toxascaris infection in dogs", "PROBLEM", 38, 66], ["helminthic parasites", "PROBLEM", 157, 177], ["increased Th2 response", "PROBLEM", 232, 254], ["IL", "TEST", 278, 280], ["IL", "TEST", 284, 286], ["IL", "TEST", 290, 292], ["IL", "TEST", 296, 298], ["IL", "TEST", 303, 305], ["eosinophils", "TEST", 310, 321], ["remarkable", "OBSERVATION_MODIFIER", 3, 13], ["trait", "OBSERVATION", 14, 19], ["infection", "OBSERVATION", 49, 58], ["helminthic parasites", "OBSERVATION", 157, 177], ["increased", "OBSERVATION_MODIFIER", 232, 241], ["Th2 response", "OBSERVATION", 242, 254], ["high", "OBSERVATION_MODIFIER", 259, 263]]], ["Toxocara larvae can causes severe hyper eosinophilia and allergic involvements with effect on IgE and IL-5.", [["Toxocara larvae", "DISEASE", 0, 15], ["eosinophilia", "DISEASE", 40, 52], ["allergic involvements", "DISEASE", 57, 78], ["Toxocara larvae", "ORGANISM", 0, 15], ["IgE", "GENE_OR_GENE_PRODUCT", 94, 97], ["IL-5", "GENE_OR_GENE_PRODUCT", 102, 106], ["IgE", "PROTEIN", 94, 97], ["IL-5", "PROTEIN", 102, 106], ["Toxocara larvae", "PROBLEM", 0, 15], ["severe hyper eosinophilia", "PROBLEM", 27, 52], ["allergic involvements", "PROBLEM", 57, 78], ["IgE and IL", "TREATMENT", 94, 104], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["hyper", "OBSERVATION_MODIFIER", 34, 39], ["eosinophilia", "OBSERVATION", 40, 52], ["allergic involvements", "OBSERVATION", 57, 78]]], ["Consequently, the production of specific antibodies provides the most complete evidence for Toxocara infection, which is the base of diagnostic tests such as ELISA and Western blot for reactivity to larval TES antigen [11\u201313].BackgroundIran, a Middle Eastern country, possesses several climatological areas with particular characteristics in each region; this would have a significant bias on the epidemiology of Toxocara/Toxascaris species.", [["Toxocara infection", "DISEASE", 92, 110], ["Toxocara/Toxascaris species", "DISEASE", 413, 440], ["Toxocara", "ORGANISM", 92, 100], ["TES antigen", "GENE_OR_GENE_PRODUCT", 206, 217], ["Toxocara", "ORGANISM", 413, 421], ["Toxascaris species", "ORGANISM", 422, 440], ["specific antibodies", "PROTEIN", 32, 51], ["larval TES antigen", "PROTEIN", 199, 217], ["specific antibodies", "PROBLEM", 32, 51], ["Toxocara infection", "PROBLEM", 92, 110], ["diagnostic tests", "TEST", 133, 149], ["ELISA", "TEST", 158, 163], ["larval TES antigen", "TEST", 199, 217], ["Toxocara/Toxascaris species", "PROBLEM", 413, 440], ["infection", "OBSERVATION", 101, 110], ["Middle", "ANATOMY_MODIFIER", 244, 250], ["several", "OBSERVATION_MODIFIER", 278, 285], ["climatological", "OBSERVATION_MODIFIER", 286, 300], ["particular characteristics", "OBSERVATION_MODIFIER", 312, 338], ["significant", "OBSERVATION_MODIFIER", 373, 384], ["bias", "OBSERVATION", 385, 389]]], ["In the previous studies the infection of dogs and cats with Toxocara species in different parts of Iran has been shown [14].", [["infection", "DISEASE", 28, 37], ["Toxocara species", "DISEASE", 60, 76], ["dogs", "ORGANISM", 41, 45], ["cats", "ORGANISM", 50, 54], ["Toxocara species", "ORGANISM", 60, 76], ["dogs", "SPECIES", 41, 45], ["cats", "SPECIES", 50, 54], ["the infection of dogs", "PROBLEM", 24, 45], ["Toxocara species", "PROBLEM", 60, 76], ["infection", "OBSERVATION", 28, 37]]], ["Despite the prevalence of Toxocara canis in the most areas, molecular studies on cat nematodes in Shiraz, in south-central Iran showed that, the most prevalent one is T. cati [15].", [["Toxocara canis", "DISEASE", 26, 40], ["Toxocara canis", "ORGANISM", 26, 40], ["cat nematodes", "ORGANISM", 81, 94], ["T. cati", "ORGANISM", 167, 174], ["Toxocara canis", "SPECIES", 26, 40], ["cat", "SPECIES", 81, 84], ["T. cati", "SPECIES", 167, 174], ["Toxocara canis", "SPECIES", 26, 40], ["T. cati", "SPECIES", 167, 174], ["Toxocara canis", "PROBLEM", 26, 40], ["molecular studies", "TEST", 60, 77], ["Toxocara canis", "OBSERVATION", 26, 40]]], ["Toxocara vitulorum is frequently found in ruminants.", [["Toxocara vitulorum", "DISEASE", 0, 18], ["Toxocara vitulorum", "ORGANISM", 0, 18], ["Toxocara vitulorum", "SPECIES", 0, 18], ["Toxocara vitulorum", "SPECIES", 0, 18], ["Toxocara vitulorum", "TEST", 0, 18]]], ["Its main hosts are cattle and buffalo in tropical and sub-tropical regions [16].", [["cattle", "ORGANISM", 19, 25], ["buffalo", "ORGANISM_SUBDIVISION", 30, 37], ["cattle", "SPECIES", 19, 25], ["cattle", "SPECIES", 19, 25], ["buffalo", "SPECIES", 30, 37], ["main", "OBSERVATION_MODIFIER", 4, 8], ["hosts", "OBSERVATION_MODIFIER", 9, 14], ["tropical", "OBSERVATION_MODIFIER", 41, 49], ["sub", "OBSERVATION_MODIFIER", 54, 57], ["tropical", "ANATOMY_MODIFIER", 58, 66]]], ["It has been reported that 16% (95% CI: 11\u201321%; 470 out of 3031 samples) of soil samples gathered from public parks of the Iran were positive for Toxocara spp. eggs [17].BackgroundOn the other hand, due to increasing body of work on Toxocara prevalence in various human/animal hosts in Iran, a comprehensive review would be exceedingly beneficial for appraising progresses about this zoonosis.", [["samples", "ANATOMY", 63, 70], ["soil samples", "ANATOMY", 75, 87], ["Toxocara spp", "DISEASE", 145, 157], ["Toxocara", "DISEASE", 232, 240], ["zoonosis", "DISEASE", 383, 391], ["samples", "CANCER", 63, 70], ["soil samples", "CANCER", 75, 87], ["Toxocara spp", "ORGANISM", 145, 157], ["body", "ORGANISM_SUBDIVISION", 216, 220], ["Toxocara", "ORGANISM", 232, 240], ["human", "ORGANISM", 263, 268], ["human", "SPECIES", 263, 268], ["Toxocara spp", "SPECIES", 145, 157], ["human", "SPECIES", 263, 268], ["CI", "TEST", 35, 37], ["soil samples", "TEST", 75, 87], ["the Iran", "TEST", 118, 126], ["Toxocara spp", "PROBLEM", 145, 157], ["this zoonosis", "PROBLEM", 378, 391]]], ["Therefore, this meta-analysis attempts to fill the current gaps and provides insights into parasite prevalence with respect to host type, Toxocara and Toxascaris species, and geographical region in the country.Study area ::: MethodsIran has a population of approximately 80 million (as of 2015), and is located between 25\u00b03\u02b9 and 39\u00b047\u02b9N and 44\u00b05\u02b9 and 63\u00b018\u02b9E, which covers a wide territory in the Middle East area (1,648,195 km2).", [["MethodsIran", "CHEMICAL", 225, 236], ["Toxascaris species", "ORGANISM", 151, 169], ["Toxocara and Toxascaris species", "TREATMENT", 138, 169], ["MethodsIran", "TREATMENT", 225, 236], ["population", "OBSERVATION_MODIFIER", 243, 253], ["approximately", "OBSERVATION_MODIFIER", 257, 270], ["80 million", "OBSERVATION_MODIFIER", 271, 281], ["wide", "OBSERVATION_MODIFIER", 375, 379], ["territory", "OBSERVATION_MODIFIER", 380, 389], ["Middle", "ANATOMY_MODIFIER", 397, 403], ["East", "ANATOMY_MODIFIER", 404, 408]]], ["The country borders Afghanistan and Pakistan to the east, Iraq and Turkey to the west, the Persian Gulf and Oman Sea to the south, and Azerbaijan, Armenia, and Turkmenistan to the north.", [["Armenia", "ANATOMY", 147, 154]]], ["The Iranian plateau climate is generally hot and dry, however the Caspian Sea coast in northern parts, comprising Golestan, Mazandaran and Guilan provinces, is Mediterranean-like, demonstrating heavy rainfalls, vegetation-enriched, surrounded by dense forests and a diverse range of carnivorous animals These geo-ecological features would provide a well-established setting for most parasites, e.g. soil-transmitted helminthiases, to localize in the area and parasitize many canid species.", [["rainfalls", "DISEASE", 200, 209], ["vegetation", "PROBLEM", 211, 221], ["most parasites", "PROBLEM", 378, 392], ["transmitted helminthiases", "PROBLEM", 404, 429], ["plateau climate", "OBSERVATION", 12, 27], ["generally", "OBSERVATION_MODIFIER", 31, 40], ["hot", "OBSERVATION", 41, 44], ["vegetation", "OBSERVATION", 211, 221], ["dense", "OBSERVATION_MODIFIER", 246, 251], ["forests", "OBSERVATION", 252, 259], ["canid species", "OBSERVATION", 475, 488]]], ["Also, the country is a mountainous region with several mountain ranges, mostly located at the western and northern parts such as Zagros mountain ranges with colder winters and heavy snowfalls.", [["mountain ranges", "OBSERVATION_MODIFIER", 55, 70], ["heavy snowfalls", "OBSERVATION", 176, 191]]], ["The annual precipitation is 680 mm in the eastern part of the plain and more than 1700 mm in the western parts [18\u201321].Search strategy ::: MethodsThe PRISMA protocol (preferred reporting items for systematic reviews and meta-analysis) was employed to conduct this meta-analysis [22].", [["Methods", "TREATMENT", 139, 146], ["The PRISMA protocol", "TREATMENT", 146, 165], ["systematic reviews", "TEST", 197, 215], ["meta-analysis", "TEST", 220, 233], ["annual", "OBSERVATION_MODIFIER", 4, 10], ["precipitation", "OBSERVATION_MODIFIER", 11, 24], ["680 mm", "OBSERVATION_MODIFIER", 28, 34]]], ["In order to assess the prevalence of T. canis, T. cati and T. leonina in humans and carnivores of different parts of Iran, we investigated the available online articles of both Persian (SID, Iran Medex, Magiran, Iran Doc) and English (PubMed, Science Direct, Scopus, Ovid) databases.", [["T. canis", "DISEASE", 37, 45], ["T. canis", "ORGANISM", 37, 45], ["T. cati", "ORGANISM", 47, 54], ["T. leonina", "ORGANISM", 59, 69], ["humans", "ORGANISM", 73, 79], ["T. canis", "SPECIES", 37, 45], ["T. cati", "SPECIES", 47, 54], ["T. leonina", "SPECIES", 59, 69], ["humans", "SPECIES", 73, 79], ["T. canis", "SPECIES", 37, 45], ["T. cati", "SPECIES", 47, 54], ["T. leonina", "SPECIES", 59, 69], ["humans", "SPECIES", 73, 79], ["T. canis", "PROBLEM", 37, 45]]], ["A combination of the following search terms were employed in our literature searches as follows: (\u201cToxocariasis\u201d OR \u201cToxocara infection\u201d OR \u201cToxocara canis\u201d OR \u201cToxocara cati\u201d OR \u201cToxascaris leonina\u201d) AND (\u201cCarnivora\u201d OR \u201cHuman\u201d) AND (\u201cPrevalence\u201d OR \u201cEpidemiology\u201d) AND (\u201cIran\u201d).Study selection and data extraction ::: MethodsAfter hand searching in bibliographic list of obtained full-text records for any related literature as well as removing duplicates, two independent reviewers screened the titles and abstracts for initial inclusion.", [["Toxocariasis", "DISEASE", 99, 111], ["Toxocara infection", "DISEASE", 117, 135], ["Toxocara canis", "DISEASE", 141, 155], ["Human", "ORGANISM", 222, 227], ["Toxocara canis", "SPECIES", 141, 155], ["Human", "SPECIES", 222, 227], ["Toxocariasis", "TEST", 99, 111], ["Toxocara infection", "PROBLEM", 117, 135], ["Toxocara canis", "TEST", 141, 155], ["Toxocara cati", "TEST", 161, 174], ["Study selection", "TEST", 280, 295]]], ["Finally, those records that met the following inclusion criteria were eligible to enter our meta-analysis: (A) Peer-reviewed originally-published papers both in English or Persian; (B) Being available online between April 1969 till June 2019; (C) Cross-sectional investigations that assessed the prevalence of Toxocara spp. in various carnivores and human populations in Iran; (D) Studies that detected Toxocara infection using at least one of the parasitological, serological and molecular methods; (e) exact total sample size, positive samples and the respective prevalence rates were available.", [["sample", "ANATOMY", 516, 522], ["samples", "ANATOMY", 538, 545], ["Toxocara spp", "DISEASE", 310, 322], ["Toxocara infection", "DISEASE", 403, 421], ["Toxocara spp", "ORGANISM", 310, 322], ["human", "ORGANISM", 350, 355], ["Toxocara", "ORGANISM", 403, 411], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 350, 355], ["Cross-sectional investigations", "TEST", 247, 277], ["Toxocara spp", "PROBLEM", 310, 322], ["Toxocara infection", "PROBLEM", 403, 421], ["the parasitological", "TEST", 444, 463], ["the respective prevalence rates", "TEST", 550, 581], ["various", "OBSERVATION_MODIFIER", 327, 334], ["carnivores", "OBSERVATION_MODIFIER", 335, 345], ["Toxocara infection", "OBSERVATION", 403, 421], ["size", "OBSERVATION_MODIFIER", 523, 527]]], ["Empirical studies and any kind of review papers were excluded and failed for further analysis.", [["Empirical studies", "TEST", 0, 17], ["further analysis", "TEST", 77, 93]]], ["A detailed variable of each of articles, including: province, year of publication, study design, sample size, detection method, and prevalence rates, in addition to animal species and sampling method for animal-based investigations were gathered.", [["detection method", "TEST", 110, 126], ["prevalence rates", "TEST", 132, 148], ["animal species", "PROBLEM", 165, 179], ["sampling method", "TEST", 184, 199], ["animal-based investigations", "TEST", 204, 231]]], ["In this study, the JBI critical appraisal checklist for prevalence studies was employed [23].Study quality assessment ::: MethodsThe JBI checklist was used for quality assessment of the included articles.", [["this study", "TEST", 3, 13], ["prevalence studies", "TEST", 56, 74], ["Study quality assessment", "TEST", 93, 117], ["Methods", "TREATMENT", 122, 129], ["The JBI checklist", "TEST", 129, 146], ["quality assessment", "TEST", 160, 178]]], ["Briefly, a study can be awarded a maximum of one star for each numbered item.", [["a study", "TEST", 9, 16]]], ["The papers with a total score of \u22646 and \u2265 7 points were specified as the moderate and high quality, respectively.", [["a total score", "TEST", 16, 29], ["moderate", "OBSERVATION_MODIFIER", 73, 81], ["high", "OBSERVATION_MODIFIER", 86, 90]]], ["Based on the obtained score, the authors have decided to include and exclude the papers [23].Meta-analysis ::: MethodsBriefly, meta-analysis was yielded as a forest plot representing the prevalence estimates and related confidence intervals of each study along with summary measures.", [["a forest plot", "PROBLEM", 156, 169], ["each study", "TEST", 244, 254], ["summary measures", "TREATMENT", 266, 282]]], ["Also, the heterogeneity was analyzed using STATA statistical software (Version 8.2) to calculate Cochran\u2019s Q and I2 statistics.", [["STATA statistical software", "TEST", 43, 69], ["Version", "TEST", 71, 78]]], ["I2 values of 25, 50, and 75% were considered as low, moderate and high heterogeneity, respectively [24].", [["I2 values", "TEST", 0, 9], ["low, moderate and high heterogeneity", "PROBLEM", 48, 84], ["low", "OBSERVATION_MODIFIER", 48, 51], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["high", "OBSERVATION_MODIFIER", 66, 70], ["heterogeneity", "OBSERVATION_MODIFIER", 71, 84]]], ["Furthermore, the funnel plot based on Egger\u2019s regression test illustrates publication bias and small study effects.", [["the funnel plot", "TEST", 13, 28], ["regression test", "TEST", 46, 61], ["publication bias", "TEST", 74, 90], ["small study effects", "PROBLEM", 95, 114], ["small", "OBSERVATION_MODIFIER", 95, 100]]], ["In the current study, I2 was substantial; therefore, we used a random effects model at a 95% CI, to give a more conservative estimate of the Toxocara infection prevalence.Hosts ::: ResultsFollowing systematic search of eight databases, totally 28 records human studies and 56 animal investigations were found eligible regarding Toxocara/Toxascaris (Fig. 1).", [["Toxocara infection", "DISEASE", 141, 159], ["Toxocara", "ORGANISM", 141, 149], ["human", "ORGANISM", 255, 260], ["Toxocara", "ORGANISM", 328, 336], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 255, 260], ["the current study", "TEST", 3, 20], ["the Toxocara infection prevalence", "PROBLEM", 137, 170], ["human studies", "TEST", 255, 268], ["animal investigations", "TEST", 276, 297], ["substantial", "OBSERVATION_MODIFIER", 29, 40], ["Toxocara infection", "OBSERVATION", 141, 159]]], ["During a 19-years period, 11,781 human individuals were examined and the calculated weighted prevalence was 9.3% (95% CI: 6.1\u201313.1%) (Tables 1 and 2).", [["human", "ORGANISM", 33, 38], ["individuals", "ORGANISM", 39, 50], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["the calculated weighted prevalence", "TEST", 69, 103], ["CI", "TEST", 118, 120], ["Tables", "TEST", 134, 140]]], ["The trend line of human Toxocara/Toxascaris infection demonstrated that the prevalence has declined in spite of increased bulk of work on human population (Additional file 2: Figure S2).", [["Toxocara/Toxascaris infection", "DISEASE", 24, 53], ["human", "ORGANISM", 18, 23], ["Toxocara/Toxascaris", "ORGANISM", 24, 43], ["human", "ORGANISM", 138, 143], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 138, 143], ["human Toxocara", "TREATMENT", 18, 32], ["Toxascaris infection", "PROBLEM", 33, 53], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["bulk", "OBSERVATION_MODIFIER", 122, 126]]], ["Most records (10 studies) were conducted in both rural and urban circumstances, however seroprevalence was mostly predominant in urban regions with 14% (95% CI: 5.6\u201325.3%) (No showed data).", [["seroprevalence", "TREATMENT", 88, 102], ["CI", "TEST", 157, 159]]], ["People under 20 years old were mostly examined by serodiagnosis approach, indicating 8.2% (95% CI: 4.6\u201312.7%) seroprevalence rate (Additional file 3: Figure S3).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["CI", "TEST", 95, 97], ["seroprevalence rate", "TEST", 110, 129]]]], "PMC6986850": [["Social Morality during Epidemics in CinemaMany films dealing with epidemics have tended to see panic as an inevitable social response; their main focus has been the process of authorities withholding information to guard against chaos or the circulation of misinformation by the media.", [["panic", "DISEASE", 95, 100], ["epidemics", "PROBLEM", 66, 75], ["panic", "PROBLEM", 95, 100]]], ["For example, in Panic on the Streets (1950, directed by Elia Kazan), to avoid mass panic across the city of New Orleans, the US Public Health Service and the police agree to not notify the press of a death resulting from pneumonic plague.", [["Panic", "DISEASE", 16, 21], ["panic", "DISEASE", 83, 88], ["death", "DISEASE", 200, 205], ["pneumonic plague", "DISEASE", 221, 237], ["Panic", "PROBLEM", 16, 21], ["mass panic", "PROBLEM", 78, 88], ["a death", "PROBLEM", 198, 205], ["pneumonic plague", "PROBLEM", 221, 237], ["mass", "OBSERVATION", 78, 82], ["pneumonic", "OBSERVATION", 221, 230]]], ["Appearing in the same year, The Killer That Stalked New York (1950, Earl McEvoy) was based on an actual threat of smallpox that occurred in New York in 1947.", [["smallpox", "DISEASE", 114, 122]]], ["In the film, public health officials develop a widespread vaccination program, but after the necessary serum runs out, the city descends into mass panic\u2014after the authorities tried to cover up this information.", [["serum", "ANATOMY", 103, 108], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["the necessary serum runs", "TEST", 89, 113], ["mass", "OBSERVATION", 142, 146]]], ["In the UK film 80,000 Suspects (1963, Val Guest), the doctor tackling an outbreak of smallpox uses a quarantining process with the explicitly mentioned goal of reducing the chances of public panic.", [["smallpox", "DISEASE", 85, 93], ["panic", "DISEASE", 191, 196], ["smallpox", "TREATMENT", 85, 93], ["a quarantining process", "TREATMENT", 99, 121], ["public panic", "PROBLEM", 184, 196]]], ["In Morte a Venezia (1971, Luchino Visconti), a film based on the 1912 novel by German author Thomas Mann, Der Tod in Venedig [Death in Venice], the city authorities do not inform those on vacation of cholera problems within the city for fear they will frantically leave\u2014an approach also taken by town officials in John Ford\u2019s depiction of a community during a typhoid epidemic, Dr. Bull (1933).", [["cholera", "DISEASE", 200, 207], ["typhoid", "DISEASE", 360, 367], ["cholera problems", "PROBLEM", 200, 216]]], ["Another common feature is defiance of the film\u2019s protagonists against a perceived lack of official information.", [["the film", "TEST", 38, 46]]], ["For example, in Quiet Killer (1992, Sheldon Larry), when the doctor realizes that her patient has succumbed to plague, she tries to push authorities to warn the citizens of New York, against considerable reluctance from the mayor, who envisages widespread panic.Social Morality during Epidemics in CinemaOther films, however, have gone further and tried to examine some of the causes of this fear and panic; in many films, the roots lie in society\u2019s response to perceived declines in social morality.", [["roots", "ANATOMY", 427, 432], ["panic", "DISEASE", 256, 261], ["panic", "DISEASE", 401, 406], ["patient", "ORGANISM", 86, 93], ["roots", "ORGAN", 427, 432], ["patient", "SPECIES", 86, 93], ["panic", "PROBLEM", 256, 261], ["panic", "PROBLEM", 401, 406]]], ["One of the earliest examples is Die Pest in Florenz [The Plague of Florence] (1918, Fritz Lang), which focused on the real outbreak of the Black Death in Florence in the mid-14th century and portrayed death from plague as a response to immoral behavior and sexual debauchery.", [["Death", "DISEASE", 145, 150], ["death", "DISEASE", 201, 206], ["plague", "DISEASE", 212, 218]]], ["The connection between disease and deteriorating social morality came from actual observations of contemporaries at the time, for example, the views of Giovanni Villani (Nuova Cronica) and Giovanni Boccaccio (Decameron).", [["Giovanni Villani", "ORGANISM", 152, 168], ["The connection between disease", "PROBLEM", 0, 30], ["Giovanni Villani (Nuova Cronica", "TREATMENT", 152, 183], ["Giovanni Boccaccio (Decameron)", "TREATMENT", 189, 219], ["disease", "OBSERVATION", 23, 30], ["deteriorating", "OBSERVATION_MODIFIER", 35, 48]]], ["In several films, the plague became used as an explicit punishment for immorality and wrongdoing: The Pied Piper (1972, Jacques Demy), The Hour of the Pig (1993, Leslie Megahey), and especially Anazapta (2002, Alberto Sciamma), in which plague was a supposed consequence of the brutal rape of a lord\u2019s wife by the village.Social Morality during Epidemics in CinemaSimilar kinds of existentialist angst and pessimism over social values in connection with the Black Death were later famously exploited by Ingmar Bergman in The Seventh Seal (1957), Lars von Trier in Epidemic (1987), Luis Puenzo in The Plague (1992), and Christopher Smith in The Black Death (2010).", [["immorality", "DISEASE", 71, 81], ["Death", "DISEASE", 464, 469], ["several films", "TEST", 3, 16]]], ["Those 4 films focus especially on intolerance in the form of scapegoating and persecution of women as witches, but visualization of dread had already appeared earlier in lesser known films, such as Singoalla (1949, Christian-Jaque), H\u00e4xan (1922, Benjamin Christensen), and Skeleton on Horseback (1937, Hugo Haas).", [["women", "ORGANISM", 93, 98], ["women", "SPECIES", 93, 98], ["Those 4 films focus", "TEST", 0, 19], ["intolerance", "PROBLEM", 34, 45], ["Skeleton", "ANATOMY", 273, 281]]], ["In the film Trollsyn (1994, Ola Solum), set in Norway, the initial stage of the Black Death outbreak is presented as mass hysteria among the villagers: crying and shouting, desperate prayers, suicides, and frantic searching for buboes and panicked movements.", [["Death", "DISEASE", 86, 91], ["hysteria", "DISEASE", 122, 130], ["the Black Death outbreak", "PROBLEM", 76, 100], ["mass hysteria", "PROBLEM", 117, 130], ["crying", "PROBLEM", 152, 158]]], ["Also, in reference to social decline, one scene shows simultaneously the aggressive inquisition of a female scapegoat while amid the chaos a couple are having sex and others have taken off their clothes and are rolling down a grassy hill.Social Morality during Epidemics in CinemaMany films focusing on outbreaks of epidemic disease focus on outbreaks of senseless violence indicative of a society completely out of control.", [["epidemic disease", "PROBLEM", 316, 332]]], ["In The Horseman on the Roof (1995, Jean-Paul Rappeneau), set during a cholera epidemic in 19th-century Manosque, southern France, the film\u2019s protagonist, Angelo, is captured by a paranoid mob who accuse him of poisoning the town fountain and take him to the authorities.", [["cholera", "DISEASE", 70, 77], ["paranoid", "DISEASE", 179, 187], ["poisoning", "DISEASE", 210, 219], ["Roof", "ANATOMY_MODIFIER", 23, 27]]], ["Elsewhere, in the Masque of the Red Death (1964, Roger Corman [adapted in 1989 by Larry Brand/Jeffrey Delman]), which focuses on a fictional disease with loose parallels to plague, rural villagers become increasingly desperate and seek to escape the devastating death, only to have soldiers shoot them down by crossbow.", [["Death", "DISEASE", 36, 41], ["death", "DISEASE", 262, 267], ["a fictional disease", "PROBLEM", 129, 148], ["loose parallels", "PROBLEM", 154, 169], ["the devastating death", "PROBLEM", 246, 267], ["loose", "OBSERVATION_MODIFIER", 154, 159]]], ["In Jezebel (1939, William Wyler), chaotic and violent scenes of 19th-century New Orleans are overlaid with a dramatic, flashing, capitalized \u201cYELLOW FEVER\u201d text across the screen, as if to heighten the emphasis on uncontrolled panic.Social Morality during Epidemics in CinemaAnother aspect of declining social morality is linked to scapegoating; stigmatization and blame have long been connected with epidemics.", [["panic", "DISEASE", 227, 232], ["scapegoating", "DISEASE", 332, 344], ["YELLOW FEVER", "PROBLEM", 142, 154], ["the screen", "TEST", 168, 178], ["uncontrolled panic", "PROBLEM", 214, 232], ["dramatic", "OBSERVATION_MODIFIER", 109, 117]]], ["It is well known that the Black Death brought mass persecution of Jews in various parts of Europe (13), and families were gathered up and burned alive.", [["Death", "DISEASE", 32, 37], ["the Black Death", "PROBLEM", 22, 37], ["Black", "OBSERVATION_MODIFIER", 26, 31], ["mass", "OBSERVATION", 46, 50]]], ["More recently, Muslims were blamed for poisoning water systems during the 1994 plague outbreak in Surat, India (14), and the HIV/AIDS pandemic from the 1980s led to extreme prejudice against homosexuals and intravenous drug users (15).", [["intravenous", "ANATOMY", 207, 218], ["poisoning", "DISEASE", 39, 48], ["HIV/AIDS pandemic", "DISEASE", 125, 142], ["HIV", "SPECIES", 125, 128], ["poisoning water systems", "PROBLEM", 39, 62], ["the HIV/AIDS pandemic", "PROBLEM", 121, 142]]], ["Globalization and the fear that exotic diseases can be transported into modern urban environments (16), together with increased access to air travel (17), has to some extent heightened these kinds of concerns about scapegoating.", [["exotic diseases", "DISEASE", 32, 47], ["scapegoating", "DISEASE", 215, 227], ["exotic diseases", "PROBLEM", 32, 47], ["exotic diseases", "OBSERVATION", 32, 47]]], ["Viruses know no borders and thus become easily entangled with contemporary anxieties over migration and refugees (18).", [["contemporary anxieties", "PROBLEM", 62, 84]]], ["Asian populations in Chinatowns of various Western cities were victimized in the wake of severe acute respiratory syndrome (SARS) (19), and studies performed in Hong Kong revealed that the public actually anticipated this kind of outcome (20).Social Morality during Epidemics in CinemaNot surprisingly, then, popular culture has often tended to present epidemics as a foreign invasion (2,21), especially given the moral associations often drawn between disease and social and cultural phenomena through metaphors such as corruption, decay, and pollution (11).", [["acute respiratory syndrome", "DISEASE", 96, 122], ["SARS", "DISEASE", 124, 128], ["severe acute respiratory syndrome", "PROBLEM", 89, 122], ["popular culture", "TEST", 309, 324], ["a foreign invasion", "PROBLEM", 366, 384], ["disease", "PROBLEM", 453, 460], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndrome", "OBSERVATION", 102, 122], ["foreign invasion", "OBSERVATION", 368, 384]]], ["For example, in the Sherlock Holmes story The Giant Rat of Sumatra (not penned by Conan Doyle), Professor Moriarty prepares to import plague to Britain by acquiring infected rats from Southeast Asia (5).", [["rats", "ORGANISM", 174, 178], ["rats", "SPECIES", 174, 178], ["Giant", "OBSERVATION_MODIFIER", 46, 51]]], ["Accordingly, in some recent Hollywood films, the direction of disease movement is typically east to west, or at least from developing to developed countries, and plays on common stereotypes, including concepts of orientalization and othering (4,22).", [["some recent Hollywood films", "TEST", 16, 43], ["disease movement", "PROBLEM", 62, 78], ["disease", "OBSERVATION", 62, 69]]], ["The film Contagion (2011, Steven Soderbergh), although widely lauded for its accurate depiction of the mechanisms of disease transmission and epidemiology, can be seen to neatly fit within Wald\u2019s outbreak narrative framework, in which a pathogen is brought into the developed world after contact with migrants and visitors from lesser developed areas (4,6).", [["The film Contagion", "TEST", 0, 18], ["disease transmission", "PROBLEM", 117, 137]]], ["Evie Kendal noted that the virus that hit the United States in Outbreak (1995, Wolfgang Petersen) was thought to have originated in Africa, whereas in Contagion and The Crazies (1973, George Romero), the disease originates in Asia (4).Social Morality during Epidemics in CinemaIn more recent years, however, the othering narrative has also taken new forms, in which an undeveloped or traditional society under threat of an epidemic is heroically saved by outside forces.", [["the virus", "PROBLEM", 23, 32], ["the disease", "PROBLEM", 200, 211], ["virus", "OBSERVATION", 27, 32], ["Africa", "OBSERVATION_MODIFIER", 132, 138], ["disease", "OBSERVATION", 204, 211]]], ["This narrative can be seen in the popular film set in China, Wolf Warrior II [Zhan lang II] (2017, Jing Wu), which tries to favorably present Chinese attempts to control a fictional disease (lamanla) based on Ebola in Africa.", [["Ebola", "DISEASE", 209, 214], ["Ebola", "ORGANISM", 209, 214], ["a fictional disease (lamanla)", "PROBLEM", 170, 199], ["Ebola", "OBSERVATION", 209, 214]]], ["In The Painted Veil (2006, John Curran), a 1920s rural village in China is unable to deal with a cholera outbreak until a British bacteriologist comes along to investigate and in the end selflessly gives his own life.Resistance and Normalcy during Epidemics Depicted in CinemaAlthough epidemics can produce panicked responses that lead to the unraveling of the social fabric, this response is not the only outcome, as the literature (both historical and contemporary sociological) has argued (13,23).", [["cholera", "DISEASE", 97, 104], ["Resistance", "PROBLEM", 217, 227]]], ["In a related way, some films have also shown that extreme reactions during epidemics often have a specific purpose, and, paradoxically, elements of unrest (e.g., resistance to authorities and violence) can be society\u2019s way of attempting to return to a state of normalcy and cohesiveness.", [["some films", "TEST", 18, 28], ["extreme reactions", "PROBLEM", 50, 67], ["unrest", "PROBLEM", 148, 154]]], ["Indeed, although according to Michel Foucault, sickness and disease became an arena through which authorities and elites tried to exert social controls (24), epidemics can also become a context in which those lower down the social hierarchy vent frustrations, leading to conflict, often as a way of protecting freedoms or traditions and customary practices.", [["sickness and disease", "DISEASE", 47, 67], ["sickness", "PROBLEM", 47, 55], ["disease", "PROBLEM", 60, 67]]], ["Good early cinematic examples of lower class involvement include The Citadel (1937, King Vidor), with its scenes of working class miners resisting medical authority during a tuberculosis outbreak, and 1918 (1985, Ken Harrison), in which residents of a small Texas community resolutely try to continue their normal lives, functions, and networks despite the scale of deaths from influenza.Resistance and Normalcy during Epidemics Depicted in CinemaIn recent times, more nuanced views about how societies respond to epidemics can be found in films, especially showing how extreme reactions tend to not be intrinsically associated with the disease itself but rather to be a way of dealing with top-down repression impinging on freedoms and liberties.", [["tuberculosis", "DISEASE", 174, 186], ["deaths", "DISEASE", 366, 372], ["influenza", "DISEASE", 378, 387], ["influenza", "PROBLEM", 378, 387], ["Resistance", "PROBLEM", 388, 398], ["epidemics", "PROBLEM", 514, 523], ["extreme reactions", "PROBLEM", 570, 587], ["the disease itself", "PROBLEM", 633, 651], ["lower class", "OBSERVATION_MODIFIER", 33, 44], ["influenza", "OBSERVATION", 378, 387], ["disease", "OBSERVATION", 637, 644]]], ["Although perpetuating some elements of othering (6), the US-based film Contagion is a good example of a film that deals with social movements from below, in the process criticizing contemporary trends toward avarice and self-interest, which are further exposed during the epidemic.", [["the US", "TEST", 53, 59], ["a film", "TEST", 102, 108]]], ["However, much of this unrest is connected to unsatisfactory responses to the disease by authorities.", [["the disease", "PROBLEM", 73, 84], ["disease", "OBSERVATION", 77, 84]]], ["Most fears stem from an absence of information from reputable sources, leaving a vacuum for dubious intelligence to emerge on alternative platforms, where intrigue and speculation become almost comparable types of contagion.", [["dubious intelligence", "PROBLEM", 92, 112]]], ["Overall, a tension emerges between the medical authorities\u2019 advised procedure of forcible isolation and quarantine, which conflicts with very contemporary demands for maintenance of ordinary patterns of social networking and communication.", [["forcible isolation", "TREATMENT", 81, 99], ["quarantine", "TREATMENT", 104, 114], ["tension", "OBSERVATION", 11, 18]]], ["This response has strong parallels in history, where communities have been shown to cling strongly to their sociability.", [["strong", "OBSERVATION_MODIFIER", 18, 24]]], ["Religious rituals such as the Jan\u0101za blessing continued unabated in the Middle East during Second Pandemic plagues (25), and the influenza pandemic of 1918\u20131920 has been cited as the foremost example in modern history of continued social bonds in times of excessive deaths (26).Resistance and Normalcy during Epidemics Depicted in CinemaAnother film demonstrating similar issues is Blindness (2008, Fernando Meirelles), which deals with a fictional disease that causes epidemic blindness, leading to collective hysteria.", [["Pandemic plagues", "DISEASE", 98, 114], ["influenza", "DISEASE", 129, 138], ["1918\u20131920", "CHEMICAL", 151, 160], ["deaths", "DISEASE", 266, 272], ["Blindness", "DISEASE", 382, 391], ["blindness", "DISEASE", 478, 487], ["hysteria", "DISEASE", 511, 519], ["Religious rituals", "TREATMENT", 0, 17], ["the Jan\u0101za blessing", "TREATMENT", 26, 45], ["excessive deaths", "PROBLEM", 256, 272], ["Resistance", "PROBLEM", 278, 288], ["CinemaAnother film", "TEST", 331, 349], ["Blindness", "PROBLEM", 382, 391], ["a fictional disease", "PROBLEM", 437, 456], ["epidemic blindness", "PROBLEM", 469, 487], ["collective hysteria", "PROBLEM", 500, 519], ["Middle", "ANATOMY_MODIFIER", 72, 78], ["similar", "OBSERVATION_MODIFIER", 364, 371], ["issues", "OBSERVATION", 372, 378], ["Blindness", "OBSERVATION", 382, 391], ["epidemic", "OBSERVATION_MODIFIER", 469, 477], ["blindness", "OBSERVATION", 478, 487]]], ["Overall, the film considers the human capacity for prejudice, indifference, selfishness, and an easy resort to aggression and violence.", [["selfishness", "DISEASE", 76, 87], ["aggression", "DISEASE", 111, 121], ["violence", "DISEASE", 126, 134], ["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["the film", "TEST", 9, 17]]], ["As more citizens contract the disease, the normal functioning of society is upturned: strict government quarantines of the infected are imposed by use of physical force.", [["the disease", "PROBLEM", 26, 37], ["disease", "OBSERVATION", 30, 37], ["infected", "OBSERVATION", 123, 131]]], ["Just as with Contagion, however, this action provokes unrest not connected to the disease but to perceived arbitrary and ruthless actions of elites and authorities.", [["the disease", "PROBLEM", 78, 89], ["disease", "OBSERVATION", 82, 89]]], ["We see scenes in which resources such as food begin to be distributed inequitably, and people begin to exploit their positions by withholding food in exchange for other resources, including coerced sex.", [["people", "SPECIES", 87, 93]]], ["Most of the violent confrontation stems from hostilities between those subject to quarantines and those managing the confined environments.Resistance and Normalcy during Epidemics Depicted in CinemaThese aspects of extreme disdain for the withholding of perceived societal freedoms are not found solely in Western films but in films from Asia too, such as the recent popular movie Flu (2013, Kim Sung-su), set in South Korea, which plays on recent experiences with SARS and influenza by focusing on responses to an outbreak of a fictional disease with parallels to the strain of avian influenza A(H5N1) virus.", [["Normalcy", "DISEASE", 154, 162], ["SARS", "DISEASE", 465, 469], ["influenza", "DISEASE", 474, 483], ["avian influenza A(H5N1) virus", "DISEASE", 579, 608], ["avian influenza A(H5N1) virus", "ORGANISM", 579, 608], ["avian influenza", "SPECIES", 579, 594], ["A(H5N1) virus", "SPECIES", 595, 608], ["avian influenza A(H5N1) virus", "SPECIES", 579, 608], ["Resistance", "PROBLEM", 139, 149], ["Western films", "TEST", 306, 319], ["SARS", "PROBLEM", 465, 469], ["influenza", "PROBLEM", 474, 483], ["a fictional disease", "PROBLEM", 527, 546], ["avian influenza A(H5N1) virus", "PROBLEM", 579, 608]]], ["On the one hand, many scenes capture the frenzied breakdown of social norms.", [["breakdown", "OBSERVATION_MODIFIER", 50, 59]]], ["As first details of the disease emerge, the film\u2019s protagonist, Ji-goo, is seen in a mall among people frantically making phone calls and rushing to leave the city.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["the film", "TEST", 40, 48]]], ["Of note, when infected citizens are forcibly moved to camps, elements of compassion and cohesion develop among camp residents; the most violent reactions come from and are directed toward authorities managing the site.", [["the most violent reactions", "PROBLEM", 127, 153]]], ["The film also reflects on distrust of elites and authorities with medical knowledge and power; rumors are spread that the infected are killed rather than treated.", [["The film", "TEST", 0, 8], ["rumors", "PROBLEM", 95, 101], ["infected", "OBSERVATION_MODIFIER", 122, 130]]], ["This theme again has broad parallels to history and the riots that occurred during 19th- and 20th-century cholera outbreaks, opposing medical staff and governments (27).", [["cholera", "DISEASE", 106, 113]]], ["Note that several films set in China and Hong Kong produced in the immediate aftermath of the 2003 SARS outbreak aimed to present an optimal governmental response: Profoundly Affecting [Jingxing dingpo] (2003, Jia Wang/Dong Shen), Feidian rensheng (2003, Wai-Man Cheng), and Golden Chicken 2 [Gam gai 2] (2003, Leung Chun Chiu).Resistance and Normalcy during Epidemics Depicted in CinemaAside from freedoms and liberties, other films have highlighted how societies sometimes move toward unrest\u2014through either resistance to authorities or physical violence\u2014as a response to perceived infringements on customary and traditional practices that have occurred during an epidemic outbreak.", [["SARS", "DISEASE", 99, 103], ["Chicken", "SPECIES", 282, 289], ["several films", "TEST", 10, 23], ["Gam gai", "TEST", 293, 300], ["Resistance", "PROBLEM", 328, 338], ["Epidemics", "PROBLEM", 359, 368], ["other films", "TEST", 422, 433], ["traditional practices", "TREATMENT", 614, 635]]], ["One of the clearest demonstrations of this response appears in the 2006 readaptation of The Painted Veil, which follows a British bacteriologist working to prevent the spread of cholera in a small village in rural China in the 1920s, set within a broader context of distrust through heightened nationalist tensions.", [["cholera", "DISEASE", 178, 185], ["cholera", "PROBLEM", 178, 185], ["spread", "OBSERVATION_MODIFIER", 168, 174], ["small", "OBSERVATION_MODIFIER", 191, 196]]], ["In this film we see no signs of fear or panic from the local population, despite many deaths within the community; the inhabitants are more concerned about maintaining ordinary patterns of living and sociability.", [["panic", "DISEASE", 40, 45], ["deaths", "DISEASE", 86, 92], ["this film", "TEST", 3, 12], ["fear", "PROBLEM", 32, 36], ["panic", "PROBLEM", 40, 45], ["no signs of", "UNCERTAINTY", 20, 31]]], ["Although we must be aware of the potential effects of the orientalist imagination when considering a film such as The Painted Veil, medical history points to its accuracy.", [["the orientalist imagination", "TREATMENT", 54, 81], ["a film", "TEST", 99, 105]]], ["In rural China during the 1920s and 1930s, elite medical reformers\u2019 disregard for village internal politics and power dynamics limited the effectiveness of their public health prevention policies, as locals continued the same routines (28).", [["village internal politics", "TREATMENT", 82, 107]]], ["The same issues also appear in older productions set in China; in Horse Thief [Dao ma zei] (1986, Tian Zhuangzhuang), set during a disease outbreak in Tibet in the 1920s, people living out in the steppe or grasslands continue their very same daily functions, stopping only to pray for the disease to cease.ConclusionsCinema is not reality, and elements of fear leading to panic and chaos are likely to persist in dramatic representations of disease, purely for entertainment value.", [["panic", "DISEASE", 372, 377], ["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177], ["Dao ma zei", "SPECIES", 79, 89], ["the disease", "PROBLEM", 285, 296], ["fear", "PROBLEM", 356, 360], ["panic", "PROBLEM", 372, 377], ["disease", "PROBLEM", 441, 448], ["entertainment value", "TEST", 461, 480], ["disease", "OBSERVATION", 441, 448]]], ["These representations may be problematic in 2 interrelated ways.", [["may be", "UNCERTAINTY", 22, 28]]], ["First, \u201cthe image of a panicked mob makes exciting footage in disaster movies, but it obscures a broad range of possible public reactions\u201d (29).", [["public reactions", "PROBLEM", 121, 137]]], ["Second, the public perception of how epidemic diseases behave is substantially influenced by the media and popular culture (2,4,6,30); parts of this perception are sometimes adopted as scientific facts (31,32).", [["how epidemic diseases", "PROBLEM", 33, 54], ["popular culture", "TEST", 107, 122]]], ["Similar issues have recently been brought to our attention regarding the widespread and incorrect diagnostic use of images of persons with a disease that is wrongly assumed to be plague (33,34) and media perpetuation of several recent misguided anxieties over how the Ebola virus is spread (35,36).ConclusionsIn this article, however, we have shown that many films focusing on social responses to epidemic disease outbreaks also shine a light on another side of how people react.", [["Ebola", "DISEASE", 268, 273], ["persons", "ORGANISM", 126, 133], ["Ebola virus", "ORGANISM", 268, 279], ["people", "ORGANISM", 466, 472], ["persons", "SPECIES", 126, 133], ["Ebola virus", "SPECIES", 268, 279], ["people", "SPECIES", 466, 472], ["Ebola virus", "SPECIES", 268, 279], ["a disease", "PROBLEM", 139, 148], ["several recent misguided anxieties", "PROBLEM", 220, 254], ["the Ebola virus", "PROBLEM", 264, 279], ["many films", "TEST", 354, 364], ["epidemic disease outbreaks", "PROBLEM", 397, 423], ["Ebola virus", "OBSERVATION", 268, 279]]], ["Although on the one hand, fear and panic can be connected to a perceived breakdown in social morality, on the other hand, disruptive reactions can also work toward societal cohesion to protect freedoms, privileges, and customs under threat.", [["panic", "DISEASE", 35, 40], ["panic", "PROBLEM", 35, 40], ["a perceived breakdown in social morality", "PROBLEM", 61, 101], ["disruptive reactions", "PROBLEM", 122, 142]]], ["In the films mentioned in this article, a recurring lesson is the failure of imposed mass isolation techniques, largely resulting from weak compliance (4).", [["the films", "TEST", 3, 12], ["imposed mass isolation techniques", "TREATMENT", 77, 110], ["mass", "OBSERVATION", 85, 89], ["weak", "OBSERVATION_MODIFIER", 135, 139]]], ["These films also show situations similar to ongoing problems with Ebola in Africa today, where communal suspicions and distrust of the decisions of outside authorities are rife (37\u201339), violent resistance and outcry occur within communities (40), and localized attempts continue to maintain customary practices in terms of the treatment of the dead (41).", [["Ebola", "DISEASE", 66, 71], ["Ebola", "ORGANISM", 66, 71], ["These films", "TEST", 0, 11], ["situations", "PROBLEM", 22, 32], ["Ebola", "PROBLEM", 66, 71], ["customary practices", "TREATMENT", 291, 310], ["the treatment", "TREATMENT", 323, 336], ["Ebola", "OBSERVATION", 66, 71]]]]}